Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12562644,time to progression,The median time to progression was 16 weeks (95% CI 9-22).,Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562644/),weeks,16,501,DB01229,Paclitaxel
,12562644,area under the plasma concentration-time curve (AUC),Pharmacokinetic analyses revealed that the mean area under the plasma concentration-time curve (AUC) of orally administered paclitaxel (+/- standard deviation) was 3757.6 +/- 939.4 ng.h/ml in week 1 and 3928.4 +/- 1281 ng.h/ml in week 2.,Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562644/),[h·ng] / [ml],3757.6,502,DB01229,Paclitaxel
,12562644,area under the plasma concentration-time curve (AUC),Pharmacokinetic analyses revealed that the mean area under the plasma concentration-time curve (AUC) of orally administered paclitaxel (+/- standard deviation) was 3757.6 +/- 939.4 ng.h/ml in week 1 and 3928.4 +/- 1281 ng.h/ml in week 2.,Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562644/),[h·ng] / [ml],3928.4,503,DB01229,Paclitaxel
,21308709,absolute recoveries,"The absolute recoveries of pinaverium bromide and the internal standard were 99.7-111.7 and 106.2%, respectively.",A sensitive and specific liquid chromatography/tandem mass spectrometry method for determination of pinaverium bromide in human plasma: application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308709/),%,99.7-111.7,698,DB01229,Paclitaxel
,21308709,absolute recoveries,"The absolute recoveries of pinaverium bromide and the internal standard were 99.7-111.7 and 106.2%, respectively.",A sensitive and specific liquid chromatography/tandem mass spectrometry method for determination of pinaverium bromide in human plasma: application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308709/),%,106.2,699,DB01229,Paclitaxel
>,11996502,plasma protein binding,"Considering lipophilic antineoplastic agents, we tested this approach to analyze paclitaxel under unfavourable circumstances (i.e., weekly low-dose regimen, plasma protein binding >90%, UV detection at 229 nm).",On-line solid-phase extraction and determination of paclitaxel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996502/),%,90,900,DB01229,Paclitaxel
,11996502,recovery,"The excellent quality control data (recovery: 95.6-100.7%, inter-assay relative standard deviation on 5 days: 1.3-3.2%, accuracy: 0.9-2.7%) and the detection limit of 19 nM indicates the usefulness of this method for the analysis of paclitaxel in plasma using on-line solid-phase extraction.",On-line solid-phase extraction and determination of paclitaxel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996502/),%,95.6-100.7,901,DB01229,Paclitaxel
,11996502,detection limit,"The excellent quality control data (recovery: 95.6-100.7%, inter-assay relative standard deviation on 5 days: 1.3-3.2%, accuracy: 0.9-2.7%) and the detection limit of 19 nM indicates the usefulness of this method for the analysis of paclitaxel in plasma using on-line solid-phase extraction.",On-line solid-phase extraction and determination of paclitaxel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996502/),nM,19,902,DB01229,Paclitaxel
,34266890,overall response rate,The overall response rate was 65% (80% in CCOC).,Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34266890/),%,65,1740,DB01229,Paclitaxel
,26170666,zeta potential,The formed NPs had a zeta potential of +15.9-23.3 mV and showed high colloidal stability.,"The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26170666/),mv,15.,2176,DB01229,Paclitaxel
,16696191,"constant of transport rate of speed, K10","The constant of transport rate of speed, K10 (0.55 h(-1)), was much smaller in the microemulsion group compared with the Taxol group (1.55 h(-l)).","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),1/[h],0.55,2213,DB01229,Paclitaxel
,16696191,"constant of transport rate of speed, K10","The constant of transport rate of speed, K10 (0.55 h(-1)), was much smaller in the microemulsion group compared with the Taxol group (1.55 h(-l)).","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),h(-l),1.55,2214,DB01229,Paclitaxel
,16696191,mean retention time,"The mean retention time was 3.89 h in microemulsion group and 2.52 h in the Taxol group, showing the elimination rate was much slower in the former than in the latter.","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),h,3.89,2215,DB01229,Paclitaxel
,16696191,mean retention time,"The mean retention time was 3.89 h in microemulsion group and 2.52 h in the Taxol group, showing the elimination rate was much slower in the former than in the latter.","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),h,2.52,2216,DB01229,Paclitaxel
,22184370,PFS,"Median PFS was 7.2 months (95% CI, 5.3 to 8.1 months) in arm A, 5.7 months (95% CI, 4.6 to 8.0 months) in arm B, and 4.6 months (95% CI, 1.9 to 6.7 months) in arm C.","Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184370/),,4,2562,DB01229,Paclitaxel
,22184370,Objective response rates,"Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively.","Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184370/),%,37,2563,DB01229,Paclitaxel
,22184370,Objective response rates,"Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively.","Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184370/),%,19,2564,DB01229,Paclitaxel
,22184370,Objective response rates,"Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively.","Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184370/),%,27,2565,DB01229,Paclitaxel
,15726368,LD(50),"Tolerability to mice is remarkable, such that the lethal dose (LD(50)) was ninefold greater than that of the commercial formulation (LD(50) = 326 microM and 37 microM, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),μM,326,3822,DB01229,Paclitaxel
,15726368,LD(50),"Tolerability to mice is remarkable, such that the lethal dose (LD(50)) was ninefold greater than that of the commercial formulation (LD(50) = 326 microM and 37 microM, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),μM,37,3823,DB01229,Paclitaxel
,15726368,t(1/2),"At equimolar doses, the association of paclitaxel oleate with LDE results in remarkable changes in the drug pharmacokinetic parameters when compared to commercial paclitaxel (t(1/2)=218 min and 184 min, AUC=1,334 microg h/ml and 707 microg h/ml and CL=0.125 ml/min and 0.236 ml/min, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),min,218,3824,DB01229,Paclitaxel
,15726368,t(1/2),"At equimolar doses, the association of paclitaxel oleate with LDE results in remarkable changes in the drug pharmacokinetic parameters when compared to commercial paclitaxel (t(1/2)=218 min and 184 min, AUC=1,334 microg h/ml and 707 microg h/ml and CL=0.125 ml/min and 0.236 ml/min, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),min,184,3825,DB01229,Paclitaxel
,15726368,AUC,"At equimolar doses, the association of paclitaxel oleate with LDE results in remarkable changes in the drug pharmacokinetic parameters when compared to commercial paclitaxel (t(1/2)=218 min and 184 min, AUC=1,334 microg h/ml and 707 microg h/ml and CL=0.125 ml/min and 0.236 ml/min, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),[h·μg] / [ml],"1,334",3826,DB01229,Paclitaxel
,15726368,AUC,"At equimolar doses, the association of paclitaxel oleate with LDE results in remarkable changes in the drug pharmacokinetic parameters when compared to commercial paclitaxel (t(1/2)=218 min and 184 min, AUC=1,334 microg h/ml and 707 microg h/ml and CL=0.125 ml/min and 0.236 ml/min, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),[h·μg] / [ml],707,3827,DB01229,Paclitaxel
,15726368,CL,"At equimolar doses, the association of paclitaxel oleate with LDE results in remarkable changes in the drug pharmacokinetic parameters when compared to commercial paclitaxel (t(1/2)=218 min and 184 min, AUC=1,334 microg h/ml and 707 microg h/ml and CL=0.125 ml/min and 0.236 ml/min, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),[ml] / [min],0.125,3828,DB01229,Paclitaxel
,15726368,CL,"At equimolar doses, the association of paclitaxel oleate with LDE results in remarkable changes in the drug pharmacokinetic parameters when compared to commercial paclitaxel (t(1/2)=218 min and 184 min, AUC=1,334 microg h/ml and 707 microg h/ml and CL=0.125 ml/min and 0.236 ml/min, respectively).",Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726368/),[ml] / [min],0.236,3829,DB01229,Paclitaxel
,14614002,clearance,"The mean (+/- SE) values for clearance, volume of distribution at steady state, and the apparent terminal half-lives of the three dose groups during cycle 1 were 243 +/- 5 ml/min/m(2), 423 +/- 58 l/m(2), and 32.2 +/- 4.5 h, respectively.",Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614002/),[min·ml] / [m(2],243,3970,DB01229,Paclitaxel
,14614002,volume of distribution at steady state,"The mean (+/- SE) values for clearance, volume of distribution at steady state, and the apparent terminal half-lives of the three dose groups during cycle 1 were 243 +/- 5 ml/min/m(2), 423 +/- 58 l/m(2), and 32.2 +/- 4.5 h, respectively.",Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614002/),[l] / [m(2],423,3971,DB01229,Paclitaxel
,14614002,apparent terminal half-lives,"The mean (+/- SE) values for clearance, volume of distribution at steady state, and the apparent terminal half-lives of the three dose groups during cycle 1 were 243 +/- 5 ml/min/m(2), 423 +/- 58 l/m(2), and 32.2 +/- 4.5 h, respectively.",Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14614002/),h,32.2,3972,DB01229,Paclitaxel
,22337803,resolution,The validation and stability results show that propylparaben (PP) is a suitable internal standard (resolution 7.70 ± 0.15 min) for the estimation of TAX in micro volume rat plasma.,A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),min,7.70,4497,DB01229,Paclitaxel
,22337803,retention time,"TAX and PP are separated by isocratic reversed-phase high-performance liquid chromatography with diode array UV method with a retention time of 8.0 ± 0.25 and 5.3 ± 0.15 min, respectively, with a total run time of 10 min.",A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),min,8.0,4498,DB01229,Paclitaxel
,22337803,retention time,"TAX and PP are separated by isocratic reversed-phase high-performance liquid chromatography with diode array UV method with a retention time of 8.0 ± 0.25 and 5.3 ± 0.15 min, respectively, with a total run time of 10 min.",A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),min,5.3,4499,DB01229,Paclitaxel
,22337803,total run time,"TAX and PP are separated by isocratic reversed-phase high-performance liquid chromatography with diode array UV method with a retention time of 8.0 ± 0.25 and 5.3 ± 0.15 min, respectively, with a total run time of 10 min.",A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),min,10,4500,DB01229,Paclitaxel
,22337803,limit of detection (LOD),"The limit of detection (LOD) and LLOQ of the method are 5 and 10 ng/mL, respectively.",A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),[ng] / [ml],5,4501,DB01229,Paclitaxel
,22337803,limit of detection (LOD),"The limit of detection (LOD) and LLOQ of the method are 5 and 10 ng/mL, respectively.",A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),[ng] / [ml],10,4502,DB01229,Paclitaxel
,22337803,LLOQ,"The limit of detection (LOD) and LLOQ of the method are 5 and 10 ng/mL, respectively.",A simple and rapid 3D view method for selective and sensitive determination of paclitaxel in micro volume rat plasma by LC-diode array UV and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337803/),[ng] / [ml],10,4503,DB01229,Paclitaxel
,18510173,AUCs,"After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses.",Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510173/),[h·μg] / [ml],1.29,4730,DB01229,Paclitaxel
,18510173,AUCs,"After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses.",Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510173/),[h·μg] / [ml],1.60,4731,DB01229,Paclitaxel
,18510173,AUCs,"After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses.",Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510173/),[h·μg] / [ml],1.85,4732,DB01229,Paclitaxel
,12811513,area under the concentration-time curve (AUC),"The doses of each drug ranged from an area under the concentration-time curve (AUC) of 5 to 6 for carboplatin, 135 to 175 mg/m(2) for paclitaxel, and 300 to 1000 mg/m(2) for gemcitabine.","Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811513/),[mg] / [m(2],5 to 6,4780,DB01229,Paclitaxel
,12811513,area under the concentration-time curve (AUC),"The doses of each drug ranged from an area under the concentration-time curve (AUC) of 5 to 6 for carboplatin, 135 to 175 mg/m(2) for paclitaxel, and 300 to 1000 mg/m(2) for gemcitabine.","Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811513/),[mg] / [m(2],135 to 175,4781,DB01229,Paclitaxel
,12621462,MTD,Mucositis was the dose-limiting toxicity and the MTD was 60 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),mg,60,5056,DB01229,Paclitaxel
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],7.7,5057,DB01229,Paclitaxel
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],26.3,5058,DB01229,Paclitaxel
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],14.8,5059,DB01229,Paclitaxel
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],47.4,5060,DB01229,Paclitaxel
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],423.2,5061,DB01229,Paclitaxel
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],2581,5062,DB01229,Paclitaxel
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],732.8,5063,DB01229,Paclitaxel
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],4590,5064,DB01229,Paclitaxel
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,28.6,5065,DB01229,Paclitaxel
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,38.5,5066,DB01229,Paclitaxel
,19521262,survival,The median survival was 14.8 months.,Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19521262/),month,14.8,5673,DB01229,Paclitaxel
,30298303,overall survival,"Median overall survival and progression-free survival was 9.73 [95%CI:9.73-13.5] and 7.53 (95%CI:6.05-12.8) months, respectively.",Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30298303/),month,9.73,5702,DB01229,Paclitaxel
,30298303,progression-free survival,"Median overall survival and progression-free survival was 9.73 [95%CI:9.73-13.5] and 7.53 (95%CI:6.05-12.8) months, respectively.",Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30298303/),month,7.53,5703,DB01229,Paclitaxel
,30298303,half-life,Enzalutamide reached steady-state levels between day 22 and 29 and the mean half-life of nab-paclitaxel was 19.6 ± 4.7 h.,Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30298303/),h,19.6,5704,DB01229,Paclitaxel
,20845471,AUC(0-96 h),"In subjects, AUC(0-96 h) values in pleural fluid and plasma were 17831 ± 6439 µg h/mL and 778 ± 328 µg h/mL, respectively, and T(max) values were initial time and 6.67 h after administration and the corresponding C(max) values were 558 ± 44 µg/mL and 12.89 ± 6.86 µg/mL, respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[h·μg] / [ml],17831,7383,DB01229,Paclitaxel
,20845471,AUC(0-96 h),"In subjects, AUC(0-96 h) values in pleural fluid and plasma were 17831 ± 6439 µg h/mL and 778 ± 328 µg h/mL, respectively, and T(max) values were initial time and 6.67 h after administration and the corresponding C(max) values were 558 ± 44 µg/mL and 12.89 ± 6.86 µg/mL, respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[h·μg] / [ml],778,7384,DB01229,Paclitaxel
,20845471,T(max),"In subjects, AUC(0-96 h) values in pleural fluid and plasma were 17831 ± 6439 µg h/mL and 778 ± 328 µg h/mL, respectively, and T(max) values were initial time and 6.67 h after administration and the corresponding C(max) values were 558 ± 44 µg/mL and 12.89 ± 6.86 µg/mL, respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),h,initial time,7385,DB01229,Paclitaxel
,20845471,T(max),"In subjects, AUC(0-96 h) values in pleural fluid and plasma were 17831 ± 6439 µg h/mL and 778 ± 328 µg h/mL, respectively, and T(max) values were initial time and 6.67 h after administration and the corresponding C(max) values were 558 ± 44 µg/mL and 12.89 ± 6.86 µg/mL, respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),h,6.67,7386,DB01229,Paclitaxel
,20845471,C(max),"In subjects, AUC(0-96 h) values in pleural fluid and plasma were 17831 ± 6439 µg h/mL and 778 ± 328 µg h/mL, respectively, and T(max) values were initial time and 6.67 h after administration and the corresponding C(max) values were 558 ± 44 µg/mL and 12.89 ± 6.86 µg/mL, respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[μg] / [ml],558,7387,DB01229,Paclitaxel
,20845471,C(max),"In subjects, AUC(0-96 h) values in pleural fluid and plasma were 17831 ± 6439 µg h/mL and 778 ± 328 µg h/mL, respectively, and T(max) values were initial time and 6.67 h after administration and the corresponding C(max) values were 558 ± 44 µg/mL and 12.89 ± 6.86 µg/mL, respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[μg] / [ml],12.89,7388,DB01229,Paclitaxel
,20845471,T(1/2,"The T(1/2,IP), CL(IP) and Vd(IP) values in pleural fluid were 76 ± 48 h, 0.005 ± 0.002 L/h m(2) and 0.53 ± 0.23 L/m(2), respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),h,76,7389,DB01229,Paclitaxel
,20845471,CL,"The T(1/2,IP), CL(IP) and Vd(IP) values in pleural fluid were 76 ± 48 h, 0.005 ± 0.002 L/h m(2) and 0.53 ± 0.23 L/m(2), respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[h·l] / [m(2],0.005,7390,DB01229,Paclitaxel
,20845471,Vd(IP),"The T(1/2,IP), CL(IP) and Vd(IP) values in pleural fluid were 76 ± 48 h, 0.005 ± 0.002 L/h m(2) and 0.53 ± 0.23 L/m(2), respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[l] / [m(2],0.53,7391,DB01229,Paclitaxel
,20845471,"T(1/2,pla)","The T(1/2,pla), CL(pla), and Vd(pla) values in plasma were 68.34 ± 56.74 h, 0.184 ± 0.080 L/h m(2), and 17.53 ± 16.57 L/m(2), respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),h,68.34,7392,DB01229,Paclitaxel
,20845471,CL(pla),"The T(1/2,pla), CL(pla), and Vd(pla) values in plasma were 68.34 ± 56.74 h, 0.184 ± 0.080 L/h m(2), and 17.53 ± 16.57 L/m(2), respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[h·l] / [m(2],0.184,7393,DB01229,Paclitaxel
,20845471,Vd(pla),"The T(1/2,pla), CL(pla), and Vd(pla) values in plasma were 68.34 ± 56.74 h, 0.184 ± 0.080 L/h m(2), and 17.53 ± 16.57 L/m(2), respectively.",Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845471/),[l] / [m(2],17.53,7394,DB01229,Paclitaxel
,17310470,limit of detection,The limit of detection for each analyte was 1 ng/mL.,Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),[ng] / [ml],1,10156,DB01229,Paclitaxel
,17310470,overall recoveries,"The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively.",Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),%,89.0,10157,DB01229,Paclitaxel
,17310470,overall recoveries,"The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively.",Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),%,91.1,10158,DB01229,Paclitaxel
,17310470,total analysis time,The total analysis time was only 9.0 min.,Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),min,9.0,10159,DB01229,Paclitaxel
,11484417,Cmax,"The mean Cmax and AUC0-infinity values were 2.57 microM and 12.06 microM at the 135 mg/m2 dose level while at the 175 mg/m2 dose the values increased to 4.96 microM and 9.52 microM.h/l, respectively.",Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11484417/),μM,2.57,10581,DB01229,Paclitaxel
,11484417,Cmax,"The mean Cmax and AUC0-infinity values were 2.57 microM and 12.06 microM at the 135 mg/m2 dose level while at the 175 mg/m2 dose the values increased to 4.96 microM and 9.52 microM.h/l, respectively.",Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11484417/),μM,4.96,10582,DB01229,Paclitaxel
,11484417,AUC0-infinity,"The mean Cmax and AUC0-infinity values were 2.57 microM and 12.06 microM at the 135 mg/m2 dose level while at the 175 mg/m2 dose the values increased to 4.96 microM and 9.52 microM.h/l, respectively.",Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11484417/),μM,12.06,10583,DB01229,Paclitaxel
,11484417,AUC0-infinity,"The mean Cmax and AUC0-infinity values were 2.57 microM and 12.06 microM at the 135 mg/m2 dose level while at the 175 mg/m2 dose the values increased to 4.96 microM and 9.52 microM.h/l, respectively.",Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11484417/),[h·μM] / [l],9.52,10584,DB01229,Paclitaxel
,15752379,first order rate constant,The concentration of CrEL in the gastrointestinal tract decreased with time with a first order rate constant of 1.73 h(-1).,Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752379/),1/[h],1.73,10866,DB01229,Paclitaxel
,15752379,apparent paclitaxel clearance,"Estimated apparent paclitaxel clearance and volume of distribution were 127 l h(-1) and 409 l, respectively.",Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752379/),[l] / [h],127,10867,DB01229,Paclitaxel
,15752379,volume of distribution,"Estimated apparent paclitaxel clearance and volume of distribution were 127 l h(-1) and 409 l, respectively.",Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752379/),l,409,10868,DB01229,Paclitaxel
,30105668,Objective response rate,"Objective response rate was 28% (all partial responses), and 13 (52%) patients had a best response of stable disease.","Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105668/),%,28,11177,DB01229,Paclitaxel
,23579358,AUC,"A Bayesian dose-escalation model was used to identify feasible daily or weekly everolimus doses given with paclitaxel (200 mg/m(2) q21 days) and carboplatin (AUC 6 mg/mL/min q21 days) (step 1) and paclitaxel (200 mg/m(2) q21 days), carboplatin (AUC 6 mg/mL/min q21 days), and bevacizumab (15 mg/kg q21 days) (step 2).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),[mg] / [min·ml],6,11334,DB01229,Paclitaxel
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,16.7,11335,DB01229,Paclitaxel
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,30.8,11336,DB01229,Paclitaxel
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,30.0,11337,DB01229,Paclitaxel
,22669574,half-life,Pharmacokinetic studies of BIIB036 in tumor-bearing mice revealed a half-life of approximately three days suggesting twice a week dosing would be necessary to maintain efficacy.,The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669574/),d,three,12423,DB01229,Paclitaxel
,28495530,Papp,"The permeability of PTX by EMNP was 3.5-fold (Papp = 0.425 nm/s) and 16.2-fold (Papp = 394.1 nm/s) higher than free PTX in MDCK-MDR1 cell monolayers and intestinal mucosal tissue, respectively.",Erythrocyte membrane nanoparticles improve the intestinal absorption of paclitaxel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28495530/),[nm] / [s],0.425,12701,DB01229,Paclitaxel
,28495530,Papp,"The permeability of PTX by EMNP was 3.5-fold (Papp = 0.425 nm/s) and 16.2-fold (Papp = 394.1 nm/s) higher than free PTX in MDCK-MDR1 cell monolayers and intestinal mucosal tissue, respectively.",Erythrocyte membrane nanoparticles improve the intestinal absorption of paclitaxel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28495530/),[nm] / [s],394.1,12702,DB01229,Paclitaxel
,7541151,time to progression,"The median time to progression was 9 months (range, 1 to 20 months).",Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),month,9,12822,DB01229,Paclitaxel
,7541151,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 125 mg/m2 for paclitaxel and 48 mg/m2 for doxorubicin.,Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],125,12823,DB01229,Paclitaxel
,7541151,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 125 mg/m2 for paclitaxel and 48 mg/m2 for doxorubicin.,Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],48,12824,DB01229,Paclitaxel
,7541151,MTDs,"The MTDs of this schedule were 60 mg/m2 and 150 mg/m2 for doxorubicin and paclitaxel, respectively.",Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],60,12825,DB01229,Paclitaxel
,7541151,MTDs,"The MTDs of this schedule were 60 mg/m2 and 150 mg/m2 for doxorubicin and paclitaxel, respectively.",Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],150,12826,DB01229,Paclitaxel
,22888230,oral bioavailability,"An in vivo pharmacokinetic study showed that the oral bioavailability of paclitaxel-loaded LCNPs (13.16%) was 2.1 times that of Taxol(®) (the commercial formulation of paclitaxel, 6.39%).",Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888230/),%,13.16,13009,DB01229,Paclitaxel
,22888230,oral bioavailability,"An in vivo pharmacokinetic study showed that the oral bioavailability of paclitaxel-loaded LCNPs (13.16%) was 2.1 times that of Taxol(®) (the commercial formulation of paclitaxel, 6.39%).",Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888230/),%,6.39,13010,DB01229,Paclitaxel
,8603456,AUC,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[min·μg] / [ml],334,13160,DB01229,Paclitaxel
,8603456,AUC,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[min·μg] / [ml],1540,13161,DB01229,Paclitaxel
,8603456,total clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],4.8,13162,DB01229,Paclitaxel
,8603456,total clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],1.1,13163,DB01229,Paclitaxel
,8603456,biliary clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],2.6,13164,DB01229,Paclitaxel
,8603456,biliary clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],0.5,13165,DB01229,Paclitaxel
,8603456,elimination half-life,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),min,62,13166,DB01229,Paclitaxel
,8603456,elimination half-life,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),min,40,13167,DB01229,Paclitaxel
,8603456,volume of distribution,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),ml,424,13168,DB01229,Paclitaxel
,8603456,volume of distribution,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),ml,65,13169,DB01229,Paclitaxel
,12569296,maximal i.p. versus plasma concentration ratio,"The maximal i.p. versus plasma concentration ratio ranged from 17 to 95 (average 45), while the i.p. versus systemic exposure ratio varied between 105 and 555 (average 207).",Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12569296/),,45,14977,DB01229,Paclitaxel
,12845579,run-time,"Furthermore, a very short run-time (3 min) fulfilled the need for monitoring plasma levels of docetaxel from large-scale clinical studies.",A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845579/),,3,15126,DB01229,Paclitaxel
,11038035,time to progression (TTP),"After an overall median follow-up time of 22 months (range 4-39+), the median time to progression (TTP) was 4.5 months and the median duration of response was 8 months (range 3-16).",Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038035/),month,4.5,15145,DB01229,Paclitaxel
,11038035,duration of response,"After an overall median follow-up time of 22 months (range 4-39+), the median time to progression (TTP) was 4.5 months and the median duration of response was 8 months (range 3-16).",Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038035/),month,8,15146,DB01229,Paclitaxel
,25600579,relative oral bioavailability,"In addition, in pharmacokinetic studies, drug plasma levels were observed for at least 24 h leading to a relative oral bioavailability between 60% and 80% for PTX complexed with cyclodextrin and loaded in pegylated poly(anhydride) nanoparticles after oral gavage.","Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600579/),%,60,15497,DB01229,Paclitaxel
,25600579,relative oral bioavailability,"In addition, in pharmacokinetic studies, drug plasma levels were observed for at least 24 h leading to a relative oral bioavailability between 60% and 80% for PTX complexed with cyclodextrin and loaded in pegylated poly(anhydride) nanoparticles after oral gavage.","Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600579/),%,80,15498,DB01229,Paclitaxel
,18791718,Total clearance of unbound,Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV).,Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18791718/),[l] / [h],845,16338,DB01229,Paclitaxel
,18791718,solubility,The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma.,Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18791718/),[ng] / [ml],405,16339,DB01229,Paclitaxel
,18791718,time to 90% cumulative input,The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 +/- 0.16 h.,Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18791718/),h,1.14,16340,DB01229,Paclitaxel
,12960116,area under the concentration-time curve,"Patients received suramin followed by paclitaxel (175-200 mg/m(2)) and carboplatin area under the concentration-time curve of 6 mg/ml/min, every 3 weeks.",Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12960116/),[mg] / [min·ml],6,16396,DB01229,Paclitaxel
>,12960116,peak concentrations,The initial suramin dose resulted in the targeted concentrations of 10-20 microM at 48 h in 5 of the first 6 patients treated but also resulted in peak concentrations > 50 microM in all patients.,Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12960116/),μM,50,16397,DB01229,Paclitaxel
,12960116,time to tumor progression,"The median time to tumor progression is 8.5 months (range, 3-27+ months) for 12 evaluable patients.",Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12960116/),month,8.5,16398,DB01229,Paclitaxel
,12928126,overall response rate,The overall response rate for all patients was 64% (95% CI: 43-82%).,Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12928126/),%,64,17003,DB01229,Paclitaxel
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,6.28,17149,DB01229,Paclitaxel
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,9.63,17150,DB01229,Paclitaxel
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,3.15,17151,DB01229,Paclitaxel
,12051884,progression-free survival (PSF),At a median follow-up of 30 months patients with residual disease after surgery (n = 10) had a median progression-free survival (PSF) of 13 months; for the optimally debulked group (n = 15) the actuarial PFS was 60% at 48 months.,Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12051884/),month,13,17283,DB01229,Paclitaxel
,27189323,overall response rate,The overall response rate was 54.5 %.,A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27189323/),%,54.5,17773,DB01229,Paclitaxel
,16319513,MTD,"The MTD of paclitaxel was presumed to be 60 mg/m(2), because 50.0% of patients (2/4) developed DLTs (mainly grade 3 anorexia).",Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319513/),mg,60,17786,DB01229,Paclitaxel
,16319513,RD,"Therefore, the RD of paclitaxel was estimated to be 50 mg/m(2).",Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319513/),[mg] / [m(2],50,17787,DB01229,Paclitaxel
,16319513,preliminary response rate,The preliminary response rate was 62.5% (5/8) at the RD.,Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319513/),%,62.5,17788,DB01229,Paclitaxel
,7543702,overall response,"Among 10 patients, there was one complete response and seven partial responses (overall response, 80%).",Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7543702/),%,80,17829,DB01229,Paclitaxel
,7543702,Response rates,Response rates in both regimens were approximately 20%.,Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7543702/),%,20,17830,DB01229,Paclitaxel
,15641487,area under the curve (AUC),Maximum tolerated dose of CI-994 was determined to be 4 mg/m2 administered for 7 consecutive days following paclitaxel at a dose of 225 mg/m2 and carboplatin at an area under the curve (AUC) of 6 every 21 days.,Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641487/),,6,18295,DB01229,Paclitaxel
,15641487,AUC,The combination of CI-994 at a dose of 4 mg/m2 administered orally for 7 consecutive days can be safely coadministered with paclitaxel at a dose of 225 mg/m2 and carboplatin at an AUC of 6 on day 1 of a 21-day cycle.,Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15641487/),,6,18296,DB01229,Paclitaxel
,8996141,neutrophil nadir,The mean neutrophil nadir was 4.0 x 10(9)/L.,Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996141/),,4.0 x 10(9),19297,DB01229,Paclitaxel
,8996141,maximum-tolerated dose,"Dose-limiting toxicity was reached at 100 mg/m2 with two of three patients experiencing a treatment delay, thus defining a maximum-tolerated dose of 80 mg/m2 in this group of heavily pretreated patients on this weekly schedule.",Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996141/),[mg] / [m2],80,19298,DB01229,Paclitaxel
,32131561,stability,The results show that Egg yolk phosphatidylcholine PC98T (PC) significantly increased the stability of CX-PC-casein nanoparticles (NPs) (192.6 nm) from 5 min (CX-β-casein-NPs) to 2.5 h at 37 °C.,Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),min,5,19344,DB01229,Paclitaxel
,32131561,stability,The results show that Egg yolk phosphatidylcholine PC98T (PC) significantly increased the stability of CX-PC-casein nanoparticles (NPs) (192.6 nm) from 5 min (CX-β-casein-NPs) to 2.5 h at 37 °C.,Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),h,2.5,19345,DB01229,Paclitaxel
,32131561,tumor inhibition rate,"When CX-PC-casein-NPs were intravenously administrated to mice implanted with A375 tumors (CX dose = 16 mg/kg bodyweight), the tumor inhibition rate reached 56.2%, which was comparable to that of paclitaxel (57.3%) at a dose of 4 mg/kg bodyweight.",Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),%,56.2,19346,DB01229,Paclitaxel
,32131561,tumor inhibition rate,"When CX-PC-casein-NPs were intravenously administrated to mice implanted with A375 tumors (CX dose = 16 mg/kg bodyweight), the tumor inhibition rate reached 56.2%, which was comparable to that of paclitaxel (57.3%) at a dose of 4 mg/kg bodyweight.",Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32131561/),%,57.3,19347,DB01229,Paclitaxel
,10885606,overall response rate,"After independent review, partial response was recorded in 6 patients (overall response rate, 15%; 95% confidence limit (CI), 7.7-29.8%) and stable disease was recorded in 15 patients (38%).",A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885606/),%,15,19429,DB01229,Paclitaxel
,10885606,duration of response,The median duration of response was 5.1 months (range: 3.1-7.2).,A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885606/),month,5.1,19430,DB01229,Paclitaxel
,10885606,pain control time,The median pain control time was 4.5 months (range: 0-8) and the median time to performance status worsening was 2.3 months (range: 0-4.5).,A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885606/),month,4.5,19431,DB01229,Paclitaxel
,10885606,time to performance status worsening,The median pain control time was 4.5 months (range: 0-8) and the median time to performance status worsening was 2.3 months (range: 0-4.5).,A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885606/),month,2.3,19432,DB01229,Paclitaxel
,22748771,PDI,"Optimization of various process variables were carried out and optimized formulation was found to have particle size of 226 ± 17.61 nm, PDI of 0.343 ± 0.070, zeta potential of +39.9 ± 3.79 mV and encapsulation efficiency of 71.91 ± 3.16%.",Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748771/),,0.343,19570,DB01229,Paclitaxel
,22748771,zeta potential,"Optimization of various process variables were carried out and optimized formulation was found to have particle size of 226 ± 17.61 nm, PDI of 0.343 ± 0.070, zeta potential of +39.9 ± 3.79 mV and encapsulation efficiency of 71.91 ± 3.16%.",Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748771/),mv,+,19571,DB01229,Paclitaxel
,22748771,zeta potential,"Optimization of various process variables were carried out and optimized formulation was found to have particle size of 226 ± 17.61 nm, PDI of 0.343 ± 0.070, zeta potential of +39.9 ± 3.79 mV and encapsulation efficiency of 71.91 ± 3.16%.",Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748771/),mv,39.9,19572,DB01229,Paclitaxel
,22748771,encapsulation efficiency,"Optimization of various process variables were carried out and optimized formulation was found to have particle size of 226 ± 17.61 nm, PDI of 0.343 ± 0.070, zeta potential of +39.9 ± 3.79 mV and encapsulation efficiency of 71.91 ± 3.16%.",Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748771/),%,71.91,19573,DB01229,Paclitaxel
,22748771,IC50,"This was subsequently corroborated by MTT assay, which revealed IC50 value of 29.37 μg/ml for developed layersome formulation in contrast to 35.42 μg/ml for free drug.",Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748771/),[μg] / [ml],29.37,19574,DB01229,Paclitaxel
,22748771,IC50,"This was subsequently corroborated by MTT assay, which revealed IC50 value of 29.37 μg/ml for developed layersome formulation in contrast to 35.42 μg/ml for free drug.",Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748771/),[μg] / [ml],35.42,19575,DB01229,Paclitaxel
,23681836,terminal t 1/2,"It was observed the terminal t 1/2 and MRT of paclitaxel were significantly (p = 0.002 and 0.001) reduced by MI, respectively, from 11.0 ± 2.2 and 5.6 ± 1.0 h to 7.7 ± 1.7 and 4.0 ± 0.3 h.",Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681836/),h,11.0,20212,DB01229,Paclitaxel
,23681836,terminal t 1/2,"It was observed the terminal t 1/2 and MRT of paclitaxel were significantly (p = 0.002 and 0.001) reduced by MI, respectively, from 11.0 ± 2.2 and 5.6 ± 1.0 h to 7.7 ± 1.7 and 4.0 ± 0.3 h.",Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681836/),h,7.7,20213,DB01229,Paclitaxel
,23681836,MRT,"It was observed the terminal t 1/2 and MRT of paclitaxel were significantly (p = 0.002 and 0.001) reduced by MI, respectively, from 11.0 ± 2.2 and 5.6 ± 1.0 h to 7.7 ± 1.7 and 4.0 ± 0.3 h.",Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681836/),h,5.6,20214,DB01229,Paclitaxel
,23681836,MRT,"It was observed the terminal t 1/2 and MRT of paclitaxel were significantly (p = 0.002 and 0.001) reduced by MI, respectively, from 11.0 ± 2.2 and 5.6 ± 1.0 h to 7.7 ± 1.7 and 4.0 ± 0.3 h.",Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681836/),h,4.0,20215,DB01229,Paclitaxel
,25853480,drug-loading content,Further experiments showed that the F127-CS/NaC micelles had a higher drug-loading content of 12.8% and a lower critical micelle concentration (CMC) of 2.5 × 10-3 mol/L compared with F127-PAA/NaC micelles.,Preparation of sodium cholate-based micelles through non-covalent ıbonding interaction and application as oral delivery systems for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853480/),%,12.8,20445,DB01229,Paclitaxel
,25853480,critical micelle concentration (CMC),Further experiments showed that the F127-CS/NaC micelles had a higher drug-loading content of 12.8% and a lower critical micelle concentration (CMC) of 2.5 × 10-3 mol/L compared with F127-PAA/NaC micelles.,Preparation of sodium cholate-based micelles through non-covalent ıbonding interaction and application as oral delivery systems for paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853480/),[mol] / [l],2.5 × 10-3,20446,DB01229,Paclitaxel
,7908791,half-lives,"The plasma disposition of paclitaxel in rabbits (7 mg/kg, 1 h i.v. inf.) was biphasic with half-lives of 0.36 and 6.36 h, and AUC was 9.46 micrograms.hr/ml.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),h,0.36,20685,DB01229,Paclitaxel
,7908791,half-lives,"The plasma disposition of paclitaxel in rabbits (7 mg/kg, 1 h i.v. inf.) was biphasic with half-lives of 0.36 and 6.36 h, and AUC was 9.46 micrograms.hr/ml.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),h,6.36,20686,DB01229,Paclitaxel
,7908791,AUC,"The plasma disposition of paclitaxel in rabbits (7 mg/kg, 1 h i.v. inf.) was biphasic with half-lives of 0.36 and 6.36 h, and AUC was 9.46 micrograms.hr/ml.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),[h·μg] / [ml],9.46,20687,DB01229,Paclitaxel
,7908791,half-lives,"The half-lives and AUC were 0.25 h, 2.23 h and 117.93 micrograms.hr/ml.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),h,0.25,20688,DB01229,Paclitaxel
,7908791,AUC,"The half-lives and AUC were 0.25 h, 2.23 h and 117.93 micrograms.hr/ml.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),[h·μg] / [ml],117.93,20689,DB01229,Paclitaxel
,7908791,AUC(oral)/AUC,"AUC(oral)/AUC(i.v.) ratio in the bile, liver, tumor and plasma was 18.91, 6.71, 0.83 and 0.45%, respectively.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),%,18.91,20690,DB01229,Paclitaxel
,7908791,AUC(oral)/AUC,"AUC(oral)/AUC(i.v.) ratio in the bile, liver, tumor and plasma was 18.91, 6.71, 0.83 and 0.45%, respectively.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),%,6.71,20691,DB01229,Paclitaxel
,7908791,AUC(oral)/AUC,"AUC(oral)/AUC(i.v.) ratio in the bile, liver, tumor and plasma was 18.91, 6.71, 0.83 and 0.45%, respectively.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),%,0.83,20692,DB01229,Paclitaxel
,7908791,AUC(oral)/AUC,"AUC(oral)/AUC(i.v.) ratio in the bile, liver, tumor and plasma was 18.91, 6.71, 0.83 and 0.45%, respectively.",[Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908791/),%,0.45,20693,DB01229,Paclitaxel
,23349317,MTD,The MTD was 650 mg/m(2) every 3 weeks.,Phase I study of GRN1005 in recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23349317/),[mg] / [m],650,21821,DB01229,Paclitaxel
,31330211,zeta potential,The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of -27.6 mv.,The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),mv,-,22319,DB01229,Paclitaxel
,31330211,zeta potential,The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of -27.6 mv.,The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),mv,27.6,22320,DB01229,Paclitaxel
,31330211,encapsulation efficiency (EE),"The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively.",The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),%,92.64,22321,DB01229,Paclitaxel
,31330211,drug loading (DL),"The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively.",The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31330211/),%,6.96,22322,DB01229,Paclitaxel
,10999729,Cmax,"Mean paclitaxel Cmax values approached plasma concentrations achieved with clinically relevant parenteral dose schedules, averaging 268+/-164 ng/ml.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),[ng] / [ml],268,22526,DB01229,Paclitaxel
,10999729,AUC,"AUC values averaged 3306+/-1977 ng x h/ ml, which was significantly lower than AUC values achieved with clinically relevant i.v. paclitaxel dose schedules.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),[h·ng] / [ml],3306,22527,DB01229,Paclitaxel
at,10999729,steady-state plasma paclitaxel concentrations,"However, computer simulations using pharmacokinetic parameters derived from the present study demonstrated that pharmacodynamically relevant steady-state plasma paclitaxel concentrations of at least 0.06 microM would be achieved after protracted once daily and twice daily dosing with oral paclitaxel and cyclosporin A.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),μ,0.06,22528,DB01229,Paclitaxel
,10999729,AUC ratios,"Paclitaxel metabolites were detectable in three patients, and the 6-alpha-hydroxypaclitaxel: paclitaxel and 3-p-hydroxypaclitaxel:paclitaxel AUC ratios averaged 0.63 and 0.86, respectively; these values were substantially higher than values reported in patients treated with i.v. paclitaxel.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),,0.63,22529,DB01229,Paclitaxel
,10999729,AUC ratios,"Paclitaxel metabolites were detectable in three patients, and the 6-alpha-hydroxypaclitaxel: paclitaxel and 3-p-hydroxypaclitaxel:paclitaxel AUC ratios averaged 0.63 and 0.86, respectively; these values were substantially higher than values reported in patients treated with i.v. paclitaxel.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),,0.86,22530,DB01229,Paclitaxel
less,17091249,C (max),MAC-321 was rapidly absorbed with a mean C (max) value of less than 1 h.,Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091249/),h,1,22557,DB01229,Paclitaxel
,17091249,terminal phase elimination half-life,The median terminal phase elimination half-life was 45 h (range 20-228 h).,Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091249/),h,45,22558,DB01229,Paclitaxel
,11852999,absolute gran,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),1/[(mm)^3],200,22892,DB01229,Paclitaxel
,11852999,time to this nadir,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,9,22893,DB01229,Paclitaxel
,11852999,platelet nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),k,163,22894,DB01229,Paclitaxel
,11852999,time to this nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,8,22895,DB01229,Paclitaxel
,30016392,progression-free survival (mPFS),"In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with median progression-free survival (mPFS) of 5.8 months (95% CI: 3.28-18.54).",Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30016392/),month,5,23183,DB01229,Paclitaxel
,30016392,mPFS,"The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8 months (95% CI: 2.76-21.25).",Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30016392/),month,5.8,23184,DB01229,Paclitaxel
,10100705,AUC,The target AUC ranged from 31.5 to 45 microM x h.,Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100705/),h·μM,31.5 to 45,24215,DB01229,Paclitaxel
,16988826,AUC dose,"Plasma and urine concentrations of LC and ALC from 11 patients on carboplatin therapy (1 h intravenous infusion; AUC dose 4.8 +/- 1.1 mg/ml min) in combination with docetaxel, paclitaxel or vinorelbine, were determined by high-performance liquid chromatography with fluorimetric detection.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[mg] / [min·ml],4.8,24369,DB01229,Paclitaxel
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],47.8,24370,DB01229,Paclitaxel
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],7.04,24371,DB01229,Paclitaxel
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],115,24372,DB01229,Paclitaxel
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],480,24373,DB01229,Paclitaxel
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],41,24374,DB01229,Paclitaxel
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],89,24375,DB01229,Paclitaxel
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],1.67,24376,DB01229,Paclitaxel
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],9.05,24377,DB01229,Paclitaxel
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],4.02,24378,DB01229,Paclitaxel
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],7.97,24379,DB01229,Paclitaxel
greater,28688270,recoveries,The recoveries were greater than 90% with low matrix effects.,"Simultaneous quantitative analysis of polyethylene glycol (PEG), PEGylated paclitaxel and paclitaxel in rats by MS/MSALL technique with hybrid quadrupole time-of-flight mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688270/),%,90,24621,DB01229,Paclitaxel
,23085332,systemic exposure,"Although the mean systemic exposure to paclitaxel after oral administration of the solid dispersion formulation was slightly lower compared to the paclitaxel premix solution (190±63.1ng/mLh for vs. 247±100ng/mLh), the systemic exposure to paclitaxel is clinically relevant [1,2].",Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23085332/),[ng] / [mlh],190,24710,DB01229,Paclitaxel
,23085332,systemic exposure,"Although the mean systemic exposure to paclitaxel after oral administration of the solid dispersion formulation was slightly lower compared to the paclitaxel premix solution (190±63.1ng/mLh for vs. 247±100ng/mLh), the systemic exposure to paclitaxel is clinically relevant [1,2].",Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23085332/),[ng] / [mlh],247,24711,DB01229,Paclitaxel
,12228205,area under the concentration-time curve (AUC),"One hundred patients with ABC received paclitaxel 135 mg/m(2) (group 1, n = 20) and carboplatin area under the concentration-time curve (AUC) of 2.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),,2,25349,DB01229,Paclitaxel
,12228205,overall response rate (ORR),"The overall response rate (ORR) among 95 assessable patients was 62%, including 8% complete responses and 54% partial responses.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),%,62,25350,DB01229,Paclitaxel
,12228205,time to response,"The median time to response was 1.8 months, and the median duration of response was 13.3 months.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,1.8,25351,DB01229,Paclitaxel
,12228205,duration of response,"The median time to response was 1.8 months, and the median duration of response was 13.3 months.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,13.3,25352,DB01229,Paclitaxel
,12228205,time to progression,The median time to progression was 4.8 months.,Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,4.8,25353,DB01229,Paclitaxel
,11822754,peak plasma levels (Cmax,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[μg] / [ml],18.56,25768,DB01229,Paclitaxel
,11822754,peak plasma levels (Cmax,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[μg] / [ml],40.85,25769,DB01229,Paclitaxel
,11822754,area under the plasma concentration-time curve (AUC,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[h·μg] / [ml],9.99,25770,DB01229,Paclitaxel
,11822754,area under the plasma concentration-time curve (AUC,"A nonproportional increase in gemcitabine peak plasma levels (Cmax, from 18.56 +/- 4.94 to 40.85 +/- 14.85 microg/ml) and area under the plasma concentration-time curve (AUC, from 9.99 +/- 2.75 to 25.01 +/- 9.87 h x microg/ml) at 1,500 and 2,000 mg/m, respectively, was observed, suggesting the occurrence of saturation kinetics at higher doses.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[h·μg] / [ml],25.01,25771,DB01229,Paclitaxel
,11822754,time,"A significant relationship between neutropenia and time of paclitaxel plasma levels > or = 0.05 micromol/l was observed, with a predicted time of 10.4 h to decrease cell count by 50%.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),,10.4,25772,DB01229,Paclitaxel
,11822754,effective concentration,"A correlation was also observed between percentage reduction of platelet count and gemcitabine Cmax, with a predicted effective concentration to induce a 50% decrease of 14.3 microg/ml.",Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822754/),[μg] / [ml],14.3,25773,DB01229,Paclitaxel
,24719309,maximum rate for saturable distribution,The rapid disappearance of circulating paclitaxel was driven by its fast distribution to peripheral compartments; maximum rate for saturable distribution (325000 μg/h) was 40-fold greater than that for saturable elimination (8070 μg/h).,Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24719309/),[μg] / [h],325000,26088,DB01229,Paclitaxel
,24719309,saturable elimination,The rapid disappearance of circulating paclitaxel was driven by its fast distribution to peripheral compartments; maximum rate for saturable distribution (325000 μg/h) was 40-fold greater than that for saturable elimination (8070 μg/h).,Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24719309/),[μg] / [h],8070,26089,DB01229,Paclitaxel
,11720431,C(max),"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),μM,0.10,26762,DB01229,Paclitaxel
,11720431,C(max),"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),μM,0.31,26763,DB01229,Paclitaxel
,11720431,AUC,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),[μM] / [h],1.29,26764,DB01229,Paclitaxel
,11720431,AUC,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),[μM] / [h],2.61,26765,DB01229,Paclitaxel
,11720431,excretion,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel excretion in faeces was 38.8 +/- 13.0% of the administered dose, whereas this value was 18.3 +/-15.5% for the polysorbate 80 formulation.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),%,38.8,26766,DB01229,Paclitaxel
,11720431,excretion,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel excretion in faeces was 38.8 +/- 13.0% of the administered dose, whereas this value was 18.3 +/-15.5% for the polysorbate 80 formulation.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),%,18.3,26767,DB01229,Paclitaxel
,32307730,m/z,"Quantification was performed using a triple quadrupole mass spectrometer through multiple reaction monitoring in positive mode, using the m/z 830.3 → 548.8 and m/z 876.3 → 307.7 transitions for DTX and paclitaxel, respectively.",An improved LC-MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307730/),,876.3,27088,DB01229,Paclitaxel
,32307730,m/z,"Quantification was performed using a triple quadrupole mass spectrometer through multiple reaction monitoring in positive mode, using the m/z 830.3 → 548.8 and m/z 876.3 → 307.7 transitions for DTX and paclitaxel, respectively.",An improved LC-MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32307730/),,307.7,27089,DB01229,Paclitaxel
,16628131,recovery,The assay had good recovery (87.96+/-14.05 and 90.57+/-9.63 for docetaxel and paclitaxel respectively) and precision: the within-day and between-days relative standard deviation of the mean for docetaxel (0.015-3 mg/L) and paclitaxel was always <10%.,Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628131/),,87.96,27640,DB01229,Paclitaxel
,16628131,recovery,The assay had good recovery (87.96+/-14.05 and 90.57+/-9.63 for docetaxel and paclitaxel respectively) and precision: the within-day and between-days relative standard deviation of the mean for docetaxel (0.015-3 mg/L) and paclitaxel was always <10%.,Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628131/),,90.57,27641,DB01229,Paclitaxel
,12107555,area under the curve (AUC),When docetaxel was delivered at 15 mg/kg the area under the curve (AUC) of the peritoneal fluid was significantly higher with intraperitoneal administration (110.6 microg/ml.min) as compared to intravenous administration (0.043 microg/ml.min; P=0.0079).,Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),[μg] / [min·ml],110.6,28339,DB01229,Paclitaxel
,12107555,area under the curve (AUC),When docetaxel was delivered at 15 mg/kg the area under the curve (AUC) of the peritoneal fluid was significantly higher with intraperitoneal administration (110.6 microg/ml.min) as compared to intravenous administration (0.043 microg/ml.min; P=0.0079).,Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),[μg] / [min·ml],0.043,28340,DB01229,Paclitaxel
,12107555,AUC,"Conversely, at the same dose the AUC of the plasma was significantly lower with intraperitoneal administration (0.11 microg/ml.min) as compared to intravenous administration (4.25 microg/ml.min; P=0.0079).",Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),[μg] / [min·ml],0.11,28341,DB01229,Paclitaxel
,12107555,AUC,"Conversely, at the same dose the AUC of the plasma was significantly lower with intraperitoneal administration (0.11 microg/ml.min) as compared to intravenous administration (4.25 microg/ml.min; P=0.0079).",Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),[μg] / [min·ml],4.25,28342,DB01229,Paclitaxel
,12107555,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 976 for intraperitoneal administration as opposed to 0.01 for intravenous delivery.,Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),,976,28343,DB01229,Paclitaxel
,12107555,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 976 for intraperitoneal administration as opposed to 0.01 for intravenous delivery.,Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),,0.01,28344,DB01229,Paclitaxel
,12107555,AUC ratio,The AUC ratio for intraperitoneal docetaxel at 150 mg/kg was 3004.,Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107555/),,3004,28345,DB01229,Paclitaxel
,10453729,peak plasma levels,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),μM,3.00,29077,DB01229,Paclitaxel
,10453729,peak plasma levels,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),μM,4.15,29078,DB01229,Paclitaxel
,10453729,area under the curve (AUC,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),h·μM,14.3,29079,DB01229,Paclitaxel
,10453729,area under the curve (AUC,High-dose progesterone increased the peak plasma levels (3.00 +/- 0.94 vs. 4.15 +/- 1.63 microM; P = 0.029; mean +/- SD) and the area under the curve (AUC; 14.3 +/- 4.75 vs. 17.3 +/- 5.59 microM x h; P = 0.006) of paclitaxel.,A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10453729/),h·μM,17.3,29080,DB01229,Paclitaxel
,22067579,area under the drug concentration-time curve ratio,"The intraperitoneal/plasma area under the drug concentration-time curve ratio was 2,003.3:1.",Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22067579/),:1,"2,003.3",29177,DB01229,Paclitaxel
,9155536,minimum concentration,"The minimum concentration of paclitaxel for measurable cytotoxicity was 3 nM for both cell lines, but the drug was more toxic to the A549 cells.",Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9155536/),nM,3,29651,DB01229,Paclitaxel
,9155536,minimum concentration,"The minimum concentration for measurable radiosensitisation was 3 nM for A375 and approximately 0.1 nM for A549, but whereas above 3 nM the radiosensitivity increased in A375, it decreased above 1 nM for A549.",Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9155536/),nM,3,29652,DB01229,Paclitaxel
,9155536,minimum concentration,"The minimum concentration for measurable radiosensitisation was 3 nM for A375 and approximately 0.1 nM for A549, but whereas above 3 nM the radiosensitivity increased in A375, it decreased above 1 nM for A549.",Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9155536/),nM,0.1,29653,DB01229,Paclitaxel
,26579476,flow rate,Chromatographic separation was performed on a Phenomenex Gemini C18 column (50 mm×2.0 mm; 5 μm) using stepwise gradient elution with acetonitrile-water and 0.2 mmol/L lithium carbonate at a flow rate of 0.5 mL/min.,Determination of ginsenoside compound K in human plasma by liquid chromatography-tandem mass spectrometry of lithium adducts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579476/),[ml] / [min],0.5,29677,DB01229,Paclitaxel
,15173077,maximum tolerated dosage,"Therefore, the maximum tolerated dosage was determined to be 390 mg/m(2).","Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15173077/),[mg] / [m(2],390,29756,DB01229,Paclitaxel
,11142688,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of paclitaxel after i.v. administration (175 mg/m2) was 16.2 +/- 1.7 microM x h and after oral administration (300 mg/m2) 3.8 +/- 1.5 microM x h.,Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),h·μM,16.2,29843,DB01229,Paclitaxel
,11142688,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of paclitaxel after i.v. administration (175 mg/m2) was 16.2 +/- 1.7 microM x h and after oral administration (300 mg/m2) 3.8 +/- 1.5 microM x h.,Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),h·μM,3.8,29844,DB01229,Paclitaxel
,11142688,total fecal excretion,"Following i.v. infusion of paclitaxel, total fecal excretion was 56 +/- 25%, with the metabolite 6alpha-hydroxypaclitaxel being the main excretory product (37 +/- 18%).",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,56,29845,DB01229,Paclitaxel
,11142688,total fecal excretion,"Following i.v. infusion of paclitaxel, total fecal excretion was 56 +/- 25%, with the metabolite 6alpha-hydroxypaclitaxel being the main excretory product (37 +/- 18%).",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,37,29846,DB01229,Paclitaxel
,11142688,total fecal excretion,"After oral administration of paclitaxel, total fecal excretion was 76 +/- 21%, of which paclitaxel accounted for 61 +/- 14%.",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,76,29847,DB01229,Paclitaxel
,11142688,total fecal excretion,"After oral administration of paclitaxel, total fecal excretion was 76 +/- 21%, of which paclitaxel accounted for 61 +/- 14%.",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,61,29848,DB01229,Paclitaxel
,32158208,encapsulation efficiency,ER-targeting liposomes had a particle size of 137.93±1.22 nm and an acceptable encapsulation efficiency of 88.07±1.25%.,"Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32158208/),%,88.07,29899,DB01229,Paclitaxel
,24369111,drug loading,CF-PTX was found to have drug loading of 6 mg/ml similar to Cremophor EL based marketed paclitaxel formulation.,"Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24369111/),[mg] / [ml],6,29912,DB01229,Paclitaxel
,24369111,mean residence time (MRT,Pharmacokinetic and biodistribution studies showed sustained plasma concentration of paclitaxel depicted by higher mean residence time (MRT; 18.2±1.8 h) and elimination half life (12.8±0.6 h) with CF-PTX formulation as compared to marketed formulation which showed 4.4±0.2 h MRT and 3.6±0.4 h half life.,"Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24369111/),h,18.2,29913,DB01229,Paclitaxel
,24369111,elimination half life,Pharmacokinetic and biodistribution studies showed sustained plasma concentration of paclitaxel depicted by higher mean residence time (MRT; 18.2±1.8 h) and elimination half life (12.8±0.6 h) with CF-PTX formulation as compared to marketed formulation which showed 4.4±0.2 h MRT and 3.6±0.4 h half life.,"Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24369111/),h,12.8,29914,DB01229,Paclitaxel
,24369111,MRT,Pharmacokinetic and biodistribution studies showed sustained plasma concentration of paclitaxel depicted by higher mean residence time (MRT; 18.2±1.8 h) and elimination half life (12.8±0.6 h) with CF-PTX formulation as compared to marketed formulation which showed 4.4±0.2 h MRT and 3.6±0.4 h half life.,"Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24369111/),h,4.4,29915,DB01229,Paclitaxel
,24369111,half life,Pharmacokinetic and biodistribution studies showed sustained plasma concentration of paclitaxel depicted by higher mean residence time (MRT; 18.2±1.8 h) and elimination half life (12.8±0.6 h) with CF-PTX formulation as compared to marketed formulation which showed 4.4±0.2 h MRT and 3.6±0.4 h half life.,"Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24369111/),h,3.6,29916,DB01229,Paclitaxel
,7961108,half life,Pharmacokinetic studies performed using high-performance liquid chromatography demonstrated that plasma concentrations of paclitaxel increased during the 24-h infusion and declined immediately upon cessation of the infusion with a half life of 13.1-24.6 h (75-180 mg/m2).,Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961108/),h,13.1-24.6,29930,DB01229,Paclitaxel
,10378993,area under the plasma concentration vs time curve (AUC),"For the 3-h 175 mg m-2 dose, the area under the plasma concentration vs time curve (AUC) was (mean+/-SD) 16.9+/-4.8 h x micromol x l-1, whereas the AUCs were 5.5+/-1.2 and 4.3+/-0.9 h x micromol x l-1 for the 96-h 140 mg m-2 and 105 mg m-2 doses, respectively.",Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10378993/),[h·μM] / [l],16.9,30314,DB01229,Paclitaxel
,10378993,AUCs,"For the 3-h 175 mg m-2 dose, the area under the plasma concentration vs time curve (AUC) was (mean+/-SD) 16.9+/-4.8 h x micromol x l-1, whereas the AUCs were 5.5+/-1.2 and 4.3+/-0.9 h x micromol x l-1 for the 96-h 140 mg m-2 and 105 mg m-2 doses, respectively.",Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10378993/),[h·μM] / [l],5.5,30315,DB01229,Paclitaxel
,10378993,AUCs,"For the 3-h 175 mg m-2 dose, the area under the plasma concentration vs time curve (AUC) was (mean+/-SD) 16.9+/-4.8 h x micromol x l-1, whereas the AUCs were 5.5+/-1.2 and 4.3+/-0.9 h x micromol x l-1 for the 96-h 140 mg m-2 and 105 mg m-2 doses, respectively.",Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10378993/),[h·μM] / [l],4.3,30316,DB01229,Paclitaxel
,10691029,maximum tolerated dose,"The maximum tolerated dose, at a one dose per day for 5-day schedule, was 37.5 mg/kg for BrC16HT compared to 12.5 for Taxol administered IP, and was 12.5-25 mg/kg for either agent administered IV.",Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691029/),[mg] / [kg],37.5,30467,DB01229,Paclitaxel
,10691029,maximum tolerated dose,"The maximum tolerated dose, at a one dose per day for 5-day schedule, was 37.5 mg/kg for BrC16HT compared to 12.5 for Taxol administered IP, and was 12.5-25 mg/kg for either agent administered IV.",Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691029/),,12.5,30468,DB01229,Paclitaxel
,10691029,maximum tolerated dose,"The maximum tolerated dose, at a one dose per day for 5-day schedule, was 37.5 mg/kg for BrC16HT compared to 12.5 for Taxol administered IP, and was 12.5-25 mg/kg for either agent administered IV.",Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691029/),[mg] / [kg],12.5-25,30469,DB01229,Paclitaxel
,29478415,peak-reach time,The drug distribution in different tissues showed that the peak-reach time was 2 h in the PTX group and 6 h in both NP groups.,Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478415/),h,2,30669,DB01229,Paclitaxel
,29478415,peak-reach time,The drug distribution in different tissues showed that the peak-reach time was 2 h in the PTX group and 6 h in both NP groups.,Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478415/),h,6,30670,DB01229,Paclitaxel
,14962724,MTD,The MTD of 3-weekly BMS-184476 was 30 mg/m(2).,Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962724/),[mg] / [m(2],30,30788,DB01229,Paclitaxel
,14962724,objective response rate,The objective response rate in 17 previously untreated or minimally pretreated patients with breast cancer treated at 35 mg/m(2)/week of BMS-184476 was 59% (95% Confidence Interval (CI): 33-82%).,Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962724/),%,59,30789,DB01229,Paclitaxel
,29175440,zeta potential,"Liposomal system was found to have 162.8 ± 4.1 nm size, zeta potential of -5.6 ± 0.14 mV and 2-fold increase in drug loading to 5.8 mol % for PTX due to double loading.",Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175440/),mv,-5.6,31229,DB01229,Paclitaxel
,17921708,MTD,The MTD of paclitaxel were determined as 140 mg/m2.,Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921708/),[mg] / [m2],140,31230,DB01229,Paclitaxel
,30317534,Response rate,Response rate was 37.5% for cohort 1 and 30.4% for cohort 2.,Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317534/),%,37.5,31239,DB01229,Paclitaxel
,30317534,Response rate,Response rate was 37.5% for cohort 1 and 30.4% for cohort 2.,Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317534/),%,30.4,31240,DB01229,Paclitaxel
,33634324,MTD,The MTD of PICN was determined to be 295 mg/m2 both as a monotherapy and in combination with carboplatin at AUC 5.,A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33634324/),[mg] / [m2],295,31385,DB01229,Paclitaxel
,33634324,response rate,PICN monotherapy yielded a response rate of 20% in unresectable BTCs.,A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33634324/),%,20,31386,DB01229,Paclitaxel
,12736110,clearance (CL),A change in body surface area (BSA) of 0.1 m(2) typically caused a change in clearance (CL) of 22.3 l/h and an increase in bilirubin of 10 microM typically caused a decrease in CL of 41 l/h.,Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12736110/),[l] / [h],22.3,31525,DB01229,Paclitaxel
,12736110,CL,A change in body surface area (BSA) of 0.1 m(2) typically caused a change in clearance (CL) of 22.3 l/h and an increase in bilirubin of 10 microM typically caused a decrease in CL of 41 l/h.,Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12736110/),[l] / [h],41,31526,DB01229,Paclitaxel
,33614470,clearance,"For a dose of 175 mg m-2, the estimated clearance of total plasma paclitaxel was 21.55 L h-1.",Population Pharmacokinetics and Exposure-Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33614470/),[l] / [h],21.55,31669,DB01229,Paclitaxel
,9796957,oral bioavailability,"Calculated relative to the area under the plasma concentration-time curve of i.v. administered paclitaxel in mice treated without cyclosporin A, the oral bioavailability of paclitaxel increased from 9.3% up to 67% with coadministration of cyclosporin A.",Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796957/),%,9.3,31811,DB01229,Paclitaxel
,9796957,oral bioavailability,"Calculated relative to the area under the plasma concentration-time curve of i.v. administered paclitaxel in mice treated without cyclosporin A, the oral bioavailability of paclitaxel increased from 9.3% up to 67% with coadministration of cyclosporin A.",Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796957/),%,67,31812,DB01229,Paclitaxel
,12796368,half-life,Pharmacokinetic studies demonstrated a short half-life (1-5 h) independent of dose.,A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12796368/),h,1-5,31900,DB01229,Paclitaxel
,12111107,volume of the central compartment (V1,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),l,2.59,32136,DB01229,Paclitaxel
,12111107,V2,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),l,1.81,32137,DB01229,Paclitaxel
,12111107,V3,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),l,1.61,32138,DB01229,Paclitaxel
,12111107,intercompartmental clearance between central and peripheral compartments (Q12,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),[l] / [h],1.44,32139,DB01229,Paclitaxel
,12111107,Q13,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),[l] / [h],0.155,32140,DB01229,Paclitaxel
,12111107,maximal elimination rate (Vmax,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),[ml] / [h],0.193,32141,DB01229,Paclitaxel
,12111107,concentration at half Vmax (Km,"The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2.59 l), volumes of two peripheral compartments (V2=1.81 l, V3=1.61 l), intercompartmental clearance between central and peripheral compartments (Q12=1.44 l/h, Q13=0.155 l/h), maximal elimination rate (Vmax=0.193 ml/h), and concentration at half Vmax (Km=0.122 ml/l).",A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12111107/),[ml] / [l],0.122,32142,DB01229,Paclitaxel
,31196355,IC50,"H6 showed potent anti-proliferative ability with IC50 values from 7 to 47 nM, and remarkable ability to reduce tumor growth in several xenograft models including taxol resistant tumor models.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),nM,7 to 47,32409,DB01229,Paclitaxel
,31196355,drug loading,"The prepared H6/MPEG-PCL micelles had a drug loading of 3.79 ± 0.001%, an encapsulation efficiency of 98.00 ± 0.41%, a mean particle size of 30.45 ± 0.18nm and a polydispersity index (PDI) of 0.096 ± 0.009.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),%,3.79,32410,DB01229,Paclitaxel
,31196355,encapsulation efficiency,"The prepared H6/MPEG-PCL micelles had a drug loading of 3.79 ± 0.001%, an encapsulation efficiency of 98.00 ± 0.41%, a mean particle size of 30.45 ± 0.18nm and a polydispersity index (PDI) of 0.096 ± 0.009.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),%,98.00,32411,DB01229,Paclitaxel
,31196355,polydispersity index (PDI),"The prepared H6/MPEG-PCL micelles had a drug loading of 3.79 ± 0.001%, an encapsulation efficiency of 98.00 ± 0.41%, a mean particle size of 30.45 ± 0.18nm and a polydispersity index (PDI) of 0.096 ± 0.009.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),,0.096,32412,DB01229,Paclitaxel
,11899652,overall response rate,Two (4%) patients had a complete response and 21 (45%) patients had a partial response for an overall response rate of 49% (95% confidence interval: 35%-63%).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),%,49,32571,DB01229,Paclitaxel
,11899652,duration of response,"The median survival was 17.7 months, median duration of response was 8.6 months, and median time to disease progression was 6.3 months.","Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),month,8.6,32572,DB01229,Paclitaxel
,11899652,time to disease progression,"The median survival was 17.7 months, median duration of response was 8.6 months, and median time to disease progression was 6.3 months.","Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),month,6.3,32573,DB01229,Paclitaxel
,11899652,peak plasma concentrations,Responders had higher peak plasma concentrations of paclitaxel than nonresponders (4.46 vs. 2.9 micrograms/mL; P = 0.02).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),[μg] / [ml],4.46,32574,DB01229,Paclitaxel
,11899652,peak plasma concentrations,Responders had higher peak plasma concentrations of paclitaxel than nonresponders (4.46 vs. 2.9 micrograms/mL; P = 0.02).,"Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11899652/),[μg] / [ml],2.9,32575,DB01229,Paclitaxel
,12782943,terminal half-life,The disposition of total paclitaxel in plasma was characterized by a bi-exponential elimination (terminal half-life 9.17 h) and a total clearance of 19.4 l/h/m2.,Distribution of paclitaxel in plasma and cerebrospinal fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782943/),h,9.17,32686,DB01229,Paclitaxel
,12782943,total clearance,The disposition of total paclitaxel in plasma was characterized by a bi-exponential elimination (terminal half-life 9.17 h) and a total clearance of 19.4 l/h/m2.,Distribution of paclitaxel in plasma and cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782943/),[l] / [h·m2],19.4,32687,DB01229,Paclitaxel
,12782943,unbound drug CL,The fraction of unbound paclitaxel in plasma ranged from 7.6 to 12.4% (unbound drug CL 176 l/h/m2).,Distribution of paclitaxel in plasma and cerebrospinal fluid. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782943/),[l] / [h·m2],176,32688,DB01229,Paclitaxel
,12782943,plasma clearance,"The plasma clearance of CrEL was 0.332 l/h/m2, whereas CrEL levels were undetectable in CSF (below 0.5 microl/ml).",Distribution of paclitaxel in plasma and cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782943/),[l] / [h·m2],0.332,32689,DB01229,Paclitaxel
,12782943,unbound CSF:unbound plasma concentration ratios,"Concentrations of paclitaxel in CSF (range 45.5-162 pg/ml) and unbound CSF:unbound plasma concentration ratios (range 0.093-9.53%) progressively increased up to 24 h, with a mean unbound drug fraction in CSF of 84+/-3.6% (range 81-88%).",Distribution of paclitaxel in plasma and cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782943/),%,0,32690,DB01229,Paclitaxel
,12782943,unbound drug fraction,"Concentrations of paclitaxel in CSF (range 45.5-162 pg/ml) and unbound CSF:unbound plasma concentration ratios (range 0.093-9.53%) progressively increased up to 24 h, with a mean unbound drug fraction in CSF of 84+/-3.6% (range 81-88%).",Distribution of paclitaxel in plasma and cerebrospinal fluid. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782943/),%,84,32691,DB01229,Paclitaxel
,25924991,area under the curve,"This dose-escalating, phase I study was designed to identify the recommended dose of ipilimumab (3 or 10 mg/kg) by evaluating dose-limiting toxicity (DLT; Cycles 3 and 4) in phased combination with PTX (175 mg/m(2)) and CBDCA (area under the curve = 6) in Japanese patients with advanced NSCLC.",Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25924991/),,6,32777,DB01229,Paclitaxel
,29091899,half-life,"The pharmacokinetic properties of 99mTc-SpHL-DTPA-PTX and 99mTc-SpHL-folate-DTPA-PTX decreased in a monophasic manner showing half-life of 400.1 and 541.8min, respectively.",Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29091899/),min,400.1,32957,DB01229,Paclitaxel
,29091899,half-life,"The pharmacokinetic properties of 99mTc-SpHL-DTPA-PTX and 99mTc-SpHL-folate-DTPA-PTX decreased in a monophasic manner showing half-life of 400.1 and 541.8min, respectively.",Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29091899/),min,541.8,32958,DB01229,Paclitaxel
,17028453,area under the curve (AUC),"The mean area under the curve (AUC) was 6,193 ng/ml x h (CV 46%), the mean plasma clearance (Clp) was 19.7 l/h/m2 (CV 45%), and the volume of distribution at steady state (Vss) was 121.6 l/m2 (CV 52%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),[ng] / [h·ml],"6,193",33635,DB01229,Paclitaxel
,17028453,plasma clearance (Clp),"The mean area under the curve (AUC) was 6,193 ng/ml x h (CV 46%), the mean plasma clearance (Clp) was 19.7 l/h/m2 (CV 45%), and the volume of distribution at steady state (Vss) was 121.6 l/m2 (CV 52%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),[l] / [h·m2],19.7,33636,DB01229,Paclitaxel
,17028453,volume of distribution at steady state (Vss),"The mean area under the curve (AUC) was 6,193 ng/ml x h (CV 46%), the mean plasma clearance (Clp) was 19.7 l/h/m2 (CV 45%), and the volume of distribution at steady state (Vss) was 121.6 l/m2 (CV 52%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),[l] / [m2],121.6,33637,DB01229,Paclitaxel
,17028453,mean residence time (MRT),"The mean residence time (MRT) was 7.6 h (CV 46%), the mean distribution half-life (t1/2 alpha) of PAC(tot) was 0.4 h (CV 62%), and the elimination half-life (t1/2 beta) 10.0 h (CV 42%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),h,7.6,33638,DB01229,Paclitaxel
,17028453,distribution half-life (t1/2 alpha),"The mean residence time (MRT) was 7.6 h (CV 46%), the mean distribution half-life (t1/2 alpha) of PAC(tot) was 0.4 h (CV 62%), and the elimination half-life (t1/2 beta) 10.0 h (CV 42%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),h,0.4,33639,DB01229,Paclitaxel
,17028453,elimination half-life (t1/2 beta),"The mean residence time (MRT) was 7.6 h (CV 46%), the mean distribution half-life (t1/2 alpha) of PAC(tot) was 0.4 h (CV 62%), and the elimination half-life (t1/2 beta) 10.0 h (CV 42%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),h,10.0,33640,DB01229,Paclitaxel
,17028453,Maximum plasma concentration Cmax,"Maximum plasma concentration Cmax was 3,161 ng/ml (CV 36%).",PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17028453/),[ng] / [ml],"3,161",33641,DB01229,Paclitaxel
>,9164207,T,"Neutropenia was more pronounced than could be expected on the basis of the historical times above a threshold concentration greater than 0.1 mumol/L (T > or = 0.1 mumol/L) or 0.05 mumol/L (T > or = 0.05 mumol/L), and thrombocytopenia was less than could be expected from historical sigmoidal Emax models.",Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164207/),[μM] / [l],0.1,33662,DB01229,Paclitaxel
>,9164207,T,"Neutropenia was more pronounced than could be expected on the basis of the historical times above a threshold concentration greater than 0.1 mumol/L (T > or = 0.1 mumol/L) or 0.05 mumol/L (T > or = 0.05 mumol/L), and thrombocytopenia was less than could be expected from historical sigmoidal Emax models.",Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164207/),[μM] / [l],0.05,33663,DB01229,Paclitaxel
,11571729,apparent steady-state plasma concentrations,"The mean values (+/- standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM +/- 0.5 nM for topotecan lactone, 5.6 nM +/- 2.1 nM for total topotecan, and 40.1 nM +/- 16.8 nM for paclitaxel.",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),nM,2.3,33685,DB01229,Paclitaxel
,11571729,apparent steady-state plasma concentrations,"The mean values (+/- standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM +/- 0.5 nM for topotecan lactone, 5.6 nM +/- 2.1 nM for total topotecan, and 40.1 nM +/- 16.8 nM for paclitaxel.",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),nM,5.6,33686,DB01229,Paclitaxel
,11571729,apparent steady-state plasma concentrations,"The mean values (+/- standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM +/- 0.5 nM for topotecan lactone, 5.6 nM +/- 2.1 nM for total topotecan, and 40.1 nM +/- 16.8 nM for paclitaxel.",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),nM,40.1,33687,DB01229,Paclitaxel
,11571729,objective response rate,"There were seven partial responses (Phase II) contributing to an objective response rate of 28% and a median survival time of 11.7 months (range, 0.6-20.1 months).",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),%,28,33688,DB01229,Paclitaxel
,11571729,survival time,"There were seven partial responses (Phase II) contributing to an objective response rate of 28% and a median survival time of 11.7 months (range, 0.6-20.1 months).",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),month,11.7,33689,DB01229,Paclitaxel
,30082554,Cmax,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[μg] / [ml],229.02,34082,DB01229,Paclitaxel
,30082554,Cmax,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[μg] / [ml],210.68,34083,DB01229,Paclitaxel
,30082554,AUC0-336,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[h·μg] / [ml],24298.29,34084,DB01229,Paclitaxel
,30082554,AUC0-336,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[h·μg] / [ml],25809.33,34085,DB01229,Paclitaxel
,34264503,area under the curve,All patients received intravenous infusions of paclitaxel 200 mg/m2 and carboplatin (area under the curve 6.0) immediately prior to investigational products for 4-6 cycles.,"Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34264503/),,6.0,34347,DB01229,Paclitaxel
,34264503,PFS,"Estimated median PFS was 7.72 and 7.62 months in the FKB238 and bevacizumab arms, respectively (hazard ratio 0.97; 95% CI 0.82-1.16).","Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34264503/),month,7.72,34348,DB01229,Paclitaxel
,34264503,PFS,"Estimated median PFS was 7.72 and 7.62 months in the FKB238 and bevacizumab arms, respectively (hazard ratio 0.97; 95% CI 0.82-1.16).","Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34264503/),month,7.62,34349,DB01229,Paclitaxel
,29263668,ζ-potential,The size of PTX-CMs was 53.61±0.75 nm and the ζ-potential was -19.73±0.68 mV.,Sodium cholate-enhanced polymeric micelle system for tumor-targeting delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29263668/),mv,-,35113,DB01229,Paclitaxel
,29263668,ζ-potential,The size of PTX-CMs was 53.61±0.75 nm and the ζ-potential was -19.73±0.68 mV.,Sodium cholate-enhanced polymeric micelle system for tumor-targeting delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29263668/),mv,19.73,35114,DB01229,Paclitaxel
,28868573,MTD,"Thus, the MTD of PM-paclitaxel was determined as 390 mg/m2 (level 4).",Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28868573/),[mg] / [m2],390,35154,DB01229,Paclitaxel
,33960504,AUC0-∞,AUC0-∞ was 5033.5 ± 1401.1 ng.h/mL for oPac+E and 5595.9 ± 1264.1 ng.h/mL with IVP.,Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960504/),[h·ng] / [ml],5033.5,35541,DB01229,Paclitaxel
,33960504,AUC0-∞,AUC0-∞ was 5033.5 ± 1401.1 ng.h/mL for oPac+E and 5595.9 ± 1264.1 ng.h/mL with IVP.,Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960504/),[h·ng] / [ml],5595.9,35542,DB01229,Paclitaxel
,33960504,absolute bioavailability,Mean absolute bioavailability of oPac+E was 12% (CV% = 23%).,Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33960504/),%,12,35543,DB01229,Paclitaxel
,23293114,MTD,"The MTD for afatinib in regimens A (n = 26) and B (n = 21) was determined as 20 mg and 30 mg following DLTs in five and four patients in cycle 1, respectively.","A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,20,36248,DB01229,Paclitaxel
,23293114,MTD,"The MTD for afatinib in regimens A (n = 26) and B (n = 21) was determined as 20 mg and 30 mg following DLTs in five and four patients in cycle 1, respectively.","A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,30,36249,DB01229,Paclitaxel
,23293114,MTD,The MTD of afatinib was 20 mg with cisplatin-paclitaxel and 30 mg with cisplatin-5-fluorouracil.,"A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,20,36250,DB01229,Paclitaxel
,23293114,MTD,The MTD of afatinib was 20 mg with cisplatin-paclitaxel and 30 mg with cisplatin-5-fluorouracil.,"A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293114/),mg,30,36251,DB01229,Paclitaxel
,33870151,MTD/RP2D,The MTD/RP2D was 100 mg/m2.,"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33870151/),mg,100,37193,DB01229,Paclitaxel
,33870151,disease control rate (DCR),The disease control rate (DCR) with TVB-2640 monotherapy was 42%; no patient treated with monotherapy had a complete or partial response (CR or PR).,"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33870151/),%,42,37194,DB01229,Paclitaxel
,12176795,terminal half-life,"RPR 109881A exhibited a high total body clearance, a large distribution volume and long terminal half-life of 20 h.",Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12176795/),h,20,37369,DB01229,Paclitaxel
,16272696,IC50,The result was YM-231146 (IC50=0.080 microM).,"YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272696/),μM,0.080,37835,DB01229,Paclitaxel
>,16272696,IC50,"However, YM-231146 did not inhibit cancer cell proliferation at these concentrations (IC50>5 microM).","YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272696/),μM,5,37836,DB01229,Paclitaxel
,16274945,B/P ratios,"A fold enhancement in the B/P ratios of 1.88 and 2.68 was observed at the 400 and 800 microg/kg doses respectively, when the protein was protected from metabolic degradation with PIs.","Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16274945/),,1.88,38447,DB01229,Paclitaxel
,16274945,B/P ratios,"A fold enhancement in the B/P ratios of 1.88 and 2.68 was observed at the 400 and 800 microg/kg doses respectively, when the protein was protected from metabolic degradation with PIs.","Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16274945/),,2.68,38448,DB01229,Paclitaxel
,17541593,minimum time,"The disappearance rate of implants was dose dependent (minimum time, 18.5 days).",Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541593/),d,18.5,39443,DB01229,Paclitaxel
,17541593,elimination half-life,Detectable serum CR011-vcMMAE >or=1 microg/mL (approximately 0.01 microM) was observed for >30 days post-dose; CR011-vcMMAE showed an elimination half-life of 10.3 days.,Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541593/),d,10.3,39444,DB01229,Paclitaxel
,33894017,apparent oral clearance (CL/F),"The predicted apparent oral clearance (CL/F) and volume of distribution (Vc /F) were 479 L/day and 152 L, respectively.","A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33894017/),[l] / [d],479,40077,DB01229,Paclitaxel
,33894017,volume of distribution (Vc /F),"The predicted apparent oral clearance (CL/F) and volume of distribution (Vc /F) were 479 L/day and 152 L, respectively.","A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33894017/),l,152,40078,DB01229,Paclitaxel
,11688520,overall response rate,"The overall response rate to GET was 92% (95% CI, 77.53%-98.25%); CR 31% and PR 61%.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,92,40254,DB01229,Paclitaxel
,11688520,overall response rate,"After six courses of GET, 25 patients received HDCT, leading to an overall response rate of 96% with 58% CR.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,96,40255,DB01229,Paclitaxel
,11688520,progression free survival,"Median progression free survival is 21 months, while median overall survival has not yet been reached.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),month,21,40256,DB01229,Paclitaxel
,17606724,maximum tolerated dose,The maximum tolerated dose was 100 mg/m(2) twice weekly.,A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17606724/),,100,41254,DB01229,Paclitaxel
,32819305,Overall response rate,Overall response rate was 49.6% in BCD-022 arm and 43.6% in reference trastuzumab arm.,Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32819305/),%,49.6,41399,DB01229,Paclitaxel
,32819305,Overall response rate,Overall response rate was 49.6% in BCD-022 arm and 43.6% in reference trastuzumab arm.,Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32819305/),%,43.6,41400,DB01229,Paclitaxel
more,14507946,trough levels,Trastuzumab trough levels were more than 20 mug/mL by the end of cycle 1.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),[μg] / [ml],20,41489,DB01229,Paclitaxel
,14507946,half-life,"The half-life of trastuzumab was estimated to be 18 to 27 days, although this may be an underestimate.","Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),d,18 to 27,41490,DB01229,Paclitaxel
,14507946,objective response rate,The investigator-assessed objective response rate was 59% (four complete and 15 partial responses) and seven patients (22%) had stable disease.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),%,59,41491,DB01229,Paclitaxel
,14507946,duration of response,The median duration of response was 10.5 months and median time to progression was 12.2 months.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),month,10.5,41492,DB01229,Paclitaxel
,14507946,time to progression,The median duration of response was 10.5 months and median time to progression was 12.2 months.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),month,12.2,41493,DB01229,Paclitaxel
,10497151,saturable transport was half-maximal,The value at which the saturable transport was half-maximal was 0.55 microM.,Pharmacokinetic models for the saturable distribution of paclitaxel. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497151/),μM,0.55,41494,DB01229,Paclitaxel
,10497151,K(d),The K(d) values of the binding models were 0.06 to 0.12 microM.,Pharmacokinetic models for the saturable distribution of paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497151/),μM,0.06 to 0.12,41495,DB01229,Paclitaxel
,10497151,K(m),K(m) for the elimination ranged in the different models from 2.5 to 5.6 microM.,Pharmacokinetic models for the saturable distribution of paclitaxel. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497151/),μM,2.5 to 5.6,41496,DB01229,Paclitaxel
,16333310,clearance,"The mean+/-SD values for clearance, distribution volume at steady state and terminal half-life during cycle 1 were 317+/-60 ml min(-1) m(-2), 258+/-96 l m(-2) and 30.8+/-7.7 h, respectively.",A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16333310/),[ml] / [(m)^2·min],317,41933,DB01229,Paclitaxel
,16333310,distribution volume at steady state,"The mean+/-SD values for clearance, distribution volume at steady state and terminal half-life during cycle 1 were 317+/-60 ml min(-1) m(-2), 258+/-96 l m(-2) and 30.8+/-7.7 h, respectively.",A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16333310/),[l] / [(m)^2],258,41934,DB01229,Paclitaxel
,16333310,terminal half-life,"The mean+/-SD values for clearance, distribution volume at steady state and terminal half-life during cycle 1 were 317+/-60 ml min(-1) m(-2), 258+/-96 l m(-2) and 30.8+/-7.7 h, respectively.",A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16333310/),h,30.8,41935,DB01229,Paclitaxel
,22345119,area under curve (AUC),Patients received BIBF 1120 (starting dose 50 mg b.i.d.) on days 2-21 and paclitaxel (200 mg/m2) and carboplatin [area under curve (AUC)=6 mg/ml/min] on day 1 of each 21-day cycle.,"A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345119/),[mg] / [min·ml],6,42235,DB01229,Paclitaxel
,22345119,AUC,BIBF 1120 200 mg b.i.d. had no clinically relevant influence on the PK of paclitaxel 200 mg/m2 and carboplatin AUC 6 mg/ml/min and vice versa.,"A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345119/),[mg] / [min·ml],6,42236,DB01229,Paclitaxel
,22619258,half-life,Within 6 months it fell with a half-life of 1.9 months to 0.40%±0.35%.,Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22619258/),month,1.9,42913,DB01229,Paclitaxel
,22619258,half-life,It dropped with a half-life of 45 days to 1.5%±0.6% of dose (0.3 μmol/L) within 6 months.,Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22619258/),d,45,42914,DB01229,Paclitaxel
,12711638,half-inhibitory concentration,The P-gp of both species was saturated at the half-inhibitory concentration ( approximately 13 micro M) produced by i.v. infusion.,Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12711638/),μM,13,43111,DB01229,Paclitaxel
,32694153,progression-free survival,"Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4-18.4], median overall survival was 9.7 m (95% CI, 7.0-14).",Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694153/),m,5.9,43180,DB01229,Paclitaxel
,32694153,overall survival,"Median progression-free survival was 5.9 m [95% confidence interval (CI), 3.4-18.4], median overall survival was 9.7 m (95% CI, 7.0-14).",Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694153/),m,9.7,43181,DB01229,Paclitaxel
,11583191,MTD,At the second step (75 mg/m2 of epirubicin) the MTD of docetaxel was 80 mg/m2.,Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583191/),[mg] / [m2],80,43811,DB01229,Paclitaxel
,11583191,Overall response rate,"Overall response rate was 73% in 42 out of 58 patients, with no apparent epirubicin dose-related effect.",Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583191/),%,73,43812,DB01229,Paclitaxel
,9626220,MTD,"In contrast, the MTD for patients who did not receive ACs was 240 mg/m2, and myelosuppression, gastrointestinal toxicity, and fatigue were the DLTs.",Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626220/),,240,43961,DB01229,Paclitaxel
,19232851,flow rate,"Sample separation was performed on a reverse-phase HPLC column at 30 degrees C by using a mobile phase of acetonitrile-methanol-0.02 M ammonium acetate buffer (pH 5.0) (20:47.5:32.5, v/v/v) at flow rate of 1.0 mL/min The UV absorbance of the samples was measured at the wavelength of 230 nm.",PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19232851/),[ml] / [min],1.0,44287,DB01229,Paclitaxel
,19232851,limits of quantification (LOQ),"The limits of quantification (LOQ) were 10.0 ng/mL in the plasma samples and 20.0 ng/g in the tissue samples, respectively.",PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19232851/),[ng] / [ml],10.0,44288,DB01229,Paclitaxel
,19232851,limits of quantification (LOQ),"The limits of quantification (LOQ) were 10.0 ng/mL in the plasma samples and 20.0 ng/g in the tissue samples, respectively.",PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19232851/),[ng] / [g],20.0,44289,DB01229,Paclitaxel
,10447584,area under the plasma concentration-versus-time curves (AUC),"The mean paclitaxel area under the plasma concentration-versus-time curves (AUC) for the 125-mg/m(2) dose level (II) was 7.0 +/- 3.6 h micromol(-1) l(-1), for the 175-mg/m(2) dose level (III) 10.6 +/- 2.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[h] / [l·μmol],7.0,44420,DB01229,Paclitaxel
,10447584,area under the plasma concentration-versus-time curves (AUC),"The mean paclitaxel area under the plasma concentration-versus-time curves (AUC) for the 125-mg/m(2) dose level (II) was 7.0 +/- 3.6 h micromol(-1) l(-1), for the 175-mg/m(2) dose level (III) 10.6 +/- 2.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),,10.6,44421,DB01229,Paclitaxel
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],1.9,44422,DB01229,Paclitaxel
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],3.4,44423,DB01229,Paclitaxel
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],4.3,44424,DB01229,Paclitaxel
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[h·μM] / [l],3.8,44425,DB01229,Paclitaxel
>,10447584,t,"In this study, relevant pharmacokinetic parameters of paclitaxel like AUC, C(max) and the paclitaxel plasma concentration above the pharmacologically relevant 0.1-micromol/l threshold concentration (t > 0.1 microM) when administered in combination with cisplatin, etoposide and bleomycin (PEB) were not statistically different from paclitaxel data of historical controls.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),μM,0.1,44426,DB01229,Paclitaxel
,29556370,circulation half-life,"Results: Compared with free PTX, the FA-PTX, PTX-EB and FA-PTX-EB prodrugs increased circulation half-life in mice from 2.19 to 3.82, 4.41, and 7.51 h, respectively.",A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556370/),h,2.19 to 3.82,44862,DB01229,Paclitaxel
,29556370,circulation half-life,"Results: Compared with free PTX, the FA-PTX, PTX-EB and FA-PTX-EB prodrugs increased circulation half-life in mice from 2.19 to 3.82, 4.41, and 7.51 h, respectively.",A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556370/),h,4.41,44863,DB01229,Paclitaxel
,29556370,circulation half-life,"Results: Compared with free PTX, the FA-PTX, PTX-EB and FA-PTX-EB prodrugs increased circulation half-life in mice from 2.19 to 3.82, 4.41, and 7.51 h, respectively.",A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556370/),h,7.51,44864,DB01229,Paclitaxel
,8094996,terminal half-life,"At the highest doses, the Taxotere plasma profile was typically triphasic, with a terminal half-life of 13.5 +/- 7.5 (SD) h, a plasma clearance of 21.1 +/- 5.3 liters/h/m2, and a distribution volume of 72 +/- 40 liters/m2.",Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094996/),h,13.5,44876,DB01229,Paclitaxel
,8094996,plasma clearance,"At the highest doses, the Taxotere plasma profile was typically triphasic, with a terminal half-life of 13.5 +/- 7.5 (SD) h, a plasma clearance of 21.1 +/- 5.3 liters/h/m2, and a distribution volume of 72 +/- 40 liters/m2.",Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094996/),[l] / [h·m2],21.1,44877,DB01229,Paclitaxel
,8094996,distribution volume,"At the highest doses, the Taxotere plasma profile was typically triphasic, with a terminal half-life of 13.5 +/- 7.5 (SD) h, a plasma clearance of 21.1 +/- 5.3 liters/h/m2, and a distribution volume of 72 +/- 40 liters/m2.",Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094996/),[l] / [m2],72,44878,DB01229,Paclitaxel
,9045347,area under the concentration-time curve (AUC),"For non-small cell lung cancer patients, the mean area under the concentration-time curve (AUC) per 300 mg/m2 carboplatin was 3.52 mg/mL x min (range, 1.94 to 5.83) for the sequence C-->P and 3.62 mg/mL x min (range, 1.91 to 5.01) for the sequence P-->C.",Clinical pharmacology of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9045347/),[mg] / [min·ml],3.52,44879,DB01229,Paclitaxel
,9045347,area under the concentration-time curve (AUC),"For non-small cell lung cancer patients, the mean area under the concentration-time curve (AUC) per 300 mg/m2 carboplatin was 3.52 mg/mL x min (range, 1.94 to 5.83) for the sequence C-->P and 3.62 mg/mL x min (range, 1.91 to 5.01) for the sequence P-->C.",Clinical pharmacology of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9045347/),[mg] / [min·ml],3.62,44880,DB01229,Paclitaxel
,9045347,AUC,"For ovarian cancer patients, the mean AUC per 300 mg/m2 carboplatin was 3.83 mg/mL x min (range, 2.72 to 6.10), showing no difference when compared with data derived from non-small cell lung cancer patients (P = .13).",Clinical pharmacology of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9045347/),[mg] / [min·ml],3.83,44881,DB01229,Paclitaxel
,9045347,AUC (AUC50),Modeling of the relationship between the carboplatin AUC and the decrease in platelets revealed a 50% decrease in platelets at a carboplatin AUC (AUC50) of 6.3 mg/mL x min.,Clinical pharmacology of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9045347/),[mg] / [min·ml],6.3,44882,DB01229,Paclitaxel
,9045347,AUC50,This contrasts with historical data documenting a carboplatin AUC50 of 4.0 mg/mL x min.,Clinical pharmacology of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9045347/),[mg] / [min·ml],4.0,44883,DB01229,Paclitaxel
,16779869,total run time,"The total run time, including equilibration, was 8 min, using a gradient of acetonitrile and 10 mM ammonium formate, pH 4.0.",Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16779869/),min,8,46246,DB01229,Paclitaxel
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],"1,521",46568,DB01229,Paclitaxel
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],692,46569,DB01229,Paclitaxel
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],848,46570,DB01229,Paclitaxel
,15756013,area under the curve,"The maximum tolerated dose was established as BMS-214662 (160 mg/m(2)), paclitaxel (225 mg/m(2)) and carboplatin (area under the curve = 6 on day 1), every 21 days.","A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756013/),,6,46641,DB01229,Paclitaxel
,23537412,oral relative bioavailability,"In addition, the oral relative bioavailability of paclitaxel when loaded in nanoparticles pegylated with poly(ethylene glycol) 2000 (PEG) was found to be 85%.",[Mucopenetrating nanoparticles: vehicles for the oral administration of paclitaxel]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23537412/),%,85,47100,DB01229,Paclitaxel
,30088048,AUC5,"No DLT was observed with A(20 mg)/C(AUC5)/P(175 mg/m2), determined as the RP2D for A/C/P.",A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088048/),[mg] / [m2],175,47819,DB01229,Paclitaxel
,32266855,combination index,"When a human ovarian cancer cells line (A2780s) was treated with both PTX and 4-HPR, there was a synergistic anti-cancer effect demonstrated with a average combination index of 0.44.",Mixed micelles of TPGS and Soluplus® for co-delivery of paclitaxel and fenretinide: in vitro and in vivo anticancer study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32266855/),,0,47914,DB01229,Paclitaxel
,12538457,plasmatic peak,"At 175 mg/m(2) mean +/- SD values for docetaxel plasmatic peak, area under the curve, clearance, volume of distribution, and terminal half-life were 6.7 +/- 1.7 microg/ml, 9.7 +/- 4 microg.h/ml, 34.2 +/- 12 liters/h, and 122.7 +/- 124 liters, respectively.",Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538457/),[μg] / [ml],6.7,48420,DB01229,Paclitaxel
,12538457,terminal half-life,"At 175 mg/m(2) mean +/- SD values for docetaxel plasmatic peak, area under the curve, clearance, volume of distribution, and terminal half-life were 6.7 +/- 1.7 microg/ml, 9.7 +/- 4 microg.h/ml, 34.2 +/- 12 liters/h, and 122.7 +/- 124 liters, respectively.",Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538457/),l,122.7,48421,DB01229,Paclitaxel
higher,20347897,relative oral bioavailability,"For PTX-CD NP and PTX-HPCD NP, these sustained levels of the anticancer drug were found to be between 27 and 33-fold higher than the reported value of drug activity whereas the relative oral bioavailability of paclitaxel was calculated to be higher than 80%.",Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347897/),%,80,48490,DB01229,Paclitaxel
,20975068,progression-free survival,"Median progression-free survival was 34 weeks (95% CI, 29.1 to 40.7 weeks).",Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975068/),weeks,34,48656,DB01229,Paclitaxel
,16203787,C(max),"Pharmacokinetics following single i.v. administration of ixabepilone at its MTD (10 mg/kg) were biexponential with C(max) of 12.5 micromol/L, elimination half-life of 19.2 hours, and total area under the curve of 5.8 micromol/L-h.","In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203787/),[μM] / [l],12.5,48703,DB01229,Paclitaxel
,16203787,elimination half-life,"Pharmacokinetics following single i.v. administration of ixabepilone at its MTD (10 mg/kg) were biexponential with C(max) of 12.5 micromol/L, elimination half-life of 19.2 hours, and total area under the curve of 5.8 micromol/L-h.","In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203787/),h,19.2,48704,DB01229,Paclitaxel
,16203787,total area under the curve,"Pharmacokinetics following single i.v. administration of ixabepilone at its MTD (10 mg/kg) were biexponential with C(max) of 12.5 micromol/L, elimination half-life of 19.2 hours, and total area under the curve of 5.8 micromol/L-h.","In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203787/),[μM] / [l-h],5.8,48705,DB01229,Paclitaxel
,21571911,hepatic extraction of drug,Peak concentrations were lower (∼50%) with greater hepatic extraction of drug (∼42%) following HAI than i.v. infusion based on area under the curve comparison of drug exposure.,"Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21571911/),%,∼42,48744,DB01229,Paclitaxel
,22859311,AUC,"In addition, AUC (5.43 µg•h/ml) and Cmax (1.44 µg/ml) of smPSH were higher than those (1.81 µg•h/ml and 0.73 µg/ml) of PTX solution.",Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859311/),[h·μg] / [ml],5.43,49222,DB01229,Paclitaxel
,22859311,Cmax,"In addition, AUC (5.43 µg•h/ml) and Cmax (1.44 µg/ml) of smPSH were higher than those (1.81 µg•h/ml and 0.73 µg/ml) of PTX solution.",Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859311/),[μg] / [ml],1.44,49223,DB01229,Paclitaxel
,22859311,Cmax,"In addition, AUC (5.43 µg•h/ml) and Cmax (1.44 µg/ml) of smPSH were higher than those (1.81 µg•h/ml and 0.73 µg/ml) of PTX solution.",Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859311/),[h·μg] / [ml],1.81,49224,DB01229,Paclitaxel
,22859311,Cmax,"In addition, AUC (5.43 µg•h/ml) and Cmax (1.44 µg/ml) of smPSH were higher than those (1.81 µg•h/ml and 0.73 µg/ml) of PTX solution.",Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22859311/),[μg] / [ml],0.73,49225,DB01229,Paclitaxel
,11532317,total clearance,"The total clearance was reduced (from 3.6 ml/h for free drug to 2.9, 1.97 and 1.41 for ungrafted, 2 and 5 kDa PEG conjugates, respectively).","Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11532317/),[ml] / [h],3.6,49746,DB01229,Paclitaxel
,11532317,total clearance,"The total clearance was reduced (from 3.6 ml/h for free drug to 2.9, 1.97 and 1.41 for ungrafted, 2 and 5 kDa PEG conjugates, respectively).","Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11532317/),,2.9,49747,DB01229,Paclitaxel
,11532317,total clearance,"The total clearance was reduced (from 3.6 ml/h for free drug to 2.9, 1.97 and 1.41 for ungrafted, 2 and 5 kDa PEG conjugates, respectively).","Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11532317/),[ml] / [h],1.97,49748,DB01229,Paclitaxel
,11532317,total clearance,"The total clearance was reduced (from 3.6 ml/h for free drug to 2.9, 1.97 and 1.41 for ungrafted, 2 and 5 kDa PEG conjugates, respectively).","Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11532317/),,1.41,49749,DB01229,Paclitaxel
,25036904,flow rate,"The separation was performed on a ZorbaxSB-C18 column (3.5μm, 2.1mm×100mm) at a flow rate of 0.2ml/min, using acetonitrile/water containing 0.1% formic acid (v/v) as mobile phase.",Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),[ml] / [min],0.2,49977,DB01229,Paclitaxel
,25036904,ion,"The MS/MS ion transit ions monitored were 1444.4→623.8 for MTC-220, 876.4→307.9 for paclitaxel, 631.2→531.2 for MDA-linker and 830.2→549.1 for the internal standard.",Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),,1444.4,49978,DB01229,Paclitaxel
,25036904,ion,"The MS/MS ion transit ions monitored were 1444.4→623.8 for MTC-220, 876.4→307.9 for paclitaxel, 631.2→531.2 for MDA-linker and 830.2→549.1 for the internal standard.",Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),,623.8,49979,DB01229,Paclitaxel
,25036904,ion,"The MS/MS ion transit ions monitored were 1444.4→623.8 for MTC-220, 876.4→307.9 for paclitaxel, 631.2→531.2 for MDA-linker and 830.2→549.1 for the internal standard.",Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),,876.4,49980,DB01229,Paclitaxel
,25036904,ion,"The MS/MS ion transit ions monitored were 1444.4→623.8 for MTC-220, 876.4→307.9 for paclitaxel, 631.2→531.2 for MDA-linker and 830.2→549.1 for the internal standard.",Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),,631.2,49981,DB01229,Paclitaxel
,25036904,ion,"The MS/MS ion transit ions monitored were 1444.4→623.8 for MTC-220, 876.4→307.9 for paclitaxel, 631.2→531.2 for MDA-linker and 830.2→549.1 for the internal standard.",Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),,830.2,49982,DB01229,Paclitaxel
greater,25036904,recoveries,The average recoveries of three compounds were greater than 85.0%.,Simultaneous quantification of MTC-220 and its metabolites in beagle dog plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036904/),%,85.0,49983,DB01229,Paclitaxel
,21837682,area under the drug concentration-time curve (AUC) ratio,The intraperitoneal/plasma area under the drug concentration-time curve (AUC) ratio was 596.9:1.,Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21837682/),:1,596.9,51235,DB01229,Paclitaxel
over,18621626,area under the curve (AUC),Eligible patients aged 18-75 years with previously untreated stage IIIB/IV NSCLC received paclitaxel 175 mg/m2 over 3 hours followed by carboplatin area under the curve (AUC) 5 over 1 hour and flavopiridol 30-85 mg/m2 over 24 hours every 3 weeks for 3 cycles.,Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18621626/),h,1,51681,DB01229,Paclitaxel
,14506145,volume of distribution,"At 1100 mg/m(2), DHA-paclitaxel had a mean (CV%) volume of distribution of 7.5 (64) liters, beta half-life of 112 (56) h, and clearance of 0.11 (30) liters/h.",Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506145/),l,7.5,51978,DB01229,Paclitaxel
,14506145,beta half-life,"At 1100 mg/m(2), DHA-paclitaxel had a mean (CV%) volume of distribution of 7.5 (64) liters, beta half-life of 112 (56) h, and clearance of 0.11 (30) liters/h.",Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506145/),h,112,51979,DB01229,Paclitaxel
,14506145,clearance,"At 1100 mg/m(2), DHA-paclitaxel had a mean (CV%) volume of distribution of 7.5 (64) liters, beta half-life of 112 (56) h, and clearance of 0.11 (30) liters/h.",Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506145/),[l] / [h],0.11,51980,DB01229,Paclitaxel
,14506145,C(max),"Paclitaxel PK parameters at 1100 mg/m(2) were: C(max), 282 (46) ng/ml; AUC, 10,705 (60) ng/ml x h; and terminal half-life, 85 (101) h.",Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506145/),[ng] / [ml],282,51981,DB01229,Paclitaxel
,14506145,AUC,"Paclitaxel PK parameters at 1100 mg/m(2) were: C(max), 282 (46) ng/ml; AUC, 10,705 (60) ng/ml x h; and terminal half-life, 85 (101) h.",Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506145/),[ng] / [h·ml],"10,705",51982,DB01229,Paclitaxel
,14506145,terminal half-life,"Paclitaxel PK parameters at 1100 mg/m(2) were: C(max), 282 (46) ng/ml; AUC, 10,705 (60) ng/ml x h; and terminal half-life, 85 (101) h.",Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506145/),h,85,51983,DB01229,Paclitaxel
,10092957,alpha,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),min,4.5,52392,DB01229,Paclitaxel
,10092957,beta,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),min,38.3,52393,DB01229,Paclitaxel
,10092957,gamma half-lives,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),h,12.2,52394,DB01229,Paclitaxel
,10092957,volume of distribution,"Docetaxel is widely distributed in tissues with a mean volume of distribution of 74 L/m2 after 100 mg/m2, every 3 weeks.",Clinical pharmacokinetics of docetaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),[l] / [m2],74,52395,DB01229,Paclitaxel
,10092957,total body clearance,"The mean total body clearance after this schedule is approximately 22 L/h/m2, principally because of hepatic metabolism by the cytochrome P450 (CYP)3A4 system and biliary excretion into the faeces.",Clinical pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),[l] / [h·m2],22,52396,DB01229,Paclitaxel
<,10092957,Renal excretion,Renal excretion is minimal (< 5%).,Clinical pharmacokinetics of docetaxel. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),%,5,52397,DB01229,Paclitaxel
,29559563,Overall response rates,"Overall response rates in ovarian cancer and glioma monotherapy dose-expansion arms were 6% and 0%, respectively.","Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559563/),%,6,52695,DB01229,Paclitaxel
,29559563,Overall response rates,"Overall response rates in ovarian cancer and glioma monotherapy dose-expansion arms were 6% and 0%, respectively.","Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29559563/),%,0,52696,DB01229,Paclitaxel
,22872523,objective response rate,The objective response rate was 56 % among patients with measurable disease at baseline who received motesanib in combination with taxane-based chemotherapy.,Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872523/),%,56,53291,DB01229,Paclitaxel
,22872523,objective response rate,The objective response rate of 56 % suggests a potential benefit of motesanib in combination with taxane-based chemotherapy.,Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872523/),%,56,53292,DB01229,Paclitaxel
,21637945,polydispersity index,The mean particle size of SLNs was 96 ± 4.4 nm with a low polydispersity index of 0.162 ± 0.04 and zeta potential of 39.1 ± 0.8 mV.,Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),,0.162,53346,DB01229,Paclitaxel
,21637945,zeta potential,The mean particle size of SLNs was 96 ± 4.4 nm with a low polydispersity index of 0.162 ± 0.04 and zeta potential of 39.1 ± 0.8 mV.,Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),mv,39.1,53347,DB01229,Paclitaxel
,21637945,drug,The drug entrapment efficiency was found to be 75.42 ± 1.5% with a loading capacity of 31.5 ± 2.1% (w/w).,Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),%,75.42,53348,DB01229,Paclitaxel
,21637945,entrapment efficiency,The drug entrapment efficiency was found to be 75.42 ± 1.5% with a loading capacity of 31.5 ± 2.1% (w/w).,Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),%,75.42,53349,DB01229,Paclitaxel
,21637945,loading capacity,The drug entrapment efficiency was found to be 75.42 ± 1.5% with a loading capacity of 31.5 ± 2.1% (w/w).,Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),%,31.5,53350,DB01229,Paclitaxel
,21637945,w/w,The drug entrapment efficiency was found to be 75.42 ± 1.5% with a loading capacity of 31.5 ± 2.1% (w/w).,Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),%,31.5,53351,DB01229,Paclitaxel
,21637945,C (max),"PTX-SLNs produced a high mean C (max) (10,274 ng/ml) compared with that of free paclitaxel solution (3,087 ng/ml).",Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),[ng] / [ml],"10,274",53352,DB01229,Paclitaxel
,21637945,C (max),"PTX-SLNs produced a high mean C (max) (10,274 ng/ml) compared with that of free paclitaxel solution (3,087 ng/ml).",Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21637945/),[ng] / [ml],"3,087",53353,DB01229,Paclitaxel
,30520341,time above threshold concentration,"First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [Tc >0.05]).",Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520341/),μM,0.05,53846,DB01229,Paclitaxel
>,30520341,Tc,"First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [Tc >0.05]).",Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520341/),,0.05,53847,DB01229,Paclitaxel
,30520341,Tc,"Patients with predicted low-activity CYP2C8 had shorter Tc >0.05 after adjustment for age, body surface area and race (9.65 vs 11.03 hrs, β = 5.47, p = 0.02).",Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520341/),h,9.65,53848,DB01229,Paclitaxel
,30520341,Tc,"Patients with predicted low-activity CYP2C8 had shorter Tc >0.05 after adjustment for age, body surface area and race (9.65 vs 11.03 hrs, β = 5.47, p = 0.02).",Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520341/),h,11.03,53849,DB01229,Paclitaxel
,30520341,Tc,"Patients with predicted low-activity SLCO1B1 had longer Tc >0.05 (12.12 vs 10.15 hrs, β = 0.85, p = 0.012).",Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520341/),h,12.12,53850,DB01229,Paclitaxel
,30520341,Tc,"Patients with predicted low-activity SLCO1B1 had longer Tc >0.05 (12.12 vs 10.15 hrs, β = 0.85, p = 0.012).",Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520341/),h,10.15,53851,DB01229,Paclitaxel
,18365196,t (1/2),T (1/2) of paclitaxel oleate associated to the nanoemulsion was greater than that of paclitaxel (t (1/2) = 15.4 +/- 4.7 and 3.5 +/- 0.80 h).,"Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365196/),h,15.4,53860,DB01229,Paclitaxel
,18365196,t (1/2),T (1/2) of paclitaxel oleate associated to the nanoemulsion was greater than that of paclitaxel (t (1/2) = 15.4 +/- 4.7 and 3.5 +/- 0.80 h).,"Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365196/),h,3.5,53861,DB01229,Paclitaxel
,26296295,MTD,"The MTD was determined as afatinib 40mg with paclitaxel 80mg/m(2), which proved tolerable with repeated dosing.","A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26296295/),mg,40,54291,DB01229,Paclitaxel
,21307819,area,"Single or combination chemotherapy with paclitaxel, docetaxel, carboplatin, and trastuzumab was administered to 9 baboons at a mean (SD) gestational age of 117 (26) days (paclitaxel, 100 mg/m2 [n = 2]; docetaxel, 100 mg/m2 [n = 2]; paclitaxel, 175 mg/m2 with carboplatin, area under the curve of 6 at standard dosage [n = 2] and 50% dosage [n = 1]; docetaxel, 75 mg/m2 with carboplatin, area under the curve 6 [n = 1]; and docetaxel, 75 mg/m2 with trastuzumab, 8 mg/kg [n = 1]).","Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21307819/),,6,54625,DB01229,Paclitaxel
,21307819,transplacental passages,"The transplacental passages of trastuzumab were 85.0% and 3.0%, 2 and 26 hours after trastuzumab infusion, respectively.","Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21307819/),%,85.0,54626,DB01229,Paclitaxel
,21307819,transplacental passages,"The transplacental passages of trastuzumab were 85.0% and 3.0%, 2 and 26 hours after trastuzumab infusion, respectively.","Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21307819/),%,3.0,54627,DB01229,Paclitaxel
,27094691,arterial wall concentration,"There were no statistically significant differences in the mean arterial wall concentration from the treated iliac artery between group-B1 (15.24 ± 21.29 ng/mg) and B3 (15.68 ± 16.33 ng/mg), or in the PTX wall concentration measured at different time points.",Pharmacokinetic Evaluation of Two Paclitaxel-Coated Balloons with Different Drug Load in a Short-Term Porcine Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094691/),[ng] / [mg],15.24,54997,DB01229,Paclitaxel
,27094691,arterial wall concentration,"There were no statistically significant differences in the mean arterial wall concentration from the treated iliac artery between group-B1 (15.24 ± 21.29 ng/mg) and B3 (15.68 ± 16.33 ng/mg), or in the PTX wall concentration measured at different time points.",Pharmacokinetic Evaluation of Two Paclitaxel-Coated Balloons with Different Drug Load in a Short-Term Porcine Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094691/),[ng] / [mg],15.68,54998,DB01229,Paclitaxel
,22205462,ratio of AUC,The ratio of AUC in lymph nodes of group A to group B was 0.75 and that in intraperitoneal lavage fluid was 1.25.,[Preparation of carbon nanoparticle paclitaxel suspension and pharmacokinetic study of intraperitoneal chemotherapy]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22205462/),,0.75,55513,DB01229,Paclitaxel
,22205462,ratio of AUC,The ratio of AUC in lymph nodes of group A to group B was 0.75 and that in intraperitoneal lavage fluid was 1.25.,[Preparation of carbon nanoparticle paclitaxel suspension and pharmacokinetic study of intraperitoneal chemotherapy]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22205462/),,1.25,55514,DB01229,Paclitaxel
,22205462,t1/2,The t1/2 of paclitaxel in intraperitoneal lavage fluid of group A was 0.88 as long as that of Group B.,[Preparation of carbon nanoparticle paclitaxel suspension and pharmacokinetic study of intraperitoneal chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22205462/),,0.88,55515,DB01229,Paclitaxel
,22205462,t1/2,The t1/2 of paclitaxel in lymph nodes of group A was 1.10 as long as that of Group B. CNS has a high absorption capacity with paclitaxel.,[Preparation of carbon nanoparticle paclitaxel suspension and pharmacokinetic study of intraperitoneal chemotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22205462/),,1.10,55516,DB01229,Paclitaxel
,10550567,Clearance (CL),"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],3. 57,55584,DB01229,Paclitaxel
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55585,DB01229,Paclitaxel
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55586,DB01229,Paclitaxel
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55587,DB01229,Paclitaxel
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],3.67,55588,DB01229,Paclitaxel
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55589,DB01229,Paclitaxel
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55590,DB01229,Paclitaxel
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55591,DB01229,Paclitaxel
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55592,DB01229,Paclitaxel
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55593,DB01229,Paclitaxel
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55594,DB01229,Paclitaxel
,10550567,central (,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55595,DB01229,Paclitaxel
,10550567,central (,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55596,DB01229,Paclitaxel
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55597,DB01229,Paclitaxel
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55598,DB01229,Paclitaxel
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55599,DB01229,Paclitaxel
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55600,DB01229,Paclitaxel
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55601,DB01229,Paclitaxel
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55602,DB01229,Paclitaxel
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],3.67,55603,DB01229,Paclitaxel
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55604,DB01229,Paclitaxel
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55605,DB01229,Paclitaxel
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55606,DB01229,Paclitaxel
,10550567,volumes of distribution,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],158,55607,DB01229,Paclitaxel
,10550567,CL,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],7.3,55608,DB01229,Paclitaxel
,10550567,intercompartmental clearance (Q),"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],4. 6,55609,DB01229,Paclitaxel
,10550567,intercompartmental clearance (Q),"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.69,55610,DB01229,Paclitaxel
,10550567,V1,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],4. 6,55611,DB01229,Paclitaxel
,10550567,V1,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.69,55612,DB01229,Paclitaxel
,10550567,V2,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],2.6,55613,DB01229,Paclitaxel
,12510856,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of paclitaxel was significantly (p<0.01) increased in severe carbon tetrachloride-induced hepatic failure rabbits (1,364.54 +/- 382.07 ng/ml x hr) compared to that of normal rabbits (567.52 +/- 141.88 ng/ml x hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (803.1 +/- 208.81 ng/ml x hr).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),[ng] / [h·ml],"1,364.54",55767,DB01229,Paclitaxel
,12510856,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of paclitaxel was significantly (p<0.01) increased in severe carbon tetrachloride-induced hepatic failure rabbits (1,364.54 +/- 382.07 ng/ml x hr) compared to that of normal rabbits (567.52 +/- 141.88 ng/ml x hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (803.1 +/- 208.81 ng/ml x hr).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),[ng] / [h·ml],567.52,55768,DB01229,Paclitaxel
,12510856,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of paclitaxel was significantly (p<0.01) increased in severe carbon tetrachloride-induced hepatic failure rabbits (1,364.54 +/- 382.07 ng/ml x hr) compared to that of normal rabbits (567.52 +/- 141.88 ng/ml x hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (803.1 +/- 208.81 ng/ml x hr).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),[ng] / [h·ml],803.1,55769,DB01229,Paclitaxel
,12510856,volume of distribution (Vd),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),l,6.25,55770,DB01229,Paclitaxel
,12510856,volume of distribution (Vd),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),l,11.65,55771,DB01229,Paclitaxel
,12510856,elimination rate constant(beta),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),1/[hr],0.09,55772,DB01229,Paclitaxel
,12510856,elimination rate constant(beta),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),l,11.65,55773,DB01229,Paclitaxel
,12510856,elimination rate constant(beta),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),1/[hr],0.12,55774,DB01229,Paclitaxel
,12510856,elimination rate constant(beta),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),l,9.46,55775,DB01229,Paclitaxel
,12510856,elimination rate constant(beta),"The volume of distribution (Vd) (6.25 +/- 1.56 L) and the elimination rate constant(beta) (0.09 +/- 0.025 hr(-1)) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits (11.65 +/- 2.91 L, 0.12 +/- 0.030 hr(-1)), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (9.46 +/- 2.37 L, 0.10 +/- 0.026 hr').",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),hr',0.10,55776,DB01229,Paclitaxel
,12510856,Total body clearance (CLt),"Total body clearance (CLt) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits (0.733 +/- 0.183 L/hr/kg) was significantly (p<0.01) decreased compared to that of normal rabbits (1.762 +/- 0.440 L/hr/kg), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (1.245 +/- 0.311 L/hr/kg).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),[l] / [h·kg],0.733,55777,DB01229,Paclitaxel
,12510856,Total body clearance (CLt),"Total body clearance (CLt) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits (0.733 +/- 0.183 L/hr/kg) was significantly (p<0.01) decreased compared to that of normal rabbits (1.762 +/- 0.440 L/hr/kg), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (1.245 +/- 0.311 L/hr/kg).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),[l] / [h·kg],1.762,55778,DB01229,Paclitaxel
,12510856,Total body clearance (CLt),"Total body clearance (CLt) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits (0.733 +/- 0.183 L/hr/kg) was significantly (p<0.01) decreased compared to that of normal rabbits (1.762 +/- 0.440 L/hr/kg), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (1.245 +/- 0.311 L/hr/kg).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),[l] / [h·kg],1.245,55779,DB01229,Paclitaxel
,12510856,half-life(t 1/2),"The half-life(t 1/2) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits (7.71 +/- 2.16 hr) was significantly (p<0.05) increased compared to that of normal rabbits (5.75 +/- 1.44 hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (6.77 +/- 1.76 hr).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),h,7.71,55780,DB01229,Paclitaxel
,12510856,half-life(t 1/2),"The half-life(t 1/2) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits (7.71 +/- 2.16 hr) was significantly (p<0.05) increased compared to that of normal rabbits (5.75 +/- 1.44 hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (6.77 +/- 1.76 hr).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),h,5.75,55781,DB01229,Paclitaxel
,12510856,half-life(t 1/2),"The half-life(t 1/2) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits (7.71 +/- 2.16 hr) was significantly (p<0.05) increased compared to that of normal rabbits (5.75 +/- 1.44 hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits (6.77 +/- 1.76 hr).",Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510856/),h,6.77,55782,DB01229,Paclitaxel
,17516069,time to progression,The median time to progression was 1.4 months (95% CI of 1.2-2.4 months).,A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516069/),month,1.4,55948,DB01229,Paclitaxel
,17516069,elimination half-life,"The mean milataxel elimination half-life was 64 h and the mean area under the plasma concentration-time curve was 1,708 ng h/ml.",A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516069/),h,64,55949,DB01229,Paclitaxel
,17516069,area under the plasma concentration-time curve,"The mean milataxel elimination half-life was 64 h and the mean area under the plasma concentration-time curve was 1,708 ng h/ml.",A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516069/),[h·ng] / [ml],"1,708",55950,DB01229,Paclitaxel
,30420181,duration of response,"Median (95% confidence interval) duration of response in the 10 and 30 mg/kg cohorts was 12.6 (4.3-20.2) and 16.6 (8.2-not estimable) months, respectively.",Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30420181/),month,12.6,56339,DB01229,Paclitaxel
,30420181,duration of response,"Median (95% confidence interval) duration of response in the 10 and 30 mg/kg cohorts was 12.6 (4.3-20.2) and 16.6 (8.2-not estimable) months, respectively.",Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30420181/),month,16.6,56340,DB01229,Paclitaxel
>,29512471,TC,To evaluate the association of pharmacokinetic parameter TC > 0.05 of paclitaxel (PTX) and its therapeutic efficacy and toxicity in patients with solid tumors.,TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.05,56356,DB01229,Paclitaxel
>,29512471,TC,The patients' PTX TC > 0.05 (the time during which PTX plasma concentration exceed 0.05µmol/L) were calculated based on pharmacokinetic analysis.,TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.05,56357,DB01229,Paclitaxel
>,29512471,TC,"The results showed that: (1) the concentrations of PTX in these 295 patients ranged from 0.0358-0.127 µmol/L; (2) the PTX TC > 0.05 ranged from 14 to 38h with a median time of 27h; (3) among all treatment cycles, there was a statistically significant difference in the PTX TC > 0.05 between CR+PR and SD+PD; (4) with the increasing value of TC > 0.05, level of leukopenia and leukopenic fever increased; (5) high PTX TC > 0.05 led to the occurrence of neutropenia, neutropenic fever, severe anemia, and severe peripheral neurotoxicity.",TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.,56358,DB01229,Paclitaxel
,29512471,TC,"The results showed that: (1) the concentrations of PTX in these 295 patients ranged from 0.0358-0.127 µmol/L; (2) the PTX TC > 0.05 ranged from 14 to 38h with a median time of 27h; (3) among all treatment cycles, there was a statistically significant difference in the PTX TC > 0.05 between CR+PR and SD+PD; (4) with the increasing value of TC > 0.05, level of leukopenia and leukopenic fever increased; (5) high PTX TC > 0.05 led to the occurrence of neutropenia, neutropenic fever, severe anemia, and severe peripheral neurotoxicity.",TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),h,14 to 38,56359,DB01229,Paclitaxel
>,29512471,TC,"The results showed that: (1) the concentrations of PTX in these 295 patients ranged from 0.0358-0.127 µmol/L; (2) the PTX TC > 0.05 ranged from 14 to 38h with a median time of 27h; (3) among all treatment cycles, there was a statistically significant difference in the PTX TC > 0.05 between CR+PR and SD+PD; (4) with the increasing value of TC > 0.05, level of leukopenia and leukopenic fever increased; (5) high PTX TC > 0.05 led to the occurrence of neutropenia, neutropenic fever, severe anemia, and severe peripheral neurotoxicity.",TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.05,56360,DB01229,Paclitaxel
>,29512471,TC,"Taken together, our results indicated that the pharmacokinetic parameter PTX TC > 0.05 was an effective measure of treatment efficacy and toxicity in patients with solid tumors.",TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.05,56361,DB01229,Paclitaxel
>,29512471,TC,"Maintaining PTX TC > 0.05 at 26 to 30h could improve its efficacy and reduce the incidence of leukopenia, neutropenia, anemia, and peripheral neurotoxicity in these patients.",TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.05,56362,DB01229,Paclitaxel
>,29512471,TC,PTX TC > 0.05 is a key pharmacokinetic parameter of PTX which should be monitored to optimize individual treatment in patients with solid tumors.,TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29512471/),,0.05,56363,DB01229,Paclitaxel
,12480272,area under the curve (AUC),The area under the curve (AUC) was significantly higher in the microemulsion group (34.98 microg ml(-1) h) than that in the Taxol group (21.98 microg ml(-1) h).,An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12480272/),[h·μg] / [ml],34.98,56369,DB01229,Paclitaxel
,12480272,area under the curve (AUC),The area under the curve (AUC) was significantly higher in the microemulsion group (34.98 microg ml(-1) h) than that in the Taxol group (21.98 microg ml(-1) h).,An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12480272/),[h·μg] / [ml],21.98,56370,DB01229,Paclitaxel
,12480272,K(10),"Also, the K(10) was much smaller in the microemulsion group (0.57 h(-1)) compared with the Taxol group (1.29 h(-1)), showing the elimination rate was much slower in the former than in the latter.",An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12480272/),1/[h],0.57,56371,DB01229,Paclitaxel
,12480272,K(10),"Also, the K(10) was much smaller in the microemulsion group (0.57 h(-1)) compared with the Taxol group (1.29 h(-1)), showing the elimination rate was much slower in the former than in the latter.",An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12480272/),1/[h],1.29,56372,DB01229,Paclitaxel
,17362316,area under the curve (AUC),"Eligible patients with relapsed epithelial ovarian cancer and prior treatment with platinum- and paclitaxel-based therapy were treated with an escalating regimen of carboplatin (day 1) at an area under the curve (AUC) of 4-6 and 1-h infusions of paclitaxel (days 1, 8, and 15) at 50-80 mg/m(2) cycled at 3-week intervals.",A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),,4-6,56831,DB01229,Paclitaxel
,17362316,AUC,The maximum tolerated dose of carboplatin was an AUC of 5 and 80 mg/m(2) for paclitaxel.,A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),[mg] / [m(2],5,56832,DB01229,Paclitaxel
,17362316,AUC,The maximum tolerated dose of carboplatin was an AUC of 5 and 80 mg/m(2) for paclitaxel.,A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),[mg] / [m(2],80,56833,DB01229,Paclitaxel
,17362316,response rate,"Of nine patients evaluable for a radiographic response, the response rate was 66.6% with a complete response of 33.3%.",A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),%,66.6,56834,DB01229,Paclitaxel
,17362316,complete response,"Of nine patients evaluable for a radiographic response, the response rate was 66.6% with a complete response of 33.3%.",A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),%,33,56835,DB01229,Paclitaxel
,17362316,AUC,The combination of carboplatin given every 3 weeks at an AUC of 5 and 1-h weekly paclitaxel at 80 mg/m(2) is a feasible and reasonably well-tolerated regimen and may have significant antitumor activity in relapsed ovarian cancer patients.,A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),h,5,56836,DB01229,Paclitaxel
,17362316,AUC,The combination of carboplatin given every 3 weeks at an AUC of 5 and 1-h weekly paclitaxel at 80 mg/m(2) is a feasible and reasonably well-tolerated regimen and may have significant antitumor activity in relapsed ovarian cancer patients.,A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362316/),h,1,56837,DB01229,Paclitaxel
,30633968,IC50,Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM).,"Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,2.9,57230,DB01229,Paclitaxel
,30633968,IC50,"The CYP2C8 IC50 of 4.5 μM in RLM for saroglitazar, supported the use of rats for this DDI study.","Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,4.5,57231,DB01229,Paclitaxel
,16680462,AUC,"The AUC (mean +/- standard deviation) values of paclitaxel after oral administration without CsA and with CsA were 476 +/- 254 and 967 +/- 779 ng/ml h, respectively.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),[ng] / [h·ml],476,57895,DB01229,Paclitaxel
,16680462,AUC,"The AUC (mean +/- standard deviation) values of paclitaxel after oral administration without CsA and with CsA were 476 +/- 254 and 967 +/- 779 ng/ml h, respectively.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),[ng] / [h·ml],967,57896,DB01229,Paclitaxel
,16680462,T (max),"T (max) was 4.0 +/- 0.9 h after oral paclitaxel without CsA, and 6.0 +/- 3.1 h after oral paclitaxel with CsA.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),h,4.0,57897,DB01229,Paclitaxel
,16680462,T (max),"T (max) was 4.0 +/- 0.9 h after oral paclitaxel without CsA, and 6.0 +/- 3.1 h after oral paclitaxel with CsA.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),h,6.0,57898,DB01229,Paclitaxel
,25675244,critical micelle concentration (CMC),It can self-assemble into core-shell micelles with a low critical micelle concentration (CMC) at 3.48 mg/L.,Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),[mg] / [l],3.48,58095,DB01229,Paclitaxel
,25675244,area under the plasma concentration-time curve (AUC0-∞),"Pharmacokinetics and biodistribution studies (10 mg/kg) showed the area under the plasma concentration-time curve (AUC0-∞) and mean residence time (MRT0-∞) for PEG-G3-RA8/PTX and Taxol were 12.006 ± 0.605 mg/L h, 2.264 ± 0.041 h and 15.966 ± 1.614 mg/L h, 1.726 ± 0.097 h, respectively.",Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),[mg] / [h·l],12.006,58096,DB01229,Paclitaxel
,25675244,mean residence time (MRT0-∞),"Pharmacokinetics and biodistribution studies (10 mg/kg) showed the area under the plasma concentration-time curve (AUC0-∞) and mean residence time (MRT0-∞) for PEG-G3-RA8/PTX and Taxol were 12.006 ± 0.605 mg/L h, 2.264 ± 0.041 h and 15.966 ± 1.614 mg/L h, 1.726 ± 0.097 h, respectively.",Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),h,2.264,58097,DB01229,Paclitaxel
,25675244,mean residence time (MRT0-∞),"Pharmacokinetics and biodistribution studies (10 mg/kg) showed the area under the plasma concentration-time curve (AUC0-∞) and mean residence time (MRT0-∞) for PEG-G3-RA8/PTX and Taxol were 12.006 ± 0.605 mg/L h, 2.264 ± 0.041 h and 15.966 ± 1.614 mg/L h, 1.726 ± 0.097 h, respectively.",Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25675244/),h,1.726,58098,DB01229,Paclitaxel
,9773805,MTD,The MTD of the 96 h paclitaxel infusion was 180 mg/m2 with filgrastim support.,Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773805/),[mg] / [m2],180,58252,DB01229,Paclitaxel
greater,9773805,steady-state paclitaxel concentrations (Css),Mucosal and granulocyte toxicity were correlated with steady-state paclitaxel concentrations (Css) greater than 0.100 micromol/l.,Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773805/),[μM] / [l],0.100,58253,DB01229,Paclitaxel
,16963486,bioavailability,"IDN 5390 was rapidly absorbed after oral administration, with good bioavailability (43%).","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),%,43,58263,DB01229,Paclitaxel
,16963486,clearance,"The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),[l] / [kg],2.6,58264,DB01229,Paclitaxel
,16963486,clearance,"The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),[l] / [kg],1.4,58265,DB01229,Paclitaxel
,16963486,clearance,"The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),[l] / [kg],0.9,58266,DB01229,Paclitaxel
,16963486,half-life,"The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),min,24,58267,DB01229,Paclitaxel
,16963486,half-life,"The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),min,36,58268,DB01229,Paclitaxel
,16963486,half-life,"The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),min,54,58269,DB01229,Paclitaxel
,16963486,percentage excreted,"The percentage excreted as metabolites after an oral dose (42%) was higher than that after the i.v. dose (33%), suggesting a first-pass effect.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),%,42,58270,DB01229,Paclitaxel
,16963486,percentage excreted,"The percentage excreted as metabolites after an oral dose (42%) was higher than that after the i.v. dose (33%), suggesting a first-pass effect.","Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16963486/),%,33,58271,DB01229,Paclitaxel
,16926835,area under the plasma concentration-time curve,"The median (range) area under the plasma concentration-time curve of paclitaxel was 2.06 (1.15-3.47) microg h ml(-1) and 1.97 (0.58-3.22) microg h ml(-1) after oral administration of SMEOF#3 and Taxol, respectively, and 4.69 (3.90-6.09) microg h ml(-1) after intravenous Taxol.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),[h·μg] / [ml],2.06,58417,DB01229,Paclitaxel
,16926835,area under the plasma concentration-time curve,"The median (range) area under the plasma concentration-time curve of paclitaxel was 2.06 (1.15-3.47) microg h ml(-1) and 1.97 (0.58-3.22) microg h ml(-1) after oral administration of SMEOF#3 and Taxol, respectively, and 4.69 (3.90-6.09) microg h ml(-1) after intravenous Taxol.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),[h·μg] / [ml],1.97,58418,DB01229,Paclitaxel
,16926835,area under the plasma concentration-time curve,"The median (range) area under the plasma concentration-time curve of paclitaxel was 2.06 (1.15-3.47) microg h ml(-1) and 1.97 (0.58-3.22) microg h ml(-1) after oral administration of SMEOF#3 and Taxol, respectively, and 4.69 (3.90-6.09) microg h ml(-1) after intravenous Taxol.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),[h·μg] / [ml],4.69,58419,DB01229,Paclitaxel
,16926835,T(max),"Oral SMEOF#3 resulted in a lower median T(max) of 2.0 (0.5-2.0) h than orally applied Taxol (T(max)=4.0 (0.8-6.1) h, P=0.02).",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),h,2.0,58420,DB01229,Paclitaxel
,16926835,T(max),"Oral SMEOF#3 resulted in a lower median T(max) of 2.0 (0.5-2.0) h than orally applied Taxol (T(max)=4.0 (0.8-6.1) h, P=0.02).",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),h,4.0,58421,DB01229,Paclitaxel
,16926835,apparent bioavailability,"The median apparent bioavailability of paclitaxel was 40 (19-83)% and 55 (9-70)% for the oral SMEOF#3 and oral Taxol formulation, respectively.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),%,40,58422,DB01229,Paclitaxel
,16926835,apparent bioavailability,"The median apparent bioavailability of paclitaxel was 40 (19-83)% and 55 (9-70)% for the oral SMEOF#3 and oral Taxol formulation, respectively.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),%,55,58423,DB01229,Paclitaxel
,8656256,steady-state paclitaxel concentration (Css),"The median steady-state paclitaxel concentration (Css) in 23 assessable patients was 0.047 mumol/L (range, .023 to .176).",Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656256/),[μM] / [l],0.047,58451,DB01229,Paclitaxel
,10944133,MTD,"The MTD of docetaxel/CPT-11 was 50/60 mg/m(2) (level 5A), or 60/50 mg/m(2) (level 5B).",Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944133/),mg,50,59017,DB01229,Paclitaxel
,18239973,maximal intraperitoneal paclitaxel concentration,"Mean maximal intraperitoneal paclitaxel concentration was 101 mg/L, which was an average of 1178 times higher than the peak plasma levels.",Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18239973/),[mg] / [l],101,59303,DB01229,Paclitaxel
,18239973,peritoneal fluid versus plasma AUC ratio,The peritoneal fluid versus plasma AUC ratio was 1462 for the 2-h HIPEC duration and 366 for the total 5-day study period.,Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18239973/),,1462,59304,DB01229,Paclitaxel
,18239973,peritoneal fluid versus plasma AUC ratio,The peritoneal fluid versus plasma AUC ratio was 1462 for the 2-h HIPEC duration and 366 for the total 5-day study period.,Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18239973/),,366,59305,DB01229,Paclitaxel
,9796961,area under the concentration versus time curve (AUC),"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],1448,59876,DB01229,Paclitaxel
,9796961,area under the concentration versus time curve (AUC),"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],1786,59877,DB01229,Paclitaxel
,9796961,AUC,"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],252,59878,DB01229,Paclitaxel
,9796961,AUC,"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],486,59879,DB01229,Paclitaxel
,9213323,MTDs,The MTDs for patients with a history of prior chemotherapy were 75 mg/m2 of docetaxel and 700 mg/m2 of cyclophosphamide.,Docetaxel and cyclophosphamide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213323/),[mg] / [m2],75,60319,DB01229,Paclitaxel
,9213323,MTDs,The MTDs for patients with a history of prior chemotherapy were 75 mg/m2 of docetaxel and 700 mg/m2 of cyclophosphamide.,Docetaxel and cyclophosphamide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213323/),[mg] / [m],700,60320,DB01229,Paclitaxel
,9213323,MTDs,"For patients with no prior chemotherapy, the MTDs were 75 mg/m2 of docetaxel and 800 mg/m2 of cyclophosphamide.",Docetaxel and cyclophosphamide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213323/),[mg] / [m],75,60321,DB01229,Paclitaxel
,2878719,alpha half-life,"Following a 60- to 360-minute infusion, the plasma disappearance is biexponential, with harmonic mean alpha half-life and beta half-life values of 16.2 minutes and 6.4 hours, respectively.",High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),min,16.2,60531,DB01229,Paclitaxel
,2878719,beta half-life,"Following a 60- to 360-minute infusion, the plasma disappearance is biexponential, with harmonic mean alpha half-life and beta half-life values of 16.2 minutes and 6.4 hours, respectively.",High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),h,6.4,60532,DB01229,Paclitaxel
,2878719,Volumes of distribution,Volumes of distribution for the theoretical central compartment (VDc) and at steady state (VDss) were 8.6 and 67.1 L/m2.,High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),[l] / [m2],8.6,60533,DB01229,Paclitaxel
,2878719,Volumes of distribution,Volumes of distribution for the theoretical central compartment (VDc) and at steady state (VDss) were 8.6 and 67.1 L/m2.,High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),[l] / [m2],67.1,60534,DB01229,Paclitaxel
,2878719,at steady state (VDss),Volumes of distribution for the theoretical central compartment (VDc) and at steady state (VDss) were 8.6 and 67.1 L/m2.,High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),[l] / [m2],8.6,60535,DB01229,Paclitaxel
,2878719,at steady state (VDss),Volumes of distribution for the theoretical central compartment (VDc) and at steady state (VDss) were 8.6 and 67.1 L/m2.,High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),[l] / [m2],67.1,60536,DB01229,Paclitaxel
,2878719,plasma clearance,Mean plasma clearance was 253 ml/minute/m2.,High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),[ml] / [m2·min],253,60537,DB01229,Paclitaxel
,2878719,Urinary clearance,Urinary clearance was 29.3 ml/minute/m2 and 5.9% +/- 8.8% of the drug was identified in 48-hour urine collections.,High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878719/),[ml] / [m2·min],29.3,60538,DB01229,Paclitaxel
,15868146,clearance (CL),"Population estimates from the base model for clearance (CL) and volume of distribution of the central compartment (V1) of trastuzumab were 0.225 L/day, and 2.95 L, respectively.",Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15868146/),[l] / [d],0.225,61518,DB01229,Paclitaxel
,15868146,volume of distribution of the central compartment (V1),"Population estimates from the base model for clearance (CL) and volume of distribution of the central compartment (V1) of trastuzumab were 0.225 L/day, and 2.95 L, respectively.",Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15868146/),l,2.95,61519,DB01229,Paclitaxel
,15868146,terminal halflife (t1/2),Estimated terminal halflife (t1/2) based on the population estimate was 28.5 days.,Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15868146/),d,28.5,61520,DB01229,Paclitaxel
,11106262,areas under the concentration-time curve,GF120918 increased the plasma values for areas under the concentration-time curve of oral paclitaxel in wild-type mice by 6.6-fold from 408 to 2701 ng x ml(-1) h.,Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),[h·ng] / [ml],408,61727,DB01229,Paclitaxel
,11106262,areas under the concentration-time curve,GF120918 increased the plasma values for areas under the concentration-time curve of oral paclitaxel in wild-type mice by 6.6-fold from 408 to 2701 ng x ml(-1) h.,Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),[h·ng] / [ml],2701,61728,DB01229,Paclitaxel
,11106262,oral bioavailability,"Calculated relative to their respective values for area under the concentration-time curve after i.v. administration, GF120918 increased the oral bioavailability of paclitaxel in wild-type mice from 8.5 to 40.2%.",Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),%,8.5,61729,DB01229,Paclitaxel
,11106262,oral bioavailability,"Calculated relative to their respective values for area under the concentration-time curve after i.v. administration, GF120918 increased the oral bioavailability of paclitaxel in wild-type mice from 8.5 to 40.2%.",Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),%,40.2,61730,DB01229,Paclitaxel
,25461804,maximum concentrations,"The mean maximum concentrations of CDDP and PTX in perfusate were, respectively, 24.8±10.4 μg ml(-1) and 69.8±14.3 μg ml(-1); in plasma were 1.87±0.4 μg ml(-1) and 0.055±0.009 μg ml(-1).",Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25461804/),[μg] / [ml],24.8,61759,DB01229,Paclitaxel
,25461804,maximum concentrations,"The mean maximum concentrations of CDDP and PTX in perfusate were, respectively, 24.8±10.4 μg ml(-1) and 69.8±14.3 μg ml(-1); in plasma were 1.87±0.4 μg ml(-1) and 0.055±0.009 μg ml(-1).",Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25461804/),[μg] / [ml],69.8,61760,DB01229,Paclitaxel
,25461804,maximum concentrations,"The mean maximum concentrations of CDDP and PTX in perfusate were, respectively, 24.8±10.4 μg ml(-1) and 69.8±14.3 μg ml(-1); in plasma were 1.87±0.4 μg ml(-1) and 0.055±0.009 μg ml(-1).",Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25461804/),[μg] / [ml],1.87,61761,DB01229,Paclitaxel
,25461804,maximum concentrations,"The mean maximum concentrations of CDDP and PTX in perfusate were, respectively, 24.8±10.4 μg ml(-1) and 69.8±14.3 μg ml(-1); in plasma were 1.87±0.4 μg ml(-1) and 0.055±0.009 μg ml(-1).",Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25461804/),[μg] / [ml],0.055,61762,DB01229,Paclitaxel
,25461804,concentrations,"The mean concentrations of CDDP and PTX in peritoneum at the end of HIPEC were 23.3±8.0 μg g(-1) and 30.1±18.3 μg(-1)g(-1), respectively.",Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25461804/),1/[μg],30.1,61763,DB01229,Paclitaxel
,25461804,penetration,"The penetration of PTX into the peritoneal wall, determined by IMS, was about 0.5 mm.",Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25461804/),mm,0.5,61764,DB01229,Paclitaxel
,11800024,area under the concentration-time curve (AUC),Patients with advanced NSCLC were treated with escalating docetaxel doses in combination with a fixed-target area under the concentration-time curve (AUC) of 5 mg min/ml of carboplatin on day 1 of a 3-4-week cycle.,Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800024/),[mg·min] / [ml],5,62822,DB01229,Paclitaxel
,11800024,AUC,"The MTD was docetaxel 60 mg/m2 with a carboplatin target AUC of 5 mg min/ml, and the dose-limiting toxicities in two of four patients were neutropenia and thrombocytopenia.",Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800024/),[mg·min] / [ml],5,62823,DB01229,Paclitaxel
,11800024,response rate,"Of 16 patients, 5 showed an objective response (response rate 31%; 95% CI 14-56%).",Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800024/),%,31,62824,DB01229,Paclitaxel
,11800024,AUC,Docetaxel 50 mg/m2 under the carboplatin target AUC of 5 mg x min/ml using the Chatelut formula was the recommended dose for phase II study.,Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11800024/),[mg·min] / [ml],5,62825,DB01229,Paclitaxel
,11180089,time to treatment failure,"Median time to treatment failure was 1 month (95% confidence interval [CI], 1-2 mos) and median survival was 7 months (95% CI, 6-10 mos).",A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180089/),month,1,63427,DB01229,Paclitaxel
,11180089,survival,"Median time to treatment failure was 1 month (95% confidence interval [CI], 1-2 mos) and median survival was 7 months (95% CI, 6-10 mos).",A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180089/),month,7,63428,DB01229,Paclitaxel
,11180089,Time to tumor progression,Time to tumor progression was 1 month.,A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180089/),month,1,63429,DB01229,Paclitaxel
,10706091,bioavailability,"Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48% after oral delivery.","IDN5109, a taxane with oral bioavailability and potent antitumor activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10706091/),%,48,64535,DB01229,Paclitaxel
,11549208,area under the blood concentration-time curve (AUC),The area under the blood concentration-time curve (AUC) of CsA when combined with docetaxel 75 mg/m2 was 31.0+/-9.3 mg/l h (mean +/- SD).,Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549208/),[mg] / [h·l],31.0,64700,DB01229,Paclitaxel
,18597837,Complete response,Complete response by CA-125 was 75%.,"Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18597837/),%,75,64712,DB01229,Paclitaxel
,18597837,AUC,"The recommended dose of PPX of 135 mg/m(2) with carboplatin (AUC = 6) in newly diagnosed ovarian cancer was feasible for multiple cycles, but hematologic toxicity was greater compared with standard carboplatin and 3-hour paclitaxel.","Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18597837/),,6,64713,DB01229,Paclitaxel
,9816202,area under the concentration-time curve (AUC),"The carboplatin dose was chosen to produce a target area under the concentration-time curve (AUC) of 3.75 mg-min/ml according to a previously published formula (A. H. Calvert et al., J. Clin Oncol., 7: 1748-1756, 1989).",Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816202/),[mg-min] / [ml],3.75,65332,DB01229,Paclitaxel
,9816202,Total clearances,"Total clearances of carboplatin were 67.2 +/- 28.8 ml/min and 64.6 +/- 27.9 ml/min in the absence and presence of Taxol, respectively (P = 0.56).",Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816202/),[ml] / [min],67.2,65333,DB01229,Paclitaxel
,9816202,Total clearances,"Total clearances of carboplatin were 67.2 +/- 28.8 ml/min and 64.6 +/- 27.9 ml/min in the absence and presence of Taxol, respectively (P = 0.56).",Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816202/),[ml] / [min],64.6,65334,DB01229,Paclitaxel
,9816202,AUC,The AUC of free carboplatin (3.45 mg-min/ml) obtained in the absence of Taxol was not significantly different from that measured in the presence of Taxol (3.27 mg-min/ml).,Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816202/),[mg-min] / [ml],3.45,65335,DB01229,Paclitaxel
,9816202,AUC,The AUC of free carboplatin (3.45 mg-min/ml) obtained in the absence of Taxol was not significantly different from that measured in the presence of Taxol (3.27 mg-min/ml).,Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816202/),[mg-min] / [ml],3.27,65336,DB01229,Paclitaxel
,9816202,AUC,The AUC of carboplatin in both the absence and presence of Taxol agreed with the projected target AUC of 3.75 mg-min/ml.,Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816202/),[mg-min] / [ml],3.75,65337,DB01229,Paclitaxel
,33671266,recurrence-free,"The median recurrence-free and overall survival were 28.3 months and 40.8 months, respectively (median follow-up 29.1 months).","A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33671266/),month,28.3,65936,DB01229,Paclitaxel
,33671266,overall survival,"The median recurrence-free and overall survival were 28.3 months and 40.8 months, respectively (median follow-up 29.1 months).","A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33671266/),month,40.8,65937,DB01229,Paclitaxel
,21140147,AUC,"Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Schedule 2/1) or as a continuous daily dose for 3-week cycles (CDD schedule) in combination with paclitaxel (175-200 mg/m(2)) plus carboplatin (AUC 6 mg min/ml) on day one of each of 4 cycles.",Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21140147/),[mg·min] / [ml],6,65955,DB01229,Paclitaxel
,21140147,AUC,The MTD for Schedule 2/1 was sunitinib 25 mg plus paclitaxel 175 mg/m(2) and carboplatin AUC 6 mg min/ml.,Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21140147/),[mg·min] / [ml],6,65956,DB01229,Paclitaxel
>,8996159,P-T,"No sequence-dependent pharmacokinetic interactions for the P area under the concentration-time curve (P-AUC), maximal plasma concentration (P-Cmax), or time above a threshold concentration of 0.1 mumol/L (P-T > or = 0.1 mumol/L) were observed.",Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),[μM] / [l],0.1,66953,DB01229,Paclitaxel
,8996159,plasma ultrafiltrate AUC of C (CpUF-AUC),"The mean plasma ultrafiltrate AUC of C (CpUF-AUC) at the dosage of 300 mg/m2 for the sequence C-->P was 3.52 mg/mL.min (range, 1.94 to 5.83) and 3.62 mg/mL.min for the sequence P-->C (range, 1.91 to 5.01), which is not significantly different (P = .55).",Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),[mg] / [min·ml],3.52,66954,DB01229,Paclitaxel
,8996159,plasma ultrafiltrate AUC of C (CpUF-AUC),"The mean plasma ultrafiltrate AUC of C (CpUF-AUC) at the dosage of 300 mg/m2 for the sequence C-->P was 3.52 mg/mL.min (range, 1.94 to 5.83) and 3.62 mg/mL.min for the sequence P-->C (range, 1.91 to 5.01), which is not significantly different (P = .55).",Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),[mg] / [min·ml],3.62,66955,DB01229,Paclitaxel
>,8996159,P-T,"The median survival duration was best correlated with the P dose (4.8 months for doses < 175 mg/m2 v 7.9 months for doses > or = 175 mg/m2, P = .07; P-T > or = 0.1 mumol/L, 4.8 months for < 15 hours v 8.2 months for > or = 15 hours, P = .06).",Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),[μM] / [l],0.1,66956,DB01229,Paclitaxel
,8996159,P-T,"The median survival duration was best correlated with the P dose (4.8 months for doses < 175 mg/m2 v 7.9 months for doses > or = 175 mg/m2, P = .07; P-T > or = 0.1 mumol/L, 4.8 months for < 15 hours v 8.2 months for > or = 15 hours, P = .06).",Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),month,4,66957,DB01229,Paclitaxel
,8996159,P-T,"The median survival duration was best correlated with the P dose (4.8 months for doses < 175 mg/m2 v 7.9 months for doses > or = 175 mg/m2, P = .07; P-T > or = 0.1 mumol/L, 4.8 months for < 15 hours v 8.2 months for > or = 15 hours, P = .06).",Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),month,8,66958,DB01229,Paclitaxel
> or =,8996159,P-T,The pharmacokinetic parameter P-T > or = 0.1 mumol/L was related to improved survival in this study.,Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996159/),[μM] / [l],0.1,66959,DB01229,Paclitaxel
,30187352,apparent drug concentration,"The dissolution rate and extent of the ASD was remarkably improved compared with a physical mixture (PM) of PTX, HPMCAS-MF, and Poloxamer 188 (F68), reaching an apparent drug concentration of 25-30 μg/mL and maintaining it for more than 2 h.",Effect of supersaturation on the oral bioavailability of paclitaxel/polymer amorphous solid dispersion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30187352/),[μg] / [ml],25-30,67005,DB01229,Paclitaxel
,23893887,flow rate,"The separation was achieved on a C18 column at 30 °C using an acetonitrile-ammonium acetate buffer (pH 5.0, 0.02 m; 55:45, v/v) at a flow rate of 1.0 mL/min; UV detection was used at 227 nm.",Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893887/),[ml] / [min],1.0,67156,DB01229,Paclitaxel
,23893887,limit of detection,"The limit of detection was 6 ng/mL in plasma, 8 ng/g in heart and 12.5 ng/g in other tissues.",Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893887/),[ng] / [ml],6,67157,DB01229,Paclitaxel
,23893887,limit of detection,"The limit of detection was 6 ng/mL in plasma, 8 ng/g in heart and 12.5 ng/g in other tissues.",Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893887/),[ng] / [g],8,67158,DB01229,Paclitaxel
,23893887,limit of detection,"The limit of detection was 6 ng/mL in plasma, 8 ng/g in heart and 12.5 ng/g in other tissues.",Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893887/),[ng] / [g],12.5,67159,DB01229,Paclitaxel
,23893887,limit,"The limit of quantitation was 25 ng/mL in plasma and heart, 125 ng/g in other tissues.",Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893887/),[ng] / [g],125,67160,DB01229,Paclitaxel
,23893887,extraction recoveries,The extraction recoveries ranged from 70.1 to 109.5%.,Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893887/),%,70.1 to 109.5,67161,DB01229,Paclitaxel
,19723673,linear clearance (CL),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),[l] / [d],0.273,67519,DB01229,Paclitaxel
,19723673,maximum nonlinear clearance (V(max)/K(m)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),[l] / [d],28.4,67520,DB01229,Paclitaxel
,19723673,central volume of distribution (V(1)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),[l] / [d],28.4,67521,DB01229,Paclitaxel
,19723673,central volume of distribution (V(1)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),l,3.95,67522,DB01229,Paclitaxel
,19723673,peripheral volume of distribution (V(2)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),[l] / [d],28.4,67523,DB01229,Paclitaxel
,19723673,peripheral volume of distribution (V(2)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),l,3.95,67524,DB01229,Paclitaxel
,19723673,peripheral volume of distribution (V(2)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),l,2.59,67525,DB01229,Paclitaxel
,19723673,Michaelis-Menten constant (K(m)),"For a typical male patient with colorectal cancer (80 kg, 60 years old), the estimates for the linear clearance (CL), the maximum nonlinear clearance (V(max)/K(m)), the central volume of distribution (V(1)), the peripheral volume of distribution (V(2)), and the Michaelis-Menten constant (K(m)) are 0.273 L/d, 28.4 L/d, 3.95 L, 2.59 L, and 0.426 mcg/mL, respectively.",Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723673/),[mcg] / [ml],0.426,67526,DB01229,Paclitaxel
,17075322,time above 0.1 micro,Area under the concentration-time curve and the time above 0.1 micromol/l (T>0.1) concentration threshold in the severe hepatic dysfunction patients who received paclitaxel 70 mg/m approximated pharmacokinetics of paclitaxel in patients with normal liver function who received 130 mg/m.,Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075322/),,0.1,68325,DB01229,Paclitaxel
,17075322,T>,Area under the concentration-time curve and the time above 0.1 micromol/l (T>0.1) concentration threshold in the severe hepatic dysfunction patients who received paclitaxel 70 mg/m approximated pharmacokinetics of paclitaxel in patients with normal liver function who received 130 mg/m.,Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075322/),,0.1,68326,DB01229,Paclitaxel
,9923536,AUC,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[min·μg] / [ml],2227,69829,DB01229,Paclitaxel
,9923536,AUC,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[min·μg] / [ml],245,69830,DB01229,Paclitaxel
,9923536,total clearance,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[ml] / [min],0.8,69831,DB01229,Paclitaxel
,9923536,total clearance,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[ml] / [min],7.0,69832,DB01229,Paclitaxel
,9923536,elimination half-life,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),min,92,69833,DB01229,Paclitaxel
,9923536,elimination half-life,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),min,18,69834,DB01229,Paclitaxel
,20845453,critical micelle concentration (CMC),The critical micelle concentration (CMC) values of DHC decreased from 0.26 to 0.16 mg/mL as the DS of deoxycholic acid group increased.,"Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845453/),[mg] / [ml],0.26,70011,DB01229,Paclitaxel
,20845453,critical micelle concentration (CMC),The critical micelle concentration (CMC) values of DHC decreased from 0.26 to 0.16 mg/mL as the DS of deoxycholic acid group increased.,"Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845453/),[mg] / [ml],0.16,70012,DB01229,Paclitaxel
,20845453,drug loading,PTX was successfully loaded in DHC micelles with a high drug loading (31.68 ± 0.14%) and entrapment efficiency (77.57 ± 0.51%).,"Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845453/),%,31.68,70013,DB01229,Paclitaxel
,20845453,en,PTX was successfully loaded in DHC micelles with a high drug loading (31.68 ± 0.14%) and entrapment efficiency (77.57 ± 0.51%).,"Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845453/),%,77.57,70014,DB01229,Paclitaxel
,20845453,particle size,The particle size of PTX-loaded DHC micelles ranged from 203.35 ± 2.19 to 236.70 ± 3.40 nm as the DS of deoxycholic acid group increased.,"Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845453/),nm,203.35,70015,DB01229,Paclitaxel
,20845453,particle size,The particle size of PTX-loaded DHC micelles ranged from 203.35 ± 2.19 to 236.70 ± 3.40 nm as the DS of deoxycholic acid group increased.,"Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845453/),nm,236.70,70016,DB01229,Paclitaxel
,22904239,progression-free survival,The median progression-free survival was 6.3 months (95% confidence interval 5.5-8.1).,"Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904239/),month,6.3,70028,DB01229,Paclitaxel
,17409987,maximum tolerated,"Dose-limiting toxicities (diarrhea, rash, asthenia, and hypotension) occurred at the 200- and 150-mg dose levels of CI-1033; the maximum tolerated dose was 100 mg.",A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17409987/),,100,71097,DB01229,Paclitaxel
,17409987,survival time,Median survival time was 12.4 months; median progression-free survival was 5.1 months.,A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17409987/),month,12.4,71098,DB01229,Paclitaxel
,17409987,progression-free survival,Median survival time was 12.4 months; median progression-free survival was 5.1 months.,A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17409987/),month,5.1,71099,DB01229,Paclitaxel
,23833564,AUC,Patients in the CP group received paclitaxel 175 mg/m(2) IV and carboplatin [AUC=6] IV every 3 weeks.,Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),,6,71366,DB01229,Paclitaxel
,23833564,Response rates,"Response rates by modified WHO criteria were 29.4% (I group), 27.8% (D group), and 11.1% (CP group).",Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),%,29.4,71367,DB01229,Paclitaxel
,23833564,Response rates,"Response rates by modified WHO criteria were 29.4% (I group), 27.8% (D group), and 11.1% (CP group).",Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),%,27.8,71368,DB01229,Paclitaxel
,23833564,Response rates,"Response rates by modified WHO criteria were 29.4% (I group), 27.8% (D group), and 11.1% (CP group).",Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23833564/),%,11.1,71369,DB01229,Paclitaxel
,32762829,flow rate,"The HPLC assay was performed isocratically on a reversed-phase C18 μ-Bondapack column using a mobile phase of acetonitrile:water (45:55, v/v) at a flow rate of 1.2 mL/min, and the analytes were detected at 230 nm.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),[ml] / [min],1.2,71765,DB01229,Paclitaxel
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,10.94,71766,DB01229,Paclitaxel
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,12.4,71767,DB01229,Paclitaxel
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,16.81,71768,DB01229,Paclitaxel
,15663292,AUCs,"Using Bailer's method, a significant difference was observed in the AUCs of paclitaxel administrated alone and with rIL-2 pretreatment (928.2 +/- 136.8 vs 2549.6 +/- 131.3 ng.h.ml(-1), p <0.0001).",Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663292/),[h·ng] / [ml],928.2,71939,DB01229,Paclitaxel
,15663292,AUCs,"Using Bailer's method, a significant difference was observed in the AUCs of paclitaxel administrated alone and with rIL-2 pretreatment (928.2 +/- 136.8 vs 2549.6 +/- 131.3 ng.h.ml(-1), p <0.0001).",Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663292/),[h·ng] / [ml],2549.6,71940,DB01229,Paclitaxel
,15663292,elimination half-life,Pretreatment with rIL-2 resulted in a 3-fold increase in the oral bioavailability of paclitaxel without altering its elimination half-life (0.798 vs 0.747 h).,Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663292/),h,0.798,71941,DB01229,Paclitaxel
,15663292,elimination half-life,Pretreatment with rIL-2 resulted in a 3-fold increase in the oral bioavailability of paclitaxel without altering its elimination half-life (0.798 vs 0.747 h).,Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663292/),h,0.747,71942,DB01229,Paclitaxel
,30553305,drug loading capacity,"The drug loading capacity and entrapment efficiency of PTX-loaded CR PMs were 35.24 ± 1.58% and 86.99 ± 12.26%, respectively.",Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30553305/),%,35.24,71977,DB01229,Paclitaxel
,30553305,entrapment efficiency,"The drug loading capacity and entrapment efficiency of PTX-loaded CR PMs were 35.24 ± 1.58% and 86.99 ± 12.26%, respectively.",Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30553305/),%,86.99,71978,DB01229,Paclitaxel
,18164866,peak plasma level,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.23,72240,DB01229,Paclitaxel
,18164866,peak plasma level,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.32,72241,DB01229,Paclitaxel
,18164866,peak plasma level,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.52,72242,DB01229,Paclitaxel
,18164866,AUC,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.44,72243,DB01229,Paclitaxel
,18164866,AUC,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.61,72244,DB01229,Paclitaxel
,18164866,AUC,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.96,72245,DB01229,Paclitaxel
>,18164866,duration of drug concentration,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.05,72246,DB01229,Paclitaxel
,18164866,duration of drug concentration,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),h,1.9,72247,DB01229,Paclitaxel
,18164866,duration of drug concentration,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),h,3.0,72248,DB01229,Paclitaxel
>,18164866,t,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),[μM] / [l],0.05,72249,DB01229,Paclitaxel
,18164866,t,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),h,1.6,72250,DB01229,Paclitaxel
,18164866,t,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),h,1.9,72251,DB01229,Paclitaxel
,18164866,t,"For Dose Levels I (15 mg/m(2)), II (20 mg/m(2)), and III (25 mg/m(2)), the mean peak plasma level was 0.23 +/- 0.06 micromol/l, 0.32 +/- 0.05 micromol/l, and 0.52 +/- 0.14 micromol/l, respectively; AUC was 0.44 +/- 0.09 micromol/l, 0.61 +/- 0.1 micromol/l, and 0.96 +/- 0.23 micromol/l, respectively; and duration of drug concentration >0.05 micromol/l (t > 0.05 micromol/l) was 1.6 +/- 0.3 h, 1.9 +/- 0.2 h, and 3.0 +/- 0.9 h, respectively.",Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164866/),h,3.0,72252,DB01229,Paclitaxel
,2882837,half-lives,"Taxol disappearance from plasma was biphasic; half-lives of the first and second phases after a 275 mg/m2 dose were 0.32 and 8.6 h, respectively.",Phase I clinical and pharmacokinetic study of taxol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),h,0.32,72315,DB01229,Paclitaxel
,2882837,half-lives,"Taxol disappearance from plasma was biphasic; half-lives of the first and second phases after a 275 mg/m2 dose were 0.32 and 8.6 h, respectively.",Phase I clinical and pharmacokinetic study of taxol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),h,8.6,72316,DB01229,Paclitaxel
,2882837,apparent volume of distribution,"The apparent volume of distribution was 55 liters/m2, and the peak plasma concentration with a dose of 275 mg/m2, which occurred immediately postinfusion, was approximately 8 microM.",Phase I clinical and pharmacokinetic study of taxol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),[l] / [m2],55,72317,DB01229,Paclitaxel
,2882837,peak plasma concentration,"The apparent volume of distribution was 55 liters/m2, and the peak plasma concentration with a dose of 275 mg/m2, which occurred immediately postinfusion, was approximately 8 microM.",Phase I clinical and pharmacokinetic study of taxol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),μM,8,72318,DB01229,Paclitaxel
,12065559,overall response rate,"Among 34 patients, complete response was observed in three patients and partial response in 15, for an overall response rate of 53% (95% confidence interval, 35% to 70%).",Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065559/),%,53,72501,DB01229,Paclitaxel
,12065559,time to progression,"The median time to progression was 5.6 months (range, 4 to 10 months).",Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065559/),month,5.6,72502,DB01229,Paclitaxel
,32114508,Ki,"Paclitaxel is an inhibitor of OATP1B1 and OATP1B3, with Ki of 0.579 ± 0.107 and 5.29 ± 3.87 μM, respectively.",Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32114508/),μM,0.579,72604,DB01229,Paclitaxel
,32114508,Ki,"Paclitaxel is an inhibitor of OATP1B1 and OATP1B3, with Ki of 0.579 ± 0.107 and 5.29 ± 3.87 μM, respectively.",Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32114508/),μM,5.29,72605,DB01229,Paclitaxel
,32114508,Ki,"Preincubation potentiated its inhibitory effect on both OATP1B1 and OATP1B3, with Ki of 0.154 ± 0.031 and 0.624 ± 0.183 μM, respectively.",Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32114508/),μM,0.154,72606,DB01229,Paclitaxel
,32114508,Ki,"Preincubation potentiated its inhibitory effect on both OATP1B1 and OATP1B3, with Ki of 0.154 ± 0.031 and 0.624 ± 0.183 μM, respectively.",Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32114508/),μM,0.624,72607,DB01229,Paclitaxel
,10963645,Urinary excretion,"Urinary excretion over 48 hours was low, with a mean of 0.8 +/- 0.36% of the administered dose.","Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963645/),%,0.8,73058,DB01229,Paclitaxel
,16699792,FCR,"The LDE and paclitaxel oleate FCR were similar (0.092 +/- 0.039 and 0.069 +/- 0.027 h(-1), respectively, n = 5, P = 0.390).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),1/[h],0.092,73340,DB01229,Paclitaxel
,16699792,FCR,"The LDE and paclitaxel oleate FCR were similar (0.092 +/- 0.039 and 0.069 +/- 0.027 h(-1), respectively, n = 5, P = 0.390).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),1/[h],0.069,73341,DB01229,Paclitaxel
,16699792,FCR,"FCR of paclitaxel oleate associated to LDE was smaller than that of paclitaxel-cremophor (0.231 +/- 0.128 h(-1), P = 0.028).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),1/[h],0.231,73342,DB01229,Paclitaxel
,16699792,T (1/2 ),"Paclitaxel oleate T (1/2 )and AUC were greater than those of paclitaxel-cremophor (T (1/2 )=( )14.51 +/- 3.23 and 6.62 +/- 2.05 h and AUC = 2.49 +/- 0.35 and 1.26 +/- 0.40, respectively, P = 0.009, P = 0.004).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),h,14.51,73343,DB01229,Paclitaxel
,16699792,T (1/2 ),"Paclitaxel oleate T (1/2 )and AUC were greater than those of paclitaxel-cremophor (T (1/2 )=( )14.51 +/- 3.23 and 6.62 +/- 2.05 h and AUC = 2.49 +/- 0.35 and 1.26 +/- 0.40, respectively, P = 0.009, P = 0.004).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),h,6.62,73344,DB01229,Paclitaxel
,16699792,AUC,"Paclitaxel oleate T (1/2 )and AUC were greater than those of paclitaxel-cremophor (T (1/2 )=( )14.51 +/- 3.23 and 6.62 +/- 2.05 h and AUC = 2.49 +/- 0.35 and 1.26 +/- 0.40, respectively, P = 0.009, P = 0.004).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),,2.49,73345,DB01229,Paclitaxel
,16699792,AUC,"Paclitaxel oleate T (1/2 )and AUC were greater than those of paclitaxel-cremophor (T (1/2 )=( )14.51 +/- 3.23 and 6.62 +/- 2.05 h and AUC = 2.49 +/- 0.35 and 1.26 +/- 0.40, respectively, P = 0.009, P = 0.004).",Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699792/),,1.26,73346,DB01229,Paclitaxel
,23127487,terminal plasma half-life,The terminal plasma half-life of total platinum after DCP administration ranged from 41.86 to 77.20 hours without significant dose dependency.,Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23127487/),h,41.86 to 77.20,74413,DB01229,Paclitaxel
,23127487,terminal plasma half-life,"However, the terminal plasma half-life of free platinum concentrations ranged from 42.34 to 61.07 hours.",Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23127487/),h,42.34 to 61.07,74414,DB01229,Paclitaxel
,20473611,overall response rate,The overall response rate was encouraging; 43% including 11 patients with prior chemotherapy.,"Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20473611/),%,43,75148,DB01229,Paclitaxel
,9800643,flow rates,"The mobile phase consisted of Phosphate buffer (30 mM, pH = 3)-acetonitrile (47:53, v/v) with the flow rates of 1.1 and 1.3 ml min-1 for clean-up and analytical columns, respectively.",A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9800643/),[ml] / [min],1.1,75266,DB01229,Paclitaxel
,9800643,flow rates,"The mobile phase consisted of Phosphate buffer (30 mM, pH = 3)-acetonitrile (47:53, v/v) with the flow rates of 1.1 and 1.3 ml min-1 for clean-up and analytical columns, respectively.",A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9800643/),[ml] / [min],1.3,75267,DB01229,Paclitaxel
,9800643,recovery,The extraction method showed a recovery of 92% for docetaxel.,A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9800643/),%,92,75268,DB01229,Paclitaxel
,9800643,retention times,"In this system, the retention times of docetaxel and Paclitaxel were 7.2 and 8.5 min, respectively.",A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9800643/),min,7.2,75269,DB01229,Paclitaxel
,9800643,retention times,"In this system, the retention times of docetaxel and Paclitaxel were 7.2 and 8.5 min, respectively.",A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9800643/),min,8.5,75270,DB01229,Paclitaxel
,9800643,detection limit,The detection limit of docetaxel in plasma is 2.5 ng ml-1.,A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9800643/),[ng] / [ml],2.5,75271,DB01229,Paclitaxel
,11331328,clearance,"Mean +/- SD values for clearance, volume of distribution at steady-state, and terminal half-life were 220 +/- 89 mL/min/m2, 402 +/- 231 L/m2, and 40.8 +/- 21.8 hours, respectively.","Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11331328/),[ml] / [m2·min],220,76529,DB01229,Paclitaxel
,11331328,volume of distribution at steady-state,"Mean +/- SD values for clearance, volume of distribution at steady-state, and terminal half-life were 220 +/- 89 mL/min/m2, 402 +/- 231 L/m2, and 40.8 +/- 21.8 hours, respectively.","Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11331328/),[l] / [m2],402,76530,DB01229,Paclitaxel
,11331328,terminal half-life,"Mean +/- SD values for clearance, volume of distribution at steady-state, and terminal half-life were 220 +/- 89 mL/min/m2, 402 +/- 231 L/m2, and 40.8 +/- 21.8 hours, respectively.","Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11331328/),h,40.8,76531,DB01229,Paclitaxel
,24170767,plasma elimination half-life,"In combination with paclitaxel, weekly dosing of BAY 80-6946 is sufficient to reach sustained response in all animals bearing patient-derived non-small cell lung cancer xenografts, despite a short plasma elimination half-life (1 hour) in mice.",BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170767/),h,1,76638,DB01229,Paclitaxel
,31306829,saturated attachment ratio,The saturated attachment ratio of DSPE-PEG 2000 was 0.4%.,Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31306829/),%,0.4,76939,DB01229,Paclitaxel
,31306829,area-under-the-curve (AUC,"Moreover, pharmacokinetics results showed that DSPE-PEG-PNCs achieved a higher area-under-the-curve (AUC, 4.43 ± 0.19 mg/L*h) and lower clearance rate (1.08 ± 0.16 L/h/kg) compared to PNCs with an AUC of 2.48 ± 0.18 mg/L*h and a clearance rate of 1.89 ± 0.15 L/h/kg.",Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31306829/),[mg] / [h·l],4.43,76940,DB01229,Paclitaxel
,31306829,clearance rate,"Moreover, pharmacokinetics results showed that DSPE-PEG-PNCs achieved a higher area-under-the-curve (AUC, 4.43 ± 0.19 mg/L*h) and lower clearance rate (1.08 ± 0.16 L/h/kg) compared to PNCs with an AUC of 2.48 ± 0.18 mg/L*h and a clearance rate of 1.89 ± 0.15 L/h/kg.",Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31306829/),[l] / [h·kg],1.08,76941,DB01229,Paclitaxel
,31306829,AUC,"Moreover, pharmacokinetics results showed that DSPE-PEG-PNCs achieved a higher area-under-the-curve (AUC, 4.43 ± 0.19 mg/L*h) and lower clearance rate (1.08 ± 0.16 L/h/kg) compared to PNCs with an AUC of 2.48 ± 0.18 mg/L*h and a clearance rate of 1.89 ± 0.15 L/h/kg.",Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31306829/),[mg] / [h·l],2.48,76942,DB01229,Paclitaxel
,31306829,clearance rate,"Moreover, pharmacokinetics results showed that DSPE-PEG-PNCs achieved a higher area-under-the-curve (AUC, 4.43 ± 0.19 mg/L*h) and lower clearance rate (1.08 ± 0.16 L/h/kg) compared to PNCs with an AUC of 2.48 ± 0.18 mg/L*h and a clearance rate of 1.89 ± 0.15 L/h/kg.",Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31306829/),[l] / [h·kg],1.89,76943,DB01229,Paclitaxel
,8797769,peak plasma Cremophor concentrations,"At the 175-mg/m2 dose level, peak plasma Cremophor concentrations of 1 microL/mL or more were achieved in eight of 10 patients during both the 3-hour and the 6-hour infusions; with the 24-hour infusion, only one patient achieved a peak plasma Cremophor concentration of 1 microL/mL or more.","Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797769/),[μl] / [ml],1,77655,DB01229,Paclitaxel
,8797769,peak plasma Cremophor concentration,"At the 175-mg/m2 dose level, peak plasma Cremophor concentrations of 1 microL/mL or more were achieved in eight of 10 patients during both the 3-hour and the 6-hour infusions; with the 24-hour infusion, only one patient achieved a peak plasma Cremophor concentration of 1 microL/mL or more.","Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797769/),[μl] / [ml],1,77656,DB01229,Paclitaxel
,8797769,total time that the plasma concentration,"The eight patients who achieved plasma Cremophor concentrations of 1 microL/mL during the 3-hour infusion were above this level 30 minutes into the infusion; the total time that the plasma concentration was greater than 1 microL/mL was 8.9 +/- 5.0 hours (mean +/- standard deviation; range, 4.1-15.6 hours).","Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797769/),h,8.9,77657,DB01229,Paclitaxel
,8797769,total time that the,"For the eight patients who achieved plasma Cremophor concentrations of 1 microL/mL during the 6-hour infusion, the total time that the concentration was greater than 1 microL/mL was 10.2 +/- 9.0 hours (range, 0.3-21.9 hours).","Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797769/),h,10.2,77658,DB01229,Paclitaxel
,8797769,peak plasma Cremophor concentration,The patient who received paclitaxel at a dose of 135 mg/m2 achieved a peak plasma Cremophor concentration of 1 microL/mL or more only during the 3-hour infusion.,"Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797769/),[μl] / [ml],1,77659,DB01229,Paclitaxel
,16551860,plasma half-life,BMS-275183 was rapidly absorbed with a mean plasma half-life of 22 hours.,"Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551860/),h,22,78109,DB01229,Paclitaxel
,16551860,M,"The main toxicity is peripheral neuropathy, and the MTD is 200 mg/m2.","Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551860/),,200,78110,DB01229,Paclitaxel
,31252010,permeability,"Among the directly compressed liquisolid tabs, LTP-10 exhibited highest CDR of 98.70 ± 2.68% and permeability of 61.59%.","Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31252010/),%,61.59,78156,DB01229,Paclitaxel
<,31252010,IC50,The IC50 of <20 mmol/L indicated remarkable cytotoxic potential on human gastro-enteric tumor cancerous cell lines (NCI-N87).,"Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31252010/),[mM] / [l],20,78157,DB01229,Paclitaxel
,31252010,Cmax,Pharmacokinetics revealed Cmax of 536.48 ± 4.63 μg/L at 1.64 ± 0.44 h for LTP-10 indicating enhancement in bioavailability (5.43 fold) of paclitaxel on oral administration.,"Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31252010/),[μg] / [l],536.48,78158,DB01229,Paclitaxel
,11054441,area under the plasma concentration versus time curve (AUC),Fifty-eight patients were treated with escalating doses of paclitaxel ranging from 54 to 94.5 mg/m(2) and carboplatin area under the plasma concentration versus time curve (AUC) ranging from 6 to 9 mg.,Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),mg,6 to 9,78361,DB01229,Paclitaxel
,11054441,AUC,"The MTD was determined for the following two groups: (1) previously treated patients, where paclitaxel and carboplatin doses were escalated; and (2) chemotherapy-naïve patients, where paclitaxel dose was escalated and carboplatin AUC was fixed at 6 mg.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),mg,6,78362,DB01229,Paclitaxel
,11054441,AUC,"In previously treated patients, no DLTs occurred at the first dose level (paclitaxel 54 mg/m(2) and carboplatin AUC 6 mg.min/mL).",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],6,78363,DB01229,Paclitaxel
,11054441,AUC,"However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],67.5,78364,DB01229,Paclitaxel
,11054441,AUC,"However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],81,78365,DB01229,Paclitaxel
,11054441,AUC,"However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],94.5,78366,DB01229,Paclitaxel
,11054441,AUC,"In chemotherapy-naïve patients, one of 17 developed DLT at paclitaxel 81 mg/m(2) and carboplatin AUC 6 mg/mL.min.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg] / [min·ml],6,78367,DB01229,Paclitaxel
,11054441,time that,"There was prolongation of the terminal phase of paclitaxel elimination as evidenced by an increased time that plasma paclitaxel concentration was >/= 0.05 micromol/L, ranging from 16.6 +/- 6.7 hours to 41.5 +/- 9.8 hours for paclitaxel doses of 54.5 mg/m(2) to 94.5 mg/m(2), respectively.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),h,16.6,78368,DB01229,Paclitaxel
,11054441,time that,"There was prolongation of the terminal phase of paclitaxel elimination as evidenced by an increased time that plasma paclitaxel concentration was >/= 0.05 micromol/L, ranging from 16.6 +/- 6.7 hours to 41.5 +/- 9.8 hours for paclitaxel doses of 54.5 mg/m(2) to 94.5 mg/m(2), respectively.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),h,41.5,78369,DB01229,Paclitaxel
,11054441,AUC,"In previously treated patients, the recommended phase II dose is paclitaxel 67.5 mg/m(2), carboplatin AUC 6 mg.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),,6,78370,DB01229,Paclitaxel
,7481867,area under the concentration-time curve (AUC),"Paclitaxel 250 mg/m2 was infused over 24 hours, followed by a 1-hour carboplatin infusion, with doses escalated between area under the concentration-time curve (AUC) targets of 8 and 20.","A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481867/),,8,78822,DB01229,Paclitaxel
,7481867,area under the concentration-time curve (AUC),"Paclitaxel 250 mg/m2 was infused over 24 hours, followed by a 1-hour carboplatin infusion, with doses escalated between area under the concentration-time curve (AUC) targets of 8 and 20.","A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481867/),,20,78823,DB01229,Paclitaxel
,7481867,AUCs,"The median duration of grade 4 neutropenia and thrombocytopenia was not significantly different between the AUCs of 8 and 18, which proved to be the maximum tolerated carboplatin dose.","A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481867/),,8,78824,DB01229,Paclitaxel
,7481867,AUCs,"The median duration of grade 4 neutropenia and thrombocytopenia was not significantly different between the AUCs of 8 and 18, which proved to be the maximum tolerated carboplatin dose.","A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481867/),,18,78825,DB01229,Paclitaxel
,7481867,AUC,"One treatment-related death occurred, and severe toxicity caused withdrawal of two patients treated at the AUC of 20.","A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481867/),,20,78826,DB01229,Paclitaxel
,7481867,AUC,Additional patients are being accrued at the AUC of 18.,"A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481867/),,18,78827,DB01229,Paclitaxel
>,27502710,Tc,"In arm B, initial paclitaxel dose was adjusted to body surface area, age, sex, and subsequent doses were guided by neutropenia and previous-cycle paclitaxel exposure [time above a plasma concentration of 0.05 µM (Tc>0.05)] determined from a single blood sample on day 2.","Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27502710/),,0.05,78991,DB01229,Paclitaxel
,27502710,Response rate,"Response rate was similar in arms A and B (31% versus 27%, P = 0.405), as was adjusted median PFS [5.5 versus 4.9 months, hazard ratio (HR) 1.16, 95% confidence interval (CI) 0.91-1.49, P = 0.228] and OS (10.1 versus 9.5 months, HR 1.05, 95% CI 0.81-1.37, P = 0.682).","Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27502710/),%,31,78992,DB01229,Paclitaxel
,27502710,Response rate,"Response rate was similar in arms A and B (31% versus 27%, P = 0.405), as was adjusted median PFS [5.5 versus 4.9 months, hazard ratio (HR) 1.16, 95% confidence interval (CI) 0.91-1.49, P = 0.228] and OS (10.1 versus 9.5 months, HR 1.05, 95% CI 0.81-1.37, P = 0.682).","Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27502710/),%,27,78993,DB01229,Paclitaxel
,7505722,body clearance,Total taxol body clearance was 256 +/- 72 ml min-1 m-2 (mean +/- SD).,Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505722/),[ml] / [(m)^2·min],256,79337,DB01229,Paclitaxel
,7505722,plasma protein binding,"Taxol plasma protein binding was 88.4% +/- 1.3% (mean +/- SD, n = 9).",Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505722/),%,88.4,79338,DB01229,Paclitaxel
,16937541,maximum plasma concentration,The maximum plasma concentration of paclitaxel was 1390 microg/L.,Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer: A case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16937541/),[μg] / [l],1390,79508,DB01229,Paclitaxel
,16937541,area under the curve,The area under the curve of paclitaxel was 4398.6 microg x h/L. Grade 2 leukopenia was encountered during the first cycle.,Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer: A case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16937541/),[h·μg] / [l],4398.6,79509,DB01229,Paclitaxel
greater,27455550,entra,The PTX-loaded BS-Lips were successfully prepared with a diameter of approximately 150 nm and an entrapment efficiency of greater than 90 percent.,Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27455550/),%,90,79745,DB01229,Paclitaxel
,11862425,recoveries,"Paclitaxel recoveries in the faeces of the control and test groups were 7.6% and 35.8%, respectively.",Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862425/),%,7.6,80072,DB01229,Paclitaxel
,11862425,recoveries,"Paclitaxel recoveries in the faeces of the control and test groups were 7.6% and 35.8%, respectively.",Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862425/),%,35.8,80073,DB01229,Paclitaxel
,27452985,Overall response rate,Overall response rate was 38.9% and median progression-free survival was 274 days.,Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27452985/),%,38.9,80900,DB01229,Paclitaxel
,27452985,progression-free survival,Overall response rate was 38.9% and median progression-free survival was 274 days.,Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27452985/),d,274,80901,DB01229,Paclitaxel
,12538463,fraction of unbound,"The fraction of unbound paclitaxel increased from 0.052 +/- 0.0018 to 0.055 +/- 0.0036 (relative increase, 6.25%; P = 0.011) with an increase in DHA-paclitaxel concentration (0-1000 microg/ml), suggesting weakly competitive drug displacement from protein-binding sites.","Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538463/),,0.052,80924,DB01229,Paclitaxel
,12538463,fraction of unbound,"The fraction of unbound paclitaxel increased from 0.052 +/- 0.0018 to 0.055 +/- 0.0036 (relative increase, 6.25%; P = 0.011) with an increase in DHA-paclitaxel concentration (0-1000 microg/ml), suggesting weakly competitive drug displacement from protein-binding sites.","Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538463/),,0.,80925,DB01229,Paclitaxel
,12538463,area under the curve,"The mean (+/- SD) area under the curve of unbound paclitaxel increased nonlinearly with dose from 0.089 +/- 0.029 microg.h/ml (at 660 mg/m(2)) to 0.624 +/- 0.216 microg.h/ml (at 1100 mg/m(2)), and was associated with the dose-limiting neutropenia in a maximum-effect model (R(2) = 0.624).","Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538463/),[h·μg] / [ml],0.089,80926,DB01229,Paclitaxel
,12538463,area under the curve,"The mean (+/- SD) area under the curve of unbound paclitaxel increased nonlinearly with dose from 0.089 +/- 0.029 microg.h/ml (at 660 mg/m(2)) to 0.624 +/- 0.216 microg.h/ml (at 1100 mg/m(2)), and was associated with the dose-limiting neutropenia in a maximum-effect model (R(2) = 0.624).","Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538463/),[h·μg] / [ml],0.624,80927,DB01229,Paclitaxel
,12538463,volume of distribution,"Extensive binding to plasma proteins may explain, in part, the unique pharmacokinetic profile of DHA-paclitaxel described previously with a small volume of distribution ( approximately 4 liters) and slow systemic clearance ( approximately 0.11 liters/h).","Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538463/),l,4,80928,DB01229,Paclitaxel
,12538463,systemic clearance,"Extensive binding to plasma proteins may explain, in part, the unique pharmacokinetic profile of DHA-paclitaxel described previously with a small volume of distribution ( approximately 4 liters) and slow systemic clearance ( approximately 0.11 liters/h).","Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538463/),[l] / [h],0.11,80929,DB01229,Paclitaxel
,28764748,overall response rate,The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients).,A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28764748/),%,22,81098,DB01229,Paclitaxel
,28764748,progression-free survival,The median progression-free survival was 20 weeks (range 8-55).,A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28764748/),weeks,20,81099,DB01229,Paclitaxel
,9717822,area under the plasma concentration versus time curves,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[h·μl] / [ml],253,82062,DB01229,Paclitaxel
,9717822,area under the plasma concentration versus time curves,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[h·μl] / [ml],680,82063,DB01229,Paclitaxel
,9717822,peak plasma levels,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[h·μl] / [ml],680,82064,DB01229,Paclitaxel
,9717822,peak plasma levels,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[μl] / [ml],3.40,82065,DB01229,Paclitaxel
,9717822,peak plasma levels,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[μl] / [ml],6.58,82066,DB01229,Paclitaxel
,9717822,terminal elimination half-life,"Disappearance of CrEL from the central plasma compartment was characterized by a terminal elimination half-life of 84.1+/-20.4 h, resulting in extended persistence of substantial levels even at 1 week after paclitaxel treatment.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),h,84.1,82067,DB01229,Paclitaxel
,9717822,volume of distribution,"The observed volume of distribution was extremely low and averaged 3.70+/-0.49 liters/m2, implying that the tumor delivery of CrEL is insignificant.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[l] / [m2],3.70,82068,DB01229,Paclitaxel
,11129729,t 1/2,Pharmacokinetic analyses revealed a low elimination-rate of Cremophor EL (CI=37.8-134 ml/h/m2; t 1/2=34.4-61.5 h) and a volume of distribution similar to the volume of the central blood compartment (Vss=4.96-7.85 l).,Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129729/),h,34.4-61.5,82296,DB01229,Paclitaxel
,11129729,Vss,Pharmacokinetic analyses revealed a low elimination-rate of Cremophor EL (CI=37.8-134 ml/h/m2; t 1/2=34.4-61.5 h) and a volume of distribution similar to the volume of the central blood compartment (Vss=4.96-7.85 l).,Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129729/),l,4.96-7.85,82297,DB01229,Paclitaxel
,16299696,limit of detection,The method was validated using a concentration range between 5 and 1000 ng/mL and had a limit of detection of 1 ng/mL.,Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299696/),[ng] / [ml],1,82587,DB01229,Paclitaxel
,21878813,bioavailability,Pharmacokinetic analysis showed 9ING41 to have a bioavailability of 4.5% and to be well distributed in tissues.,Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878813/),%,4.5,82695,DB01229,Paclitaxel
,20159815,overall response rate,"The overall response rate was 58% (95% CI, 37 to 78).","Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159815/),%,58,83433,DB01229,Paclitaxel
,20159815,progression-free survival,"Median progression-free survival was 7.2 months (95% CI, 4.7 to 10.3).","Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20159815/),month,7.2,83434,DB01229,Paclitaxel
,10389912,MTD,"Anemia, neutropenia, thrombocytopenia, and mucositis became dose limiting at the fourth dose level, defining the MTD of doxorubicin in this regimen as 50 mg/m2.",A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389912/),,50,83820,DB01229,Paclitaxel
,10389912,Apparent steady-state plasma concentrations,"Apparent steady-state plasma concentrations (mean +/- SD) of paclitaxel and doxorubicin in the three patients treated at the MTD were 33.9 +/- 12.5 nM and 15.7 +/- 1.3 nM, respectively.",A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389912/),nM,33.9,83821,DB01229,Paclitaxel
,10389912,Apparent steady-state plasma concentrations,"Apparent steady-state plasma concentrations (mean +/- SD) of paclitaxel and doxorubicin in the three patients treated at the MTD were 33.9 +/- 12.5 nM and 15.7 +/- 1.3 nM, respectively.",A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389912/),nM,15.7,83822,DB01229,Paclitaxel
,25162671,encapsulation efficiency,"The encapsulation efficiency was 91.1 ± 4.3%, and the mean diameter was 82.2 ± 7.6 nm from three batches.","Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162671/),%,91.1,84100,DB01229,Paclitaxel
,25162671,half-life time,The stealth liposomes were long-circulating showing a half-life time of 34.2 h against 13.7 h for the conventional ones.,"Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162671/),h,34.2,84101,DB01229,Paclitaxel
,25162671,half-life time,The stealth liposomes were long-circulating showing a half-life time of 34.2 h against 13.7 h for the conventional ones.,"Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25162671/),h,13.7,84102,DB01229,Paclitaxel
,14663637,overall response rate,The overall response rate was 45%.,Biweekly paclitaxel in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663637/),%,45,84371,DB01229,Paclitaxel
,14663637,time to progression,The mean time to progression was 5.4 months.,Biweekly paclitaxel in patients with metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663637/),month,5.4,84372,DB01229,Paclitaxel
,26093319,zeta potentials,"Particle sizes and zeta potentials of the micelles were in the range of 162.3-277.1 nm and 18.5-28.3 mV, respectively.",Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093319/),mv,18.5-28.3,84382,DB01229,Paclitaxel
,26093319,drug,The drug entrapment efficiencies of the micelles were within 53.6-82.5% (w/w).,Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093319/),%,53.6-82.5,84383,DB01229,Paclitaxel
,26093319,entrapment efficiencies,The drug entrapment efficiencies of the micelles were within 53.6-82.5% (w/w).,Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093319/),%,53.6-82.5,84384,DB01229,Paclitaxel
,34319586,overall response rate,The overall response rate was 20%; the median progression-free survival was 4.8 months.,A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34319586/),%,20,84852,DB01229,Paclitaxel
,34319586,progression-free survival,The overall response rate was 20%; the median progression-free survival was 4.8 months.,A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34319586/),month,4.8,84853,DB01229,Paclitaxel
,32034726,AUC,"In this cohort, the average measured AUC of partial responders was 2.4 mg·min/mL.",Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034726/),[mg·min] / [ml],2.4,84975,DB01229,Paclitaxel
,32034726,AUC,Simulations of the newly developed model-based and Calvert dosing assessed the ability to reach this study's proposed actual target AUC of 2.2-2.6 mg·min/mL.,Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32034726/),[mg·min] / [ml],2.2-2.6,84976,DB01229,Paclitaxel
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],1103.2,85610,DB01229,Paclitaxel
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85611,DB01229,Paclitaxel
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85612,DB01229,Paclitaxel
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],208.5,85613,DB01229,Paclitaxel
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],383.1,85614,DB01229,Paclitaxel
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],1.7,85615,DB01229,Paclitaxel
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],0.5,85616,DB01229,Paclitaxel
,23775475,zeta-potential,"The liposomes were found to be relatively uniform in particle size (8.166 ± 0.459 μm) with a negative zeta-potential (-12.45 ± 1.34 mv), and high entrapment efficiency (92.20 ± 2.56 %).",Paclitaxel targeting to lungs by way of liposomes prepared by the effervescent dispersion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23775475/),mv,-,86278,DB01229,Paclitaxel
,23775475,zeta-potential,"The liposomes were found to be relatively uniform in particle size (8.166 ± 0.459 μm) with a negative zeta-potential (-12.45 ± 1.34 mv), and high entrapment efficiency (92.20 ± 2.56 %).",Paclitaxel targeting to lungs by way of liposomes prepared by the effervescent dispersion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23775475/),mv,12.45,86279,DB01229,Paclitaxel
,23775475,entrapment efficiency,"The liposomes were found to be relatively uniform in particle size (8.166 ± 0.459 μm) with a negative zeta-potential (-12.45 ± 1.34 mv), and high entrapment efficiency (92.20 ± 2.56 %).",Paclitaxel targeting to lungs by way of liposomes prepared by the effervescent dispersion technique. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23775475/),%,92.20,86280,DB01229,Paclitaxel
,19520687,area under the curve (AUC),Twenty patients with inoperable NSCLC received weekly carboplatin at area under the curve (AUC) = 2 mg/ml min and paclitaxel.,Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520687/),[mg] / [min·ml],2,86385,DB01229,Paclitaxel
,19520687,AUC,"Three patients each were entered at levels 1 and 2 (level 1, paclitaxel 50 mg/m(2) and carboplatin AUC = 2 mg/ml min; level 2, 60/2), six at level 3 (70/2), five at level 4 (80/2) and three at level 5 (90/2).",Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520687/),[mg] / [min·ml],2,86386,DB01229,Paclitaxel
,19520687,Response rate (RR),Response rate (RR) was 35% (7/20) and median survival was 11.1 months.,Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520687/),%,35,86387,DB01229,Paclitaxel
,19520687,AUC,Weekly combined paclitaxel (up to 90 mg/m(2)) and carboplatin (AUC = 2 mg/ml min) was well tolerated.,Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520687/),[mg] / [min·ml],2,86388,DB01229,Paclitaxel
,10926808,concentrations,Steady state plasma topotecan lactone concentrations were a median of 1.2 ng/ml (range 0.4-8.00 ng/ml) following the first week of infusion.,A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],1.2,86426,DB01229,Paclitaxel
,10926808,steady state plasma topotecan lactone concentrations,"Mean steady state plasma topotecan lactone concentrations after the first week of infusion were 4.6, 2.0, and 1.3 ng/ml for partial response, stable disease, and progressive disease, respectively.",A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],4.6,86427,DB01229,Paclitaxel
,10926808,steady state plasma topotecan lactone concentrations,"Mean steady state plasma topotecan lactone concentrations after the first week of infusion were 4.6, 2.0, and 1.3 ng/ml for partial response, stable disease, and progressive disease, respectively.",A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],2.0,86428,DB01229,Paclitaxel
,10926808,steady state plasma topotecan lactone concentrations,"Mean steady state plasma topotecan lactone concentrations after the first week of infusion were 4.6, 2.0, and 1.3 ng/ml for partial response, stable disease, and progressive disease, respectively.",A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],1.3,86429,DB01229,Paclitaxel
,18316570,clearance,"No significant change in mean paclitaxel clearance was detected (mean +/- SD, 21.2 +/- 4.5 L/h versus 21.3 +/- 4.9 L/h) for pre- and post-atrasentan values, respectively (P = 0.434).","Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316570/),[l] / [h],21.2,87388,DB01229,Paclitaxel
,18316570,clearance,"No significant change in mean paclitaxel clearance was detected (mean +/- SD, 21.2 +/- 4.5 L/h versus 21.3 +/- 4.9 L/h) for pre- and post-atrasentan values, respectively (P = 0.434).","Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316570/),[l] / [h],21.3,87389,DB01229,Paclitaxel
,18316570,Response rate,"Response rate was 18.2%, with progression-free survival of 4.2 months, median survival of 10.6 months, and 1-year survival of 43%.","Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316570/),%,18.2,87390,DB01229,Paclitaxel
,18316570,progression-free survival,"Response rate was 18.2%, with progression-free survival of 4.2 months, median survival of 10.6 months, and 1-year survival of 43%.","Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316570/),month,4.2,87391,DB01229,Paclitaxel
,10640577,t(1/2) beta,"PEGylated liposomes were long-circulating liposomes, with an increased t(1/2) beta 48.6 h, against t(1/2) beta 9.27 h of conventional liposomes.","Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640577/),h,48.6,88076,DB01229,Paclitaxel
,10640577,t(1/2) beta,"PEGylated liposomes were long-circulating liposomes, with an increased t(1/2) beta 48.6 h, against t(1/2) beta 9.27 h of conventional liposomes.","Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640577/),h,9.27,88077,DB01229,Paclitaxel
,16533791,IC50,The IC50 of YM-359445 for VEGFR2 tyrosine kinase was 0.0085 micromol/L.,"YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16533791/),[μM] / [l],0.0085,88615,DB01229,Paclitaxel
,9782075,AUC,The mean paclitaxel AUC was 10.3+/-2.4 h micromol l-1 (range 6.8-13.9 h micromol l-1).,Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9782075/),[h·μM] / [l],10.3,88703,DB01229,Paclitaxel
,9782075,AUCs,"Quantification of the two major paclitaxel metabolites, 6alpha-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel yielded AUCs of 0.44+/-0.30 h micromol l-1 and 0.31+/-0.20 h micromol l-1, respectively.",Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9782075/),[h·μM] / [l],0.44,88704,DB01229,Paclitaxel
,9782075,AUCs,"Quantification of the two major paclitaxel metabolites, 6alpha-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel yielded AUCs of 0.44+/-0.30 h micromol l-1 and 0.31+/-0.20 h micromol l-1, respectively.",Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9782075/),[h·μM] / [l],0.31,88705,DB01229,Paclitaxel
,28552723,LE,The LE of PTX-loaded mixed micelles (13.5%) was highest in the mass ratio 5 to 3 of FA-F87-PLA to TPGS.,Enhanced effect of folated pluronic F87-PLA/TPGS mixed micelles on targeted delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552723/),%,13.5,89335,DB01229,Paclitaxel
,28552723,IC50,"The in vitro cytotoxicity assays indicated that the IC50 values for free PTX injections, PTX-loaded FA-F87-PLA micelles and PTX-loaded FA-F87-PLA/TPGS mixed micelles after 72h of incubation were 1.52, 0.42 and 0.037mg/L, respectively.",Enhanced effect of folated pluronic F87-PLA/TPGS mixed micelles on targeted delivery of paclitaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552723/),[mg] / [l],1.52,89336,DB01229,Paclitaxel
,28552723,IC50,"The in vitro cytotoxicity assays indicated that the IC50 values for free PTX injections, PTX-loaded FA-F87-PLA micelles and PTX-loaded FA-F87-PLA/TPGS mixed micelles after 72h of incubation were 1.52, 0.42 and 0.037mg/L, respectively.",Enhanced effect of folated pluronic F87-PLA/TPGS mixed micelles on targeted delivery of paclitaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552723/),[mg] / [l],0.42,89337,DB01229,Paclitaxel
,28552723,IC50,"The in vitro cytotoxicity assays indicated that the IC50 values for free PTX injections, PTX-loaded FA-F87-PLA micelles and PTX-loaded FA-F87-PLA/TPGS mixed micelles after 72h of incubation were 1.52, 0.42 and 0.037mg/L, respectively.",Enhanced effect of folated pluronic F87-PLA/TPGS mixed micelles on targeted delivery of paclitaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552723/),[mg] / [l],0.037,89338,DB01229,Paclitaxel
,19429416,critical micelle concentration (CMC),"The values of critical micelle concentration (CMC) were found to be 0.011-0.079 mg/ml, and the log CMC was linearly relative to four structure parameters, degree of substitution (DS) of chitosan unit, sulfate group, PEG unit and octyl group by mole per kilogram.",PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429416/),[mg] / [ml],0.011-0.079,89342,DB01229,Paclitaxel
,19429416,loading rate,Paclitaxel (PTX)-loaded micelles were prepared with the highest loading rate of 42.6%.,PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429416/),%,42.6,89343,DB01229,Paclitaxel
,19429416,area under the plasma concentration time curve (AUC (0-t(n))),"The area under the plasma concentration time curve (AUC (0-t(n))) of PTX-mPEGOSC2000M was 10.21+/-2.12 microg h/ml, which were 2.93 times higher than PTX-OSC and 0.83 times lower than Taxol.",PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429416/),[h·μg] / [ml],10.21,89344,DB01229,Paclitaxel
,19429416,f(t,"Rate constant of distribution phase (alpha) and rate constant of elimination phase (beta) were analyzed by linear regression with the absorbance of protein to micelles (A) and the fraction of intact micelles at 10 min (f(t, 10 min)).",PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429416/),min,10,89345,DB01229,Paclitaxel
,9010040,AUC,"The aim of this phase I study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel, combined with carboplatin at a fixed AUC of 7 mg ml-1 min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction.",A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010040/),[mg·min] / [ml],7,89693,DB01229,Paclitaxel
,9010040,AUC,"The AUC of carboplatin was 7.0 +/- 1.4 mg ml-1 min, indicating that there was no pharmacokinetic interaction.",A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010040/),[mg·min] / [ml],7.0,89694,DB01229,Paclitaxel
,33845742,cumulative release rate,"According to in vitro release studies, the cumulative release rate of PTX-loaded FA-F87-PLGA/TPGS mixed NPs was 92.04%, which was higher than that of nanoparticles without TPGS.",Preparation and in vitro/vivo evaluation of folate-conjugated pluronic F87-PLGA/TPGS mixed nanoparticles for targeted drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33845742/),%,92.04,90419,DB01229,Paclitaxel
,7907130,clearance,"Clearance was dose-dependent, with a median clearance at the lower dosages (< 400 mg/m2) of 161 mL/min/m2, and at the highest dosages (> 400 mg/m2) of 123 mL/min/m2 (P = .044).",Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907130/),[ml] / [m2·min],161,91146,DB01229,Paclitaxel
,7907130,clearance,"Clearance was dose-dependent, with a median clearance at the lower dosages (< 400 mg/m2) of 161 mL/min/m2, and at the highest dosages (> 400 mg/m2) of 123 mL/min/m2 (P = .044).",Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907130/),[ml] / [m2·min],123,91147,DB01229,Paclitaxel
,7907130,area under the concentration-versus-time curve (AUC),There was a trend toward higher median area under the concentration-versus-time curve (AUC) in those children with musculoskeletal (72 mumol/L.h; P = .054) or neurologic toxicity (54 mumol/L.h; P = .062) versus those without toxicity (30 mumol/L.h).,Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907130/),[μM] / [h·l],72,91148,DB01229,Paclitaxel
,7907130,area under the concentration-versus-time curve (AUC),There was a trend toward higher median area under the concentration-versus-time curve (AUC) in those children with musculoskeletal (72 mumol/L.h; P = .054) or neurologic toxicity (54 mumol/L.h; P = .062) versus those without toxicity (30 mumol/L.h).,Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907130/),[μM] / [h·l],54,91149,DB01229,Paclitaxel
,7907130,area under the concentration-versus-time curve (AUC),There was a trend toward higher median area under the concentration-versus-time curve (AUC) in those children with musculoskeletal (72 mumol/L.h; P = .054) or neurologic toxicity (54 mumol/L.h; P = .062) versus those without toxicity (30 mumol/L.h).,Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907130/),[μM] / [h·l],30,91150,DB01229,Paclitaxel
,25672916,MTDs,The MTDs for buparlisib were 100 mg/day in Group 1 and 80 mg/day in Group 2.,Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),[mg] / [d],100,91206,DB01229,Paclitaxel
,25672916,MTDs,The MTDs for buparlisib were 100 mg/day in Group 1 and 80 mg/day in Group 2.,Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),[mg] / [d],80,91207,DB01229,Paclitaxel
,25672916,objective response rate,"Among 25 patients with measurable disease, the confirmed objective response rate was 20% (one complete response, four partial responses).",Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),%,20,91208,DB01229,Paclitaxel
,21920419,survival time,"More importantly, in vivo anti-tumor effect exhibited the median survival time of NP/PTX treated mice (27 days) was significantly longer than those of mice treated with Taxol (24 days), physiological saline (21 days) and blank MPEG-PTMC NP (21 days).",PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920419/),d,27,91324,DB01229,Paclitaxel
,21920419,survival time,"More importantly, in vivo anti-tumor effect exhibited the median survival time of NP/PTX treated mice (27 days) was significantly longer than those of mice treated with Taxol (24 days), physiological saline (21 days) and blank MPEG-PTMC NP (21 days).",PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920419/),d,24,91325,DB01229,Paclitaxel
,21920419,survival time,"More importantly, in vivo anti-tumor effect exhibited the median survival time of NP/PTX treated mice (27 days) was significantly longer than those of mice treated with Taxol (24 days), physiological saline (21 days) and blank MPEG-PTMC NP (21 days).",PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920419/),d,21,91326,DB01229,Paclitaxel
,29139187,AUC(0-∞),"Plasma PTX was detectable for up to 5 days but not at 28 days, with area under the curve (AUC)(0-5d) 20- to 50-fold lower than the AUC(0-∞) of 6300 ng h/mL for the approved intravenous dose.",Pharmacokinetics and safety of paclitaxel delivery into porcine airway walls by a new endobronchial drug delivery catheter. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29139187/),[h·ng] / [ml],6300,91433,DB01229,Paclitaxel
,24290734,Cmax,"Mean total paclitaxel Cmax values for the test and reference formulations were 4955.0 and 5108.8 ng/mL, respectively.","Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290734/),[ng] / [ml],4955.0,91538,DB01229,Paclitaxel
,24290734,Cmax,"Mean total paclitaxel Cmax values for the test and reference formulations were 4955.0 and 5108.8 ng/mL, respectively.","Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290734/),[ng] / [ml],5108.8,91539,DB01229,Paclitaxel
,24290734,AUC0-∞,"Corresponding AUC0-∞ values were 15,853.8 and 18,550.8 ng·h/mL, respectively.","Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290734/),[h·ng] / [ml],"15,853.8",91540,DB01229,Paclitaxel
,24290734,AUC0-∞,"Corresponding AUC0-∞ values were 15,853.8 and 18,550.8 ng·h/mL, respectively.","Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24290734/),[h·ng] / [ml],"18,550.8",91541,DB01229,Paclitaxel
,18956139,MTD,"MTD was 500/135 mg/m(2) (S1), 400/40 mg/m(2) (S2), and 500/120 mg/m(2) (S3).",Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956139/),mg,500,91617,DB01229,Paclitaxel
,18956139,MTD,"MTD was 500/135 mg/m(2) (S1), 400/40 mg/m(2) (S2), and 500/120 mg/m(2) (S3).",Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956139/),mg,135,91618,DB01229,Paclitaxel
,12721265,terminal half-life,"The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min.","Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721265/),h,16.8,92005,DB01229,Paclitaxel
,12721265,volume of distribution at steady-state,"The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min.","Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721265/),l,798,92006,DB01229,Paclitaxel
,12721265,clearance,"The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min.","Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721265/),[ml] / [min],712,92007,DB01229,Paclitaxel
,11679185,AUC,"Sixty patients (15 stage IIIb and 45 stage IV) received paclitaxel 225 mg/ml on day 1, followed by carboplatin AUC 6 mg/ml per minute (Calvert formula) every 3 weeks.","Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679185/),[mg] / [min·ml],6,92189,DB01229,Paclitaxel
,11679185,overall response rate,"Among 59 evaluable patients, there was one complete response and 26 partial responses for an overall response rate of 46% (95% C.I.: 34-59%).","Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679185/),%,46,92190,DB01229,Paclitaxel
,11679185,overall survival time,"With a minimum follow-up duration of 16.5 months, the median overall survival time is 52 weeks and the 1-year survival rate is 50%.","Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679185/),weeks,52,92191,DB01229,Paclitaxel
,11679185,duration of response,Median duration of response is 20 weeks (range: 4-52) and progression-free survival is 22 weeks (range: 5-77).,"Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679185/),weeks,20,92192,DB01229,Paclitaxel
,11679185,progression-free survival,Median duration of response is 20 weeks (range: 4-52) and progression-free survival is 22 weeks (range: 5-77).,"Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679185/),weeks,22,92193,DB01229,Paclitaxel
,8558221,overall response proportion,"The overall response proportion (CRs plus PRs) was 54% (95% confidence interval, 37% to 71%).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),%,54,92272,DB01229,Paclitaxel
,8558221,time to response,"The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),weeks,12,92273,DB01229,Paclitaxel
,8558221,duration,"The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),weeks,26,92274,DB01229,Paclitaxel
,24815943,Cmax,"In plasma, DTX-HPB nanoparticles exhibited a significantly enhanced Cmax (1300.618±405.045 ng/mL vs 453.174±164.437 ng/mL, p<0.05), and AUC0-t (409.602±70.267 vs 314.924±57.426 μg/Lh, p<0.05), and a significantly reduced volume of distribution (36.635±15.189 vs 95.199±40.972 L/kg, p<0.05) compared with the Taxotere.",Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815943/),[ng] / [ml],1300.618,93749,DB01229,Paclitaxel
,24815943,Cmax,"In plasma, DTX-HPB nanoparticles exhibited a significantly enhanced Cmax (1300.618±405.045 ng/mL vs 453.174±164.437 ng/mL, p<0.05), and AUC0-t (409.602±70.267 vs 314.924±57.426 μg/Lh, p<0.05), and a significantly reduced volume of distribution (36.635±15.189 vs 95.199±40.972 L/kg, p<0.05) compared with the Taxotere.",Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815943/),[ng] / [ml],453.174,93750,DB01229,Paclitaxel
,24815943,AUC0-t,"In plasma, DTX-HPB nanoparticles exhibited a significantly enhanced Cmax (1300.618±405.045 ng/mL vs 453.174±164.437 ng/mL, p<0.05), and AUC0-t (409.602±70.267 vs 314.924±57.426 μg/Lh, p<0.05), and a significantly reduced volume of distribution (36.635±15.189 vs 95.199±40.972 L/kg, p<0.05) compared with the Taxotere.",Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815943/),[μg] / [lh],409.602,93751,DB01229,Paclitaxel
,24815943,AUC0-t,"In plasma, DTX-HPB nanoparticles exhibited a significantly enhanced Cmax (1300.618±405.045 ng/mL vs 453.174±164.437 ng/mL, p<0.05), and AUC0-t (409.602±70.267 vs 314.924±57.426 μg/Lh, p<0.05), and a significantly reduced volume of distribution (36.635±15.189 vs 95.199±40.972 L/kg, p<0.05) compared with the Taxotere.",Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815943/),[μg] / [lh],314.924,93752,DB01229,Paclitaxel
,24815943,volume of distribution,"In plasma, DTX-HPB nanoparticles exhibited a significantly enhanced Cmax (1300.618±405.045 ng/mL vs 453.174±164.437 ng/mL, p<0.05), and AUC0-t (409.602±70.267 vs 314.924±57.426 μg/Lh, p<0.05), and a significantly reduced volume of distribution (36.635±15.189 vs 95.199±40.972 L/kg, p<0.05) compared with the Taxotere.",Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815943/),[l] / [kg],36.635,93753,DB01229,Paclitaxel
,24815943,volume of distribution,"In plasma, DTX-HPB nanoparticles exhibited a significantly enhanced Cmax (1300.618±405.045 ng/mL vs 453.174±164.437 ng/mL, p<0.05), and AUC0-t (409.602±70.267 vs 314.924±57.426 μg/Lh, p<0.05), and a significantly reduced volume of distribution (36.635±15.189 vs 95.199±40.972 L/kg, p<0.05) compared with the Taxotere.",Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24815943/),[l] / [kg],95.199,93754,DB01229,Paclitaxel
,28196905,progression-free survival,"Median progression-free survival of gastric cancer patients (n = 16) treated at the MTD was 2.97 (95% confidence interval, 1.67-5.40) months (Fig. 1).","A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196905/),month,2.97,93935,DB01229,Paclitaxel
,27446541,area under the concentration-time curve (AUC),"After paclitaxel administration, 125 mg of carboplatin was administered over 1 h to achieve a target area under the concentration-time curve (AUC) of 5.0 mg•min/ml using the Calvert formula.",Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27446541/),[mg·min] / [ml],5.0,94269,DB01229,Paclitaxel
,27446541,AUC,"The time interval between the end of carboplatin administration and hemodialysis initiation was 1 h at the first cycle, 16 h at the second cycle and 20 h at the third cycle, and the AUC obtained was 2.86, 4.16 and 6.0 mg•min/ml, respectively.",Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27446541/),[mg·min] / [ml],2.86,94270,DB01229,Paclitaxel
,27446541,AUC,"The time interval between the end of carboplatin administration and hemodialysis initiation was 1 h at the first cycle, 16 h at the second cycle and 20 h at the third cycle, and the AUC obtained was 2.86, 4.16 and 6.0 mg•min/ml, respectively.",Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27446541/),[mg·min] / [ml],4.16,94271,DB01229,Paclitaxel
,27446541,AUC,"The time interval between the end of carboplatin administration and hemodialysis initiation was 1 h at the first cycle, 16 h at the second cycle and 20 h at the third cycle, and the AUC obtained was 2.86, 4.16 and 6.0 mg•min/ml, respectively.",Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27446541/),[mg·min] / [ml],6.0,94272,DB01229,Paclitaxel
,9498685,extraction recoveries,"The extraction recoveries of spiked paclitaxel and docetaxel to drug-free human plasma were 89.6+/-8.52 and 93.7+/-5.0%, respectively.",Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498685/),%,89.6,96294,DB01229,Paclitaxel
,9498685,extraction recoveries,"The extraction recoveries of spiked paclitaxel and docetaxel to drug-free human plasma were 89.6+/-8.52 and 93.7+/-5.0%, respectively.",Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498685/),%,93.7,96295,DB01229,Paclitaxel
,8826613,peak plasma concentrations (Cmax),Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],8.9,96648,DB01229,Paclitaxel
,8826613,terminal half-life,Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,0.6,96649,DB01229,Paclitaxel
,8826613,Cmax,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],1.6,96650,DB01229,Paclitaxel
,8826613,terminal half-life,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,7.4,96651,DB01229,Paclitaxel
,8826613,half-life,"Although the CPT-11 tumor levels were similar to the plasma concentrations for early time points, drug levels decreased more slowly in the tumor compared to plasma (half-life, 5.0 h).",Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,5.0,96652,DB01229,Paclitaxel
,8826613,half-life,SN-38 tumor levels reached concentrations in the range of 0.32-0.34 micrograms/g and decayed with a half-life of 6.9 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,6.9,96653,DB01229,Paclitaxel
,19738417,MTD,"The MTD of the combination of CAI and paclitaxel is 250 mg daily and 200 mg/m(2) q3weeks, respectively.",A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738417/),mg,250,97276,DB01229,Paclitaxel
,10506711,overall response rate,The overall response rate was 16% (2 patients achieved a complete response and 5 patients achieved a partial response).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),%,16,97318,DB01229,Paclitaxel
,10506711,duration of response,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4.3,97319,DB01229,Paclitaxel
,10506711,overall survival,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.6,97320,DB01229,Paclitaxel
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,3.1,97321,DB01229,Paclitaxel
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4. 9,97322,DB01229,Paclitaxel
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.1,97323,DB01229,Paclitaxel
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,12,97324,DB01229,Paclitaxel
,11487715,area under the concentration-time curve (AUC),Dose escalation of paclitaxel from 60 to 300 mg/m(2) resulted in a significant decrease in the area under the concentration-time curve (AUC) of CsA from 24.4+/-9.9 to 17.6+/-2.8 mg/l.h (p=0.03) (n=28).,Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11487715/),[mg] / [h·l],24.4,97393,DB01229,Paclitaxel
,11487715,area under the concentration-time curve (AUC),Dose escalation of paclitaxel from 60 to 300 mg/m(2) resulted in a significant decrease in the area under the concentration-time curve (AUC) of CsA from 24.4+/-9.9 to 17.6+/-2.8 mg/l.h (p=0.03) (n=28).,Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11487715/),[mg] / [h·l],17.6,97394,DB01229,Paclitaxel
,24134039,radius of gyration,"Molecular dynamics simulations showed a high degree of hydration of the core, and a radius of gyration of 2.8 ± 0.2 nm.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),nm,2.8,97803,DB01229,Paclitaxel
,24134039,hydrodynamic radius,"The hydrodynamic radius of the target was found to be 15.8 nm by dynamic light scattering, an observation indicative of aggregation.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),,15.8,97804,DB01229,Paclitaxel
,24134039,elimination,"Using a two component model, the elimination and distribution half-lives were 2.65 h and 38.2 h, respectively.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),h,2.65,97805,DB01229,Paclitaxel
,24134039,distribution half-lives,"Using a two component model, the elimination and distribution half-lives were 2.65 h and 38.2 h, respectively.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),h,38.2,97806,DB01229,Paclitaxel
,7587959,plasma Cmax,"The analysis of drug concentrations by HPLC indicated that the plasma Cmax (13.0 +/- 3.1 and 25.7 +/- 2.8 micrograms/ml, respectively) were reached at the 2nd hr.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [ml],13.0,99122,DB01229,Paclitaxel
,7587959,plasma Cmax,"The analysis of drug concentrations by HPLC indicated that the plasma Cmax (13.0 +/- 3.1 and 25.7 +/- 2.8 micrograms/ml, respectively) were reached at the 2nd hr.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [ml],25.7,99123,DB01229,Paclitaxel
,7587959,CL,"The values of CL were low (0.06 and 0.1 ml/min, respectively), and t1/2 beta values of 3.0 and 3.7 hr were found, after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[ml] / [min],0.06,99124,DB01229,Paclitaxel
,7587959,CL,"The values of CL were low (0.06 and 0.1 ml/min, respectively), and t1/2 beta values of 3.0 and 3.7 hr were found, after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[ml] / [min],0.1,99125,DB01229,Paclitaxel
,7587959,t1/2 beta,"The values of CL were low (0.06 and 0.1 ml/min, respectively), and t1/2 beta values of 3.0 and 3.7 hr were found, after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),h,3.0,99126,DB01229,Paclitaxel
,7587959,t1/2 beta,"The values of CL were low (0.06 and 0.1 ml/min, respectively), and t1/2 beta values of 3.0 and 3.7 hr were found, after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),h,3.7,99127,DB01229,Paclitaxel
,7587959,tissue concentrations,"The highest tissue concentrations were observed in the liver (50.2 +/- 3.1 and 92.0 +/- 9.5 micrograms/g respectively), followed by the pancreas (39.3 +/- 9.9 micrograms/g) and the ovary (53.4 +/- 5.6 micrograms/g) after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],50.2,99128,DB01229,Paclitaxel
,7587959,tissue concentrations,"The highest tissue concentrations were observed in the liver (50.2 +/- 3.1 and 92.0 +/- 9.5 micrograms/g respectively), followed by the pancreas (39.3 +/- 9.9 micrograms/g) and the ovary (53.4 +/- 5.6 micrograms/g) after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],92.0,99129,DB01229,Paclitaxel
,7587959,tissue concentrations,"The highest tissue concentrations were observed in the liver (50.2 +/- 3.1 and 92.0 +/- 9.5 micrograms/g respectively), followed by the pancreas (39.3 +/- 9.9 micrograms/g) and the ovary (53.4 +/- 5.6 micrograms/g) after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],39.3,99130,DB01229,Paclitaxel
,7587959,tissue concentrations,"The highest tissue concentrations were observed in the liver (50.2 +/- 3.1 and 92.0 +/- 9.5 micrograms/g respectively), followed by the pancreas (39.3 +/- 9.9 micrograms/g) and the ovary (53.4 +/- 5.6 micrograms/g) after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],53.4,99131,DB01229,Paclitaxel
,7587959,Cmax,"In the case of the colic tissue, paclitaxel Cmax were 14.4 +/- 0.8 and 32.8 +/- 3.5 micrograms/g at the 3rd hr, respectively, with sustained drug levels still detectable 24 hr after treatment.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],14.4,99132,DB01229,Paclitaxel
,7587959,Cmax,"In the case of the colic tissue, paclitaxel Cmax were 14.4 +/- 0.8 and 32.8 +/- 3.5 micrograms/g at the 3rd hr, respectively, with sustained drug levels still detectable 24 hr after treatment.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],32.8,99133,DB01229,Paclitaxel
,7587959,Cmax,"Paclitaxel Cmax values of 12.7 +/- 3.0 and 53.4 +/- 5.6 micrograms/g were detected in the ovary after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],12.7,99134,DB01229,Paclitaxel
,7587959,Cmax,"Paclitaxel Cmax values of 12.7 +/- 3.0 and 53.4 +/- 5.6 micrograms/g were detected in the ovary after 18 and 36 mg/kg, respectively.",Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587959/),[μg] / [g],53.4,99135,DB01229,Paclitaxel
,19299904,MTD,"The MTD was determined to be 30 mg/m(2), as 2 of 3 patients developed dose-limiting toxicities, grade 3 febrile neutropenia and diarrhea.",Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299904/),[mg] / [m],30,99179,DB01229,Paclitaxel
,19299904,RD,"Therefore, the RD was determined to be 20 mg/m(2).",Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299904/),[mg] / [m(2],20,99180,DB01229,Paclitaxel
,20934500,drug-loading coefficient,"The drug-loading coefficient and encapsulation ratio of optimized formulation were 8.2±0.6% and 90.4±2.3%, respectively.",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),%,8.2,99421,DB01229,Paclitaxel
,20934500,encapsulation ratio,"The drug-loading coefficient and encapsulation ratio of optimized formulation were 8.2±0.6% and 90.4±2.3%, respectively.",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),%,90.4,99422,DB01229,Paclitaxel
,20934500,mean,"Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days).",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),d,28,99423,DB01229,Paclitaxel
,20934500,mean,"Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days).",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),d,20,99424,DB01229,Paclitaxel
,20934500,mean,"Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days).",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),d,23,99425,DB01229,Paclitaxel
,20934500,survive time,"Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days).",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),d,28,99426,DB01229,Paclitaxel
,20934500,survive time,"Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days).",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),d,20,99427,DB01229,Paclitaxel
,20934500,survive time,"Furthermore, in vivo anti-glioblastoma effect exhibited the mean survive time of MPEG-NP/PTX (28 days) was much longer than those of Taxol injection (20 days) and NP/PTX (23 days).",Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20934500/),d,23,99428,DB01229,Paclitaxel
,15265561,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of paclitaxel by oral paclitaxel were 836, 1,602 and 3,076 ng/mlh, which increased dose-dependently (P < 0.006, r = 0.9996).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],836,99912,DB01229,Paclitaxel
,15265561,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of paclitaxel by oral paclitaxel were 836, 1,602 and 3,076 ng/mlh, which increased dose-dependently (P < 0.006, r = 0.9996).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],"1,602",99913,DB01229,Paclitaxel
,15265561,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of paclitaxel by oral paclitaxel were 836, 1,602 and 3,076 ng/mlh, which increased dose-dependently (P < 0.006, r = 0.9996).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],"3,076",99914,DB01229,Paclitaxel
,15265561,AUCs,"The AUCs of paclitaxel by the oral paclitaxel prodrug were 1,646, 3,079 and 5,998 ng/mlh, also increased dose-dependently (P < 0.003, r = 0.9999).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],"1,646",99915,DB01229,Paclitaxel
,15265561,AUCs,"The AUCs of paclitaxel by the oral paclitaxel prodrug were 1,646, 3,079 and 5,998 ng/mlh, also increased dose-dependently (P < 0.003, r = 0.9999).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],"3,079",99916,DB01229,Paclitaxel
,15265561,AUCs,"The AUCs of paclitaxel by the oral paclitaxel prodrug were 1,646, 3,079 and 5,998 ng/mlh, also increased dose-dependently (P < 0.003, r = 0.9999).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],"5,998",99917,DB01229,Paclitaxel
,15265561,AUC,"The AUC of paclitaxel by the intravenous administration of paclitaxel (2 mg/kg) was 3,992 ng/mlh.",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [mlh],"3,992",99918,DB01229,Paclitaxel
,15265561,absolute bioavailability (AB%),The mean absolute bioavailability (AB%) of paclitaxel was 1.6% by the oral administration of paclitaxel.,Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),%,1.6,99919,DB01229,Paclitaxel
,15265561,AB%,"The mean AB% of paclitaxel by the prodrug was 6.3%, which was 3.94-fold higher than the oral paclitaxel.",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),%,6.3,99920,DB01229,Paclitaxel
,15265561,peak concentration of paclitaxel (C(max)),"The peak concentration of paclitaxel (C(max)) in the dose of 350 mg/kg (50 mg/kg as paclitaxel) of prodrug was 339 ng/ml, which was significantly higher (P < 0.01) than the dose of 50 mg/kg of paclitaxel (104 ng/ml).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [ml],339,99921,DB01229,Paclitaxel
,15265561,peak concentration of paclitaxel (C(max)),"The peak concentration of paclitaxel (C(max)) in the dose of 350 mg/kg (50 mg/kg as paclitaxel) of prodrug was 339 ng/ml, which was significantly higher (P < 0.01) than the dose of 50 mg/kg of paclitaxel (104 ng/ml).",Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265561/),[ng] / [ml],104,99922,DB01229,Paclitaxel
,16085137,LOD,"The LOD and LOQ were 5 and 10 ng/ml, respectively, for paclitaxel using a microsample volume (100 microl) of plasma sample.",Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085137/),[ng] / [ml],5,100302,DB01229,Paclitaxel
,16085137,LOQ,"The LOD and LOQ were 5 and 10 ng/ml, respectively, for paclitaxel using a microsample volume (100 microl) of plasma sample.",Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085137/),[ng] / [ml],10,100303,DB01229,Paclitaxel
,25723092,Drug payloads,Drug payloads ranged from 1.32 to 3.62 mg Ptx/g of formulation.,In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25723092/),mg·p,1.32 to 3.62,100729,DB01229,Paclitaxel
,10694566,MTD,The MTD for paclitaxel with PSC 833 was 122.5 mg/m(2).,"Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694566/),[mg] / [m(2],122.5,101073,DB01229,Paclitaxel
,32081942,oral bioavailability,"The oral bioavailability of T-13 and T-26 was determined to be 10.71% and 65.79%, respectively.","T-13 and T-26, the novel taxanes with improved oral bioavailability in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32081942/),%,10.71,102155,DB01229,Paclitaxel
,32081942,oral bioavailability,"The oral bioavailability of T-13 and T-26 was determined to be 10.71% and 65.79%, respectively.","T-13 and T-26, the novel taxanes with improved oral bioavailability in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32081942/),%,65.79,102156,DB01229,Paclitaxel
,29464110,Objective response rates,"Objective response rates were 12% (TAK-228 QD), 18% (TAK-228+P) and 0% (TAK-228 QW).",Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464110/),%,12,102850,DB01229,Paclitaxel
,29464110,Objective response rates,"Objective response rates were 12% (TAK-228 QD), 18% (TAK-228+P) and 0% (TAK-228 QW).",Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464110/),%,18,102851,DB01229,Paclitaxel
,29464110,Objective response rates,"Objective response rates were 12% (TAK-228 QD), 18% (TAK-228+P) and 0% (TAK-228 QW).",Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29464110/),%,0,102852,DB01229,Paclitaxel
,19889612,area under the curve,"Patients with advanced gynecological malignancies received BIBF 1120 twice-daily (b.i.d.) continuously at 100, 150, 200 or 250 mg, combined with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5 min.mg/ml) every 3 weeks.",A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889612/),[mg·min] / [ml],5,102862,DB01229,Paclitaxel
,19889612,MTD,The MTD was defined as 200 mg b.i.d.,A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889612/),,200,102863,DB01229,Paclitaxel
,11268499,area under the concentration-time curve (AUC),Carboplatin was administered at an area under the concentration-time curve (AUC) of 6.,Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268499/),,6,102971,DB01229,Paclitaxel
,11268499,overall response,"Thirty of the 37 patients responded to the chemotherapy, demonstrating an overall response of 81%.",Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268499/),%,81,102972,DB01229,Paclitaxel
,11268499,overall survival,"The mean overall survival was 20 months (25% quartile: 19, median and 75% quartile not reached).",Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268499/),month,20,102973,DB01229,Paclitaxel
,18398152,area under the concentration time curve,"Eligible patients received carboplatin targeted to an area under the concentration time curve of 6 mg . min/mL and paclitaxel 200 mg/m(2), both on day 1 of a 3-week cycle; daily oral AZD2171 at either 30 mg or 45 mg commenced day 2 of cycle 1.","Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18398152/),[mg·min] / [ml],6,103063,DB01229,Paclitaxel
,18398152,response rate,"After radiology review, confirmed responses were observed in nine patients (response rate, 45%; 95% CI, 23% to 68%); all but one enrolled patient showed evidence of tumor shrinkage, some with cavitation.","Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18398152/),%,45,103064,DB01229,Paclitaxel
,17549476,AUC0-t,"AUC0-t values for bevacizumab when administered alone or in combination with chemotherapy were 6,747 +/- 1,872 and 7,366 +/- 1,599 microg/ml x day, respectively.",Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549476/),[μg] / [d·ml],"6,747",103239,DB01229,Paclitaxel
,17549476,AUC0-t,"AUC0-t values for bevacizumab when administered alone or in combination with chemotherapy were 6,747 +/- 1,872 and 7,366 +/- 1,599 microg/ml x day, respectively.",Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549476/),[μg] / [d·ml],"7,366",103240,DB01229,Paclitaxel
,17549476,AUC0-t,"AUC0-t values for paclitaxel with or without concomitantly administered bevacizumab were 10.9 +/- 2.9 and 10.3 +/- 3.7 microg/ml x day, respectively.",Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549476/),[μg] / [d·ml],10.9,103241,DB01229,Paclitaxel
,17549476,AUC0-t,"AUC0-t values for paclitaxel with or without concomitantly administered bevacizumab were 10.9 +/- 2.9 and 10.3 +/- 3.7 microg/ml x day, respectively.",Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549476/),[μg] / [d·ml],10.3,103242,DB01229,Paclitaxel
,10507770,cumulative dose,The median cumulative dose was 449 mg m(-2).,A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10507770/),[mg] / [(m)^2],449,104021,DB01229,Paclitaxel
,10507770,overall response rate,The overall response rate was 20.8% with a median duration of 11.0 weeks (range 2.4-52.6).,A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10507770/),%,20.8,104022,DB01229,Paclitaxel
,10507770,clearance,A mean clearance of 19.6 l h(-1) m(-2) and an area under the curve of 6.00 microg ml(-1) h(-1) was found in the pharmacokinetic analysis.,A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10507770/),[l] / [(m)^2·h],19.6,104023,DB01229,Paclitaxel
,10507770,area under the curve,A mean clearance of 19.6 l h(-1) m(-2) and an area under the curve of 6.00 microg ml(-1) h(-1) was found in the pharmacokinetic analysis.,A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10507770/),[μg] / [h·ml],6.00,104024,DB01229,Paclitaxel
,31820303,area under the curve (AUC0-t),"The results showed that 14 days pretreatment of licorice could decrease the area under the curve (AUC0-t) (from 7483.08 ± 528.78 to 6679.12 ± 266.56 mg/L × h) (P < 0.01), and increase the total clearance (CL) (from 0.36 ± 0.02 to 0.39 ± 0.02 L/h/kg) of paclitaxel (P < 0.01).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[mg] / [h·l],7483.08,104099,DB01229,Paclitaxel
,31820303,area under the curve (AUC0-t),"The results showed that 14 days pretreatment of licorice could decrease the area under the curve (AUC0-t) (from 7483.08 ± 528.78 to 6679.12 ± 266.56 mg/L × h) (P < 0.01), and increase the total clearance (CL) (from 0.36 ± 0.02 to 0.39 ± 0.02 L/h/kg) of paclitaxel (P < 0.01).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[mg] / [h·l],6679.12,104100,DB01229,Paclitaxel
,31820303,total clearance (CL),"The results showed that 14 days pretreatment of licorice could decrease the area under the curve (AUC0-t) (from 7483.08 ± 528.78 to 6679.12 ± 266.56 mg/L × h) (P < 0.01), and increase the total clearance (CL) (from 0.36 ± 0.02 to 0.39 ± 0.02 L/h/kg) of paclitaxel (P < 0.01).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[l] / [h·kg],0.36,104101,DB01229,Paclitaxel
,31820303,total clearance (CL),"The results showed that 14 days pretreatment of licorice could decrease the area under the curve (AUC0-t) (from 7483.08 ± 528.78 to 6679.12 ± 266.56 mg/L × h) (P < 0.01), and increase the total clearance (CL) (from 0.36 ± 0.02 to 0.39 ± 0.02 L/h/kg) of paclitaxel (P < 0.01).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[l] / [h·kg],0.39,104102,DB01229,Paclitaxel
,31820303,AUC0-t,"However, a single co-administration of licorice did not significantly alter the pharmacokinetic parameters of paclitaxel, such as AUC0-t (from 7483.08 ± 528.78 to 7201.24 ± 292.76 mg/L × h) (P > 0.05) and CL (from 0.36 ± 0.02 to 0.36 ± 0.01 L/h/kg) (P > 0.05).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[mg] / [h·l],7483.08,104103,DB01229,Paclitaxel
,31820303,AUC0-t,"However, a single co-administration of licorice did not significantly alter the pharmacokinetic parameters of paclitaxel, such as AUC0-t (from 7483.08 ± 528.78 to 7201.24 ± 292.76 mg/L × h) (P > 0.05) and CL (from 0.36 ± 0.02 to 0.36 ± 0.01 L/h/kg) (P > 0.05).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[mg] / [h·l],7201.24,104104,DB01229,Paclitaxel
,31820303,CL,"However, a single co-administration of licorice did not significantly alter the pharmacokinetic parameters of paclitaxel, such as AUC0-t (from 7483.08 ± 528.78 to 7201.24 ± 292.76 mg/L × h) (P > 0.05) and CL (from 0.36 ± 0.02 to 0.36 ± 0.01 L/h/kg) (P > 0.05).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[l] / [h·kg],0.36,104105,DB01229,Paclitaxel
,31820303,CL,"However, a single co-administration of licorice did not significantly alter the pharmacokinetic parameters of paclitaxel, such as AUC0-t (from 7483.08 ± 528.78 to 7201.24 ± 292.76 mg/L × h) (P > 0.05) and CL (from 0.36 ± 0.02 to 0.36 ± 0.01 L/h/kg) (P > 0.05).",Herb-Drug Interaction Potential of Licorice Extract and Paclitaxel: A Pharmacokinetic Study in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31820303/),[l] / [h·kg],0.36,104106,DB01229,Paclitaxel
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],5,104363,DB01229,Paclitaxel
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],7,104364,DB01229,Paclitaxel
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],9,104365,DB01229,Paclitaxel
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],11,104366,DB01229,Paclitaxel
,10080614,AUC,Thrombocytopenia was observed at a carboplatin AUC of 11 mg/mL x minute after course 2 and thereafter.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],11,104367,DB01229,Paclitaxel
,10080614,duration of time,End-of-infusion plasma paclitaxel concentrations and median duration of time above 0.05 microM were similar in course 1 versus course 2 at the 135 and 175 mg/m2 dose levels.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),μM,0,104368,DB01229,Paclitaxel
,10080614,overall response rate,"Of the 36 patients entered onto the study, one experienced a complete response and 17 had partial responses, for an overall response rate of 50%.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),%,50,104369,DB01229,Paclitaxel
,10080614,AUC,The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],7,104370,DB01229,Paclitaxel
,10080614,AUC,The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],9,104371,DB01229,Paclitaxel
,11139311,area under the plasma concentration-time curve (AUC),The mean area under the plasma concentration-time curve (AUC) of paclitaxel after oral drug administration in combination with GF120918 was 3.27 +/- 1.67 microM x h.,Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139311/),h·μM,3.27,104794,DB01229,Paclitaxel
,11139311,AUC,In our previously performed study of 120 mg/m(2)oral paclitaxel in combination with CsA the mean AUC of paclitaxel was 2.55 +/- 2.29 microM x h.,Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139311/),h·μM,2.55,104795,DB01229,Paclitaxel
,11139311,AUC,After i.v. administration of paclitaxel the mean AUC was 15.92( )+/- 2.46 microM x h.,Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139311/),h·μM,15.92,104796,DB01229,Paclitaxel
>,12383484,recovery,"The method involves solid-phase extraction from cyano cartridges (recovery >80%), HPLC separation on Symmetry C(18) (4.6 x 150 mm), on isocratic mobile phase of water-acetonitrile-acetic acid (49:50:1) and detection at 227 nm.",High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383484/),%,80,105689,DB01229,Paclitaxel
,12383484,Retention times,"Retention times of IDN 5390 and IDN 5517 (internal standard, I.S.) were 9.1 and 10.5 min, respectively.",High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383484/),min,9.1,105690,DB01229,Paclitaxel
,12383484,Retention times,"Retention times of IDN 5390 and IDN 5517 (internal standard, I.S.) were 9.1 and 10.5 min, respectively.",High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383484/),min,10.5,105691,DB01229,Paclitaxel
,12383484,LOQ,LOQ was 0.050 micro g/ml.,High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383484/),[μg] / [ml],0.050,105692,DB01229,Paclitaxel
,8622023,overall response rate,"The overall response rate was 72% (28 of 39 patients; 95% confidence interval [CI], 55% to 85%), with 8% complete responses (CRs) (three of 39; 95% CI, 2% to 21%) and a median response duration of 9 months.",Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622023/),%,72,105947,DB01229,Paclitaxel
,8622023,overall survival time,"The median overall survival time for all patients is 23 months, with a median follow-up duration of 28 months.",Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622023/),month,23,105948,DB01229,Paclitaxel
,9331121,area under the concentration-time curve (AUC),A phase I trial performed at the University of North Carolina was designed to evaluate paclitaxel 250 mg/m2 given over 24 hours plus escalating doses of carboplatin starting at an area under the concentration-time curve (AUC) dose of 8 supported by peripheral blood stem cells and filgrastim in the treatment of advanced NSCLC.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,8,106755,DB01229,Paclitaxel
,9331121,AUC,The maximum tolerated dose of carboplatin combined with paclitaxel 250 mg/m2 administered over 24 hours was defined at an AUC of 18.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,18,106756,DB01229,Paclitaxel
,9331121,AUC,This regimen is currently being tested in patients with locally advanced NSCLC by the Cancer and Leukemia Group B: patients receive two cycles of induction therapy with paclitaxel 250 mg/m2 over 3 hours followed by carboplatin at an AUC of 18 supported by peripheral blood stem cells and filgrastim.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,18,106757,DB01229,Paclitaxel
,26775401,area under the curve,The area under the curve value of the niosome-recipient group (3.22 ± 0.255 μg h/mL) was significantly higher compared to that of the Taxol group (0.725 ± 0.163 μg h/mL).,Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),[h·μg] / [ml],3.22,106861,DB01229,Paclitaxel
,26775401,area under the curve,The area under the curve value of the niosome-recipient group (3.22 ± 0.255 μg h/mL) was significantly higher compared to that of the Taxol group (0.725 ± 0.163 μg h/mL).,Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),[h·μg] / [ml],0.725,106862,DB01229,Paclitaxel
,26775401,mean residence time,"The mean residence time and the elimination half-life of paclitaxel were 1.66 ± 0.133 h and 1.15 ± 0.085 h for Taxol administration, respectively.",Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),h,1.66,106863,DB01229,Paclitaxel
,26775401,elimination half-life,"The mean residence time and the elimination half-life of paclitaxel were 1.66 ± 0.133 h and 1.15 ± 0.085 h for Taxol administration, respectively.",Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),h,1.15,106864,DB01229,Paclitaxel
,26775401,elimination half-life,"The elimination half-life (7.63 ± 0.380 h) and the mean residence time (11.0 ± 0.6 h) of paclitaxel were significantly increased, and a pronounced delay was observed in general excretion of paclitaxel from plasma (0.0925 ± 0.00490 h(-1)) after niosomal administration.",Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),h,7.63,106865,DB01229,Paclitaxel
,26775401,mean residence time,"The elimination half-life (7.63 ± 0.380 h) and the mean residence time (11.0 ± 0.6 h) of paclitaxel were significantly increased, and a pronounced delay was observed in general excretion of paclitaxel from plasma (0.0925 ± 0.00490 h(-1)) after niosomal administration.",Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),h,11.0,106866,DB01229,Paclitaxel
,26775401,general excretion,"The elimination half-life (7.63 ± 0.380 h) and the mean residence time (11.0 ± 0.6 h) of paclitaxel were significantly increased, and a pronounced delay was observed in general excretion of paclitaxel from plasma (0.0925 ± 0.00490 h(-1)) after niosomal administration.",Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26775401/),1/[h],0.0925,106867,DB01229,Paclitaxel
,26699227,LD50,"Safety of intravenously administered PTX-PEG-HSA was confirmed through lower hemolytic activity, a 2.2-fold and 1.2-fold increase in LD50 (113.4 mg/kg) over Taxol® and PTX-HSA alongside the absence of local venous irritation.",Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26699227/),[mg] / [kg],113.4,107225,DB01229,Paclitaxel
>,31077432,PTXTc,"In cycle 1, with the same PTX dose, average PTXTc > 0.05 was 37 hours (range = 18-57 hours).",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),,0.05,107471,DB01229,Paclitaxel
,31077432,PTXTc,"In cycle 1, with the same PTX dose, average PTXTc > 0.05 was 37 hours (range = 18-57 hours).",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),h,37,107472,DB01229,Paclitaxel
,31077432,Objective response rate,"Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms.",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),%,32,107473,DB01229,Paclitaxel
,31077432,Objective response rate,"Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms.",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),%,26,107474,DB01229,Paclitaxel
,31077432,overall survival,"Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms.",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),month,21.0,107475,DB01229,Paclitaxel
,31077432,overall survival,"Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms.",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),month,24.0,107476,DB01229,Paclitaxel
,31077432,Progression-free survival,"Progression-free survival was slightly improved in PK arm (4.67 vs 4.17 months, P = .026).",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),month,4.67,107477,DB01229,Paclitaxel
,31077432,Progression-free survival,"Progression-free survival was slightly improved in PK arm (4.67 vs 4.17 months, P = .026).",Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077432/),month,4.17,107478,DB01229,Paclitaxel
,21155819,diameter,"The mean diameter, polydispersity index, zeta-potential and entrapment efficiency of the liposomes were 501.60 ± 15.43 nm, 0.28 ± 0.02, -20.93 ± 0.06 mV and 95.17 ± 0.32%, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),nm,501.60,107894,DB01229,Paclitaxel
,21155819,polydispersity index,"The mean diameter, polydispersity index, zeta-potential and entrapment efficiency of the liposomes were 501.60 ± 15.43 nm, 0.28 ± 0.02, -20.93 ± 0.06 mV and 95.17 ± 0.32%, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),mv,0.28,107895,DB01229,Paclitaxel
,21155819,zeta-potential,"The mean diameter, polydispersity index, zeta-potential and entrapment efficiency of the liposomes were 501.60 ± 15.43 nm, 0.28 ± 0.02, -20.93 ± 0.06 mV and 95.17 ± 0.32%, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),mv,0.28,107896,DB01229,Paclitaxel
,21155819,entrapment efficiency,"The mean diameter, polydispersity index, zeta-potential and entrapment efficiency of the liposomes were 501.60 ± 15.43 nm, 0.28 ± 0.02, -20.93 ± 0.06 mV and 95.17 ± 0.32%, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),mv,-,107897,DB01229,Paclitaxel
,21155819,entrapment efficiency,"The mean diameter, polydispersity index, zeta-potential and entrapment efficiency of the liposomes were 501.60 ± 15.43 nm, 0.28 ± 0.02, -20.93 ± 0.06 mV and 95.17 ± 0.32%, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),mv,20.93,107898,DB01229,Paclitaxel
,21155819,entrapment efficiency,"The mean diameter, polydispersity index, zeta-potential and entrapment efficiency of the liposomes were 501.60 ± 15.43 nm, 0.28 ± 0.02, -20.93 ± 0.06 mV and 95.17 ± 0.32%, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),%,95.17,107899,DB01229,Paclitaxel
,21155819,area under the curve,"The liposome carrier decreased the area under the curve and terminal half-life of paclitaxel compared with paclitaxel injection ranging from 0.352 ± 0.031 mg/l*h and 0.0671 ± 0.144 h to 0.748 ± 0.062 mg/l*h and 1.978 ± 0.518 h, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),[mg] / [h·l],0.352,107900,DB01229,Paclitaxel
,21155819,area under the curve,"The liposome carrier decreased the area under the curve and terminal half-life of paclitaxel compared with paclitaxel injection ranging from 0.352 ± 0.031 mg/l*h and 0.0671 ± 0.144 h to 0.748 ± 0.062 mg/l*h and 1.978 ± 0.518 h, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),[mg] / [h·l],0.748,107901,DB01229,Paclitaxel
,21155819,terminal half-life,"The liposome carrier decreased the area under the curve and terminal half-life of paclitaxel compared with paclitaxel injection ranging from 0.352 ± 0.031 mg/l*h and 0.0671 ± 0.144 h to 0.748 ± 0.062 mg/l*h and 1.978 ± 0.518 h, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),h,0.0671,107902,DB01229,Paclitaxel
,21155819,terminal half-life,"The liposome carrier decreased the area under the curve and terminal half-life of paclitaxel compared with paclitaxel injection ranging from 0.352 ± 0.031 mg/l*h and 0.0671 ± 0.144 h to 0.748 ± 0.062 mg/l*h and 1.978 ± 0.518 h, respectively.",Preparation and the in-vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21155819/),h,1.978,107903,DB01229,Paclitaxel
,9491787,plasma protein binding,The reported plasma protein binding of both compounds ranged from 76 to 97% in different animal species.,Preclinical pharmacokinetics of paclitaxel and docetaxel. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491787/),%,76 to 97,108312,DB01229,Paclitaxel
,9331119,area under the concentration-time curve,"This phase II study was performed to investigate the efficacy of a 3-hour 225 mg/m2 paclitaxel infusion (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) followed 24 hours later by a 30-minute infusion of carboplatin (dosed to an area under the concentration-time curve of 6) in patients with stage IIIA, IIIB, or IV non-small cell lung cancer.",Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331119/),,6,108479,DB01229,Paclitaxel
,9331119,overall response rate,The overall response rate was 57% (14% complete and 43% partial responses).,Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331119/),%,57,108480,DB01229,Paclitaxel
,9542121,retention times,"The retention times of paclitaxel and 7-epipaclitaxel were about 14 and 22 min, respectively.","Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542121/),min,14,108658,DB01229,Paclitaxel
,9542121,retention times,"The retention times of paclitaxel and 7-epipaclitaxel were about 14 and 22 min, respectively.","Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542121/),min,22,108659,DB01229,Paclitaxel
,17668866,MTD,The DLTs in schedule A were grade 4 hypertension and hyperbilirubinemia with an MTD of 430 mg/m(2) every 21 days.,A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668866/),mg,430,108672,DB01229,Paclitaxel
,17668866,MTD,"The DLTs in schedule B were coagulopathy, hyperkalemia, hyperbilirubinemia, elevated SGOT (n = 1, 125 mg/m(2)), peripheral neuropathy (n = 1, 200 mg/m(2)), and typhlitis (n = 1, 200 mg/m(2)) with an MTD of 182 mg/m(2) weekly x 3 every 28 days.",A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668866/),mg,182,108673,DB01229,Paclitaxel
,17668866,terminal elimination half-life,The mean terminal elimination half-life was 9.5 +/- 3.4 hr and the mean plasma clearance was 23 +/- 11 L/hr/m(2).,A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668866/),h,9.5,108674,DB01229,Paclitaxel
,17668866,plasma clearance,The mean terminal elimination half-life was 9.5 +/- 3.4 hr and the mean plasma clearance was 23 +/- 11 L/hr/m(2).,A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668866/),[h·l] / [m(2],23,108675,DB01229,Paclitaxel
<,17668866,objective response rate,The objective response rate across all dose levels and schedules was <10%.,A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17668866/),%,10,108676,DB01229,Paclitaxel
,9657225,Extraction efficiency,Extraction efficiency averaged 90%.,Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657225/),%,90,109038,DB01229,Paclitaxel
,9657225,Retention times,"Retention times were 7.7 and 6.7 min for paclitaxel and docetaxel, respectively, and the assay was linear in the range 25-1000 ng/ml.",Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657225/),min,7.7,109039,DB01229,Paclitaxel
,9657225,Retention times,"Retention times were 7.7 and 6.7 min for paclitaxel and docetaxel, respectively, and the assay was linear in the range 25-1000 ng/ml.",Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657225/),min,6.7,109040,DB01229,Paclitaxel
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2.7,109481,DB01229,Paclitaxel
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2,109482,DB01229,Paclitaxel
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.3,109483,DB01229,Paclitaxel
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.6,109484,DB01229,Paclitaxel
,10873078,MTD,"In conclusion, the MTD of this schedule is 10 mg/day and the DLTs are neutropenia and diarrhea.",Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873078/),,10,110284,DB01229,Paclitaxel
,11389998,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of Genexol-PM and Taxol in nude mice was determined to be 60 and 20 mg/kg, respectively.",In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389998/),[mg] / [kg],60,110848,DB01229,Paclitaxel
,11389998,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of Genexol-PM and Taxol in nude mice was determined to be 60 and 20 mg/kg, respectively.",In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389998/),[mg] / [kg],20,110849,DB01229,Paclitaxel
,11389998,lethal dose (LD(50)),"The median lethal dose (LD(50)) in Sprague--Dawley rats was 205.4 mg/kg (male) and 221.6 mg/kg (female) for Genexol-PM, while 8.3 mg/kg (male) and 8.8 mg/kg (female) for Taxol.",In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389998/),[mg] / [kg],205.4,110850,DB01229,Paclitaxel
,11389998,lethal dose (LD(50)),"The median lethal dose (LD(50)) in Sprague--Dawley rats was 205.4 mg/kg (male) and 221.6 mg/kg (female) for Genexol-PM, while 8.3 mg/kg (male) and 8.8 mg/kg (female) for Taxol.",In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389998/),[mg] / [kg],221.6,110851,DB01229,Paclitaxel
,11389998,lethal dose (LD(50)),"The median lethal dose (LD(50)) in Sprague--Dawley rats was 205.4 mg/kg (male) and 221.6 mg/kg (female) for Genexol-PM, while 8.3 mg/kg (male) and 8.8 mg/kg (female) for Taxol.",In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389998/),[mg] / [kg],8.3,110852,DB01229,Paclitaxel
,11389998,lethal dose (LD(50)),"The median lethal dose (LD(50)) in Sprague--Dawley rats was 205.4 mg/kg (male) and 221.6 mg/kg (female) for Genexol-PM, while 8.3 mg/kg (male) and 8.8 mg/kg (female) for Taxol.",In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389998/),[mg] / [kg],8.8,110853,DB01229,Paclitaxel
,31743348,bioavailability,"In the mouse pharmacokinetic study, oral Taxol® showed a negligible absorption, whereas DHP23002 showed a high absorption rate dependent on dosage, with a bioavailability of approximately 40% at a dose of 62.5 mg/kg.",DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31743348/),%,40,111311,DB01229,Paclitaxel
,15725561,absolute bioavailability (AB,"The absolute bioavailability (AB, %) of paclitaxel with naringin was significantly higher (3.5-6.8%, p<0.01) than the control (2.2%).",Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725561/),%,3.5-6.8,111629,DB01229,Paclitaxel
,15725561,absolute bioavailability (AB,"The absolute bioavailability (AB, %) of paclitaxel with naringin was significantly higher (3.5-6.8%, p<0.01) than the control (2.2%).",Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725561/),%,2.2,111630,DB01229,Paclitaxel
,15725561,absolute bioavailability (AB,"The absolute bioavailability (AB, %) of paclitaxel after coadministration of prodrug with naringin increased significantly (p<0.05) from 6.6 to 9.0% and 11.2%.",Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725561/),%,6.6,111631,DB01229,Paclitaxel
,15725561,absolute bioavailability (AB,"The absolute bioavailability (AB, %) of paclitaxel after coadministration of prodrug with naringin increased significantly (p<0.05) from 6.6 to 9.0% and 11.2%.",Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725561/),%,9.0,111632,DB01229,Paclitaxel
,15725561,absolute bioavailability (AB,"The absolute bioavailability (AB, %) of paclitaxel after coadministration of prodrug with naringin increased significantly (p<0.05) from 6.6 to 9.0% and 11.2%.",Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15725561/),%,11.2,111633,DB01229,Paclitaxel
,12506180,time to progression,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,11.4,111718,DB01229,Paclitaxel
,12506180,survival,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,19.5,111719,DB01229,Paclitaxel
,7939757,complete response rates,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a very active agent for the treatment of breast cancer, with associated complete response rates of 12% in patients with minimally pretreated metastatic disease.",Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7939757/),%,12,112473,DB01229,Paclitaxel
,7939757,overall response rate,Simultaneous paclitaxel and doxorubicin administration by 72-hour continuous infusion in patients with previously untreated metastatic breast cancer has yielded an overall response rate of 72% with 8% complete responses.,Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7939757/),%,72,112474,DB01229,Paclitaxel
,12044505,time to progression (TTP),"The median time to progression (TTP) was 9.6 months (range 2.5-21.8 months), median survival was 14.8 months (range 0.3-27+ months) and actuarial 1-year survival time was 55%.","Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12044505/),month,9.6,113160,DB01229,Paclitaxel
,12044505,survival,"The median time to progression (TTP) was 9.6 months (range 2.5-21.8 months), median survival was 14.8 months (range 0.3-27+ months) and actuarial 1-year survival time was 55%.","Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12044505/),month,14,113161,DB01229,Paclitaxel
,20881508,overall survival,The median overall survival was 9.8 months.,Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881508/),month,9.8,113188,DB01229,Paclitaxel
,15626582,absolute bioavailability,"The absolute bioavailability of paclitaxel with verapamil (3.9-5.4%) was significantly (p<0.05 at 5 mg/kg and 0.5 h; p<0.01 at 15 mg/kg, 3 days and 6 days) higher than that of the control (2.2%).",The effect of verapamil on the pharmacokinetics of paclitaxel in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626582/),%,3.9-5.4,113378,DB01229,Paclitaxel
,15626582,absolute bioavailability,"The absolute bioavailability of paclitaxel with verapamil (3.9-5.4%) was significantly (p<0.05 at 5 mg/kg and 0.5 h; p<0.01 at 15 mg/kg, 3 days and 6 days) higher than that of the control (2.2%).",The effect of verapamil on the pharmacokinetics of paclitaxel in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626582/),%,2.2,113379,DB01229,Paclitaxel
,15930890,AUC(0-infinity),The exposures to paclitaxel (AUC(0-infinity) = 3787 h.ng/ml) and its hydroxy metabolites when co-administered with nevirapine were comparable to the mean exposure to paclitaxel and its metabolites from eight historical controls (AUC(0-infinity) = 3614 h.ng/ml) treated with the same dose.,No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930890/),[h·ng] / [ml],3787,114153,DB01229,Paclitaxel
,15930890,AUC(0-infinity),The exposures to paclitaxel (AUC(0-infinity) = 3787 h.ng/ml) and its hydroxy metabolites when co-administered with nevirapine were comparable to the mean exposure to paclitaxel and its metabolites from eight historical controls (AUC(0-infinity) = 3614 h.ng/ml) treated with the same dose.,No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930890/),[h·ng] / [ml],3614,114154,DB01229,Paclitaxel
greater,28861682,ratio C ss /KC 50,LDHF would produce higher efficacy when the ratio C ss /KC 50 is greater than 1.,Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28861682/),,1,114267,DB01229,Paclitaxel
,31114846,objective response rate,No patients receiving emactuzumab monotherapy showed an objective response; the objective response rate for emactuzumab in combination with paclitaxel was 7% across all doses.,Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31114846/),%,7,115420,DB01229,Paclitaxel
,18337069,LD(50),"The LD(50) value of NOSC administrated by i.v. and i.p. were calculated as 102.59 and 130.53 mg/kg, respectively.",Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337069/),[mg] / [kg],102.59,115641,DB01229,Paclitaxel
,18337069,LD(50),"The LD(50) value of NOSC administrated by i.v. and i.p. were calculated as 102.59 and 130.53 mg/kg, respectively.",Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18337069/),[mg] / [kg],130.53,115642,DB01229,Paclitaxel
,11914641,Vd/F,"Compared to that observed in control mice, the apparent volume of distribution increased dramatically (Vd/F = 18.2 versus 4.1 l/kg) and the apparent plasma clearance decreased (Cl/F = 1.12 versus 1.66 l/h/kg).",Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914641/),[l] / [kg],18.2,116173,DB01229,Paclitaxel
,11914641,Vd/F,"Compared to that observed in control mice, the apparent volume of distribution increased dramatically (Vd/F = 18.2 versus 4.1 l/kg) and the apparent plasma clearance decreased (Cl/F = 1.12 versus 1.66 l/h/kg).",Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914641/),[l] / [kg],4.1,116174,DB01229,Paclitaxel
,11914641,Cl/F,"Compared to that observed in control mice, the apparent volume of distribution increased dramatically (Vd/F = 18.2 versus 4.1 l/kg) and the apparent plasma clearance decreased (Cl/F = 1.12 versus 1.66 l/h/kg).",Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914641/),[l] / [h·kg],1.12,116175,DB01229,Paclitaxel
,11914641,Cl/F,"Compared to that observed in control mice, the apparent volume of distribution increased dramatically (Vd/F = 18.2 versus 4.1 l/kg) and the apparent plasma clearance decreased (Cl/F = 1.12 versus 1.66 l/h/kg).",Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914641/),[l] / [h·kg],1.66,116176,DB01229,Paclitaxel
,34419608,bioavailability,"For orally administered MT2, the bioavailability was 1.08-1.11%.","Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34419608/),%,1.08-1.11,116822,DB01229,Paclitaxel
,34419608,protein binding rate,"In rat plasma, MT2 exhibited a protein binding rate of 93.84-94.96%.","Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34419608/),%,93.84-94.96,116823,DB01229,Paclitaxel
,11812097,area under the concentration/time curve (AUC),The carboplatin dose was chosen to produce a target area under the concentration/time curve (AUC) of 5.0 microg-min/ml according to the Calvert formula.,Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812097/),[μg-min] / [ml],5.0,116978,DB01229,Paclitaxel
,11812097,AUCs,"The pharmacokinetic study showed that the AUCs of free platinum and paclitaxel were 4.43 microg-min/ml and 15.9 microg-h/ml, respectively.",Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812097/),[μg-min] / [ml],4.43,116979,DB01229,Paclitaxel
,11812097,AUCs,"The pharmacokinetic study showed that the AUCs of free platinum and paclitaxel were 4.43 microg-min/ml and 15.9 microg-h/ml, respectively.",Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812097/),[μg-h] / [ml],15.9,116980,DB01229,Paclitaxel
,31446228,AUC,"Eligible patients with stage IV or recurrent metastatic sqNSCLC harboring FGFR1 gene amplification received escalating doses of GSK3052230 in combination with paclitaxel and carboplatin at the starting doses 200 mg/m2 and AUC of 6, respectively, in the first line setting (Arm A) or docetaxel 75 mg/m2 in second line (Arm B).","An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446228/),,6,117038,DB01229,Paclitaxel
,31446228,overall response rate,"The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B. GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy.","An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446228/),%,47,117039,DB01229,Paclitaxel
,31446228,overall response rate,"The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B. GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy.","An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446228/),%,0,117040,DB01229,Paclitaxel
,31446228,progression-free survival,"The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B. GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy.","An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446228/),month,5.5,117041,DB01229,Paclitaxel
,31446228,progression-free survival,"The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B. GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy.","An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446228/),month,4.6,117042,DB01229,Paclitaxel
,31912800,PFS,"In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027].","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,3.6,117460,DB01229,Paclitaxel
,31912800,PFS,"In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027].","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,7.3,117461,DB01229,Paclitaxel
,31912800,PFS,"In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42).","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,4.1,117462,DB01229,Paclitaxel
,31912800,PFS,"In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42).","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,7.3,117463,DB01229,Paclitaxel
,16969354,overall response rate,"In intention to treat analysis, the overall response rate was 52%, the median time to progression was 6.5 months and overall survival was 16 months.",Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969354/),%,52,117578,DB01229,Paclitaxel
,16969354,time to progression,"In intention to treat analysis, the overall response rate was 52%, the median time to progression was 6.5 months and overall survival was 16 months.",Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969354/),month,6.5,117579,DB01229,Paclitaxel
,16969354,overall survival,"In intention to treat analysis, the overall response rate was 52%, the median time to progression was 6.5 months and overall survival was 16 months.",Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969354/),month,16,117580,DB01229,Paclitaxel
,17510206,area under the concentration versus time curve,Both schedules of vorinostat (400 mg oral qd x 14 days or 300 mg bd x 7 days) were tolerated well in combination with carboplatin (area under the concentration versus time curve = 6 mg/mL x min) and paclitaxel (200 mg/m(2)).,"Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17510206/),[mg] / [min·ml],6,118497,DB01229,Paclitaxel
,18682950,MTD,Dose-limiting toxicities included neutropenia and neuropathy with a cycle 1 MTD of 210 mg/m(2).,A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18682950/),[mg] / [m],210,119060,DB01229,Paclitaxel
>,18682950,half-life,Conjugated taxanes had a prolonged half-life of >100 h.,A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18682950/),h,100,119061,DB01229,Paclitaxel
,31411540,oral bioavailability,Its oral bioavailability was approximately 95% and chemotherapeutic efficacy was better than Taxol® and nab-PTX.,Paclitaxel-encapsulated core-shell nanoparticle of cetyl alcohol for active targeted delivery through oral route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31411540/),%,95,119293,DB01229,Paclitaxel
,11138457,time to progression,"One patient with extensively pretreated ovarian carcinoma had a partial response, and eight patients with various solid tumor malignancies had stable disease with a median time to progression of 12 weeks (range 9-18 weeks).",Phase I study of docetaxel and topotecan in patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11138457/),weeks,12,119544,DB01229,Paclitaxel
,30243219,zeta potential,The average size of spherical NAC-HA-PTX micelles was 187 nm with a zeta potential of -25.38 mV.,N-acetylcysteine modified hyaluronic acid-paclitaxel conjugate for efficient oral chemotherapy through mucosal bioadhesion ability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243219/),m,25.38,119609,DB01229,Paclitaxel
,23267154,MTD,"Using carboplatin at AUC 3, the MTD of paclitaxel was 100 mg/m(2).",Phase I clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267154/),,100,120291,DB01229,Paclitaxel
,23468081,AUC,Patients received fixed doses of P (200 mg/m(2)) and C (AUC 6 mg/mL min) q21 days with intercalated BMS-690514 (Days 4-19) starting at 100 mg/day and increasing by 50 mg/day using a 3 + 3 dose escalation design until the MTD was reached.,"A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468081/),[mg] / [min·ml],6,120631,DB01229,Paclitaxel
,23468081,MTD,The MTD of intercalated BMS-609514 combined with PC was 150 mg/day.,"A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23468081/),[mg] / [d],150,120632,DB01229,Paclitaxel
,12231518,maximum administered,"Fifty-three patients were treated; the maximum administered dose was 60 mg/m(2)/wk, and the MTD was 50 mg/m(2)/wk.",Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12231518/),,60,120671,DB01229,Paclitaxel
,12231518,MTD,"Fifty-three patients were treated; the maximum administered dose was 60 mg/m(2)/wk, and the MTD was 50 mg/m(2)/wk.",Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12231518/),[mg] / [m],50,120672,DB01229,Paclitaxel
,23269869,droplet size,The average droplet size of the CLA-PTX microemulsion was approximately 176.3 ± 0.8 nm and the polydispersity index was 0.294 ± 0.024.,Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23269869/),nm,176.3,120731,DB01229,Paclitaxel
,23269869,polydispersity index,The average droplet size of the CLA-PTX microemulsion was approximately 176.3 ± 0.8 nm and the polydispersity index was 0.294 ± 0.024.,Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23269869/),,0.294,120732,DB01229,Paclitaxel
,23269869,IC(50),"In vitro cytotoxicity results showed that the IC(50) of the CLA-PTX microemulsion was 1.61 ± 0.83 μM for a C6 glioma cell line, which was similar to that of free paclitaxel and CLA-PTX solution (P > 0.05).",Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23269869/),μM,1.61,120733,DB01229,Paclitaxel
,23269869,LD(50),The results of the acute toxicity study showed that the LD(50) of CLA-PTX solution was 103.9 mg/kg.,Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23269869/),[mg] / [kg],103.9,120734,DB01229,Paclitaxel
,11723747,area under the concentration curve [AUC],"TAX (175 mg/m2) was administered intravenously (i.v.) over 3 h, and CBDCA (target area under the concentration curve [AUC], 5 mg/ml x min) over 1 h.",Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11723747/),[mg] / [min·ml],5,120943,DB01229,Paclitaxel
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,5500,122118,DB01229,Paclitaxel
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,500,122119,DB01229,Paclitaxel
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,150,122120,DB01229,Paclitaxel
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,100,122121,DB01229,Paclitaxel
,26433581,AUC,Carboplatin (AUC 6 mg/mL min) and paclitaxel (200 mg/m(2)) were administered on day 3 of a 21-day cycle.,A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433581/),[mg] / [min·ml],6,123105,DB01229,Paclitaxel
,26433581,RPTD,The RPTD was determined to be 120 mg BID.,A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433581/),mg,120,123106,DB01229,Paclitaxel
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],2.24x10(-11),123149,DB01229,Paclitaxel
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],1.97x10(-11),123150,DB01229,Paclitaxel
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],0.51x10(-11),123151,DB01229,Paclitaxel
,32968837,d,An optimized GT DcNP composition (d = 59.2 nm ±9.2 nm) was found to be suitable for IV formulation.,Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968837/),nm,59.2,123547,DB01229,Paclitaxel
,18594000,free fraction,"However, exposure to unbound paclitaxel was significantly higher after nab-paclitaxel administration, due to the increased free fraction (0.063 +/- 0.021 versus 0.024 +/- 0.009; P < 0.001).",Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594000/),,0.063,123809,DB01229,Paclitaxel
,18594000,free fraction,"However, exposure to unbound paclitaxel was significantly higher after nab-paclitaxel administration, due to the increased free fraction (0.063 +/- 0.021 versus 0.024 +/- 0.009; P < 0.001).",Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594000/),,0.024,123810,DB01229,Paclitaxel
,15969946,AUC(0-infinity),"The AUC(0-infinity) (9.42 +/- 3.18 microg h mL(-1)), clearance (0.69 +/- 0.17 L h(-1) kg(-1)), volume of distribution (10.31 +/- 4.54 L kg(-1)) and half life (1.00 +/- 0.32 h) of [3H]-paclitaxel in tumour rats were similar in rats treated with IRL 1620 or vehicle.","ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969946/),[h·μg] / [ml],9.42,125131,DB01229,Paclitaxel
,15969946,clearance,"The AUC(0-infinity) (9.42 +/- 3.18 microg h mL(-1)), clearance (0.69 +/- 0.17 L h(-1) kg(-1)), volume of distribution (10.31 +/- 4.54 L kg(-1)) and half life (1.00 +/- 0.32 h) of [3H]-paclitaxel in tumour rats were similar in rats treated with IRL 1620 or vehicle.","ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969946/),[l] / [h·kg],0.69,125132,DB01229,Paclitaxel
,15969946,volume of distribution,"The AUC(0-infinity) (9.42 +/- 3.18 microg h mL(-1)), clearance (0.69 +/- 0.17 L h(-1) kg(-1)), volume of distribution (10.31 +/- 4.54 L kg(-1)) and half life (1.00 +/- 0.32 h) of [3H]-paclitaxel in tumour rats were similar in rats treated with IRL 1620 or vehicle.","ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969946/),[l] / [kg],10.31,125133,DB01229,Paclitaxel
,15969946,half life,"The AUC(0-infinity) (9.42 +/- 3.18 microg h mL(-1)), clearance (0.69 +/- 0.17 L h(-1) kg(-1)), volume of distribution (10.31 +/- 4.54 L kg(-1)) and half life (1.00 +/- 0.32 h) of [3H]-paclitaxel in tumour rats were similar in rats treated with IRL 1620 or vehicle.","ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969946/),h,1.00,125134,DB01229,Paclitaxel
,10663639,area under the curve (AUC),The mean area under the curve (AUC) for docetaxel was 3.1 +/- 0.9 h.,Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663639/),h,3.1,125407,DB01229,Paclitaxel
,10663639,clearance,mg/l and the clearance was 34.8 +/- 9.3 l/h per m(2).,Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663639/),[h·l] / [m(2],34.8,125408,DB01229,Paclitaxel
,10663639,maximal concentrations,The cyclized oxazolidinedione metabolite M4 was most frequently present and was detected in 8 out of 24 patients with maximal concentrations between 0.022 and 0.23 mg/l.,Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663639/),[mg] / [l],0.022 and 0.23,125409,DB01229,Paclitaxel
,22571255,LD50,"The LD50 (median lethal dose) was 34.8 mg/kg for Taxol, whereas no death was observed at 160 mg/kg for the PSD.","Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22571255/),[mg] / [kg],34.8,125542,DB01229,Paclitaxel
,17255281,biological half-life,"STA-4783 exhibited linear pharmacokinetics characterized by rapid elimination from plasma (biological half-life, 1.06 +/- 0.24 h) and a low steady-state apparent volume of distribution (25.1 +/- 8.1 L/m(2)).",Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255281/),h,1.06,125751,DB01229,Paclitaxel
,17255281,steady-state apparent volume of distribution,"STA-4783 exhibited linear pharmacokinetics characterized by rapid elimination from plasma (biological half-life, 1.06 +/- 0.24 h) and a low steady-state apparent volume of distribution (25.1 +/- 8.1 L/m(2)).",Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255281/),[l] / [m(2],25.1,125752,DB01229,Paclitaxel
,10999734,area under the curve,"At that dose level, the mean area under the curve was 20.6 micromol x h, and the mean terminal half-life was 8 h.","Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999734/),h·μM,20.6,125826,DB01229,Paclitaxel
,10999734,terminal half-life,"At that dose level, the mean area under the curve was 20.6 micromol x h, and the mean terminal half-life was 8 h.","Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999734/),h,8,125827,DB01229,Paclitaxel
,21305289,bioavailability,"Following IP administration, bevacizumab was rapidly absorbed and bioavailability was 92.8%.",Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21305289/),%,92.8,127000,DB01229,Paclitaxel
,21305289,survival time,"Median survival time, which was 33 days for control mice, was increased by 24% with IP paclitaxel.",Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21305289/),d,33,127001,DB01229,Paclitaxel
,18941747,relative tissue distribution ratios,"In contrast, relative tissue distribution ratios calculated as the dose-normalized AUC(DHP 107)/AUC(Taxol) were as high as 342.0, 139.0, 112.9 and 108.2% for stomach, small intestine, large intestine and ovary, respectively.","Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941747/),%,342.0,127083,DB01229,Paclitaxel
,18941747,relative tissue distribution ratios,"In contrast, relative tissue distribution ratios calculated as the dose-normalized AUC(DHP 107)/AUC(Taxol) were as high as 342.0, 139.0, 112.9 and 108.2% for stomach, small intestine, large intestine and ovary, respectively.","Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941747/),%,139.0,127084,DB01229,Paclitaxel
,18941747,relative tissue distribution ratios,"In contrast, relative tissue distribution ratios calculated as the dose-normalized AUC(DHP 107)/AUC(Taxol) were as high as 342.0, 139.0, 112.9 and 108.2% for stomach, small intestine, large intestine and ovary, respectively.","Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941747/),%,112.9,127085,DB01229,Paclitaxel
,18941747,relative tissue distribution ratios,"In contrast, relative tissue distribution ratios calculated as the dose-normalized AUC(DHP 107)/AUC(Taxol) were as high as 342.0, 139.0, 112.9 and 108.2% for stomach, small intestine, large intestine and ovary, respectively.","Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941747/),%,108.2,127086,DB01229,Paclitaxel
,9193344,AUC,"Initial target carboplatin AUC was 10 mg/ml x min, with interpatient escalation in increments of 25%.",Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193344/),[mg] / [min·ml],10,127623,DB01229,Paclitaxel
,9193344,clearance,"Median clearance was 80.5 mL/min/m2 (range, 41.6 to 131.8).",Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193344/),[ml] / [m2·min],80.5,127624,DB01229,Paclitaxel
,9193344,maximum-tolerated systemic exposure (MTSE),The carboplatin maximum-tolerated systemic exposure (MTSE) was 13.3 mg/mL x min (level five).,Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193344/),[mg] / [min·ml],13.3,127625,DB01229,Paclitaxel
,16334804,MTD,The MTD for this regimen was 90mg/m2/week of paclitaxel for 3 weeks.,Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334804/),[mg] / [m2·week],90,128281,DB01229,Paclitaxel
,16334804,overall response rate,Tumor response occurred in 7 of the 15 patients and the overall response rate was 57.1%.,Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334804/),%,57.1,128282,DB01229,Paclitaxel
,14603484,oral bioavailability (F,The paclitaxel S-SEDDS formulation shows approximately 10-fold higher maximum concentration (C(max)) and five-fold higher oral bioavailability (F approximately 9.5%) compared with that of the orally dosed Taxol formulation (F approximately 2.0%) and the SEDDS formulation without HPMC (F approximately 1%).,Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,9.5,128322,DB01229,Paclitaxel
,14603484,F,The paclitaxel S-SEDDS formulation shows approximately 10-fold higher maximum concentration (C(max)) and five-fold higher oral bioavailability (F approximately 9.5%) compared with that of the orally dosed Taxol formulation (F approximately 2.0%) and the SEDDS formulation without HPMC (F approximately 1%).,Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,2.0,128323,DB01229,Paclitaxel
,14603484,F,The paclitaxel S-SEDDS formulation shows approximately 10-fold higher maximum concentration (C(max)) and five-fold higher oral bioavailability (F approximately 9.5%) compared with that of the orally dosed Taxol formulation (F approximately 2.0%) and the SEDDS formulation without HPMC (F approximately 1%).,Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,1,128324,DB01229,Paclitaxel
,14603484,oral bioavailability (F,"Coadministration of cyclosporin A (CsA), an inhibitor of P-glycoprotein and CYP 3A4 enzyme, at a dose of 5 mg/kg with the S-SEDDS formulation further increased the oral bioavailability (F approximately 22.6%).",Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,22.6,128325,DB01229,Paclitaxel
,19409645,time to tumor progression,Median time to tumor progression was 5.5 months by investigator assessment and median survival was 14.9 months.,"Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409645/),month,5.5,128668,DB01229,Paclitaxel
,19409645,survival,Median time to tumor progression was 5.5 months by investigator assessment and median survival was 14.9 months.,"Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409645/),month,14.9,128669,DB01229,Paclitaxel
,10905511,Cmax,"After intravenous infusion of 135 to 185 mg/m2 of paclitaxel, Cmax ranged from 2.17 to 9.17 mg/L and AUC ranged from 4.37 to 16.01 mg/h/L.",Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905511/),[mg] / [l],2.17 to 9.17,129096,DB01229,Paclitaxel
,10905511,AUC,"After intravenous infusion of 135 to 185 mg/m2 of paclitaxel, Cmax ranged from 2.17 to 9.17 mg/L and AUC ranged from 4.37 to 16.01 mg/h/L.",Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905511/),[mg] / [h·l],4.37 to 16.01,129097,DB01229,Paclitaxel
above,10905511,Cmax,"In 4 of the 6 PR patients, Cmax was above 4.38 mg/L.",Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905511/),[mg] / [l],4.38,129098,DB01229,Paclitaxel
below,10905511,Cmax,"In four of the NR patients, Cmax was equal to or below 4.04 mg/L.",Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905511/),[mg] / [l],4.04,129099,DB01229,Paclitaxel
,19633055,MTD,The MTD was defined at 180 mg/m(2).,Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19633055/),[mg] / [m],180,129668,DB01229,Paclitaxel
,19633055,total-body clearance,The median total-body clearance of Genexol-PM for all patients was 43.9 l/h.,Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19633055/),[l] / [h],43.9,129669,DB01229,Paclitaxel
,19760364,area under the curve [AUC],"Eligible patients received paclitaxel (200 mg/m(2)) and carboplatin (area under the curve [AUC]of 6 mg min mL(-1)) on day 1 and sorafenib (400 mg, twice daily) on days 2 through 19 of a 21-day cycle.",Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],6,129762,DB01229,Paclitaxel
,19760364,AUC,The present study confirmed that sorafenib at 400 mg once daily in combination with carboplatin AUC 5 mg min mL(-1) and paclitaxel 200 mg/m(2) is feasible in Japanese patients with advanced NSCLC.,Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],5,129763,DB01229,Paclitaxel
,23014737,time to progression,Five patients (13.2 %) had a partial response (PR) and 13 patients (34.2 %) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks).,A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23014737/),weeks,17,130633,DB01229,Paclitaxel
,11828945,AUC,"Based on this result, treatment in group B was initiated at doses of paclitaxel of 160 mg/m2 and carboplatin AUC 6.",Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11828945/),,6,131267,DB01229,Paclitaxel
,21401600,solubility,"The solid dispersion system at a 1/20/40 weight ratio of paclitaxel/HP-β-CD/HCO-40 had a paclitaxel solubility of about 10 mg/ml, an almost 10 000-fold increase over its aqueous solubility.",Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401600/),[mg] / [ml],10,131280,DB01229,Paclitaxel
above,21401600,precipitation time,The precipitation time of paclitaxel solid dispersion in 0.9% sodium chloride injection at a concentration of 1000 µg/ml was above 70 h at room temperature.,Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401600/),h,70,131281,DB01229,Paclitaxel
,15930349,clearance,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[h·l] / [m(2],21.13,132203,DB01229,Paclitaxel
,15930349,clearance,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[h·l] / [m(2],14.76,132204,DB01229,Paclitaxel
,15930349,volume of distribution,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[l] / [m(2],663.8,132205,DB01229,Paclitaxel
,15930349,volume of distribution,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[l] / [m(2],433.4,132206,DB01229,Paclitaxel
>,25774704,Tc,The time above a paclitaxel threshold concentration of 0.05 μmol/L (Tc > 0.05 μmol/L) is a strong predictor for paclitaxel-associated neutropenia and has been proposed as a target pharmacokinetic (PK) parameter for paclitaxel therapeutic drug monitoring and dose adaptation.,Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),[μM] / [l],0.05,132378,DB01229,Paclitaxel
>,25774704,Tc,"Up to now, individual Tc > 0.05 μmol/L values are estimated based on a published PK model of paclitaxel by using the software NONMEM.",Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),[μM] / [l],0.05,132379,DB01229,Paclitaxel
>,25774704,Tc,"Because many clinicians are not familiar with the use of NONMEM, an Excel-based dosing tool was developed to allow calculation of paclitaxel Tc > 0.05 μmol/L and give clinicians an easy-to-use tool.",Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),[μM] / [l],0.05,132380,DB01229,Paclitaxel
>,25774704,Tc,"Predictions of paclitaxel Tc > 0.05 μmol/L as calculated by the Excel tool were compared with NONMEM, whereby maximum a posteriori Bayesian estimates were obtained using the POSTHOC function.",Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),[μM] / [l],0.05,132381,DB01229,Paclitaxel
>,25774704,Tc,There was a good concordance and comparable predictive performance between Excel and NONMEM regarding predicted paclitaxel plasma concentrations and Tc > 0.05 μmol/L values.,Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),μmo,0.05,132382,DB01229,Paclitaxel
>,25774704,Tc,The median relative deviation of the estimated Tc > 0.05 μmol/L values between both programs was 1%.,Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),[μM] / [l],0.05,132383,DB01229,Paclitaxel
>,25774704,Tc,The presented Excel tool allows reliable calculation of paclitaxel Tc > 0.05 μmol/L and thus allows target concentration intervention to improve the benefit-risk ratio of the drug.,Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25774704/),[μM] / [l],0.05,132384,DB01229,Paclitaxel
,16567769,AUCs,"Mean (SE) AUCs were 22.4 (2.5) micromol/L x hour, 26.2 (2.8) micromol/L x hour, and 31.7 (5.6) micromol/L x hour for cohorts 1, 2, and 3, respectively.",Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567769/),[μM] / [h·l],22.4,132510,DB01229,Paclitaxel
,16567769,AUCs,"Mean (SE) AUCs were 22.4 (2.5) micromol/L x hour, 26.2 (2.8) micromol/L x hour, and 31.7 (5.6) micromol/L x hour for cohorts 1, 2, and 3, respectively.",Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567769/),[μM] / [h·l],26.2,132511,DB01229,Paclitaxel
,16567769,AUCs,"Mean (SE) AUCs were 22.4 (2.5) micromol/L x hour, 26.2 (2.8) micromol/L x hour, and 31.7 (5.6) micromol/L x hour for cohorts 1, 2, and 3, respectively.",Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567769/),[μM] / [h·l],31.7,132512,DB01229,Paclitaxel
,16567769,CL(tb),"There was a corresponding significant (P = .007) age-related decrease in mean (SE) paclitaxel CL(tb) (cohort 1, 11.0 [0.7] L/h/m2; cohort 2, 9.3 [0.6] L/h/m2; cohort 3, 8.2 [0.6] L/h/m2).",Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567769/),[l] / [h·m2],11.0,132513,DB01229,Paclitaxel
,16567769,CL(tb),"There was a corresponding significant (P = .007) age-related decrease in mean (SE) paclitaxel CL(tb) (cohort 1, 11.0 [0.7] L/h/m2; cohort 2, 9.3 [0.6] L/h/m2; cohort 3, 8.2 [0.6] L/h/m2).",Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567769/),[l] / [h·m2],9.3,132514,DB01229,Paclitaxel
,16567769,CL(tb),"There was a corresponding significant (P = .007) age-related decrease in mean (SE) paclitaxel CL(tb) (cohort 1, 11.0 [0.7] L/h/m2; cohort 2, 9.3 [0.6] L/h/m2; cohort 3, 8.2 [0.6] L/h/m2).",Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567769/),[l] / [h·m2],8.2,132515,DB01229,Paclitaxel
,15956976,response rate (RR),The response rate (RR) was 28% in 18 evaluable patients.,Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956976/),%,28,132862,DB01229,Paclitaxel
,24070396,clearance index,"The normalized transfer of pravastatin (clearance index) to antipyrine in the fetal-to-maternal direction (0.48 ± 0.07) was higher than its transfer in the maternal-to-fetal direction (0.36 ± 0.07, P < .01).",Transplacental transfer and distribution of pravastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24070396/),,0.,132994,DB01229,Paclitaxel
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.3 x 10(-10),133271,DB01229,Paclitaxel
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.1 x 10(-9),133272,DB01229,Paclitaxel
,8646796,limit of detection,A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[ng] / [ml],5,133273,DB01229,Paclitaxel
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],333,133274,DB01229,Paclitaxel
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],208,133275,DB01229,Paclitaxel
exceeded,8646796,Plasma binding,Plasma binding of dolastatin 10 exceeded 90%.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),%,90,133276,DB01229,Paclitaxel
,10778964,plasma clearance,"The plasma pharmacokinetics of docetaxel were not influenced by the R101933 regimen at any dose level tested, as indicated by plasma clearance values of 26.5 +/- 7.78 liters/h/m2 and 23.4 +/- 4.52 liters/h/m2 (P = 0.15) in cycles 1 and 2, respectively.",The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778964/),[l] / [h·m2],26.5,133346,DB01229,Paclitaxel
,10778964,plasma clearance,"The plasma pharmacokinetics of docetaxel were not influenced by the R101933 regimen at any dose level tested, as indicated by plasma clearance values of 26.5 +/- 7.78 liters/h/m2 and 23.4 +/- 4.52 liters/h/m2 (P = 0.15) in cycles 1 and 2, respectively.",The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778964/),[l] / [h·m2],23.4,133347,DB01229,Paclitaxel
,19209024,Peak paclitaxel plasma concentrations,Peak paclitaxel plasma concentrations were low (0.53-2.73 ng/ml) and directly related to the absolute amount of paclitaxel administered.,"Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19209024/),[ng] / [ml],0.53-2.73,133408,DB01229,Paclitaxel
,26112004,progression-free survival,"Median progression-free survival and overall survival were 2.6 and 10.7 months, respectively.",Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26112004/),month,2.6,133522,DB01229,Paclitaxel
,26112004,overall survival,"Median progression-free survival and overall survival were 2.6 and 10.7 months, respectively.",Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26112004/),month,10.7,133523,DB01229,Paclitaxel
,17205304,C (max),"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[μg] / [ml],0.42,133533,DB01229,Paclitaxel
,17205304,C (max),"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[μg] / [ml],0.48,133534,DB01229,Paclitaxel
,17205304,C (max),"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[μg] / [ml],0.39,133535,DB01229,Paclitaxel
,17205304,area under the plasma concentration-time curve,"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[h·μg] / [ml],2.83,133536,DB01229,Paclitaxel
,17205304,area under the plasma concentration-time curve,"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[h·μg] / [ml],2.01,133537,DB01229,Paclitaxel
,17205304,area under the plasma concentration-time curve,"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[h·μg] / [ml],2.67,133538,DB01229,Paclitaxel
,22172604,absolute bioavailability,"When the paclitaxel microemulsion was co-administered with silymarin (20mg/kg) orally, it caused a maximum increase in the absolute bioavailability of paclitaxel (19%).",Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22172604/),%,19,134228,DB01229,Paclitaxel
,22172604,relative bioavailability,"In addition, the relative bioavailability of the paclitaxel microemulsion was 184% as compared to Taxol® after oral dosing, whereas the mean time required to reach C(max) (T(max)) of paclitaxel was decreased in the microemulsion formulation compared with Taxol®, suggesting faster absorption.",Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22172604/),%,184,134229,DB01229,Paclitaxel
,11488519,AUC,"A total of 18 patients were treated with a dose of carboplatin determined by GFR, to attain a target AUC of 6 or 7 mg/ml x min.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[mg] / [min·ml],6,134506,DB01229,Paclitaxel
,11488519,AUC,"A total of 18 patients were treated with a dose of carboplatin determined by GFR, to attain a target AUC of 6 or 7 mg/ml x min.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[mg] / [min·ml],7,134507,DB01229,Paclitaxel
,11488519,peak concentration,"The peak concentration of paclitaxel obtained at the end of the infusion (9.1 vs 4.5 microg/ml), and the plasma ethanol concentration (40.0 vs 20.5 mg/dl) were higher following the shorter duration infusion.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[μg] / [ml],9.1,134508,DB01229,Paclitaxel
,11488519,peak concentration,"The peak concentration of paclitaxel obtained at the end of the infusion (9.1 vs 4.5 microg/ml), and the plasma ethanol concentration (40.0 vs 20.5 mg/dl) were higher following the shorter duration infusion.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[μg] / [ml],4.5,134509,DB01229,Paclitaxel
,11488519,AUC,The combination of paclitaxel at a dose of 175 mg/m2 and carboplatin at a target AUC of 6-7 mg/ml min can safely be administered every 3 weeks.,Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[mg] / [min·ml],6-7,134510,DB01229,Paclitaxel
more,20719581,extraction recovery,The extraction recovery was more than 85%; the standard curve was linear over the validated concentrations range of 10-5000 ng/mL and the limit of detection was 2 ng/mL.,Development and validation of a nylon6 nanofibers mat-based SPE coupled with HPLC method for the determination of docetaxel in rabbit plasma and its application to the relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20719581/),%,85,135039,DB01229,Paclitaxel
,20719581,relative bioavailability,"On the basis of the mean AUC(0-t) and AUC(0-infinity), the relative bioavailability of the test preparation was found to be 113.1%.",Development and validation of a nylon6 nanofibers mat-based SPE coupled with HPLC method for the determination of docetaxel in rabbit plasma and its application to the relative bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20719581/),%,113.1,135040,DB01229,Paclitaxel
,9893625,AUC,"76 patients were treated with paclitaxel over three hours followed by a 30 min carboplatin infusion, dosed by the Calvert formula to a target AUC of 4.0 or 4.5 mg/min/ml-1.",The clinical development of paclitaxel and the paclitaxel/carboplatin combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893625/),[mg] / [min·ml],4.0,135154,DB01229,Paclitaxel
,9893625,AUC,"76 patients were treated with paclitaxel over three hours followed by a 30 min carboplatin infusion, dosed by the Calvert formula to a target AUC of 4.0 or 4.5 mg/min/ml-1.",The clinical development of paclitaxel and the paclitaxel/carboplatin combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9893625/),[mg] / [min·ml],4.5,135155,DB01229,Paclitaxel
,10197613,blood:plasma concentration ratio,"In the absence of CrEL, the blood:plasma concentration ratio was 1.07+/-0.004 (mean+/-SD).",Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197613/),,1.07,135264,DB01229,Paclitaxel
,28281183,overall objective response rate,The overall objective response rate was 14% (2 /14).,A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28281183/),%,14,135265,DB01229,Paclitaxel
,21537886,area under the curve (AUC),"We have evaluated the safety, tolerability, pharmacokinetics, and tumor response profile of weekly nab-paclitaxel (100 mg/m(2)) infusion together with administration of carboplatin at an area under the curve (AUC) of 6 every 3 weeks in Japanese patients with advanced non-small cell lung cancer (NSCLC).",Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537886/),,6,135758,DB01229,Paclitaxel
,21537886,AUC,Nab-paclitaxel (100 mg/m(2)) was administered without steroid or antihistamine premedication as a 30-min intravenous infusion once a week in combination with carboplatin at an AUC of 6 on day 1 of repeated 21-day cycles.,Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537886/),,6,135759,DB01229,Paclitaxel
,21537886,treatment response rate,"Seven partial responses were observed among the 18 evaluable patients, yielding a treatment response rate of 38.9%.",Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537886/),%,38.9,135760,DB01229,Paclitaxel
,21537886,AUC,The combination of nab-paclitaxel (100 mg/m(2)) administered weekly and carboplatin at an AUC of 6 every 3 weeks was well tolerated in Japanese patients with advanced NSCLC.,Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537886/),,6,135761,DB01229,Paclitaxel
,11268469,tmax,"In both treatment schedules the steady state of PACLI occurred after 3 hours, the tmax of metabolites between 3 and 4 hours.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),h,3 and 4,136130,DB01229,Paclitaxel
,11268469,steady-state concentration,The mean steady-state concentration was cmax = 5432 +/- 1238 ng/ml in the control group and cmax = 5140 +/- 2407 ng/ml in the AMI group.,Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],5432,136131,DB01229,Paclitaxel
,11268469,cmax,The mean steady-state concentration was cmax = 5432 +/- 1238 ng/ml in the control group and cmax = 5140 +/- 2407 ng/ml in the AMI group.,Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],5432,136132,DB01229,Paclitaxel
,11268469,cmax,The mean steady-state concentration was cmax = 5432 +/- 1238 ng/ml in the control group and cmax = 5140 +/- 2407 ng/ml in the AMI group.,Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],5140,136133,DB01229,Paclitaxel
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],413,136134,DB01229,Paclitaxel
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],432,136135,DB01229,Paclitaxel
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],99,136136,DB01229,Paclitaxel
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],123,136137,DB01229,Paclitaxel
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],43,136138,DB01229,Paclitaxel
,11268469,cmax,"For the serum metabolites, the findings were very similar: 6-OH-PACLI: cmax 413 +/- 153 ng/ml versus 432 +/- 304 ng/ml, 3""-OH-PACLI: cmax 99 +/- 103 ng/ml versus 123 +/- 98 ng/ml, 3"",6-DiOH-PACLI: cmax 43 +/- 55 ng/ml versus 75 +/- 85 ng/ml.",Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11268469/),[ng] / [ml],75,136139,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,286.2,136488,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,105.0,136489,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,264.2,136490,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,83.0,136491,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,854.4,136492,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,286.0,136493,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,322.1,136494,DB01229,Paclitaxel
,27881491,m/z transitions,"Quantification was performed by monitoring the m/z transitions of 286.2/105.0 for PASP-PTX, 264.2/83.0 for IS-I, 854.4/286.0 for PTX, and 322.1/184.1 for IS-II in the ESI positive mode.",Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27881491/),,184.1,136495,DB01229,Paclitaxel
,9816021,maximum tolerated dose,The maximum tolerated dose of paclitaxel by a 3-h infusion was determined to be 240 mg/m2.,Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816021/),[mg] / [m],240,136639,DB01229,Paclitaxel
,12402426,Peak peritoneal concentration,Peak peritoneal concentration was 40.0 +/- 14.5 micrograms/ml and peritoneal concentration at 24 hours after drug administration was 4.3 +/- 3.9 micrograms/ml.,[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402426/),[μg] / [ml],40.0,137388,DB01229,Paclitaxel
,12402426,peritoneal concentration at 24 hours,Peak peritoneal concentration was 40.0 +/- 14.5 micrograms/ml and peritoneal concentration at 24 hours after drug administration was 4.3 +/- 3.9 micrograms/ml.,[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402426/),[μg] / [ml],4.3,137389,DB01229,Paclitaxel
,12402426,AUC peritoneal/AUC plasma,"The median pharmacokinetic advantage (AUC peritoneal/AUC plasma) was 515 (range 22-1, 770).",[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402426/),,515,137390,DB01229,Paclitaxel
,30215146,relative tumor growth rate,"The maximum tolerated dose of TM-2 micelles was approximately 25 mg/kg in rats, and the relative tumor growth rate of Taxol (15 mg/kg), TM-2 (10 mg/kg), TM-2 (15 mg/kg) and TM-2 (40 mg/kg) in mice were 49.35%, 49.14%, 36.44 and 9.98% respectively.","Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215146/),%,49.35,137690,DB01229,Paclitaxel
,30215146,relative tumor growth rate,"The maximum tolerated dose of TM-2 micelles was approximately 25 mg/kg in rats, and the relative tumor growth rate of Taxol (15 mg/kg), TM-2 (10 mg/kg), TM-2 (15 mg/kg) and TM-2 (40 mg/kg) in mice were 49.35%, 49.14%, 36.44 and 9.98% respectively.","Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215146/),%,49.14,137691,DB01229,Paclitaxel
,30215146,relative tumor growth rate,"The maximum tolerated dose of TM-2 micelles was approximately 25 mg/kg in rats, and the relative tumor growth rate of Taxol (15 mg/kg), TM-2 (10 mg/kg), TM-2 (15 mg/kg) and TM-2 (40 mg/kg) in mice were 49.35%, 49.14%, 36.44 and 9.98% respectively.","Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215146/),%,36.44,137692,DB01229,Paclitaxel
,30215146,relative tumor growth rate,"The maximum tolerated dose of TM-2 micelles was approximately 25 mg/kg in rats, and the relative tumor growth rate of Taxol (15 mg/kg), TM-2 (10 mg/kg), TM-2 (15 mg/kg) and TM-2 (40 mg/kg) in mice were 49.35%, 49.14%, 36.44 and 9.98% respectively.","Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215146/),%,9.98,137693,DB01229,Paclitaxel
,30805953,Recoveries,"Recoveries from whole blood, liver, spleen and pancreas homogenates were 92.7-105.2% for PTX and 72.8-99.7% for CPA.",Development and validation of a rapid and sensitive UPLC-MS/MS assay for simultaneous quantification of paclitaxel and cyclopamine in mouse whole blood and tissue samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30805953/),%,92.7-105.2,138021,DB01229,Paclitaxel
,30805953,Recoveries,"Recoveries from whole blood, liver, spleen and pancreas homogenates were 92.7-105.2% for PTX and 72.8-99.7% for CPA.",Development and validation of a rapid and sensitive UPLC-MS/MS assay for simultaneous quantification of paclitaxel and cyclopamine in mouse whole blood and tissue samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30805953/),%,72.8-99.7,138022,DB01229,Paclitaxel
≥,22210018,AUC(ss),"Among patients with AUC(ss) ≥ 9.6 mg h/mL, PFS was 8.1 months versus 5.7 months for AUC(ss) < 9.6 mg h/mL and 4.6 months for placebo.",Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210018/),[h·mg] / [ml],9.6,138937,DB01229,Paclitaxel
,22210018,PFS,"Among patients with AUC(ss) ≥ 9.6 mg h/mL, PFS was 8.1 months versus 5.7 months for AUC(ss) < 9.6 mg h/mL and 4.6 months for placebo.",Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210018/),month,8.1,138938,DB01229,Paclitaxel
,22210018,PFS,"Among patients with AUC(ss) ≥ 9.6 mg h/mL, PFS was 8.1 months versus 5.7 months for AUC(ss) < 9.6 mg h/mL and 4.6 months for placebo.",Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210018/),month,5.7,138939,DB01229,Paclitaxel
,22210018,PFS,"Among patients with AUC(ss) ≥ 9.6 mg h/mL, PFS was 8.1 months versus 5.7 months for AUC(ss) < 9.6 mg h/mL and 4.6 months for placebo.",Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210018/),month,4.6,138940,DB01229,Paclitaxel
<,22210018,AUC(ss),"Among patients with AUC(ss) ≥ 9.6 mg h/mL, PFS was 8.1 months versus 5.7 months for AUC(ss) < 9.6 mg h/mL and 4.6 months for placebo.",Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210018/),[h·mg] / [ml],9.6,138941,DB01229,Paclitaxel
≥,22210018,AUC(ss),"Simulations predicted that AMG 386 15 mg/kg once weekly would result in an AUC(ss) ≥ 9.6 mg h/mL in > 90% of patients with median PFS of 8.2 months versus 5.0 months for placebo (HR [15 mg/kg vs. placebo], 0.56).",Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210018/),[h·mg] / [ml],9.6,138942,DB01229,Paclitaxel
,13678734,overall objective response rate,"There were 4 patients with a complete response and 7 with partial responses, for an overall objective response rate of 29%, among the 38 evaluable patients.",Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13678734/),%,29,140014,DB01229,Paclitaxel
,13678734,Response rates,Response rates for the subset of 13 women with tumor recurrence occurring at least 6 months after prior platinum-based therapy was 54%.,Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13678734/),%,54,140015,DB01229,Paclitaxel
,12609667,retention times,"The effluents were measured for UV absorption at 227 nm, with retention times of 8.5 and 11.0 min for paclitaxel and 2'-methylpaclitaxel, respectively.",Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12609667/),min,8.5,140276,DB01229,Paclitaxel
,12609667,retention times,"The effluents were measured for UV absorption at 227 nm, with retention times of 8.5 and 11.0 min for paclitaxel and 2'-methylpaclitaxel, respectively.",Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12609667/),min,11.0,140277,DB01229,Paclitaxel
,12609667,absolute recoveries,"At 1,000 ng/ml, the absolute recoveries of paclitaxel and 2'-methylpaclitaxel are 89 and 90%, respectively.",Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12609667/),%,89,140278,DB01229,Paclitaxel
,12609667,absolute recoveries,"At 1,000 ng/ml, the absolute recoveries of paclitaxel and 2'-methylpaclitaxel are 89 and 90%, respectively.",Quantitation of paclitaxel in micro-sample rat plasma by a sensitive reversed-phase HPLC assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12609667/),%,90,140279,DB01229,Paclitaxel
,15236435,run time,"BPU is extracted from plasma into acetonitrile:n-butyl-chloride using paclitaxel as the internal standard and separated on a Waters Symmetry C18 (3.9 x 150 mm, 5 microm) column with acetonitrile-water mobile phase (70:30, v/v) using isocratic flow at 1 mL/min for a run time of 5 min.",A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),min,5,140804,DB01229,Paclitaxel
,15236435,retention times,The retention times were 1.9 min for paclitaxel and 4.1 min for BPU.,A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),min,1.9,140805,DB01229,Paclitaxel
,15236435,retention times,The retention times were 1.9 min for paclitaxel and 4.1 min for BPU.,A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),min,4.1,140806,DB01229,Paclitaxel
,15236435,maximum plasma concentration,"Following administration of BPU 320 mg as a weekly oral dose to a patient with advanced solid tumor malignancies, the maximum plasma concentration was 2 micro g/mL and concentrations were quantifiable up to 168 h after administration.",A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15236435/),[μg] / [ml],2,140807,DB01229,Paclitaxel
,17267149,absolute bioavailability (F),"Consequently, the absolute bioavailability (F) of paclitaxel in the presence of genistein was 0.020-0.025, which was elevated more than the control group (0.016); and the relative bioavailability (Fr) of orally administered paclitaxel was increased from 1.26- to 1.55-fold.",Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267149/),,0.020-0.025,140924,DB01229,Paclitaxel
,25888272,clearance,"Following a single dose of ramucirumab IV infusion 8 mg/kg, clearance was ∼0.017 L/hour, half-life (t1/2) was 138 to 225 hours, and steady-state volume of distribution (Vss) was ∼3 L.",A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888272/),[l] / [h],∼0.017,141491,DB01229,Paclitaxel
,25888272,half-life (t1/2),"Following a single dose of ramucirumab IV infusion 8 mg/kg, clearance was ∼0.017 L/hour, half-life (t1/2) was 138 to 225 hours, and steady-state volume of distribution (Vss) was ∼3 L.",A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888272/),h,138 to 225,141492,DB01229,Paclitaxel
,25888272,steady-state volume of distribution (Vss),"Following a single dose of ramucirumab IV infusion 8 mg/kg, clearance was ∼0.017 L/hour, half-life (t1/2) was 138 to 225 hours, and steady-state volume of distribution (Vss) was ∼3 L.",A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888272/),l,∼3,141493,DB01229,Paclitaxel
,7908792,half life,"The concentration of paclitaxel in tumor tissue was not so high early time after administration, but was sustained for a long time with a half life of 12.3 hr.",[Pharmacokinetics of paclitaxel in experimental animals. Part 2. Tissue distribution]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908792/),h,12.3,141542,DB01229,Paclitaxel
,7481850,area under the concentration-time curve,"Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL.min, was administered as a 20-minute infusion immediately following paclitaxel.",Pharmacokinetics of paclitaxel and carboplatin in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481850/),[mg] / [min·ml],5,141718,DB01229,Paclitaxel
,7481850,area under the concentration-time curve,"Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL.min, was administered as a 20-minute infusion immediately following paclitaxel.",Pharmacokinetics of paclitaxel and carboplatin in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481850/),[mg] / [min·ml],7,141719,DB01229,Paclitaxel
,7481850,area under the concentration-time curve,"Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL.min, was administered as a 20-minute infusion immediately following paclitaxel.",Pharmacokinetics of paclitaxel and carboplatin in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481850/),[mg] / [min·ml],9,141720,DB01229,Paclitaxel
,7481850,area under the concentration-time curve,"Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL.min, was administered as a 20-minute infusion immediately following paclitaxel.",Pharmacokinetics of paclitaxel and carboplatin in combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481850/),[mg] / [min·ml],11,141721,DB01229,Paclitaxel
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],357,143077,DB01229,Paclitaxel
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],603,143078,DB01229,Paclitaxel
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],640,143079,DB01229,Paclitaxel
,12123338,tC0.1,"The only pharmacokinetic/pharmacodynamic relationship observed was between neutropenia and the time spent above the threshold plasma level of 0.1 micromol/l (tC0.1) of paclitaxel, with the time required to obtain a 50% decrease in neutrophil count (Et50) of GEP being 7.8 h, similar to that of EP.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[μM] / [l],0.1,143080,DB01229,Paclitaxel
,9225946,o,"The octanol:water partitioning coefficients of taxol, doxorubicin, and mitomycin were > 99, 0.52, and 0.41, which parallels the rank order of the partitioning across urothelium, i.e. taxol (approximately 50%) > > doxorubicin approximately mitomycin C (-3%).",Bladder tissue pharmacokinetics of intravesical taxol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225946/),,99,143203,DB01229,Paclitaxel
,9225946,o,"The octanol:water partitioning coefficients of taxol, doxorubicin, and mitomycin were > 99, 0.52, and 0.41, which parallels the rank order of the partitioning across urothelium, i.e. taxol (approximately 50%) > > doxorubicin approximately mitomycin C (-3%).",Bladder tissue pharmacokinetics of intravesical taxol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225946/),,0.52,143204,DB01229,Paclitaxel
,9225946,o,"The octanol:water partitioning coefficients of taxol, doxorubicin, and mitomycin were > 99, 0.52, and 0.41, which parallels the rank order of the partitioning across urothelium, i.e. taxol (approximately 50%) > > doxorubicin approximately mitomycin C (-3%).",Bladder tissue pharmacokinetics of intravesical taxol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225946/),,0.41,143205,DB01229,Paclitaxel
,10597745,area under the curve (AUC),"Patients were treated with paclitaxel at 225 mg/m2 for 3 hours followed by carboplatin at an area under the curve (AUC) of 6, 7, 8, or 9 every 3 weeks.",A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597745/),,6,143253,DB01229,Paclitaxel
,10597745,area under the curve (AUC),"Patients were treated with paclitaxel at 225 mg/m2 for 3 hours followed by carboplatin at an area under the curve (AUC) of 6, 7, 8, or 9 every 3 weeks.",A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597745/),,7,143254,DB01229,Paclitaxel
,10597745,area under the curve (AUC),"Patients were treated with paclitaxel at 225 mg/m2 for 3 hours followed by carboplatin at an area under the curve (AUC) of 6, 7, 8, or 9 every 3 weeks.",A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597745/),,8,143255,DB01229,Paclitaxel
,10597745,area under the curve (AUC),"Patients were treated with paclitaxel at 225 mg/m2 for 3 hours followed by carboplatin at an area under the curve (AUC) of 6, 7, 8, or 9 every 3 weeks.",A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597745/),,9,143256,DB01229,Paclitaxel
,10597745,AUC,An AUC of 8 is the maximum tolerated dose of carboplatin in combination with paclitaxel at 225 mg/m2 for 3 hours.,A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597745/),,8,143257,DB01229,Paclitaxel
,11504787,tissue half-life,In vivo tissue half-life was significantly longer for 2'-MOE-modified ASO than for P=S ASO (5 versus 0.5 days).,Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504787/),d,5,143401,DB01229,Paclitaxel
,11504787,tissue half-life,In vivo tissue half-life was significantly longer for 2'-MOE-modified ASO than for P=S ASO (5 versus 0.5 days).,Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504787/),d,0.5,143402,DB01229,Paclitaxel
,20094773,AUC,"1,079 previously untreated patients with advanced NSCLC were enrolled and randomized in a phase III trial (TRIBUTE) to receive either erlotinib or placebo in combination with paclitaxel 200 mg/m2 IV over 3 h and carboplatin at a calculated dose to achieve an AUC 6 mg∙min/mL.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[mg∙min] / [ml],6,144659,DB01229,Paclitaxel
,20094773,AUC(0-τ),"Mean AUC(0-τ) for erlotinib and the OSI-420 metabolite were 29,997 ng∙h/mL and 3,020 ng∙h/mL, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"29,997",144660,DB01229,Paclitaxel
,20094773,AUC(0-τ),"Mean AUC(0-τ) for erlotinib and the OSI-420 metabolite were 29,997 ng∙h/mL and 3,020 ng∙h/mL, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"3,020",144661,DB01229,Paclitaxel
,20094773,clearances,"Mean (SD) paclitaxel clearances (L/h/M(2)) were 11.7 (3.4) and 12.7 (6.7) in the placebo and erlotinib treatment groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[h·l] / [M(2],11.7,144662,DB01229,Paclitaxel
,20094773,clearances,"Mean (SD) paclitaxel clearances (L/h/M(2)) were 11.7 (3.4) and 12.7 (6.7) in the placebo and erlotinib treatment groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[h·l] / [M(2],12.7,144663,DB01229,Paclitaxel
,20094773,AUC(0-∞),"The resultant paclitaxel AUC(0-∞) (ng∙h/mL) was 18,400 (5,300) for the placebo group and 17,800 (5,500) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"18,400",144664,DB01229,Paclitaxel
,20094773,AUC(0-∞),"The resultant paclitaxel AUC(0-∞) (ng∙h/mL) was 18,400 (5,300) for the placebo group and 17,800 (5,500) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng∙h] / [ml],"17,800",144665,DB01229,Paclitaxel
,20094773,clearances,"For carboplatin, the mean (SD) clearances (L/h) were 16.8 (3.9) and 16.1 (4.4) for the placebo and erlotinib groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[l] / [h],16.8,144666,DB01229,Paclitaxel
,20094773,clearances,"For carboplatin, the mean (SD) clearances (L/h) were 16.8 (3.9) and 16.1 (4.4) for the placebo and erlotinib groups, respectively.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[l] / [h],16.1,144667,DB01229,Paclitaxel
,20094773,AUC(0-∞),"The resultant carboplatin AUC(0-∞) (ng/mL∙h) were 49,900 (9,700) for the placebo group and 48,400 (11,900) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng] / [ml∙h],"49,900",144668,DB01229,Paclitaxel
,20094773,AUC(0-∞),"The resultant carboplatin AUC(0-∞) (ng/mL∙h) were 49,900 (9,700) for the placebo group and 48,400 (11,900) for the erlotinib group.","Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20094773/),[ng] / [ml∙h],"48,400",144669,DB01229,Paclitaxel
,23589525,times to progression,"Median times to progression were 48 and 68 days in patients receiving 0.15 mg of efatutazone and 0.3 mg of efatutazone, respectively; corresponding median survival was 98 vs 138 days.","Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589525/),d,48,145788,DB01229,Paclitaxel
,23589525,times to progression,"Median times to progression were 48 and 68 days in patients receiving 0.15 mg of efatutazone and 0.3 mg of efatutazone, respectively; corresponding median survival was 98 vs 138 days.","Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589525/),d,68,145789,DB01229,Paclitaxel
,23589525,survival,"Median times to progression were 48 and 68 days in patients receiving 0.15 mg of efatutazone and 0.3 mg of efatutazone, respectively; corresponding median survival was 98 vs 138 days.","Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589525/),d,98,145790,DB01229,Paclitaxel
,23589525,survival,"Median times to progression were 48 and 68 days in patients receiving 0.15 mg of efatutazone and 0.3 mg of efatutazone, respectively; corresponding median survival was 98 vs 138 days.","Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589525/),d,138,145791,DB01229,Paclitaxel
,23589525,peak efatutazone blood level,The median peak efatutazone blood level was 8.6 ng/mL for 0.15-mg dosing vs 22.0 ng/mL for 0.3-mg twice daily dosing.,"Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589525/),[ng] / [ml],8.6,145792,DB01229,Paclitaxel
,23589525,peak efatutazone blood level,The median peak efatutazone blood level was 8.6 ng/mL for 0.15-mg dosing vs 22.0 ng/mL for 0.3-mg twice daily dosing.,"Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589525/),[ng] / [ml],22.0,145793,DB01229,Paclitaxel
<,9427267,maximum tolerated dose,The maximum tolerated dose was < or =75 mg/m2.,A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9427267/),[mg] / [m2],75,145794,DB01229,Paclitaxel
,11360664,T1/2 beta,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),h,5.18,146576,DB01229,Paclitaxel
,11360664,T1/2 beta,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),h,6.26,146577,DB01229,Paclitaxel
,11360664,T1/2 beta,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),h,6.99,146578,DB01229,Paclitaxel
,11360664,AUC,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),[h·mg] / [l],14.71,146579,DB01229,Paclitaxel
,11360664,AUC,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),[h·mg] / [l],39.09,146580,DB01229,Paclitaxel
,11360664,AUC,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),[h·mg] / [l],66.52,146581,DB01229,Paclitaxel
,11360664,Cl,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),[l] / [h],14.29,146582,DB01229,Paclitaxel
,11360664,Cl,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),[l] / [h],7.52,146583,DB01229,Paclitaxel
,11360664,Cl,"The main pharmacokinetic parameters of three groups were T1/2 beta (5.18 +/- 3.49), (6.26 +/- 2.21), and (6.99 +/- 1.45) h, AUC (14.71 +/- 0.76), (39.09 +/- 13.10), and (66.52 +/- 12.23) mg.h.L-1, Cl (14.29 +/- 0.74), (7.52 +/- 2.15), and (6.25 +/- 1.93) L.h-1, respectively.",Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360664/),[l] / [h],6.25,146584,DB01229,Paclitaxel
,7912725,MTD,"The MTD at this schedule appears to be 110 mg/m2 per course, with six of 10 patients at this level experiencing severe toxicity.",Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912725/),[mg] / [m2],110,146752,DB01229,Paclitaxel
,7577097,plasma protein binding,Docetaxel exhibited linear pharmacokinetics and long tumour retention in tumour-bearing mice; plasma protein binding ranged from 76 to 89%.,Preclinical pharmacology of docetaxel. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7577097/),%,76 to 89,147082,DB01229,Paclitaxel
,22760659,oral bioavailability,"Both compounds had favorable drug-like properties, and acceptable oral bioavailability (21-50 %) in mice, rats, and dogs.",Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22760659/),%,21-50,149424,DB01229,Paclitaxel
,12579901,T 1/2 beta,"Long-circulation nanoparticles was found to stay in the blood circulation, with T 1/2 beta 10.1 h of F68-SLN, and T 1/2 beta 4.88 h of Brij78-SLN more than one commercialized paclitaxel injection, T 1/2 beta 1.3 h.",[In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579901/),h,10.1,149650,DB01229,Paclitaxel
,12579901,T 1/2 beta,"Long-circulation nanoparticles was found to stay in the blood circulation, with T 1/2 beta 10.1 h of F68-SLN, and T 1/2 beta 4.88 h of Brij78-SLN more than one commercialized paclitaxel injection, T 1/2 beta 1.3 h.",[In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579901/),h,4.88,149651,DB01229,Paclitaxel
,12579901,T 1/2 beta,"Long-circulation nanoparticles was found to stay in the blood circulation, with T 1/2 beta 10.1 h of F68-SLN, and T 1/2 beta 4.88 h of Brij78-SLN more than one commercialized paclitaxel injection, T 1/2 beta 1.3 h.",[In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579901/),h,1.3,149652,DB01229,Paclitaxel
,22516136,relative oral bioavailability,"The relative oral bioavailability of paclitaxel delivered in nanoparticles was calculated to be 70% for PTX-NP2, 40% for PTX-NP6 and 16% in case of PTX-NP10.",Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22516136/),%,70,149799,DB01229,Paclitaxel
,22516136,relative oral bioavailability,"The relative oral bioavailability of paclitaxel delivered in nanoparticles was calculated to be 70% for PTX-NP2, 40% for PTX-NP6 and 16% in case of PTX-NP10.",Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22516136/),%,40,149800,DB01229,Paclitaxel
,22516136,relative oral bioavailability,"The relative oral bioavailability of paclitaxel delivered in nanoparticles was calculated to be 70% for PTX-NP2, 40% for PTX-NP6 and 16% in case of PTX-NP10.",Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22516136/),%,16,149801,DB01229,Paclitaxel
,27567930,solubility,"The optimal PTX-M were provided with small size (164.8±2.0nm) and spherical shape at ratio of 1: 3 (Solutol(®)HS15: Soluplus(®)), thus increasing the solubility to 15.76±0.15mg/mL in water.",Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),[mg] / [ml],15.76,150995,DB01229,Paclitaxel
,27567930,entrapment efficiency,The entrapment efficiency and drug loading of PTX-M were 98.48±0.91% and 10.59±0.09% respectively.,Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),%,98.48,150996,DB01229,Paclitaxel
,27567930,drug loading,The entrapment efficiency and drug loading of PTX-M were 98.48±0.91% and 10.59±0.09% respectively.,Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),%,10.59,150997,DB01229,Paclitaxel
,27567930,IC50,"In addition, the MTT assay demonstrated that the IC50 value of PTX-M was reduced by 40.21% (PTX-M: 22.6±2.1μg/mL, PTX: 37.8±1.4μg/mL), and in vivo anti-tumor study (15days' therapy) showed PTX-M achieved higher anti-tumor efficacy (57.66%) compared with PTX (41.13%).",Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),μ,22.6,150998,DB01229,Paclitaxel
,27567930,IC50,"In addition, the MTT assay demonstrated that the IC50 value of PTX-M was reduced by 40.21% (PTX-M: 22.6±2.1μg/mL, PTX: 37.8±1.4μg/mL), and in vivo anti-tumor study (15days' therapy) showed PTX-M achieved higher anti-tumor efficacy (57.66%) compared with PTX (41.13%).",Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),μg,37.8,150999,DB01229,Paclitaxel
,12376205,overall response rate,The overall response rate was 94% in 17 evaluable chemotherapy-nai;ve patients and 84% in 25 patients with recurrent disease.,Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),%,94,151596,DB01229,Paclitaxel
,12376205,overall response rate,The overall response rate was 94% in 17 evaluable chemotherapy-nai;ve patients and 84% in 25 patients with recurrent disease.,Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),%,84,151597,DB01229,Paclitaxel
,12376205,progression-free survival (PFS),"Median progression-free survival (PFS) was 17 months (chemotherapy-nai;ve: 23 months, recurrent: 11 months) and median overall survival was 41 months (chemotherapy-nai;ve: 48 months, recurrent: 24 months).",Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),month,17,151598,DB01229,Paclitaxel
,12376205,progression-free survival (PFS),"Median progression-free survival (PFS) was 17 months (chemotherapy-nai;ve: 23 months, recurrent: 11 months) and median overall survival was 41 months (chemotherapy-nai;ve: 48 months, recurrent: 24 months).",Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),month,23,151599,DB01229,Paclitaxel
,12376205,overall survival,"Median progression-free survival (PFS) was 17 months (chemotherapy-nai;ve: 23 months, recurrent: 11 months) and median overall survival was 41 months (chemotherapy-nai;ve: 48 months, recurrent: 24 months).",Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),month,41,151600,DB01229,Paclitaxel
,12376205,overall survival,"Median progression-free survival (PFS) was 17 months (chemotherapy-nai;ve: 23 months, recurrent: 11 months) and median overall survival was 41 months (chemotherapy-nai;ve: 48 months, recurrent: 24 months).",Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),month,48,151601,DB01229,Paclitaxel
,12376205,overall survival,"Median progression-free survival (PFS) was 17 months (chemotherapy-nai;ve: 23 months, recurrent: 11 months) and median overall survival was 41 months (chemotherapy-nai;ve: 48 months, recurrent: 24 months).",Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376205/),month,24,151602,DB01229,Paclitaxel
,25645339,flow rate,"The chromatographic separation was achieved on a C18 column (50 mm × 2.1 mm, 1.8 μm, Waters, USA) with a gradient elution program consisting of methanol and water (containing 0.1% formic acid) at a flow rate of 0.2 mL/min.",Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645339/),[ml] / [min],0.2,152108,DB01229,Paclitaxel
,25645339,extraction recoveries,The extraction recoveries of the seven compounds ranged from 62.5% to 100.5%.,Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645339/),%,62.5,152109,DB01229,Paclitaxel
,25645339,extraction recoveries,The extraction recoveries of the seven compounds ranged from 62.5% to 100.5%.,Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645339/),%,100.5,152110,DB01229,Paclitaxel
,19758898,late loss,One-year in-stent late loss was 0.52+/-0.34 mm in D5 and 0.36+/-0.50mm in D6 (p=0.20) while neointimal area was 0.99+/-0.54 mm2 in D5 and 0.77+/-0.92 mm2 in D6 (p=0.42).,One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19758898/),mm,0.52,152274,DB01229,Paclitaxel
,19758898,late loss,One-year in-stent late loss was 0.52+/-0.34 mm in D5 and 0.36+/-0.50mm in D6 (p=0.20) while neointimal area was 0.99+/-0.54 mm2 in D5 and 0.77+/-0.92 mm2 in D6 (p=0.42).,One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19758898/),mm,0.36,152275,DB01229,Paclitaxel
,19758898,neointimal area,One-year in-stent late loss was 0.52+/-0.34 mm in D5 and 0.36+/-0.50mm in D6 (p=0.20) while neointimal area was 0.99+/-0.54 mm2 in D5 and 0.77+/-0.92 mm2 in D6 (p=0.42).,One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19758898/),mm2,0.99,152276,DB01229,Paclitaxel
,19758898,neointimal area,One-year in-stent late loss was 0.52+/-0.34 mm in D5 and 0.36+/-0.50mm in D6 (p=0.20) while neointimal area was 0.99+/-0.54 mm2 in D5 and 0.77+/-0.92 mm2 in D6 (p=0.42).,One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19758898/),mm2,0.77,152277,DB01229,Paclitaxel
,10715285,AUC,"The dose of etoposide was 1, 200 mg/m(2), and the carboplatin target AUC ranged among cohorts from 12 to 32 (mg/mL) x min.","Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10715285/),[mg] / [min·ml)],12 to 32,152320,DB01229,Paclitaxel
,18794097,MTD,The MTD of LEP-ETU was identified as 325 mg/m(2).,Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794097/),[mg] / [m(2],325,152448,DB01229,Paclitaxel
,17869458,shelf-lives,"The shelf-lives of PAC at 25 degrees C in Taxol, LBMW and CMW, in an accelerated stability study, were 71, 57 and 31 days, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),d,71,152939,DB01229,Paclitaxel
,17869458,shelf-lives,"The shelf-lives of PAC at 25 degrees C in Taxol, LBMW and CMW, in an accelerated stability study, were 71, 57 and 31 days, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),d,57,152940,DB01229,Paclitaxel
,17869458,shelf-lives,"The shelf-lives of PAC at 25 degrees C in Taxol, LBMW and CMW, in an accelerated stability study, were 71, 57 and 31 days, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),d,31,152941,DB01229,Paclitaxel
,17869458,activation energy (Ea),"The activation energy (Ea) for PAC in Taxol, LBMW and CMW was 23, 16 and 14 kcal/mol, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),[kcal] / [mol],23,152942,DB01229,Paclitaxel
,17869458,activation energy (Ea),"The activation energy (Ea) for PAC in Taxol, LBMW and CMW was 23, 16 and 14 kcal/mol, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),[kcal] / [mol],16,152943,DB01229,Paclitaxel
,17869458,activation energy (Ea),"The activation energy (Ea) for PAC in Taxol, LBMW and CMW was 23, 16 and 14 kcal/mol, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),[kcal] / [mol],14,152944,DB01229,Paclitaxel
,22898996,relative tumor growth rate (T/C),Paclitaxel (20 mg/kg) co-administered with 20(s)-ginsenoside Rg3 (10 mg/kg) exhibited an effective anti-tumour activity with the relative tumor growth rate (T/C) values of 39.36% (p <0.05).,Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898996/),%,39.36,153241,DB01229,Paclitaxel
,15367419,MTD,The MTD was 30/90 and 35/80 mg/m(2) for PLD/wPTX.,Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15367419/),[mg] / [m(2],30,154765,DB01229,Paclitaxel
,15367419,MTD,The MTD was 30/90 and 35/80 mg/m(2) for PLD/wPTX.,Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15367419/),[mg] / [m(2],35/80,154766,DB01229,Paclitaxel
,29235901,CMC,The 7:3 and 5:5 micellar combinations had lower CMC values (0.034-0.042 mg/mL) than 0:10 (0.124 mg/mL).,"A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),[mg] / [ml],0.034-0.042,154921,DB01229,Paclitaxel
,29235901,CMC,The 7:3 and 5:5 micellar combinations had lower CMC values (0.034-0.042 mg/mL) than 0:10 (0.124 mg/mL).,"A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),[mg] / [ml],0.124,154922,DB01229,Paclitaxel
,29235901,entrapment efficiencies,"The entrapment efficiencies of 10:0, 7:3, and 5:5 were 53.4 ± 9.3%, 61.3 ± 0.5%, and 78.7 ± 1.66%, respectively.","A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),%,53.4,154923,DB01229,Paclitaxel
,29235901,entrapment efficiencies,"The entrapment efficiencies of 10:0, 7:3, and 5:5 were 53.4 ± 9.3%, 61.3 ± 0.5%, and 78.7 ± 1.66%, respectively.","A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),%,61.3,154924,DB01229,Paclitaxel
,29235901,entrapment efficiencies,"The entrapment efficiencies of 10:0, 7:3, and 5:5 were 53.4 ± 9.3%, 61.3 ± 0.5%, and 78.7 ± 1.66%, respectively.","A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29235901/),%,78.7,154925,DB01229,Paclitaxel
,24726707,serum concentration,The mean serum concentration of LPP1 measured 30 min following i.p. administration was 7904.6 ± 1066.1 ng/ml.,Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726707/),[ng] / [ml],7904.6,155372,DB01229,Paclitaxel
,10972480,Tumor response,Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups.,Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972480/),%,46.4,155407,DB01229,Paclitaxel
,10972480,Tumor response,Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups.,Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972480/),%,32.2,155408,DB01229,Paclitaxel
,10972480,survival time,Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups.,Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972480/),month,9.8,155409,DB01229,Paclitaxel
,10972480,survival time,Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups.,Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972480/),month,6.8,155410,DB01229,Paclitaxel
,29747311,Overall response rates (ORR),"Overall response rates (ORR) were 40% (95% CI, 24.8%-55.2%).",[Study of bioequiavailability of paclitaxel for Injection (Albumin Bound) and abraxane and the efficacy of extension treatments in patients with metastatic breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29747311/),%,40,155653,DB01229,Paclitaxel
,29747311,P,"For patients who taxane-naïve vs taxane-pretreated, the ORR were 45.5% vs 37.9%. Median PFS was 49 weeks(95% CI, 30weeks-NA).",[Study of bioequiavailability of paclitaxel for Injection (Albumin Bound) and abraxane and the efficacy of extension treatments in patients with metastatic breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29747311/),weeks,49,155654,DB01229,Paclitaxel
,26291333,EC50,"FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.","A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155958,DB01229,Paclitaxel
,26291333,EC50,Pharmacokinetics studies indicated that intraperitoneal administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.,"A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155959,DB01229,Paclitaxel
,15018990,AB%,The AB% of paclitaxel was increased significantly (P < 0.05) by quercetin from 8.0 to 10.1 and 16.2%.,Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018990/),,8,156330,DB01229,Paclitaxel
,15018990,AB%,The AB% of paclitaxel was increased significantly (P < 0.05) by quercetin from 8.0 to 10.1 and 16.2%.,Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018990/),,10,156331,DB01229,Paclitaxel
,12721761,plasma steady-state concentrations,Gemcitabine administered at a fixed dose rate of 10 mg/m(2) per min has been reported to achieve plasma steady-state concentrations ranging from 10 to 20 microM in patients with acute leukemia.,Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721761/),μM,10 to 20,157189,DB01229,Paclitaxel
,20855828,AUC,"For example, an AUC of 5 mg/mL · min is associated with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel versus 38% with gemcitabine in a non-pretreated patient.",Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20855828/),[mg] / [min·ml],5,157411,DB01229,Paclitaxel
,33099115,flow rate,"Chromatographic separation was carried out on Kinetex C18 column (1.7 μm, 100 × 2.10 mm) under an isocratic elution at a flow rate of 0.4 mL/min with a total runtime of 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),[ml] / [min],0.4,158233,DB01229,Paclitaxel
,33099115,total runtime,"Chromatographic separation was carried out on Kinetex C18 column (1.7 μm, 100 × 2.10 mm) under an isocratic elution at a flow rate of 0.4 mL/min with a total runtime of 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),min,3.5,158234,DB01229,Paclitaxel
,33099115,total run time,"Additionally, only 20 μL of rat whole blood or plasma is required and the total run time per sample is 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),min,3.5,158235,DB01229,Paclitaxel
,10811677,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) of epirubicin was higher in the TE group (2,346 ng/mL. h v 1,717 ng/mL. h; P =.002).",Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811677/),[ng] / [h·ml],"2,346",158274,DB01229,Paclitaxel
,10811677,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) of epirubicin was higher in the TE group (2,346 ng/mL. h v 1,717 ng/mL. h; P =.002).",Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811677/),[ng] / [h·ml],"1,717",158275,DB01229,Paclitaxel
,11206274,initial half-life,"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),h,0.903,158369,DB01229,Paclitaxel
,11206274,terminal half-life,"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),h,13.6,158370,DB01229,Paclitaxel
,11206274,maximum plasma concentration (Cmax),"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),μM,38.5,158371,DB01229,Paclitaxel
,11206274,AUC,"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),[μM] / [h],111.9,158372,DB01229,Paclitaxel
,11206274,volume of distribution,"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),l,411,158373,DB01229,Paclitaxel
,11206274,total clearance (Ct),"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),[ml] / [min],579,158374,DB01229,Paclitaxel
,11206274,renal clearance (Cr),"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),[ml] / [min],453,158375,DB01229,Paclitaxel
,11206274,renal elimination,"Using a twocompartment-model, the following parameters were obtained (mean, coefficient of variation): initial half-life, 0.903 h (48%); terminal half-life, 13.6 h (116%); maximum plasma concentration (Cmax), 38.5 microM (86%); AUC, 111.9 microM/h (86%); volume of distribution, 411 l (130%); total clearance (Ct), 579 ml/min (75%); renal clearance (Cr), 453 ml/min (80%); renal elimination, 76% of dose (17%).",Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206274/),%,76,158376,DB01229,Paclitaxel
,12848775,AUC,"A 25% decrease in paclitaxel CL was observed, corresponding to an 1.3-fold increase in paclitaxel AUC (from 14829 microg x l(-1) x h to 19115 microg x l(-1) x h following paclitaxel 175 mg x m(-2)) when zosuquidar Cmax was greater than 350 microg x l(-1).","A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848775/),[h·μg] / [l],14829,158458,DB01229,Paclitaxel
,12848775,AUC,"A 25% decrease in paclitaxel CL was observed, corresponding to an 1.3-fold increase in paclitaxel AUC (from 14829 microg x l(-1) x h to 19115 microg x l(-1) x h following paclitaxel 175 mg x m(-2)) when zosuquidar Cmax was greater than 350 microg x l(-1).","A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848775/),[h·μg] / [l],19115,158459,DB01229,Paclitaxel
greater,12848775,Cmax,"A 25% decrease in paclitaxel CL was observed, corresponding to an 1.3-fold increase in paclitaxel AUC (from 14829 microg x l(-1) x h to 19115 microg x l(-1) x h following paclitaxel 175 mg x m(-2)) when zosuquidar Cmax was greater than 350 microg x l(-1).","A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848775/),[μg] / [l],350,158460,DB01229,Paclitaxel
,12848775,IC50,This cut-off concentration closely corresponded to the IC50 of a sigmoidal Emax relationship (328 microg x l(-1)).,"A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848775/),[μg] / [l],328,158461,DB01229,Paclitaxel
>,12848775,Cmax,"This analysis provides a model which accurately characterized the increase in paclitaxel exposure, which is most likely to be due to P-gp inhibition in the bile canaliculi, in the presence of zosuquidar 3HCl (Cmax > 350 microg x l(-1)) and is predictive of paclitaxel pharmacokinetics following a 3 h infusion.","A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848775/),[μg] / [l],350,158462,DB01229,Paclitaxel
,33397559,zeta-potential,The mixed liposomes were found to have negative zeta-potential (-17.91 ± 1.21 mV) and relatively uniform particle size (105.88 ± 3.19 nm) with a low polydispersity index (0.21 ± 0.016).,Combination of Curcumin and Paclitaxel Liposomes Exhibits Enhanced Cytotoxicity Towards A549/A549-T Cells and Unaltered Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33397559/),mv,-,158697,DB01229,Paclitaxel
,33397559,zeta-potential,The mixed liposomes were found to have negative zeta-potential (-17.91 ± 1.21 mV) and relatively uniform particle size (105.88 ± 3.19 nm) with a low polydispersity index (0.21 ± 0.016).,Combination of Curcumin and Paclitaxel Liposomes Exhibits Enhanced Cytotoxicity Towards A549/A549-T Cells and Unaltered Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33397559/),mv,17.91,158698,DB01229,Paclitaxel
,15073098,time period above,"During the first course, the median time period above the threshold concentration was 16.3 h (range, 7.6-31.6 h), and was <15 h for 9 patients (36%).",Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073098/),h,16.3,159194,DB01229,Paclitaxel
,15073098,objective response rate,The objective response rate was 20%.,Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073098/),%,20,159195,DB01229,Paclitaxel
,22203732,MTD,MTD was 650 mg/m(2); the main dose-limiting toxicity was myelosuppression.,"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203732/),mg,650,159196,DB01229,Paclitaxel
,22203732,terminal-phase elimination half-life,Pharmacokinetics was dose linear and the mean terminal-phase elimination half-life was 3.6 hours.,"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203732/),h,3.6,159197,DB01229,Paclitaxel
,11565098,retention times,"The retention times of BAY and IS were 7.21 and 10.36 min, respectively.",High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565098/),min,7.21,159409,DB01229,Paclitaxel
,11565098,retention times,"The retention times of BAY and IS were 7.21 and 10.36 min, respectively.",High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565098/),min,10.36,159410,DB01229,Paclitaxel
,11565098,LOD,"The LOD was 5 ng/mL and 20 ng/g in the plasma and liver, respectively.",High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565098/),[ng] / [ml],5,159411,DB01229,Paclitaxel
,11565098,LOD,"The LOD was 5 ng/mL and 20 ng/g in the plasma and liver, respectively.",High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565098/),[ng] / [g],20,159412,DB01229,Paclitaxel
,16278406,maximum tolerated dose,Dose-limiting toxicity of neutropenia was encountered at 266 mg/m(2) (paclitaxel equivalents) in phase Ia and the maximum tolerated dose was 233 mg/m(2).,"A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278406/),[mg] / [m(2],233,159476,DB01229,Paclitaxel
,16278406,maximum tolerated dose,Neuropathy was dose-limiting in phase Ib with a maximum tolerated dose of 177 mg/m(2).,"A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278406/),[mg] / [m(2],177,159477,DB01229,Paclitaxel
>,16278406,half-life,Pharmacokinetic investigations indicated a prolonged half-life of >100 hours for conjugated taxanes.,"A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278406/),h,100,159478,DB01229,Paclitaxel
>,16334120,T(,"We evaluated the effects of time above paclitaxel concentrations of 0.05 micromol/l (T(>0.05) and systemic exposures (AUC) to total and unbound paclitaxel (tPAC, uPAC) on response in patients with advanced cancer treated with weekly 1-h or 3-h infusions.",Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334120/),,0.05,160654,DB01229,Paclitaxel
> or =,16334120,T,Patients with T(>0.05) > or = 20.7 hours had lower probability (p < 0.05) to progress within 12 WOT.,Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16334120/),h,20.7,160655,DB01229,Paclitaxel
,17285317,AUC,"Forty-one patients with solid tumors were enrolled, and received ABI-007 in combination with carboplatin AUC of 6 on day 1.","Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17285317/),,6,160891,DB01229,Paclitaxel
,17285317,MTD,"The MTD of ABI-007 in combination with carboplatin was 300, 100, and 125 mg/m(2) in groups A, B, and C, respectively.","Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17285317/),[mg] / [m(2],300,160892,DB01229,Paclitaxel
,17285317,MTD,"The MTD of ABI-007 in combination with carboplatin was 300, 100, and 125 mg/m(2) in groups A, B, and C, respectively.","Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17285317/),[mg] / [m(2],100,160893,DB01229,Paclitaxel
,17285317,MTD,"The MTD of ABI-007 in combination with carboplatin was 300, 100, and 125 mg/m(2) in groups A, B, and C, respectively.","Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17285317/),[mg] / [m(2],125,160894,DB01229,Paclitaxel
,11240742,survival,The median survival was 11.3 months.,Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240742/),month,11.3,161284,DB01229,Paclitaxel
,7636546,clearance,Concomitant administration of R-verapamil resulted in a decrease in mean (+/- SD) paclitaxel clearance from 179 +/- 67 mL/min/m2 to 90 +/- 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]).,Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636546/),[ml] / [m2·min],179,161477,DB01229,Paclitaxel
,7636546,clearance,Concomitant administration of R-verapamil resulted in a decrease in mean (+/- SD) paclitaxel clearance from 179 +/- 67 mL/min/m2 to 90 +/- 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]).,Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636546/),[ml] / [m2·min],90,161478,DB01229,Paclitaxel
,10511918,area under the concentration-time curve (AUC),"Likewise, patients given epirubicin 90 mg/m2 had a sudden rebound of epirubicinol plasma concentrations shortly after the start of infusion of paclitaxel 200 mg/m2, with a significant increase in the area under the concentration-time curve (AUC) of epirubicinol as compared with epirubicin alone (1.27 +/- 0.2 vs 0.61 +/- 0.1 mumol/L.h).",Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511918/),[μM] / [h·l],1.27,161516,DB01229,Paclitaxel
,10511918,area under the concentration-time curve (AUC),"Likewise, patients given epirubicin 90 mg/m2 had a sudden rebound of epirubicinol plasma concentrations shortly after the start of infusion of paclitaxel 200 mg/m2, with a significant increase in the area under the concentration-time curve (AUC) of epirubicinol as compared with epirubicin alone (1.27 +/- 0.2 vs 0.61 +/- 0.1 mumol/L.h).",Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511918/),[μM] / [h·l],0.61,161517,DB01229,Paclitaxel
,10071279,MTD,"The MTD of paclitaxel was 150 mg/m2, and adjunctive therapy with G-CSF was required to prevent febrile neutropenia.",Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071279/),[mg] / [m2],150,161889,DB01229,Paclitaxel
>,28612269,T,"Systematic data mining was performed to extract the maximum concentration (C max), clearance (CL), and time of paclitaxel plasma concentration above 0.05 µmol/L (T > 0.05 µmol/L) following monotherapy of both the widely used cremophor-diluted paclitaxel and nanoparticle albumin-bound (nab-)paclitaxel.",Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28612269/),[μM] / [l],0.05,161925,DB01229,Paclitaxel
,28612269,C max,"The most widely used dose of cremophor-diluted paclitaxel, 175 mg/m2 given as a 3-h infusion, leads to an interstudy median C max of 5.1 µmol/L [interquartile range (IQR) 4.5-5.7], CL of 12.0 L/h/m2 (IQR 10.9-12.9), and T > 0.05 µmol/L of 23.8 h (IQR 21.5-26.8).",Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28612269/),[μM] / [l],5.1,161926,DB01229,Paclitaxel
,28612269,CL,"The most widely used dose of cremophor-diluted paclitaxel, 175 mg/m2 given as a 3-h infusion, leads to an interstudy median C max of 5.1 µmol/L [interquartile range (IQR) 4.5-5.7], CL of 12.0 L/h/m2 (IQR 10.9-12.9), and T > 0.05 µmol/L of 23.8 h (IQR 21.5-26.8).",Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28612269/),[l] / [h·m2],12.0,161927,DB01229,Paclitaxel
,28612269,T > 0,"The most widely used dose of cremophor-diluted paclitaxel, 175 mg/m2 given as a 3-h infusion, leads to an interstudy median C max of 5.1 µmol/L [interquartile range (IQR) 4.5-5.7], CL of 12.0 L/h/m2 (IQR 10.9-12.9), and T > 0.05 µmol/L of 23.8 h (IQR 21.5-26.8).",Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28612269/),h,23.8,161928,DB01229,Paclitaxel
,22837069,m,"The precursor-product ion pairs used for multiple reaction monitoring were m/z 808.5 → 527.5 (docetaxel) and m/z 854.2 → 286.5 (IS, paclitaxel).","Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837069/),,808.5,162302,DB01229,Paclitaxel
,22837069,C(0),"For SID530 and Taxotere, the mean C(0) values were 1494 and 1818 ng/mL, respectively, and the AUC(last) values were 837 and 755 h ng/mL, respectively.","Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837069/),[ng] / [ml],1494,162303,DB01229,Paclitaxel
,22837069,C(0),"For SID530 and Taxotere, the mean C(0) values were 1494 and 1818 ng/mL, respectively, and the AUC(last) values were 837 and 755 h ng/mL, respectively.","Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837069/),[ng] / [ml],1818,162304,DB01229,Paclitaxel
,22837069,AUC(last),"For SID530 and Taxotere, the mean C(0) values were 1494 and 1818 ng/mL, respectively, and the AUC(last) values were 837 and 755 h ng/mL, respectively.","Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837069/),[h·ng] / [ml],837,162305,DB01229,Paclitaxel
,22837069,AUC(last),"For SID530 and Taxotere, the mean C(0) values were 1494 and 1818 ng/mL, respectively, and the AUC(last) values were 837 and 755 h ng/mL, respectively.","Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837069/),[h·ng] / [ml],755,162306,DB01229,Paclitaxel
,22729159,objective response rate (ORR),"In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).",Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729159/),%,23,162353,DB01229,Paclitaxel
,22729159,progression-free survival,"In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).",Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729159/),month,3.4,162354,DB01229,Paclitaxel
,22729159,overall survival,"In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).",Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729159/),month,11.2,162355,DB01229,Paclitaxel
,10944128,area under the curve,Paclitaxel at 175 mg/m(2) given over 3 hours and carboplatin at an area under the curve of 5 were administered on day 1 followed by oral etoposide 50 mg/m(2)/d beginning on day 2.,"Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944128/),,5,162889,DB01229,Paclitaxel
,11221957,AUC,The target AUC of i.p. carboplatin was 6.5 mg min/ml.,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),[mg·min] / [ml],6.5,162981,DB01229,Paclitaxel
,11221957,nadir,The nadir platelet counts were significantly higher (P = 0.0018) in patients treated with i.p. carboplatin with paclitaxel (12.1 +/- 4.3 x 10(4)/mm3) compared with carboplatin alone (5.2 +/- 3.3 x 10(4)/mm3) or with cyclophosphamide (5.2 +/- 4.8 x 10(4)/mm3).,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),,12.1,162982,DB01229,Paclitaxel
,11221957,nadir,The nadir platelet counts were significantly higher (P = 0.0018) in patients treated with i.p. carboplatin with paclitaxel (12.1 +/- 4.3 x 10(4)/mm3) compared with carboplatin alone (5.2 +/- 3.3 x 10(4)/mm3) or with cyclophosphamide (5.2 +/- 4.8 x 10(4)/mm3).,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),,5.2,162983,DB01229,Paclitaxel
,11221957,nadir,The nadir platelet counts were significantly higher (P = 0.0018) in patients treated with i.p. carboplatin with paclitaxel (12.1 +/- 4.3 x 10(4)/mm3) compared with carboplatin alone (5.2 +/- 3.3 x 10(4)/mm3) or with cyclophosphamide (5.2 +/- 4.8 x 10(4)/mm3).,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),,5.2,162984,DB01229,Paclitaxel
,11221957,platelet counts,The nadir platelet counts were significantly higher (P = 0.0018) in patients treated with i.p. carboplatin with paclitaxel (12.1 +/- 4.3 x 10(4)/mm3) compared with carboplatin alone (5.2 +/- 3.3 x 10(4)/mm3) or with cyclophosphamide (5.2 +/- 4.8 x 10(4)/mm3).,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),,12.1,162985,DB01229,Paclitaxel
,11221957,platelet counts,The nadir platelet counts were significantly higher (P = 0.0018) in patients treated with i.p. carboplatin with paclitaxel (12.1 +/- 4.3 x 10(4)/mm3) compared with carboplatin alone (5.2 +/- 3.3 x 10(4)/mm3) or with cyclophosphamide (5.2 +/- 4.8 x 10(4)/mm3).,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),,5.2,162986,DB01229,Paclitaxel
,11221957,platelet counts,The nadir platelet counts were significantly higher (P = 0.0018) in patients treated with i.p. carboplatin with paclitaxel (12.1 +/- 4.3 x 10(4)/mm3) compared with carboplatin alone (5.2 +/- 3.3 x 10(4)/mm3) or with cyclophosphamide (5.2 +/- 4.8 x 10(4)/mm3).,The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221957/),,5.2,162987,DB01229,Paclitaxel
,27185379,retention time,PECT hydrogel with the dose of 200μL showed about 8days' retention time and most of the injected hydrogel was located in the intestine.,Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185379/),days',8,163132,DB01229,Paclitaxel
,16715360,terminal half-life,The chemosensitizing suramin dose showed a terminal half-life of 202 h and a total body clearance of 0.029 L h(-1) m(-2) (higher than the 0.013 L h(-1) m(-2) value for MTD of suramin).,Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715360/),h,202,163342,DB01229,Paclitaxel
,16715360,total body clearance,The chemosensitizing suramin dose showed a terminal half-life of 202 h and a total body clearance of 0.029 L h(-1) m(-2) (higher than the 0.013 L h(-1) m(-2) value for MTD of suramin).,Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715360/),[l] / [(m)^2·h],0.029,163343,DB01229,Paclitaxel
,16715360,total body clearance,The chemosensitizing suramin dose showed a terminal half-life of 202 h and a total body clearance of 0.029 L h(-1) m(-2) (higher than the 0.013 L h(-1) m(-2) value for MTD of suramin).,Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715360/),[l] / [(m)^2·h],0.013,163344,DB01229,Paclitaxel
,24474574,diameter,Median diameter and original volume were 39.5 mm (range 2.7-21.8) and 14.79 mL (3.42-343.30).,Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),mm,39.5,163390,DB01229,Paclitaxel
,24474574,CEA,"Median cyst fluid CEA and amylase values were 17.10 ng/mL (0.5-14127.5) and 73.50 U/L (3.1-91,590).",Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),[ng] / [ml],17.10,163391,DB01229,Paclitaxel
,24474574,Peak plasma paclitaxel concentration,"Peak plasma paclitaxel concentration values were observed between 2 and 7 h, ranging from 0.45 to 14.73 ng/mL.",Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),[ng] / [ml],0.45 to 14.73,163392,DB01229,Paclitaxel
,24474574,concentration,The highest concentration (17.10 ng/mL at 0 h) was observed in a patient who had intracystic bleeding.,Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),[ng] / [ml],17.10,163393,DB01229,Paclitaxel
,7595709,peak plasma paclitaxel concentration,"The mean peak plasma paclitaxel concentration was 5.87 mumol/L (range, 1.99 to 7.89) for these patients, and 6.08 mumol/L (range, 0.81 to 13.81) for 17 of 19 patients who did not experience visual symptoms.",Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595709/),[μM] / [l],5.87,164219,DB01229,Paclitaxel
,7595709,peak plasma paclitaxel concentration,"The mean peak plasma paclitaxel concentration was 5.87 mumol/L (range, 1.99 to 7.89) for these patients, and 6.08 mumol/L (range, 0.81 to 13.81) for 17 of 19 patients who did not experience visual symptoms.",Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595709/),[μM] / [l],6.08,164220,DB01229,Paclitaxel
,7595709,total response rate,"In 25 assessable patients in group I at a median follow-up time of 12 months, one complete response (CR) and seven partial responses (PRs) have been observed, for a total response rate of 32% (95% confidence interval [CI], 15% to 53%).",Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595709/),%,32,164221,DB01229,Paclitaxel
,7595709,response duration,Median response durations were 7 months for group I and 4 months for group II.,Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595709/),month,7,164222,DB01229,Paclitaxel
,7595709,response duration,Median response durations were 7 months for group I and 4 months for group II.,Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595709/),month,4,164223,DB01229,Paclitaxel
,17111835,diameter,"The diameter and zeta potential of PTX-CCM were 164 nm and +23.7 mV, while those of PTX-ACM were 180 nm and -28.0 mV, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),nm,164,164303,DB01229,Paclitaxel
,17111835,diameter,"The diameter and zeta potential of PTX-CCM were 164 nm and +23.7 mV, while those of PTX-ACM were 180 nm and -28.0 mV, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),nm,180,164304,DB01229,Paclitaxel
,17111835,zeta potential,"The diameter and zeta potential of PTX-CCM were 164 nm and +23.7 mV, while those of PTX-ACM were 180 nm and -28.0 mV, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),m,23.7,164305,DB01229,Paclitaxel
,17111835,zeta potential,"The diameter and zeta potential of PTX-CCM were 164 nm and +23.7 mV, while those of PTX-ACM were 180 nm and -28.0 mV, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),m,28.0,164306,DB01229,Paclitaxel
,17111835,w/w,"The drug loading and drug encapsulation efficiency for PTX-CCM were 26.4% (w/w) and 76.2% , while those of PTX-ACM were 34.6% (w/w) and 89.9%, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),%,34.6,164307,DB01229,Paclitaxel
,17111835,uptake,"The highest uptake of PTX-CCM and PTX-ACM in liver were 64.72% and 91.84% of dose, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),%,64.72,164308,DB01229,Paclitaxel
,17111835,uptake,"The highest uptake of PTX-CCM and PTX-ACM in liver were 64.72% and 91.84% of dose, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),%,91.84,164309,DB01229,Paclitaxel
,17111835,MRT,"Meanwhile, MRT of both were 5.50 h and 51.39 h prolonged.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),h,5.50,164310,DB01229,Paclitaxel
,17111835,MRT,"Meanwhile, MRT of both were 5.50 h and 51.39 h prolonged.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),h,51.39,164311,DB01229,Paclitaxel
,17111835,uptake,"The highest uptake of PTX-CCM and PTX-ACM in spleen were 7.08% and 5.16% of dose, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),%,7.08,164312,DB01229,Paclitaxel
,17111835,uptake,"The highest uptake of PTX-CCM and PTX-ACM in spleen were 7.08% and 5.16% of dose, respectively.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),%,5.16,164313,DB01229,Paclitaxel
,17111835,MRT,"Meanwhile, MRT of both were 9.04 h and 26.82 h.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),h,9.04,164314,DB01229,Paclitaxel
,17111835,MRT,"Meanwhile, MRT of both were 9.04 h and 26.82 h.",[Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17111835/),h,26.82,164315,DB01229,Paclitaxel
,7481870,AUC,"Patients with advanced epithelial ovarian cancer were treated with first-line carboplatin (AUC = 7, using the 51Cr EDTA [edetic acid] clearance method) and escalating doses of paclitaxel.",Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481870/),,7,164479,DB01229,Paclitaxel
,7481870,AUC,"The achieved carboplatin AUC was 7 +/- 1 mg/mL.min, indicating that the pharmacokinetics of carboplatin are not affected by paclitaxel.",Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481870/),[mg] / [min·ml],7,164480,DB01229,Paclitaxel
,15867243,area under the free drug plasma concentration-time curve,Marimastat (10 or 20 mg oral administration b.i.d.) was administered continuously with paclitaxel (175 or 200 mg/m(2) as a 3-hour i.v. infusion) and carboplatin (at a dose providing an area under the free drug plasma concentration-time curve of 7 mg min/mL) administered each 3 weeks.,Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867243/),[mg·min] / [ml],7,165228,DB01229,Paclitaxel
,15867243,area under the free drug plasma concentration-time curve,The administration of marimastat (10 mg b.i.d.) with paclitaxel (200 mg/m(2)) and carboplatin at an area under the free drug plasma concentration-time curve of 7 mg min/mL was well tolerated with no apparent pharmacokinetic interaction.,Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867243/),[mg·min] / [ml],7,165229,DB01229,Paclitaxel
,20926128,P(app),"In vitro, the formulation comprising 0.5% (m/v) PAA-cysteine (100 kDa)/0.5% (m/v) GSH improved the transport of paclitaxel 6.7-fold (P(app) = 8.7 ± 1.3 × 10(-6) cm/s) in comparison to paclitaxel itself serving as buffer only control (P(app) = 1.3 ± 0.4 × 10(-6) cm/s).",Development and in vivo evaluation of an oral drug delivery system for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926128/),[cm] / [s],8.7,165408,DB01229,Paclitaxel
,20926128,P(app),"In vitro, the formulation comprising 0.5% (m/v) PAA-cysteine (100 kDa)/0.5% (m/v) GSH improved the transport of paclitaxel 6.7-fold (P(app) = 8.7 ± 1.3 × 10(-6) cm/s) in comparison to paclitaxel itself serving as buffer only control (P(app) = 1.3 ± 0.4 × 10(-6) cm/s).",Development and in vivo evaluation of an oral drug delivery system for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926128/),[cm] / [s],1.3,165409,DB01229,Paclitaxel
,20926128,P(app),"Moreover, in the presence of the formulation containing 0.5% (m/v) PAA-cysteine (250 kDa)/0.5% (m/v) GSH paclitaxel absorption was even 7.4-fold (P(app) = 9.7 ± 0.3 × 10(-6) cm/s) improved in comparison to the buffer only control.",Development and in vivo evaluation of an oral drug delivery system for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926128/),[cm] / [s],9.7,165410,DB01229,Paclitaxel
,21207228,progression-free survival,"Of the 20 patients assessable for response, 6 (30%) had an objective response and median progression-free survival was 7.8 months (95% confidence interval, 5.6, 21.0 months).",Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21207228/),month,7.8,165568,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,345,165679,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,318,165680,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,330,165681,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,340,165682,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),1,470,165683,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),,200,165684,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),,680,165685,DB01229,Paclitaxel
,11801544,NN,"The mean NN (1 x 10(6)/liter) was 345 (18 patients) for cycle 1, then 318 (17 patients), 330 (13 patients), 340 (11 patients), 470 (8 patients), 200 (8 patients), 680 (5 patients), and 545 (4 patients) for cycles 2, 3, 4, 5, 6, 7, and 8, respectively (P >0.2).",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),,545,165686,DB01229,Paclitaxel
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],29.9,165687,DB01229,Paclitaxel
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],32.8,165688,DB01229,Paclitaxel
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],2849.9,165689,DB01229,Paclitaxel
,11801544,peak concentration (C(peak),"Mean clearances (liter/h/m(2)) and peak concentration (C(peak); ng/ml) were 29.9 at cycle 1 versus 32.8 at cycle 2 (not significant) and 2849.9 at cycle 1 versus 2542.5 at cycle 2 (not significant), respectively.",Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801544/),[ng] / [ml],2542.5,165690,DB01229,Paclitaxel
,15184994,AUC,The initial cohort of three patients received carboplatin at AUC 5 mg/ml x min.,"Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15184994/),[mg] / [min·ml],5,166005,DB01229,Paclitaxel
,15184994,AUC,"No dose-limiting toxic effects occurred, thus the subsequent cohort received carboplatin at AUC 6 mg/ml x min.","Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15184994/),[mg] / [min·ml],6,166006,DB01229,Paclitaxel
,15184994,AUC,"The administered regimen of paclitaxel (225 mg/m(2) i.v. over 3 h) and carboplatin (AUC 6 mg/ml x min i.v. over 1 h) on day 1 followed by TNP-470 (60 mg/m(2) i.v. over 1 h administered thrice weekly on Monday, Wednesday, and Friday) was defined as both the maximum tolerated and optimal dose.","Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15184994/),[mg] / [min·ml],6,166007,DB01229,Paclitaxel
,15184994,survival duration,"Overall, the median survival duration was 297 days.","Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15184994/),,29,166008,DB01229,Paclitaxel
,11786588,area under the curve [AUC],The systemic exposure (area under the curve [AUC]) to CrEL was significantly higher with the 1-hour as compared with the 3-hour schedule (80.2 +/- 24.2 v. 48.5 +/- 24.1 microL x h/mL; P =.002).,Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786588/),[h·μl] / [ml],80.2,167751,DB01229,Paclitaxel
,11786588,area under the curve [AUC],The systemic exposure (area under the curve [AUC]) to CrEL was significantly higher with the 1-hour as compared with the 3-hour schedule (80.2 +/- 24.2 v. 48.5 +/- 24.1 microL x h/mL; P =.002).,Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786588/),[h·μl] / [ml],48.5,167752,DB01229,Paclitaxel
,11786588,AUC,"In contrast, the AUC of unbound paclitaxel was substantially reduced after the 1-hour infusion (0.50 +/- 0.10 v. 0.62 +/- 0.12 micromol/L x h; P =.009).",Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786588/),[μM] / [h·l],0.50,167753,DB01229,Paclitaxel
,11786588,AUC,"In contrast, the AUC of unbound paclitaxel was substantially reduced after the 1-hour infusion (0.50 +/- 0.10 v. 0.62 +/- 0.12 micromol/L x h; P =.009).",Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786588/),[μM] / [h·l],0.62,167754,DB01229,Paclitaxel
,24252806,relative bioavailability (RB),"Paclitaxel (PTX, 25mg/kg) after oral administration with LL-348 (5mg/kg), the optimal dose of LL-348 as an oral absorption enhancer of PTX, improved the relative bioavailability (RB) of PTX to 961%.",Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252806/),%,961,168170,DB01229,Paclitaxel
,12631610,survival,The median survival varied from 15.6 months for patients with a low AAG (AAG < or = 1.11 grams/liter) to 5.5 months for patients with a high AAG (AAG >/= 1.85 grams/liter).,Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631610/),month,15.6,168254,DB01229,Paclitaxel
,12631610,survival,The median survival varied from 15.6 months for patients with a low AAG (AAG < or = 1.11 grams/liter) to 5.5 months for patients with a high AAG (AAG >/= 1.85 grams/liter).,Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631610/),month,5.5,168255,DB01229,Paclitaxel
,10789718,clearance,"However, patients on schedules 1 and 3 had a higher clearance of paclitaxel (322-520 ml min(-1) m(-2)) than those on schedule 2 (165-238 ml min(-1) m(-2)).","Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789718/),[ml] / [(m)^2·min],322-520,168471,DB01229,Paclitaxel
,10789718,clearance,"However, patients on schedules 1 and 3 had a higher clearance of paclitaxel (322-520 ml min(-1) m(-2)) than those on schedule 2 (165-238 ml min(-1) m(-2)).","Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789718/),[ml] / [(m)^2·min],165-238,168472,DB01229,Paclitaxel
,10789718,Peak plasma concentrations,Peak plasma concentrations (1.66-1.93 vs. 0.86-1.32 microM) and areas under the curve (392-565 vs. 180-291 microM min(-1)) of paclitaxel were correspondingly higher on schedule 2.,"Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789718/),μM,1.66-1.93,168473,DB01229,Paclitaxel
,10789718,Peak plasma concentrations,Peak plasma concentrations (1.66-1.93 vs. 0.86-1.32 microM) and areas under the curve (392-565 vs. 180-291 microM min(-1)) of paclitaxel were correspondingly higher on schedule 2.,"Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789718/),μM,0.86-1.32,168474,DB01229,Paclitaxel
,10789718,areas under the curve,Peak plasma concentrations (1.66-1.93 vs. 0.86-1.32 microM) and areas under the curve (392-565 vs. 180-291 microM min(-1)) of paclitaxel were correspondingly higher on schedule 2.,"Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789718/),[μM] / [min],392-565,168475,DB01229,Paclitaxel
,10789718,areas under the curve,Peak plasma concentrations (1.66-1.93 vs. 0.86-1.32 microM) and areas under the curve (392-565 vs. 180-291 microM min(-1)) of paclitaxel were correspondingly higher on schedule 2.,"Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789718/),[μM] / [min],180-291,168476,DB01229,Paclitaxel
up to,32263336,drug loading,"High drug loading - up to 18 w/w% - was observed for tamoxifen, a hydrophobic drug which bears an amino group able to form ion pairs with MCH acidic functionalities.",Novel pH-responsive nanovectors for controlled release of ionisable drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32263336/),[w] / [w%],18,168792,DB01229,Paclitaxel
,17221932,flow rate,The separation of TXL was achieved within 25 min using an ODS column with 50% acetonitrile aqueous solution as a mobile phase at a flow rate of 1.0 mL/min.,Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ml] / [min],1.0,168993,DB01229,Paclitaxel
,17221932,retention times,"The eluent was monitored at 230 nm, and the resulted retention times of TXL and IS were 11.2 and 20.4 min.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),min,11.2,168994,DB01229,Paclitaxel
,17221932,retention times,"The eluent was monitored at 230 nm, and the resulted retention times of TXL and IS were 11.2 and 20.4 min.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),min,20.4,168995,DB01229,Paclitaxel
,17221932,detection limits,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],3,168996,DB01229,Paclitaxel
,17221932,detection limits,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],10,168997,DB01229,Paclitaxel
,17221932,detection limits,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],9.5,168998,DB01229,Paclitaxel
,17221932,detection limits,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],7.5,168999,DB01229,Paclitaxel
,17221932,signal-to-noise ratio,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],3,169000,DB01229,Paclitaxel
,17221932,signal-to-noise ratio,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],10,169001,DB01229,Paclitaxel
,17221932,signal-to-noise ratio,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],9.5,169002,DB01229,Paclitaxel
,17221932,signal-to-noise ratio,"The detection limits of TXL for human plasma, serum and rat plasma samples at a signal-to-noise ratio of 3 were 10, 9.5 and 7.5 ng/mL, respectively.",Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221932/),[ng] / [ml],7.5,169003,DB01229,Paclitaxel
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],12.43,169016,DB01229,Paclitaxel
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],10.04,169017,DB01229,Paclitaxel
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],2.01,169018,DB01229,Paclitaxel
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],6.99,169019,DB01229,Paclitaxel
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],271.90,169020,DB01229,Paclitaxel
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],651.38,169021,DB01229,Paclitaxel
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],59.96,169022,DB01229,Paclitaxel
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],949.01,169023,DB01229,Paclitaxel
,22837181,PFS,"The median PFS and OS were 7.8 and 16.2 months, respectively.","A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837181/),month,7.8,169114,DB01229,Paclitaxel
,22837181,PFS,"The median PFS and OS were 7.8 and 16.2 months, respectively.","A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837181/),month,16.2,169115,DB01229,Paclitaxel
,22837181,OS,"The median PFS and OS were 7.8 and 16.2 months, respectively.","A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22837181/),month,16.2,169116,DB01229,Paclitaxel
,9519477,retention times,"The retention times of paclitaxel and the I.S. were 2.8 and 4.0 min., respectively.",High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9519477/),min,2.8,169341,DB01229,Paclitaxel
,9519477,retention times,"The retention times of paclitaxel and the I.S. were 2.8 and 4.0 min., respectively.",High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9519477/),min,4.0,169342,DB01229,Paclitaxel
greater,9519477,recovery,"Paclitaxel recovery assessed at 15,250 and 500 ng/mL, was determined to be greater than 85%.",High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9519477/),%,85,169343,DB01229,Paclitaxel
,33248853,Kd,"One of the representative compounds, 5o, exhibited strong binding affinity with a Kd value of 0.15 nM, but was significantly less potent against a panel of 402 wild-type kinases at 100 nM.","Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33248853/),nM,0.15,169346,DB01229,Paclitaxel
,33248853,IC50,"The compound also potently inhibited the kinase activity of TTK with an IC50 value of 23 nM, induced chromosome missegregation and aneuploidy, and suppressed proliferation of a panel of human cancer cell lines with low μM IC50 values.","Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33248853/),nM,23,169347,DB01229,Paclitaxel
,33248853,bioavailability,Compound 5o demonstrated good oral pharmacokinetic properties with a bioavailability value of 45.3% when administered at a dose of 25 mg/kg in rats.,"Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33248853/),%,45.3,169348,DB01229,Paclitaxel
,16763792,AUC,"The maximum tolerated dose and the recommended doses for future phase II trials are bortezomib 1.2 mg/m2, paclitaxel 135 mg/m2 and carboplatin AUC = 6 for schedule A and bortezomib 1.2 mg/m2, paclitaxel 175 mg/m2 and carboplatin AUC = 6 for schedule B. Six (21.4%) partial responses (PR) were seen with schedule B.","A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763792/),,6,170052,DB01229,Paclitaxel
,29938948,drug loading content,"PTX/NMs was characterized with a size of (343.5 ± 7.3) nm, drug loading content of 26.9% ± 0.8% and entrapment efficiency of 88.6% ± 1.7% at the optimized drug/carrier ratio of 1/10, and showed a pH-sensitive sustainable drug-release and less cytotoxicity in vitro.",[Preparation and properties of paclitaxel-loaded self-assembling nano-micelles of cholesterol-bearing γ-Polyglutamic acid]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29938948/),%,26.9,171460,DB01229,Paclitaxel
,29938948,entrapment efficiency,"PTX/NMs was characterized with a size of (343.5 ± 7.3) nm, drug loading content of 26.9% ± 0.8% and entrapment efficiency of 88.6% ± 1.7% at the optimized drug/carrier ratio of 1/10, and showed a pH-sensitive sustainable drug-release and less cytotoxicity in vitro.",[Preparation and properties of paclitaxel-loaded self-assembling nano-micelles of cholesterol-bearing γ-Polyglutamic acid]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29938948/),%,88.6,171461,DB01229,Paclitaxel
,11751486,overall response rate,The overall response rate was 23%.,A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),%,23,171561,DB01229,Paclitaxel
,11751486,time to failure,"Median time to failure was 5.2 months, whereas the median survival time was 10.3 months.",A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),month,5.2,171562,DB01229,Paclitaxel
,11751486,survival time,"Median time to failure was 5.2 months, whereas the median survival time was 10.3 months.",A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),month,10.3,171563,DB01229,Paclitaxel
,11751486,Survival rates,"Survival rates after 1 and 2 years were 45 and 22%, respectively.",A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),%,45,171564,DB01229,Paclitaxel
,11751486,Survival rates,"Survival rates after 1 and 2 years were 45 and 22%, respectively.",A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),%,22,171565,DB01229,Paclitaxel
,11751486,total body clearance,"There was no significant difference (P = 0.18) between the total body clearance of paclitaxel on the first (17.4 +/- 2.9 liters/h/m(2), mean +/- SD) and sixth (15.8 +/- 4.1 liters/h/m(2)) week of therapy.",A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),[h·l] / [m(2],17.4,171566,DB01229,Paclitaxel
,11751486,total body clearance,"There was no significant difference (P = 0.18) between the total body clearance of paclitaxel on the first (17.4 +/- 2.9 liters/h/m(2), mean +/- SD) and sixth (15.8 +/- 4.1 liters/h/m(2)) week of therapy.",A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751486/),[h·l] / [m(2],15.8,171567,DB01229,Paclitaxel
,29172757,plasma uptake,"As a consequence, after intraperitoneal administration of NPTX, plasma uptake (5.029 ± 4.35 vs. 25.85 ± 2.27 µM) and intratumoral delivery (5.48 ± 5.32 vs. 38.49 ± 2.805 pmol/mg) of NPTX were greatly impaired in DC101-treated animals compared to control animals.",Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172757/),μM,5.029,172825,DB01229,Paclitaxel
,29172757,plasma uptake,"As a consequence, after intraperitoneal administration of NPTX, plasma uptake (5.029 ± 4.35 vs. 25.85 ± 2.27 µM) and intratumoral delivery (5.48 ± 5.32 vs. 38.49 ± 2.805 pmol/mg) of NPTX were greatly impaired in DC101-treated animals compared to control animals.",Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172757/),μM,25.85,172826,DB01229,Paclitaxel
,29172757,plasma uptake,"As a consequence, after intraperitoneal administration of NPTX, plasma uptake (5.029 ± 4.35 vs. 25.85 ± 2.27 µM) and intratumoral delivery (5.48 ± 5.32 vs. 38.49 ± 2.805 pmol/mg) of NPTX were greatly impaired in DC101-treated animals compared to control animals.",Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172757/),[pM] / [mg],5.48,172827,DB01229,Paclitaxel
,29172757,plasma uptake,"As a consequence, after intraperitoneal administration of NPTX, plasma uptake (5.029 ± 4.35 vs. 25.85 ± 2.27 µM) and intratumoral delivery (5.48 ± 5.32 vs. 38.49 ± 2.805 pmol/mg) of NPTX were greatly impaired in DC101-treated animals compared to control animals.",Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172757/),[pM] / [mg],38.49,172828,DB01229,Paclitaxel
less,9300570,effusion drainage rate,"Following an effusion drainage rate of less than 100 ml/24 h and full expansion of the lung, patients were treated with a single instillation of pacilitaxel administered IP(L) in 500 ml of normal saline and retained for a maximum of 96h when tolerated.",A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300570/),[ml] / [24·h],100,172914,DB01229,Paclitaxel
,9300570,clearance,The pharmacological advantages of the IP(L) administration of paclitaxel were demonstrated by the mean exposure of the pleural cavity (area under the concentration time curve) to paclitaxel after IP(L) delivery exceeding that of the plasma by approximately 370-fold (range 55-684) and by the extraordinarily slow IP(L) clearance of paclitaxel (mean +/- SE 0.49 +/- 0.07 l/m2/day; range 0.08-1.16 l/m2/day) with significant concentrations of paclitaxel persisting within the cavity for more than 48-96 h after a single IP(L) instillation.,A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300570/),[l] / [d·m2],0.49,172915,DB01229,Paclitaxel
,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],2,173364,DB01229,Paclitaxel
less,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],1,173365,DB01229,Paclitaxel
,25188785,IC50,"The IC50 value of PTX, a concentration at which 50% cells are killed, was 1.17 and 0.93 µM for Anzatax® and PTX/TS-CS-PEG-FA micelles, respectively.","In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188785/),μM,1.17,174592,DB01229,Paclitaxel
,25188785,IC50,"The IC50 value of PTX, a concentration at which 50% cells are killed, was 1.17 and 0.93 µM for Anzatax® and PTX/TS-CS-PEG-FA micelles, respectively.","In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188785/),μM,0.93,174593,DB01229,Paclitaxel
>,18826299,water solubility,The LMWC-PTX conjugate contained approximately 12 wt % PTX and showed greatly enhanced water solubility (>1 mg/mL) as compared to native PTX.,Conjugated chitosan as a novel platform for oral delivery of paclitaxel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18826299/),[mg] / [ml],1,175184,DB01229,Paclitaxel
,18826299,bioavailability,The pharmacokinetic data revealed approximately 42% of bioavailability after oral administration of 5 mg PTX/kg of the conjugate.,Conjugated chitosan as a novel platform for oral delivery of paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18826299/),%,42,175185,DB01229,Paclitaxel
,21601372,complete response (CR) rate,The complete response (CR) rate at the completion of therapy was 84%.,"Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601372/),%,84,175529,DB01229,Paclitaxel
,21601372,local regional control rate,The estimated 3-year local regional control rate was 72%.,"Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601372/),%,72,175530,DB01229,Paclitaxel
,32554315,progression-free survival,"The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively.",Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554315/),weeks,13.0,175783,DB01229,Paclitaxel
,32554315,progression-free survival,"The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively.",Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554315/),weeks,7.4,175784,DB01229,Paclitaxel
,32554315,progression-free survival,"The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively.",Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554315/),weeks,5.1,175785,DB01229,Paclitaxel
,32554315,overall survival rates,"The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively.",Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554315/),%,48,175786,DB01229,Paclitaxel
,32554315,overall survival rates,"The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively.",Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554315/),%,25,175787,DB01229,Paclitaxel
,32554315,overall survival rates,"The median progression-free survival was 13.0, 7.4 and 5.1 weeks, respectively, and the 1-year overall survival rates were 48%, 25% and 15%, respectively.",Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554315/),%,15,175788,DB01229,Paclitaxel
,9331139,area under the concentration-time curve,"Pharmacokinetic measurements were performed at all dose levels in the phase I studies, in which the use of granulocyte colony-stimulating factor in previously treated patients enabled more than twice the dose of paclitaxel to be given with low to moderate doses of carboplatin (dosed to a target area under the concentration-time curve of 4.0 mg x min x mL[-1]).",Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331139/),[mg·min] / [ml],4.0,176946,DB01229,Paclitaxel
,9331139,area under the curve,Treatment-naive patients tolerated high paclitaxel doses (270 mg/m2) with carboplatin (dosed to a target area under the curve of 4.5 mg x min x mL[-1]) without granulocyte colony-stimulating factor support.,Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331139/),[mg·min] / [ml],4.5,176947,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],6.3,177460,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],6.1,177461,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],10.6,177462,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],13.6 × 10-2,177463,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],15.1,177464,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],18.4,177465,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],45.6,177466,DB01229,Paclitaxel
,33308382,absorption rate constant (Ka),"The study on in situ perfusion showed the absorption rate constant (Ka) of PTX was enhanced from 6.3, 6.1, 10.6 and 13.6 × 10-2/min to 15.1, 18.4, 45.6 and 42.9 × 10-2/min by micelles in duodenum, jejunum, ileum and colon, respectively, indicating the PTX-Micelles could enhance the permeability of PTX in intestinal membrane.",Enhancing Oral Bioavailability by Paclitaxel Polymeric Micelles: Role of Transmembrane Pathways in the Oral Absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33308382/),1/[min],42.9 × 10-2,177467,DB01229,Paclitaxel
,23152033,AUCs(o-AUC),"The observed AUCs(o-AUC)of CBDCA in the first, second and third courses were 3. 03, 3. 44 and 3. 50mg·min/mL, respectively.",[Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23152033/),[mg·min] / [ml],3. 03,177858,DB01229,Paclitaxel
,23152033,AUCs(o-AUC),"The observed AUCs(o-AUC)of CBDCA in the first, second and third courses were 3. 03, 3. 44 and 3. 50mg·min/mL, respectively.",[Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23152033/),[mg·min] / [ml],3. 44,177859,DB01229,Paclitaxel
,23152033,AUCs(o-AUC),"The observed AUCs(o-AUC)of CBDCA in the first, second and third courses were 3. 03, 3. 44 and 3. 50mg·min/mL, respectively.",[Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23152033/),[mg·min] / [ml],3. 50,177860,DB01229,Paclitaxel
,11335792,time above the threshold concentrations,Dose reduction of CsA from 10 to 5 mg/kg resulted in a statistically significant decrease in the area under the plasma concentration-time curve (AUC) and time above the threshold concentrations of 0.1 microM (T>0.1 microM) of oral paclitaxel.,The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),μM,0.1,177953,DB01229,Paclitaxel
>,11335792,T,Dose reduction of CsA from 10 to 5 mg/kg resulted in a statistically significant decrease in the area under the plasma concentration-time curve (AUC) and time above the threshold concentrations of 0.1 microM (T>0.1 microM) of oral paclitaxel.,The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),μM,0.1,177954,DB01229,Paclitaxel
,11335792,AUC,"The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),h·μM,4.29,177955,DB01229,Paclitaxel
,11335792,T>0.1,"The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),h·μM,4.29,177956,DB01229,Paclitaxel
,11335792,T>0.1,"The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),h,12.0,177957,DB01229,Paclitaxel
>,11335792,T,"Because CsA 10 mg/kg resulted in similar paclitaxel AUC and T>0.1 microM values compared to CsA 15 mg/kg (data which we have published previously), the minimally effective dose of CsA is determined at 10 mg/kg.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),μM,0.1,177958,DB01229,Paclitaxel
,31863795,neointima area,"Arteries treated with Nanolimus showed significant reduction in neointima area (0.2 ± 0.3 mm2 vs 2.0 ± 1.2 mm2, p < 0.01) and luminal stenosis (14.2 ± 7.2% vs. 67.7 ± 24.8%, p < 0.01) compared to controls.",Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31863795/),mm2,0.2,178254,DB01229,Paclitaxel
,31863795,neointima area,"Arteries treated with Nanolimus showed significant reduction in neointima area (0.2 ± 0.3 mm2 vs 2.0 ± 1.2 mm2, p < 0.01) and luminal stenosis (14.2 ± 7.2% vs. 67.7 ± 24.8%, p < 0.01) compared to controls.",Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31863795/),mm2,2.0,178255,DB01229,Paclitaxel
,20207133,complete response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,27.3,178256,DB01229,Paclitaxel
,20207133,complete response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,18.2,178257,DB01229,Paclitaxel
,20207133,complete response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,9.1,178258,DB01229,Paclitaxel
,20207133,overall response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,90.9,178259,DB01229,Paclitaxel
,20207133,overall response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,72.7,178260,DB01229,Paclitaxel
,20207133,overall response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,63.6,178261,DB01229,Paclitaxel
,20207133,overall response rates,"The complete response rates of pleural effusion at the first, second, third and sixth month were, respectively, 27.3%, 18.2%, 9.1% and 9.1%, and overall response rates were 90.9%, 72.7%, 63.6% and 54.5%, respectively.",A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20207133/),%,54.5,178262,DB01229,Paclitaxel
,18632723,area under the concentration-time curve,Patients received paclitaxel (Taxol) (200 mg/m(2)) and carboplatin (area under the concentration-time curve 6 mg/ml/min) every 3 weeks.,Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),[mg] / [min·ml],6,179207,DB01229,Paclitaxel
,18632723,response rate,"In arm A, response evaluation criteria in solid tumors (RECIST) response rate was 36% (95% confidence interval 22% to 54%; two complete, 12 partial); 15 patients (38%) had disease stabilization for > or =4 months; median progression-free survival (intention to treat) was 6.4 months; median overall survival (OS) 10.4 months and 1-year survival rate 38%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),%,36,179208,DB01229,Paclitaxel
,18632723,progression-free survival,"In arm A, response evaluation criteria in solid tumors (RECIST) response rate was 36% (95% confidence interval 22% to 54%; two complete, 12 partial); 15 patients (38%) had disease stabilization for > or =4 months; median progression-free survival (intention to treat) was 6.4 months; median overall survival (OS) 10.4 months and 1-year survival rate 38%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),month,6.4,179209,DB01229,Paclitaxel
,18632723,overall survival (OS),"In arm A, response evaluation criteria in solid tumors (RECIST) response rate was 36% (95% confidence interval 22% to 54%; two complete, 12 partial); 15 patients (38%) had disease stabilization for > or =4 months; median progression-free survival (intention to treat) was 6.4 months; median overall survival (OS) 10.4 months and 1-year survival rate 38%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),month,10.4,179210,DB01229,Paclitaxel
,18632723,OS,"In arm B, no RECIST responses occurred; four patients had disease stabilization for > or =4 months; median OS was 132 days and 1-year survival rate 7%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),d,132,179211,DB01229,Paclitaxel
,17992531,AUC ratios,A slight trend toward increasing AUC ratios (20%) was detected in both male and female patients bearing *1G.,Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17992531/),,20,179268,DB01229,Paclitaxel
,16741060,AUC(0-infinity),"The AUC(0-infinity) (9.43 +/- 3.18 microg-hr/ml), clearance (0.69 +/- 0.17 l/hr/kg), volume of distribution (10.31 +/- 4.54 l/kg), and half-life (1.0 +/- 0.32 hrs) of paclitaxel were similar between rats treated with saline or IRL-1620.","Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741060/),[μg-hr] / [ml],9.43,179277,DB01229,Paclitaxel
,16741060,clearance,"The AUC(0-infinity) (9.43 +/- 3.18 microg-hr/ml), clearance (0.69 +/- 0.17 l/hr/kg), volume of distribution (10.31 +/- 4.54 l/kg), and half-life (1.0 +/- 0.32 hrs) of paclitaxel were similar between rats treated with saline or IRL-1620.","Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741060/),[l] / [h·kg],0.69,179278,DB01229,Paclitaxel
,16741060,volume of distribution,"The AUC(0-infinity) (9.43 +/- 3.18 microg-hr/ml), clearance (0.69 +/- 0.17 l/hr/kg), volume of distribution (10.31 +/- 4.54 l/kg), and half-life (1.0 +/- 0.32 hrs) of paclitaxel were similar between rats treated with saline or IRL-1620.","Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741060/),[l] / [kg],10.31,179279,DB01229,Paclitaxel
,16741060,half-life,"The AUC(0-infinity) (9.43 +/- 3.18 microg-hr/ml), clearance (0.69 +/- 0.17 l/hr/kg), volume of distribution (10.31 +/- 4.54 l/kg), and half-life (1.0 +/- 0.32 hrs) of paclitaxel were similar between rats treated with saline or IRL-1620.","Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741060/),h,1.0,179280,DB01229,Paclitaxel
,14623599,maximum plasma concentration,"Following administration of BPU 5 mg as a weekly oral dose to a patient with advanced solid tumor malignancies, the maximum plasma concentration was 6.5 ng/ml and concentrations were quantifiable up to 173 h after administration.",A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14623599/),[ng] / [ml],6.5,179641,DB01229,Paclitaxel
,17503047,Area Under the Curve (AUC),"The best predictive parameter for renal failure was the total Pt 24-h Area Under the Curve (AUC) with a threshold value of 25 mg h/l RR = 0.31 (95% CI 0.13 - 0.49, P < 0.01).",Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17503047/),,25,179800,DB01229,Paclitaxel
,15783070,total body clearance,"After paclitaxel was administered intravenously, total body clearance was significantly reduced by 73% and 34% relative to each control value in CCl4-treated and 5/6 Nx rats, respectively (control, 1.82+/-0.42 vs.",Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15783070/),,1,179805,DB01229,Paclitaxel
,17587314,area under the time-concentration,"Thirty patients staged as IB2-IVA according to the FIGO were treated with carboplatin (AUC 2; an area under the time-concentration of 2 mg*min/ml based on creatinine clearance) and paclitaxel (60 mg/m(2)) intravenously, every week for six cycles.",Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587314/),[mg·min] / [ml],2,179959,DB01229,Paclitaxel
<,28173641,bioavailability,"However, its oral administration is impeded by very low bioavailability (<5%) due to the P-glycopprotein (P-gp) efflux pump effect.",Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28173641/),%,5,180431,DB01229,Paclitaxel
,12852694,Response rates,"Response rates in patients with visceral and liver metastases were 57% and 50%, respectively.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),%,57,180748,DB01229,Paclitaxel
,12852694,Response rates,"Response rates in patients with visceral and liver metastases were 57% and 50%, respectively.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),%,50,180749,DB01229,Paclitaxel
,12852694,time to progression,"After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),month,8.5,180750,DB01229,Paclitaxel
,12852694,overall survival,"After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),month,17,180751,DB01229,Paclitaxel
,30121935,MTD,The MTD of paclitaxel was 90 mg/m2.,Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),[mg] / [m2],90,181464,DB01229,Paclitaxel
,30121935,RD,The RD for both S-1 and paclitaxel was 80 mg/m2 (DL 3).,Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),[mg] / [m2],80,181465,DB01229,Paclitaxel
,30121935,response rate,The response rate was 45.5% (8 of 15 patients achieved a partial response).,Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),%,45.5,181466,DB01229,Paclitaxel
,30121935,RD,"In conclusion, the RD of both S-1 and paclitaxel was 80 mg/m2 in the combination therapy for chemotherapy-naïve patients with advanced NSCLC.",Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30121935/),[mg] / [m2],80,181467,DB01229,Paclitaxel
,11948138,clearance,"In the presence of CrEL, i.v. paclitaxel clearance was 10.2 +/- 3.76 liters/h/m(2) (mean +/- SD), consistent with previous findings.",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),[h·l] / [m(2],10.2,182062,DB01229,Paclitaxel
,11948138,terminal disposition half-life,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,17.0,182063,DB01229,Paclitaxel
,11948138,terminal disposition half-life,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,28.7,182064,DB01229,Paclitaxel
,11948138,mean residence time,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,7.28,182065,DB01229,Paclitaxel
,11948138,mean residence time,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,40.7,182066,DB01229,Paclitaxel
,11948138,bioavailability,"The bioavailability of paclitaxel was 31.4 +/- 5.18%, indicating insignificant systemic concentrations after i.p. treatment.",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),%,31.4,182067,DB01229,Paclitaxel
,11948138,clearance,"CrEL levels were undetectable after i.p. dosing (<0.05 microl/ml), whereas after i.v. dosing, the mean clearance was 159 +/- 58.4 ml/h/m(2), in line with earlier observations.",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),[h·ml] / [m(2],159,182068,DB01229,Paclitaxel
,16095677,AUC,Carboplatin (AUC=6 mg x min/ml) was diluted in 500 ml 5% glucose and administered either as an intraperitoneal bolus infusion or intravenous drip infusion during 1 h.,Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095677/),[mg·min] / [ml],6,182969,DB01229,Paclitaxel
,16095677,rate constants,"The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94+/-0.79 (mean+/-SD), 1.28+/-2.50, 16.50+/-9.26, 0.99+/-0.62, and 4.14+/-1.45 (h-1), respectively.",Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095677/),1/[h],0.94,182970,DB01229,Paclitaxel
,16095677,rate constants,"The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94+/-0.79 (mean+/-SD), 1.28+/-2.50, 16.50+/-9.26, 0.99+/-0.62, and 4.14+/-1.45 (h-1), respectively.",Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095677/),1/[h],1.28,182971,DB01229,Paclitaxel
,16095677,rate constants,"The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94+/-0.79 (mean+/-SD), 1.28+/-2.50, 16.50+/-9.26, 0.99+/-0.62, and 4.14+/-1.45 (h-1), respectively.",Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095677/),1/[h],16.50,182972,DB01229,Paclitaxel
,16095677,rate constants,"The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94+/-0.79 (mean+/-SD), 1.28+/-2.50, 16.50+/-9.26, 0.99+/-0.62, and 4.14+/-1.45 (h-1), respectively.",Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095677/),1/[h],0.99,182973,DB01229,Paclitaxel
,16095677,rate constants,"The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94+/-0.79 (mean+/-SD), 1.28+/-2.50, 16.50+/-9.26, 0.99+/-0.62, and 4.14+/-1.45 (h-1), respectively.",Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16095677/),1/[h],4.14,182974,DB01229,Paclitaxel
,22271472,overall survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,15.3,183279,DB01229,Paclitaxel
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.4,183280,DB01229,Paclitaxel
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,35.0,183281,DB01229,Paclitaxel
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,16.0,183282,DB01229,Paclitaxel
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.8,183283,DB01229,Paclitaxel
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,38.2,183284,DB01229,Paclitaxel
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,35.0,183285,DB01229,Paclitaxel
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.8,183286,DB01229,Paclitaxel
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,38.2,183287,DB01229,Paclitaxel
,17576004,total area-under-the-curve (AUC(0-infinity)),"The total area-under-the-curve (AUC(0-infinity)), which determines the therapeutic effects of a dose, was found to be 29,600+/-1,690ng-h/ml for the NP formulation, which is 3.09 times of 9,570+/-1,480ng-h/l for Taxol((R)) with 10mg/kg dose i.v. injection.",In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576004/),[ng-h] / [ml],"29,600",183593,DB01229,Paclitaxel
,17576004,total area-under-the-curve (AUC(0-infinity)),"The total area-under-the-curve (AUC(0-infinity)), which determines the therapeutic effects of a dose, was found to be 29,600+/-1,690ng-h/ml for the NP formulation, which is 3.09 times of 9,570+/-1,480ng-h/l for Taxol((R)) with 10mg/kg dose i.v. injection.",In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576004/),[ng-h] / [l],"9,570",183594,DB01229,Paclitaxel
,17576004,half-life (t(1/2)),"The half-life (t(1/2)) of the drug formulated in the NPs was found to be 18.80+/-3.14h, which is 2.75 times of 6.84+/-1.39h for Taxol((R)).",In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576004/),h,18.80,183595,DB01229,Paclitaxel
,17576004,half-life (t(1/2)),"The half-life (t(1/2)) of the drug formulated in the NPs was found to be 18.80+/-3.14h, which is 2.75 times of 6.84+/-1.39h for Taxol((R)).",In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576004/),h,6.84,183596,DB01229,Paclitaxel
,17576004,distribution volume at steady state,"The distribution volume at steady state for the drug loaded in the NPs was 7.21+/-2.17l/kg, which was 2.93 times of 2.46+/-1.41l/kg for Taxol((R)).",In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576004/),[l] / [kg],7.21,183597,DB01229,Paclitaxel
,17576004,distribution volume at steady state,"The distribution volume at steady state for the drug loaded in the NPs was 7.21+/-2.17l/kg, which was 2.93 times of 2.46+/-1.41l/kg for Taxol((R)).",In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576004/),[l] / [kg],2.46,183598,DB01229,Paclitaxel
,20437465,AUC(0-24h),Oral pharmacokinetic parameters of paclitaxel were significantly altered when pretreated with Sch B. There were significant increases in AUC(0-24h) (from 297.7+/-110.3 to 838.9+/-302.1 h*ng/ml; p<0.05) and C(max) (from 51.7+/-20.1 to 136.4+/-35.5 ng/ml; p<0.05) in the presence of Sch B (25 mg/kg).,Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437465/),[h·ng] / [ml],297.7,184285,DB01229,Paclitaxel
,20437465,AUC(0-24h),Oral pharmacokinetic parameters of paclitaxel were significantly altered when pretreated with Sch B. There were significant increases in AUC(0-24h) (from 297.7+/-110.3 to 838.9+/-302.1 h*ng/ml; p<0.05) and C(max) (from 51.7+/-20.1 to 136.4+/-35.5 ng/ml; p<0.05) in the presence of Sch B (25 mg/kg).,Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437465/),[h·ng] / [ml],838.9,184286,DB01229,Paclitaxel
,20437465,C(max),Oral pharmacokinetic parameters of paclitaxel were significantly altered when pretreated with Sch B. There were significant increases in AUC(0-24h) (from 297.7+/-110.3 to 838.9+/-302.1 h*ng/ml; p<0.05) and C(max) (from 51.7+/-20.1 to 136.4+/-35.5 ng/ml; p<0.05) in the presence of Sch B (25 mg/kg).,Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437465/),[ng] / [ml],51.7,184287,DB01229,Paclitaxel
,20437465,C(max),Oral pharmacokinetic parameters of paclitaxel were significantly altered when pretreated with Sch B. There were significant increases in AUC(0-24h) (from 297.7+/-110.3 to 838.9+/-302.1 h*ng/ml; p<0.05) and C(max) (from 51.7+/-20.1 to 136.4+/-35.5 ng/ml; p<0.05) in the presence of Sch B (25 mg/kg).,Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437465/),[ng] / [ml],136.4,184288,DB01229,Paclitaxel
,26161937,solubility ratio,The theoretical solubility ratio of amorphous/crystalline PTX was 92.6 (37 °C).,A pre-formulation study of a polymeric solid dispersion of paclitaxel prepared using a quasi-emulsion solvent diffusion method to improve the oral bioavailability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26161937/),,92.6,185435,DB01229,Paclitaxel
,26161937,absolute oral bioavailability,"The absolute oral bioavailability (AOB, 20 mg/kg) of the three formulas [HPMCAS/paclitaxel/WCB = 4/1/0 (F1), 8/1/0 (F2) and 4/1/4 (F3), w/w/w] were 11.8, 13.6 and 25.6%, respectively.",A pre-formulation study of a polymeric solid dispersion of paclitaxel prepared using a quasi-emulsion solvent diffusion method to improve the oral bioavailability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26161937/),%,11.8,185436,DB01229,Paclitaxel
,26161937,absolute oral bioavailability,"The absolute oral bioavailability (AOB, 20 mg/kg) of the three formulas [HPMCAS/paclitaxel/WCB = 4/1/0 (F1), 8/1/0 (F2) and 4/1/4 (F3), w/w/w] were 11.8, 13.6 and 25.6%, respectively.",A pre-formulation study of a polymeric solid dispersion of paclitaxel prepared using a quasi-emulsion solvent diffusion method to improve the oral bioavailability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26161937/),%,13.6,185437,DB01229,Paclitaxel
,26161937,absolute oral bioavailability,"The absolute oral bioavailability (AOB, 20 mg/kg) of the three formulas [HPMCAS/paclitaxel/WCB = 4/1/0 (F1), 8/1/0 (F2) and 4/1/4 (F3), w/w/w] were 11.8, 13.6 and 25.6%, respectively.",A pre-formulation study of a polymeric solid dispersion of paclitaxel prepared using a quasi-emulsion solvent diffusion method to improve the oral bioavailability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26161937/),%,25.6,185438,DB01229,Paclitaxel
,16564654,terminal half-lives,"The liposomal formulations showed much longer terminal half-lives (12.33 and 14.23 h for FR-targeted and non-targeted liposomes, respectively) than paclitaxel in Cremophor EL (1.78 h).",A folate receptor-targeted liposomal formulation for paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16564654/),h,12.33,185703,DB01229,Paclitaxel
,16564654,terminal half-lives,"The liposomal formulations showed much longer terminal half-lives (12.33 and 14.23 h for FR-targeted and non-targeted liposomes, respectively) than paclitaxel in Cremophor EL (1.78 h).",A folate receptor-targeted liposomal formulation for paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16564654/),h,14.23,185704,DB01229,Paclitaxel
,16564654,terminal half-lives,"The liposomal formulations showed much longer terminal half-lives (12.33 and 14.23 h for FR-targeted and non-targeted liposomes, respectively) than paclitaxel in Cremophor EL (1.78 h).",A folate receptor-targeted liposomal formulation for paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16564654/),h,1.78,185705,DB01229,Paclitaxel
,33675184,AUC,Carboplatin dose was adapted on day 3 based on carboplatin clearance (CL) at day 1 in order to reach a target AUC of 24 mg.,Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),mg,24,185771,DB01229,Paclitaxel
,33675184,AUC,Measured mean AUC was 24.4 mg.min/mL per cycle (22.4 and 26.8 mg.min/mL for 10th and 90th percentiles).,Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),[mg·min] / [cycle·ml],24.4,185772,DB01229,Paclitaxel
,33675184,AUC,Measured mean AUC was 24.4 mg.min/mL per cycle (22.4 and 26.8 mg.min/mL for 10th and 90th percentiles).,Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),[mg·min] / [ml],26.8,185773,DB01229,Paclitaxel
,33675184,PFS,"With a median follow-up of 44 months (m), median PFS was 12.3 m (95% CI: 7.5-25.9) and OS was 46.3 m (95% CI: 18.6-not reached).",Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),m,12.3,185774,DB01229,Paclitaxel
,33675184,OS,"With a median follow-up of 44 months (m), median PFS was 12.3 m (95% CI: 7.5-25.9) and OS was 46.3 m (95% CI: 18.6-not reached).",Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),m,46.3,185775,DB01229,Paclitaxel
,32306775,drug loading capacity,"The modified polymeric micelles showed regular spherical shapes with small particle size of 157.1 ± 5.2 nm and high drug loading capacity of 15.96 ± 0.20 wt%, and the micelle stability in water was supported by low critical micelle concentration of 14.31 ± 0.21 μg/ml.",l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306775/),wt%,15.96,185904,DB01229,Paclitaxel
,32306775,critical micelle concentration,"The modified polymeric micelles showed regular spherical shapes with small particle size of 157.1 ± 5.2 nm and high drug loading capacity of 15.96 ± 0.20 wt%, and the micelle stability in water was supported by low critical micelle concentration of 14.31 ± 0.21 μg/ml.",l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306775/),[μg] / [ml],14.31,185905,DB01229,Paclitaxel
,32306775,relative bioavailability,"The drug-loaded micelles presented a slow and incomplete in vitro release, and the pharmacokinetic studies indicated the micelle carriers increased the relative bioavailability of PTX to 165.8% against the commercial formulation.",l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306775/),%,165.8,185906,DB01229,Paclitaxel
,7907950,terminal half-life,"After short intravenous infusions of 70-115 mg/m2 every 3 weeks, a three phase disposition profile was observed with a terminal half-life of 12 hours and a plasma clearance of 21 l/hr/m2.",Pharmacokinetics and metabolism of Taxotere (docetaxel). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907950/),h,12,186328,DB01229,Paclitaxel
,7907950,plasma clearance,"After short intravenous infusions of 70-115 mg/m2 every 3 weeks, a three phase disposition profile was observed with a terminal half-life of 12 hours and a plasma clearance of 21 l/hr/m2.",Pharmacokinetics and metabolism of Taxotere (docetaxel). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7907950/),[l] / [h·m2],21,186329,DB01229,Paclitaxel
,7987996,oral bioavailability,"Pharmacokinetic studies in BALB/c mice showed the oral bioavailability to be 20%, with 35% of the drug being excreted unchanged in the faeces over the first 24 h.","Preclinical pharmacology of 1069C85, a novel tubulin binder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987996/),%,20,188284,DB01229,Paclitaxel
up to,27315213,solubility,"Here, we present translational evaluation of a nanoformulation of PTX, which is characterized by a facile preparation, extraordinary high drug loading of 50% wt. and PTX solubility of up to 45 g/L, excellent shelf stability and controllable, sub-100 nm size.",A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27315213/),[g] / [l],45,188316,DB01229,Paclitaxel
,15645422,IC(50),"Potent in vitro anti-proliferative effects were observed against pancreatic (Capan-1, MIA-PaCa-2, BxPC-3) and ovarian (SK-OV-3, OVCAR-3, ES-2) cancer cell lines with IC(50) of 0.01-0.2 microM.",Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645422/),μM,0.01-0.2,188564,DB01229,Paclitaxel
,7913721,progression-free,"With a median potential follow-up duration of 60 weeks, the median progression-free and overall survival durations were 27 and 43 weeks, respectively.",Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913721/),weeks,27,188629,DB01229,Paclitaxel
more,7913721,serum steady-state concentrations (Css),"Paclitaxel pharmacokinetics showed a correlation between both granulocyte and mucosal toxicity, and serum steady-state concentrations (Css) more than 0.07 mumol/L.",Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913721/),[μM] / [l],0.07,188630,DB01229,Paclitaxel
,12796374,area under the curve,Patients with advanced prostate cancer (castrate and noncastrate) were administered escalating doses of weekly 1-h infusion of i.v. EMP (500-1000-1500 mg/m(2)) in combination with weekly paclitaxel (100 mg/m(2) over 1 h) and i.v. carboplatin (area under the curve 6 mg/ml-min every 4 weeks).,Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12796374/),[mg] / [ml-min],6,188636,DB01229,Paclitaxel
,10986062,CL(DOC),"Mean +/- SD CL(DOC) in cycles 1 and 2 were 75.9 +/- 79.6 L/h/m(2) and 29.2 +/- 17.3 L/h/m(2), respectively (P: <.046).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],75.9,188761,DB01229,Paclitaxel
,10986062,CL(DOC),"Mean +/- SD CL(DOC) in cycles 1 and 2 were 75.9 +/- 79.6 L/h/m(2) and 29.2 +/- 17.3 L/h/m(2), respectively (P: <.046).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],29.2,188762,DB01229,Paclitaxel
,10986062,CL(TPT),"Mean +/- SD CL(TPT) in cycles 1 and 2 were 8.5 +/- 4.4 L/h/m(2) and 9.3 +/- 3.4 L/h/m(2), respectively (P: >. 05).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],8.5,188763,DB01229,Paclitaxel
,10986062,CL(TPT),"Mean +/- SD CL(TPT) in cycles 1 and 2 were 8.5 +/- 4.4 L/h/m(2) and 9.3 +/- 3.4 L/h/m(2), respectively (P: >. 05).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],9.3,188764,DB01229,Paclitaxel
,10986062,neutrophil nadir,"Mean +/- SD neutrophil nadir in cycles 1 and 2 were 4,857 +/- 6, 738/microL and 2,808 +/- 4,518/microL, respectively (P: =.02).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),1/[μl],"4,857",188765,DB01229,Paclitaxel
,10986062,neutrophil nadir,"Mean +/- SD neutrophil nadir in cycles 1 and 2 were 4,857 +/- 6, 738/microL and 2,808 +/- 4,518/microL, respectively (P: =.02).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),1/[μl],"2,808",188766,DB01229,Paclitaxel
,21748299,area under the curve,"This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg·min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-naïve, advanced NSCLC.",Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21748299/),[mg·min] / [ml],6,188919,DB01229,Paclitaxel
,26528585,IC50,IC50 values of 9.05-18.43 ng/mL of PTX equivalent were observed in various cancer cell lines after 72 h of incubation.,pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26528585/),[ng] / [ml],9.05-18.43,188987,DB01229,Paclitaxel
,31368034,Objective response rates,"Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms).","A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368034/),%,35.0,189222,DB01229,Paclitaxel
,31368034,Objective response rates,"Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms).","A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368034/),%,20.4,189223,DB01229,Paclitaxel
,31368034,Objective response rates,"Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms).","A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368034/),%,27.8,189224,DB01229,Paclitaxel
,31368034,clinical benefit rates,"Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms).","A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368034/),%,45.0,189225,DB01229,Paclitaxel
,31368034,clinical benefit rates,"Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms).","A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368034/),%,20.4,189226,DB01229,Paclitaxel
,31368034,clinical benefit rates,"Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms).","A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31368034/),%,27.8,189227,DB01229,Paclitaxel
,11804182,Response rates,Response rates in patients with visceral and liver metastases were 78% and 55% respectively.,Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),%,78,190849,DB01229,Paclitaxel
,11804182,Response rates,Response rates in patients with visceral and liver metastases were 78% and 55% respectively.,Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),%,55,190850,DB01229,Paclitaxel
,11804182,disease-free survival,"After a median follow-up of 19 months (12-36), median disease-free survival is 11 months and median overall survival has not been reached.",Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),month,11,190851,DB01229,Paclitaxel
,11936566,clearance,The median (range) valspodar clearance was 0.40 ml/min/kg (0.07-1.40 ml/min/kg).,Pharmacokinetic study of infusional valspodar. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936566/),[ml] / [kg·min],0.40,190992,DB01229,Paclitaxel
,10981288,area-under-curve (AUC),"Of the 32 patients in phase I portion of the trial, six received irinotecan 40 mg/m2 plus carboplatin at an area-under-curve (AUC) of 6 and paclitaxel 225 mg/m2 on an every-3-week schedule (regimen A).","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),[mg] / [m2],6,191117,DB01229,Paclitaxel
,10981288,objective response rate,"The unconfirmed objective response rate in phase I was 64.5%; median time to progression and median survival were 7.1 months and 11.6 months, respectively, and 1-year survival was 46.9%.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),%,64.5,191118,DB01229,Paclitaxel
,10981288,time to progression,"The unconfirmed objective response rate in phase I was 64.5%; median time to progression and median survival were 7.1 months and 11.6 months, respectively, and 1-year survival was 46.9%.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),month,7.1,191119,DB01229,Paclitaxel
,10981288,survival,"The unconfirmed objective response rate in phase I was 64.5%; median time to progression and median survival were 7.1 months and 11.6 months, respectively, and 1-year survival was 46.9%.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),month,11.6,191120,DB01229,Paclitaxel
,10981288,objective response rate,"The unconfirmed objective response rate in phase II was 60.6%, including one complete response (CR) and 19 partial responses (PRs); one CR and 16 PRs were subsequently confirmed.","Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10981288/),%,60.6,191121,DB01229,Paclitaxel
,8616858,clearance,"The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.37,191553,DB01229,Paclitaxel
,8616858,clearance,"The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],0.33,191554,DB01229,Paclitaxel
,8616858,clearance,"The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],0.15,191555,DB01229,Paclitaxel
,8616858,clearance,"When 2 mg/kg were given with an amount of Cremophor EL-ethanol matching that of the 10-mg/kg dose level, the clearance was 0.56 L/h/kg.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],0.56,191556,DB01229,Paclitaxel
,8616858,clearances,"If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.66,191557,DB01229,Paclitaxel
,8616858,clearances,"If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.57,191558,DB01229,Paclitaxel
,8616858,clearances,"If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.62,191559,DB01229,Paclitaxel
,21321086,PFS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,7.7,192365,DB01229,Paclitaxel
,21321086,PFS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,5.8,192366,DB01229,Paclitaxel
,21321086,PFS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,8,192367,DB01229,Paclitaxel
,21321086,OS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,14.0,192368,DB01229,Paclitaxel
,21321086,OS,"Median PFS in arm A was 7.7 months, arm B 5.8 months, and arm C 8.3 months; median OS for arm A was 14.0 months, arm B 12.8 months, and arm C 14.0 months.","A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321086/),month,12.8,192369,DB01229,Paclitaxel
,32803633,overall response rate,The overall response rate was 31.3% and the clinical benefit rate was 68.8%.,Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803633/),%,31.3,192707,DB01229,Paclitaxel
,32803633,clinical benefit rate,The overall response rate was 31.3% and the clinical benefit rate was 68.8%.,Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803633/),,68.8,192708,DB01229,Paclitaxel
,11521794,overall response rate,"Activity was observed at all dose levels and at all metastatic sites, with an overall response rate of 71% (95% CI: 52.0%-85.8%).",Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),%,71,192822,DB01229,Paclitaxel
,11521794,time to progression,The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months).,Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),weeks,31.4,192823,DB01229,Paclitaxel
,11521794,survival,The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months).,Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),month,15.6,192824,DB01229,Paclitaxel
,12454106,time to progression,"The median time to progression was 3.5 months (95% CI, 1.2 to 3.9 months), and median overall survival was 6.0 months (95% CI, 2.3 months to not available).",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),month,3.5,193238,DB01229,Paclitaxel
,12454106,overall survival,"The median time to progression was 3.5 months (95% CI, 1.2 to 3.9 months), and median overall survival was 6.0 months (95% CI, 2.3 months to not available).",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),month,6.0,193239,DB01229,Paclitaxel
,12454106,area under the concentration-time curve (AUC),"Pharmacokinetics revealed that the mean area under the concentration-time curve (AUC) of oral paclitaxel was 5.0 +/- 2.3 micro mol/L/h in week 1 and 4.6 +/- 2.0 micro mol/L/h in week 2, with interpatient variabilities (coefficient of variation [%CV]) of 45% and 42%, respectively.",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),[μmol] / [h·l],5.0,193240,DB01229,Paclitaxel
,12454106,area under the concentration-time curve (AUC),"Pharmacokinetics revealed that the mean area under the concentration-time curve (AUC) of oral paclitaxel was 5.0 +/- 2.3 micro mol/L/h in week 1 and 4.6 +/- 2.0 micro mol/L/h in week 2, with interpatient variabilities (coefficient of variation [%CV]) of 45% and 42%, respectively.",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),[μmol] / [h·l],4.6,193241,DB01229,Paclitaxel
,15041708,area under the curve (AUC),"Paclitaxel was administered on day 1 as a 1-h infusion at a fixed dose of 100 mg/m(2) followed by a 1-h infusion of carboplatin targeting an area under the curve (AUC) of 2-5 mg x min/ml, with cycles repeated on days 8, 15, 29, 36, and 43.",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),[mg·min] / [ml],2-5,193329,DB01229,Paclitaxel
,15041708,AUC,Dose-limiting toxicity was observed at a carboplatin AUC of 5 mg x min/ml and consisted of treatment delay attributable to myelosuppression.,A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),[mg·min] / [ml],5,193330,DB01229,Paclitaxel
,15041708,AUC,The highest dose intensity (>95% of the planned dose over time) was achieved with a carboplatin AUC of 4 mg x min/ml.,A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),[mg·min] / [ml],4,193331,DB01229,Paclitaxel
,15041708,AUCs,"The mean (+/-SD) AUCs of unbound (Cu) and total paclitaxel were 0.662 +/- 0.186 and 7.37 +/- 1.33 micro M x h, respectively.",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),h·μM,0.662,193332,DB01229,Paclitaxel
,15041708,AUCs,"The mean (+/-SD) AUCs of unbound (Cu) and total paclitaxel were 0.662 +/- 0.186 and 7.37 +/- 1.33 micro M x h, respectively.",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),h·μM,7.37,193333,DB01229,Paclitaxel
,15041708,Clearance,"Clearance of Cu was 188 +/- 44.6 liter/h/m(2), which is not significantly different from historical data (P = 0.52).",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),[h·l] / [m(2],188,193334,DB01229,Paclitaxel
,15041708,clearance,"Cremophor EL clearance was 123 +/- 23 ml/h/m(2), similar to previous findings.",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),[h·ml] / [m(2],123,193335,DB01229,Paclitaxel
,15041708,overall response rate,"Of 37 patients evaluable for response, 1 had complete response, 19 had partial response, and 10 had stable disease, accounting for an overall response rate of 54%.",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),%,54,193336,DB01229,Paclitaxel
,15041708,AUC,"This regimen is very tolerable and effective, and the recommended doses for additional studies are paclitaxel (100 mg/m(2)), with carboplatin targeting an AUC of 4 mg x min/ml.",A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041708/),[mg·min] / [ml],4,193337,DB01229,Paclitaxel
,16258082,MTDs,"MTDs for heavily and lightly pretreated patients were 100 and 150 mg/m(2), respectively; and the dose-limiting toxicities were grade 4 neutropenia and grade 3 peripheral neuropathy, respectively.","Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16258082/),[mg] / [m(2],100,194025,DB01229,Paclitaxel
,16258082,MTDs,"MTDs for heavily and lightly pretreated patients were 100 and 150 mg/m(2), respectively; and the dose-limiting toxicities were grade 4 neutropenia and grade 3 peripheral neuropathy, respectively.","Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16258082/),[mg] / [m(2],150,194026,DB01229,Paclitaxel
,17535024,overall survival,The overall survival of the whole group was 14 months.,Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,14,194361,DB01229,Paclitaxel
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,20,194362,DB01229,Paclitaxel
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,14,194363,DB01229,Paclitaxel
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,12,194364,DB01229,Paclitaxel
,17535024,survival,"The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months.",Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535024/),month,11,194365,DB01229,Paclitaxel
,12743738,area under the concentration-time curve (AUC),"Paclitaxel was given in combination with a fixed dose of carboplatin at an area under the concentration-time curve (AUC) of 3 mg/ml x min, every 2 weeks.",Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743738/),[mg] / [min·ml],3,194714,DB01229,Paclitaxel
,12743738,MTD,"The MTD of paclitaxel proved to be 160 mg/m(2), and the DLT was neutropenia, which improved well following treatment with G-CSF.",Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743738/),[mg] / [m],160,194715,DB01229,Paclitaxel
,12743738,AUC,The recommended dose for phase II study is paclitaxel 140 mg/m(2) with a carboplatin AUC of 3 mg/ml.min.,Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743738/),[mg] / [min·ml],3,194716,DB01229,Paclitaxel
,16299241,clearance,"The population typical value of clearance of unbound paclitaxel was 301 L/h (individual clearance range, 83.7-1055 L/h).","Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299241/),[l] / [h],301,194991,DB01229,Paclitaxel
,16299241,clearance,"The population typical value of clearance of unbound paclitaxel was 301 L/h (individual clearance range, 83.7-1055 L/h).","Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299241/),[l] / [h],83.7-1055,194992,DB01229,Paclitaxel
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,-,195658,DB01229,Paclitaxel
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,45.5,195659,DB01229,Paclitaxel
,15032307,oral bioavailability,"Compared to Taxol, the oral bioavailability of paclitaxel SMEDDS increased by 28.6% to 52.7% at various doses.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,52,195660,DB01229,Paclitaxel
,15032307,time above therapeutic level,There was a significant improvement in area under the curve (AUC) and time above therapeutic level (0.1 microM) of paclitaxel SMEDDS as compared to those of Taxol following coadministration of both formulations with 40 mg cyclosporin A (CsA)/kg.,Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,0,195661,DB01229,Paclitaxel
,34311345,area under the curve [AUC],"Patients received veliparib orally twice daily (BID) in escalating doses (60-240 mg, Day -3 to 1 day after last dose of radiation) combined with weekly carboplatin (area under the curve [AUC] 2 mg/mL/min), paclitaxel (45 mg/m2), and daily radiation therapy (60 Gy in 30 fractions), followed by two cycles of veliparib (120-240 mg BID, Days -2 through 5 of each 21-day cycle), carboplatin (AUC 6 mg/mL/min, Day 1 of each cycle), and paclitaxel (200 mg/m2, Day 1 of each cycle) consolidation.",Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),[mg] / [min·ml],2,195679,DB01229,Paclitaxel
,34311345,AUC,"Patients received veliparib orally twice daily (BID) in escalating doses (60-240 mg, Day -3 to 1 day after last dose of radiation) combined with weekly carboplatin (area under the curve [AUC] 2 mg/mL/min), paclitaxel (45 mg/m2), and daily radiation therapy (60 Gy in 30 fractions), followed by two cycles of veliparib (120-240 mg BID, Days -2 through 5 of each 21-day cycle), carboplatin (AUC 6 mg/mL/min, Day 1 of each cycle), and paclitaxel (200 mg/m2, Day 1 of each cycle) consolidation.",Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),[mg] / [min·ml],6,195680,DB01229,Paclitaxel
,34311345,MTD/RP2D,The MTD/RP2D of veliparib was 240 mg BID with chemoradiotherapy followed by 120 mg BID with consolidation.,Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),mg,240,195681,DB01229,Paclitaxel
,34311345,progression-free survival (mPFS),Median progression-free survival (mPFS) was 19.6 months (95% CI: 9.7-32.6).,Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),month,19.6,195682,DB01229,Paclitaxel
,34311345,overall survival,Median overall survival was estimated to be 32.6 months (95% CI: 15.0-not reached).,Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),month,32.6,195683,DB01229,Paclitaxel
,34311345,mPFS,"In patients treated with the RP2D, mPFS was 19.6 months (95% CI: 3.0-not reached).",Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),month,19.6,195684,DB01229,Paclitaxel
,34311345,mPFS,"When combined with standard concurrent chemoradiotherapy and consolidation chemotherapy in patients with stage III NSCLC, veliparib demonstrated an acceptable safety profile and antitumor activity with an mPFS of 19.6 months.",Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311345/),month,19,195685,DB01229,Paclitaxel
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,21,195947,DB01229,Paclitaxel
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,24,195948,DB01229,Paclitaxel
,16858422,steady-state,"When orally administered as NE, PCL was rapidly absorbed reaching a steady-state value of 3.5 microg/ml in 30 minutes, and steady-state levels persisted up to 18 hours.",Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16858422/),[μg] / [ml],3.5,196232,DB01229,Paclitaxel
,16858422,absolute bioavailability,This has amounted to an absolute bioavailability of 70.62%.,Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16858422/),%,70.62,196233,DB01229,Paclitaxel
more,16858422,bioavailability,"Further, the NE formulation has enhanced the peroral bioavailability significantly to more than 70%.",Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16858422/),%,70,196234,DB01229,Paclitaxel
,11060749,IC(50),Satraplatin was selected for clinical study on the basis of possessing several promising preclinical features the first of which is it's potent in vitro growth inhibitory properties against several tumour types (mean IC(50) approximately 1 microM).,An update on satraplatin: the first orally available platinum anticancer drug. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060749/),μM,1,196447,DB01229,Paclitaxel
,11994057,AUC,"A significant increase in epirubicin AUC (+0.74 micromol l-1 h [95% CI for the difference: 0.14, 1.34] and +1.09 micromol l-1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CLTB) (-25.35 l h-1 m-2[95% CI for the difference: -50.18, -0.52] and -35.9 l h-1 m-2[95% CI for the difference -63,4,-8,36]) occurred in combination with paclitaxel 200 and 225 mg m-2 with respect to the AUC (3.16+/-0.6 micromol l-1 h) and CLTB (74.4+/-28.4 l h-1 m-2) of epirubicin followed by paclitaxel 30 h later.",Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),[h·μM] / [l],3.16,196498,DB01229,Paclitaxel
,11994057,CLTB,"A significant increase in epirubicin AUC (+0.74 micromol l-1 h [95% CI for the difference: 0.14, 1.34] and +1.09 micromol l-1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CLTB) (-25.35 l h-1 m-2[95% CI for the difference: -50.18, -0.52] and -35.9 l h-1 m-2[95% CI for the difference -63,4,-8,36]) occurred in combination with paclitaxel 200 and 225 mg m-2 with respect to the AUC (3.16+/-0.6 micromol l-1 h) and CLTB (74.4+/-28.4 l h-1 m-2) of epirubicin followed by paclitaxel 30 h later.",Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),[l] / [(m)^2·h],74.4,196499,DB01229,Paclitaxel
,11994057,tC0.1,The tC0.1 value predicted to yield a 50% decrease in neutrophil count was 7.7 h.,Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),h,7.7,196500,DB01229,Paclitaxel
,29325755,minimum inhibitory concentration (MIC),"The conjugate exhibited potential anti-fungal activity against yeast strains such as C. albicans, C. neoformans and C. parapsilosis with the minimum inhibitory concentration (MIC) equivalent to AmB ranging from 0.7 to 1.1 μg/ml while AmBisome® and AmB alone showed the MIC between 0.78 and 1.5 and 0.53-0.78 μg/ml respectively.","Amphotericin B-albumin conjugates: Synthesis, toxicity and anti-fungal activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325755/),[μg] / [ml],0.7 to 1.1,196942,DB01229,Paclitaxel
,29325755,MIC,"The conjugate exhibited potential anti-fungal activity against yeast strains such as C. albicans, C. neoformans and C. parapsilosis with the minimum inhibitory concentration (MIC) equivalent to AmB ranging from 0.7 to 1.1 μg/ml while AmBisome® and AmB alone showed the MIC between 0.78 and 1.5 and 0.53-0.78 μg/ml respectively.","Amphotericin B-albumin conjugates: Synthesis, toxicity and anti-fungal activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325755/),[μg] / [ml],0.78 and 1.5,196943,DB01229,Paclitaxel
,29325755,MIC,"The conjugate exhibited potential anti-fungal activity against yeast strains such as C. albicans, C. neoformans and C. parapsilosis with the minimum inhibitory concentration (MIC) equivalent to AmB ranging from 0.7 to 1.1 μg/ml while AmBisome® and AmB alone showed the MIC between 0.78 and 1.5 and 0.53-0.78 μg/ml respectively.","Amphotericin B-albumin conjugates: Synthesis, toxicity and anti-fungal activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325755/),[μg] / [ml],0.53-0.78,196944,DB01229,Paclitaxel
,24658629,MTD,The MTD was 350 mg/m(2).,Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24658629/),[mg] / [m(2],350,197325,DB01229,Paclitaxel
,8093854,maximum tolerated dose,The maximum tolerated dose for Taxotere administered as a 24-h infusion is 90 mg/m2.,Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8093854/),mg,90,197525,DB01229,Paclitaxel
,25775012,absolute BA%,The mean absolute BA% of PTX following SDG-T and Oraxol™ solution was 8.23 and 6.22% in comparison to i.v. administration of Taxol®.,Enhanced oral bioavailability of paclitaxel by solid dispersion granulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25775012/),%,8.23,197648,DB01229,Paclitaxel
,25775012,absolute BA%,The mean absolute BA% of PTX following SDG-T and Oraxol™ solution was 8.23 and 6.22% in comparison to i.v. administration of Taxol®.,Enhanced oral bioavailability of paclitaxel by solid dispersion granulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25775012/),%,6.22,197649,DB01229,Paclitaxel
,25775012,relative BA%,The relative BA% of PTX from SDG-T in comparison to Oraxol™ solution was 132.25% at a dose of 60 mg following oral administration.,Enhanced oral bioavailability of paclitaxel by solid dispersion granulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25775012/),%,132.25,197650,DB01229,Paclitaxel
,9738565,MTD levels,"The MTD levels of VX-710/ paclitaxel were 120 mg/m2 per hour and 60 mg/m2, respectively, in heavily pretreated patients and 120/60 to 80 mg/m2 per hour in less heavily pretreated patients.","Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9738565/),[mg] / [h·m2],120,198652,DB01229,Paclitaxel
,9738565,MTD levels,"The MTD levels of VX-710/ paclitaxel were 120 mg/m2 per hour and 60 mg/m2, respectively, in heavily pretreated patients and 120/60 to 80 mg/m2 per hour in less heavily pretreated patients.","Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9738565/),[mg] / [m2],60,198653,DB01229,Paclitaxel
,9738565,steady-state plasma concentrations (Css),"At these dose levels, VX-710 steady-state plasma concentrations (Css) ranged from 2.68 to 4.89 microg/mL, which exceeded optimal VX-710 concentrations required for MDR reversal in vitro.","Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9738565/),[μg] / [ml],2.68 to 4.89,198654,DB01229,Paclitaxel
,24927684,critical micelle concentration,"CQ conjugate had low critical micelle concentration (55.14 μg/mL), and could self assemble in aqueous condition to form polymeric micelles (PMs).",Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),[μg] / [ml],55.14,198715,DB01229,Paclitaxel
,24927684,polydispersity index (PDI),PTX-loaded CQ PMs displayed a particle size of 185.8 ± 4.6 nm and polydispersity index (PDI) of 0.134 ± 0.056.,Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),,0.134,198716,DB01229,Paclitaxel
,24927684,drug-loading content (DL),"The drug-loading content (DL) and entrapment efficiency (EE) were 33.62 ± 1.34% and 85.63 ± 1.26%, respectively.",Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),%,33.62,198717,DB01229,Paclitaxel
,24927684,entrapment efficiency (EE),"The drug-loading content (DL) and entrapment efficiency (EE) were 33.62 ± 1.34% and 85.63 ± 1.26%, respectively.",Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),%,85.63,198718,DB01229,Paclitaxel
,10219678,total run time,No interfering peaks were observed and the total run time was 10 min.,Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219678/),min,10,199044,DB01229,Paclitaxel
>,10219678,extraction recovery,The extraction recovery was > 90% for both paclitaxel and n-hexyl p-hydroxybenzoic acid.,Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219678/),%,90,199045,DB01229,Paclitaxel
,10219678,LOD,"The LOD and LOQ were 5 and 10 ng/ml, respectively, for paclitaxel using a plasma sample volume of 100 microliters.",Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219678/),[ng] / [ml],5,199046,DB01229,Paclitaxel
,10219678,LOQ,"The LOD and LOQ were 5 and 10 ng/ml, respectively, for paclitaxel using a plasma sample volume of 100 microliters.",Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219678/),[ng] / [ml],10,199047,DB01229,Paclitaxel
,11249051,progression-free,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,37.,199261,DB01229,Paclitaxel
,11249051,overall survival,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,65,199262,DB01229,Paclitaxel
,21731464,Tumor weight inhibition rates,"Tumor weight inhibition rates of mice treated with Taxol, HM-3, ALD-mPEG(5k)-HM-3, ALD-mPEG(10k)-HM-3, SC-mPEG(10k)-HM-3 and SC-mPEG(20k)-HM-3 were 44.50%, 43.92%, 37.95%, 31.64%, 20.27% and 50.23%, respectively.",In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21731464/),%,44.50,199397,DB01229,Paclitaxel
,21731464,Tumor weight inhibition rates,"Tumor weight inhibition rates of mice treated with Taxol, HM-3, ALD-mPEG(5k)-HM-3, ALD-mPEG(10k)-HM-3, SC-mPEG(10k)-HM-3 and SC-mPEG(20k)-HM-3 were 44.50%, 43.92%, 37.95%, 31.64%, 20.27% and 50.23%, respectively.",In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21731464/),%,43.92,199398,DB01229,Paclitaxel
,21731464,Tumor weight inhibition rates,"Tumor weight inhibition rates of mice treated with Taxol, HM-3, ALD-mPEG(5k)-HM-3, ALD-mPEG(10k)-HM-3, SC-mPEG(10k)-HM-3 and SC-mPEG(20k)-HM-3 were 44.50%, 43.92%, 37.95%, 31.64%, 20.27% and 50.23%, respectively.",In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21731464/),%,37.95,199399,DB01229,Paclitaxel
,21731464,Tumor weight inhibition rates,"Tumor weight inhibition rates of mice treated with Taxol, HM-3, ALD-mPEG(5k)-HM-3, ALD-mPEG(10k)-HM-3, SC-mPEG(10k)-HM-3 and SC-mPEG(20k)-HM-3 were 44.50%, 43.92%, 37.95%, 31.64%, 20.27% and 50.23%, respectively.",In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21731464/),%,31.64,199400,DB01229,Paclitaxel
,21731464,Tumor weight inhibition rates,"Tumor weight inhibition rates of mice treated with Taxol, HM-3, ALD-mPEG(5k)-HM-3, ALD-mPEG(10k)-HM-3, SC-mPEG(10k)-HM-3 and SC-mPEG(20k)-HM-3 were 44.50%, 43.92%, 37.95%, 31.64%, 20.27% and 50.23%, respectively.",In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21731464/),%,20.27,199401,DB01229,Paclitaxel
,21731464,Tumor weight inhibition rates,"Tumor weight inhibition rates of mice treated with Taxol, HM-3, ALD-mPEG(5k)-HM-3, ALD-mPEG(10k)-HM-3, SC-mPEG(10k)-HM-3 and SC-mPEG(20k)-HM-3 were 44.50%, 43.92%, 37.95%, 31.64%, 20.27% and 50.23%, respectively.",In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21731464/),%,50.23,199402,DB01229,Paclitaxel
,11496337,Cmax,"The mean Cmax treated with 40 mg/m(2), 60 mg/m(2) and 80 mg/m(2) in the weekly paclitaxel was 1.94, 2.18 and 1.54 microM, respectively.",Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11496337/),μM,1.94,199823,DB01229,Paclitaxel
,11496337,Cmax,"The mean Cmax treated with 40 mg/m(2), 60 mg/m(2) and 80 mg/m(2) in the weekly paclitaxel was 1.94, 2.18 and 1.54 microM, respectively.",Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11496337/),μM,2.18,199824,DB01229,Paclitaxel
,11496337,Cmax,"The mean Cmax treated with 40 mg/m(2), 60 mg/m(2) and 80 mg/m(2) in the weekly paclitaxel was 1.94, 2.18 and 1.54 microM, respectively.",Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11496337/),μM,1.54,199825,DB01229,Paclitaxel
,12879282,area under the curve ratio,There was a 105% increase in the area under the curve ratio of peritoneal fluid to plasma paclitaxel concentrations with hetastarch (391) vs peritoneal dialysis solution (191).,Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879282/),,39,199907,DB01229,Paclitaxel
,11118471,clearance,"RPR 109881A has a high clearance (mean, 42.6 L/h/m(2)), a large volume of distribution (mean, 952 L/m(2)), and a long terminal half-life (mean, 24 hours).","Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118471/),[h·l] / [m(2],42.6,200070,DB01229,Paclitaxel
,11118471,volume of distribution,"RPR 109881A has a high clearance (mean, 42.6 L/h/m(2)), a large volume of distribution (mean, 952 L/m(2)), and a long terminal half-life (mean, 24 hours).","Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118471/),[l] / [m(2],952,200071,DB01229,Paclitaxel
,11118471,terminal half-life,"RPR 109881A has a high clearance (mean, 42.6 L/h/m(2)), a large volume of distribution (mean, 952 L/m(2)), and a long terminal half-life (mean, 24 hours).","Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118471/),h,24,200072,DB01229,Paclitaxel
,11118471,RD,The RD of RPR 109881A given as a 1-hour infusion on days 1 and 8 of a 21-day cycle is 45 mg/m(2).,"Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118471/),mg,45,200073,DB01229,Paclitaxel
,33390325,PFS,Median PFS was 5.4 months.,"A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33390325/),month,5.4,200429,DB01229,Paclitaxel
,32502923,progression-free survival,"Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928).","A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502923/),month,8.50,201146,DB01229,Paclitaxel
,32502923,progression-free survival,"Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928).","A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502923/),month,7.90,201147,DB01229,Paclitaxel
,32502923,overall survival,"Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928).","A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502923/),month,14.90,201148,DB01229,Paclitaxel
,32502923,overall survival,"Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928).","A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502923/),month,15.80,201149,DB01229,Paclitaxel
,32502923,duration of response,"Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928).","A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502923/),month,7.70,201150,DB01229,Paclitaxel
,32502923,duration of response,"Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928).","A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32502923/),month,7.00,201151,DB01229,Paclitaxel
,31622204,encapsulation percentage,"The encapsulation percentage of PTX and DXR was 74.1 ± 1.8 % and 89.6 ± 12.3%, respectively, and the mean diameter of the liposomes was 244.4 ± 28.1 nm.",Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622204/),%,74.1,202282,DB01229,Paclitaxel
,31622204,encapsulation percentage,"The encapsulation percentage of PTX and DXR was 74.1 ± 1.8 % and 89.6 ± 12.3%, respectively, and the mean diameter of the liposomes was 244.4 ± 28.1 nm.",Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622204/),%,89.6,202283,DB01229,Paclitaxel
,31622204,inhibitory concentration 50% (IC50),Cytotoxicity studies using 4T1 breast cancer cells showed lower inhibitory concentration 50% (IC50) value for LCFL-PTX/DXR treatment (0.27 ± 0.11 µm) compared to the values of free drugs treatment.,Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622204/),µm,0.27,202284,DB01229,Paclitaxel
,9215819,peak plasma concentration,The mean peak plasma concentration of paclitaxel ranged between 5.1 and 6.2 micromol/L at doses of 175 to 225 mg/m2.,Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215819/),[μM] / [l],5.1 and 6.2,202728,DB01229,Paclitaxel
,19745765,area under the curve,"Patients received paclitaxel 200 mg/m2, carboplatin (area under the curve of 6), and F (0.05-20 mg/kg) q3 weeks for up to six cycles.","Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19745765/),,6,202814,DB01229,Paclitaxel
,8585115,flow rate,"The mobile phase was a mixture of 1 mM sodium phosphate buffer (pH 5) and acetonitrile (55.5:45.5 per volume), and the flow rate was 4.5 ml/min.",Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585115/),[ml] / [min],4.5,202831,DB01229,Paclitaxel
,8585115,recovery,"The recovery of paclitaxel from plasma at concentrations equivalent to 50, 400, and 800 micrograms/L paclitaxel in plasma was 79.1, 75.2, and 74.3%, respectively, and the retention times of the drug and IS under these conditions were 5.26 and 6.45 min, respectively.",Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585115/),%,79.1,202832,DB01229,Paclitaxel
,8585115,recovery,"The recovery of paclitaxel from plasma at concentrations equivalent to 50, 400, and 800 micrograms/L paclitaxel in plasma was 79.1, 75.2, and 74.3%, respectively, and the retention times of the drug and IS under these conditions were 5.26 and 6.45 min, respectively.",Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585115/),%,75.2,202833,DB01229,Paclitaxel
,8585115,recovery,"The recovery of paclitaxel from plasma at concentrations equivalent to 50, 400, and 800 micrograms/L paclitaxel in plasma was 79.1, 75.2, and 74.3%, respectively, and the retention times of the drug and IS under these conditions were 5.26 and 6.45 min, respectively.",Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585115/),%,74.3,202834,DB01229,Paclitaxel
,8585115,retention times,"The recovery of paclitaxel from plasma at concentrations equivalent to 50, 400, and 800 micrograms/L paclitaxel in plasma was 79.1, 75.2, and 74.3%, respectively, and the retention times of the drug and IS under these conditions were 5.26 and 6.45 min, respectively.",Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585115/),min,5.26,202835,DB01229,Paclitaxel
,8585115,retention times,"The recovery of paclitaxel from plasma at concentrations equivalent to 50, 400, and 800 micrograms/L paclitaxel in plasma was 79.1, 75.2, and 74.3%, respectively, and the retention times of the drug and IS under these conditions were 5.26 and 6.45 min, respectively.",Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585115/),min,6.45,202836,DB01229,Paclitaxel
,15196737,MTD,"The MTD of irinotecan and paclitaxel were 40 and 50 mg/m2, respectively.",A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196737/),[mg] / [m2],40,203626,DB01229,Paclitaxel
,15196737,MTD,"The MTD of irinotecan and paclitaxel were 40 and 50 mg/m2, respectively.",A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196737/),[mg] / [m2],50,203627,DB01229,Paclitaxel
,12894722,area under the plasma concentration-time curve (AUC),"Paclitaxel 175 mg/m2 was given as a 3-hour intravenous infusion, and carboplatin was dosed to the area under the plasma concentration-time curve (AUC) of 5 mg.",[Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894722/),mg,5,204107,DB01229,Paclitaxel
,12894722,AUC,"The AUC of paclitaxel and carboplatin were 15.2 and 64.56 micrograms.h/ml, respectively.",[Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894722/),[h·μg] / [ml],15.2,204108,DB01229,Paclitaxel
,12894722,AUC,"The AUC of paclitaxel and carboplatin were 15.2 and 64.56 micrograms.h/ml, respectively.",[Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894722/),[h·μg] / [ml],64.56,204109,DB01229,Paclitaxel
,16203816,tumor-cumulated activity,"Mice given paclitaxel 1 day after (111)In-DOTA-Gly3Phe-ChL6 also showed an increase in tumor-cumulated activity, 22.9 (+/- 1.3) versus 19.4 (+/- 3.3) microCi h/g/microCi (P = 0.05).",Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203816/),[h·μci] / [g·μci],22.9,204207,DB01229,Paclitaxel
,16203816,tumor-cumulated activity,"Mice given paclitaxel 1 day after (111)In-DOTA-Gly3Phe-ChL6 also showed an increase in tumor-cumulated activity, 22.9 (+/- 1.3) versus 19.4 (+/- 3.3) microCi h/g/microCi (P = 0.05).",Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203816/),[h·μci] / [g·μci],19.4,204208,DB01229,Paclitaxel
,26069505,electrophoretic mobility,The high electrophoretic mobility of ~3.5 to 1.5 μmcm/Vs confirmed the nano-size of particles.,Pharmacokinetics and biodistribution of negatively charged pectin nanoparticles encapsulating paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26069505/),[μmcm] / [vs],3.5 to 1.5,204396,DB01229,Paclitaxel
,22071785,area under the curve,"Eligible patients received TSU-68 at 200 or 400 mg twice daily and continuously in combination with carboplatin (area under the curve, 6 mg · min/mL) plus paclitaxel (200 mg/m2) on day 1 every 21 days.",Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22071785/),[mg·min] / [ml],6,204578,DB01229,Paclitaxel
,22071785,objective response rate,"The objective response rate was 39.4% (95% confidence interval, 22.9-57.9%), and median progression-free survival was 5.6 months (95% confidence interval, 3.6-7.2 months).",Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22071785/),%,39.4,204579,DB01229,Paclitaxel
,22071785,progression-free survival,"The objective response rate was 39.4% (95% confidence interval, 22.9-57.9%), and median progression-free survival was 5.6 months (95% confidence interval, 3.6-7.2 months).",Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22071785/),month,5.6,204580,DB01229,Paclitaxel
,15917657,Surface tension,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mn] / [m],37.0,205106,DB01229,Paclitaxel
,15917657,Surface tension,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mn] / [m],38.1,205107,DB01229,Paclitaxel
,15917657,critical micellar concentration,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mn] / [m],38.1,205108,DB01229,Paclitaxel
,15917657,critical micellar concentration,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mg] / [ml],0.0387,205109,DB01229,Paclitaxel
,15917657,critical micellar concentration,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mg] / [ml],0.0307,205110,DB01229,Paclitaxel
,15917657,clearance,"Over the tested dose range, the mean clearance of paclitaxel decreased from 45.1 to 16.9 L/h for Taxol, and from 50.7 to 16.4 L/h for Paxene (p > 0.05).",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[l] / [h],45.1 to 16.9,205111,DB01229,Paclitaxel
,15917657,clearance,"Over the tested dose range, the mean clearance of paclitaxel decreased from 45.1 to 16.9 L/h for Taxol, and from 50.7 to 16.4 L/h for Paxene (p > 0.05).",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[l] / [h],50.7 to 16.4,205112,DB01229,Paclitaxel
,30282466,zeta potential,"Box-Behnken design of experiment was employed to optimize PTX-SEDDS and was characterized for droplet size (29.76 ± 2.64 nm), zeta potential (-21.46 ± 2.52 mV), PDI (0.177 ± 0.012), drug content (4.97 ± 0.98 mg), entrapment efficiency (98.33 ± 0.54%) and in vitro drug release (51.03 ± 2.23% PTX at 72 h).",Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30282466/),mv,-,205121,DB01229,Paclitaxel
,30282466,zeta potential,"Box-Behnken design of experiment was employed to optimize PTX-SEDDS and was characterized for droplet size (29.76 ± 2.64 nm), zeta potential (-21.46 ± 2.52 mV), PDI (0.177 ± 0.012), drug content (4.97 ± 0.98 mg), entrapment efficiency (98.33 ± 0.54%) and in vitro drug release (51.03 ± 2.23% PTX at 72 h).",Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30282466/),mv,21.46,205122,DB01229,Paclitaxel
,30282466,entrapment efficiency,"Box-Behnken design of experiment was employed to optimize PTX-SEDDS and was characterized for droplet size (29.76 ± 2.64 nm), zeta potential (-21.46 ± 2.52 mV), PDI (0.177 ± 0.012), drug content (4.97 ± 0.98 mg), entrapment efficiency (98.33 ± 0.54%) and in vitro drug release (51.03 ± 2.23% PTX at 72 h).",Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30282466/),%,98.33,205123,DB01229,Paclitaxel
,30282466,IC50,PTX-SEDDS exhibited IC50; 1.58 ± 0.12 µM and a 52.46-folds higher cell uptake in MDA-MB-231 cells along with cellular and nuclear morphology changes.,Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30282466/),μM,1.58,205124,DB01229,Paclitaxel
>,10815934,terminal half-life,The efficacy after oral administration was only slightly lower than that found after i.v. treatment at equivalent doses; but optimal effects were comparable likely as a consequence of the long (>6 h) terminal half-life of oral IDN 5109.,Oral efficacy and bioavailability of a novel taxane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815934/),h,6,205503,DB01229,Paclitaxel
,10815934,bioavailability,The bioavailability of IDN 5109 assessed by comparing area-under-the-curve values after oral and i.v. administrations was approximately 50%.,Oral efficacy and bioavailability of a novel taxane. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815934/),%,50,205504,DB01229,Paclitaxel
,10534315,area under the plasma concentration-time curve,"Pharmacokinetic evaluation revealed a reproducible and surprisingly high paclitaxel area under the plasma concentration-time curve of 26.0 +/- 1.11 microM.h (mean +/- S.D.; n = 6; c.v. = 4.29%), and a terminal disposition half-life of approximately 29 h.",Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534315/),h·μM,26.0,205997,DB01229,Paclitaxel
,10534315,terminal disposition half-life,"Pharmacokinetic evaluation revealed a reproducible and surprisingly high paclitaxel area under the plasma concentration-time curve of 26.0 +/- 1.11 microM.h (mean +/- S.D.; n = 6; c.v. = 4.29%), and a terminal disposition half-life of approximately 29 h.",Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534315/),h,29,205998,DB01229,Paclitaxel
,10534315,cumulative urinary excretion,The cumulative urinary excretion of the parent drug was consistently low and averaged 1.58 +/- 0.417% (+/- S.D.) of the dose.,Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534315/),%,1.58,205999,DB01229,Paclitaxel
,10534315,plasma area under the plasma concentration-time curve,"The plasma area under the plasma concentration-time curve of the paclitaxel vehicle Cremophor EL, which can profoundly alter the kinetics of paclitaxel, was 114.9 +/- 5.39 microl.h/ml, and not different from historic data in patients with normal or mild renal dysfunction.",Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534315/),[h·μl] / [ml],114.9,206000,DB01229,Paclitaxel
,23703720,concentrations,"The 1-hr, 3 and 7 days vessel paclitaxel concentrations were 152.9 ± 154.5, 36.5 ± 49.5, and 0.9 ± 0.7 ng/mg respectively.",Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23703720/),,152.,206255,DB01229,Paclitaxel
,23703720,concentrations,"The 1-hr, 3 and 7 days vessel paclitaxel concentrations were 152.9 ± 154.5, 36.5 ± 49.5, and 0.9 ± 0.7 ng/mg respectively.",Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23703720/),,36.5,206256,DB01229,Paclitaxel
,23703720,concentrations,"The 1-hr, 3 and 7 days vessel paclitaxel concentrations were 152.9 ± 154.5, 36.5 ± 49.5, and 0.9 ± 0.7 ng/mg respectively.",Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23703720/),,0.9,206257,DB01229,Paclitaxel
,15737558,plasma t(1/2),The mean plasma t(1/2) was 3.8 +/- 2.3 h for total topotecan and 4.4 +/- 3.9 h for active lactone.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),h,3.8,206347,DB01229,Paclitaxel
,15737558,plasma t(1/2),The mean plasma t(1/2) was 3.8 +/- 2.3 h for total topotecan and 4.4 +/- 3.9 h for active lactone.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),h,4.4,206348,DB01229,Paclitaxel
,15737558,peritoneal / plasma AUC ratio,"The area under the curve (AUC) was proportional with dose, R = 0.54, p < 0.05 for total topotecan and the peritoneal / plasma AUC ratio was 46 +/- 30.",A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),,46,206349,DB01229,Paclitaxel
,15737558,progression-free survival (PFS),Fifteen patients who completed treatment had a median progression-free survival (PFS) of 27 months.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),month,27,206350,DB01229,Paclitaxel
,15737558,MTD,In this setting the MTD of topotecan is 20 mg/m(2) i.p.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),[mg] / [m],20,206351,DB01229,Paclitaxel
,12682786,time lag,"A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion.",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,2,206523,DB01229,Paclitaxel
,12682786,half-life,"The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both).",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,2.2,206524,DB01229,Paclitaxel
,12682786,half-life,"The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both).",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,0.23,206525,DB01229,Paclitaxel
,12682786,half-life,"The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both).",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,0.18,206526,DB01229,Paclitaxel
,16305406,mean residence time,"Further, poloxamer micelles demonstrated both the highest mean residence time of 7.34 h and volume of distribution (VSS=4.82 and VZ=5.87 L/kg) for paclitaxel.","In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305406/),h,7.34,206698,DB01229,Paclitaxel
,16305406,volume of distribution (VSS,"Further, poloxamer micelles demonstrated both the highest mean residence time of 7.34 h and volume of distribution (VSS=4.82 and VZ=5.87 L/kg) for paclitaxel.","In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305406/),[l] / [kg],4.82,206699,DB01229,Paclitaxel
,16305406,VZ,"Further, poloxamer micelles demonstrated both the highest mean residence time of 7.34 h and volume of distribution (VSS=4.82 and VZ=5.87 L/kg) for paclitaxel.","In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305406/),[l] / [kg],5.87,206700,DB01229,Paclitaxel
,16305406,mean residence time,"This was followed by prodrug loaded 'Stealth' liposomes, which showed a mean residence time of 4.96 h but were least distributed into apparent physiological volume (VSS=2.12 and VZ=3.16 L/kg).","In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305406/),h,4.96,206701,DB01229,Paclitaxel
,16305406,apparent physiological volume (VSS,"This was followed by prodrug loaded 'Stealth' liposomes, which showed a mean residence time of 4.96 h but were least distributed into apparent physiological volume (VSS=2.12 and VZ=3.16 L/kg).","In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305406/),[l] / [kg],2.12,206702,DB01229,Paclitaxel
,16305406,VZ,"This was followed by prodrug loaded 'Stealth' liposomes, which showed a mean residence time of 4.96 h but were least distributed into apparent physiological volume (VSS=2.12 and VZ=3.16 L/kg).","In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305406/),[l] / [kg],3.16,206703,DB01229,Paclitaxel
,11304775,Response rate,Response rate was 76% (28% complete).,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,76,206733,DB01229,Paclitaxel
,11304775,overall survival,Median overall survival was 29 months.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),month,29,206734,DB01229,Paclitaxel
,11304775,Urinary excretion,Urinary excretion of EPI dose went from 8.2% in E --> T to 11.8% in ET cycles.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,8.2,206735,DB01229,Paclitaxel
,11304775,Urinary excretion,Urinary excretion of EPI dose went from 8.2% in E --> T to 11.8% in ET cycles.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,11.8,206736,DB01229,Paclitaxel
,25265550,loading efficiency,"The DOX loading efficiency was as high as 91.7% and 93.5% for PEG5K-EB2 and FA-PEG5K-EB2, respectively.",Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265550/),%,91.7,206831,DB01229,Paclitaxel
,25265550,loading efficiency,"The DOX loading efficiency was as high as 91.7% and 93.5% for PEG5K-EB2 and FA-PEG5K-EB2, respectively.",Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265550/),%,93.5,206832,DB01229,Paclitaxel
,25265550,maximum tolerated dose,"The maximum tolerated dose of DOX-loaded PEG5K-EB2 micelles was 15 mg/kg in mice, which was 1.5-fold greater than that for free DOX.",Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265550/),[mg] / [kg],15,206833,DB01229,Paclitaxel
,23262201,Mw,"In vitro studies on human ovarian carcinoma A2780 cells were carried out to investigate the cytotoxicity of free PTX, HPMA copolymer-PTX conjugate with Mw of 48 kDa (P-PTX), and mP-PTX.",Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262201/),kda,48,207101,DB01229,Paclitaxel
,9007117,area under the concentration-time curve (AUC),"In preparation for the design of phase II studies in lung cancer, low-dose carboplatin, fixed at a target area under the concentration-time curve (AUC) of 4.0 or 4.5 mg x min/mL, has been combined with escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in a series of studies to establish the maximum tolerated dose of the combination.",Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9007117/),[mg·min] / [ml],4.0,207570,DB01229,Paclitaxel
,9007117,area under the concentration-time curve (AUC),"In preparation for the design of phase II studies in lung cancer, low-dose carboplatin, fixed at a target area under the concentration-time curve (AUC) of 4.0 or 4.5 mg x min/mL, has been combined with escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in a series of studies to establish the maximum tolerated dose of the combination.",Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9007117/),[mg·min] / [ml],4.5,207571,DB01229,Paclitaxel
,9007117,AUC,"In patients who had received prior chemotherapy, the maximum tolerated paclitaxel dose was 135 mg/m2 (carboplatin target AUC 4.0); the dose-limiting toxicity was febrile neutropenia.",Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9007117/),,4.0,207572,DB01229,Paclitaxel
,9007117,AUC,"Without granulocyte colony-stimulating factor support in chemotherapy-naive patients (carboplatin target AUC 4.5), and with granulocyte colony-stimulating factor in chemotherapy-pretreated patients, the current paclitaxel dose is 290 mg/m2.",Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9007117/),,4.5,207573,DB01229,Paclitaxel
,9007117,AUC,"In a study in which paclitaxel was given by 1-hour infusion with carboplatin (target AUC 4.5), a 205 mg/m2 dose was poorly tolerated.",Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9007117/),,4.5,207574,DB01229,Paclitaxel
,23842945,AUC0-24,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),[h·μg] / [l],3 566.5,207608,DB01229,Paclitaxel
,23842945,AUC0-24,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),[h·μg] / [l],443.2,207609,DB01229,Paclitaxel
,23842945,CL,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),[l] / [h·kg],1.5,207610,DB01229,Paclitaxel
,23842945,CL,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),[l] / [h·kg],2.1,207611,DB01229,Paclitaxel
,23842945,Vd,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),[l] / [kg],20.0,207612,DB01229,Paclitaxel
,23842945,Vd,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),[l] / [kg],38.4,207613,DB01229,Paclitaxel
,23842945,t1/2,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),h,9.3,207614,DB01229,Paclitaxel
,23842945,t1/2,"The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0-24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively.",Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23842945/),h,14.1,207615,DB01229,Paclitaxel
,24471503,oral bioavailability,"Oral NPs achieved drug plasma levels for at least 24 h, with an oral bioavailability of 55-80%.",Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471503/),%,55-80,207860,DB01229,Paclitaxel
,7923556,clearance (CLtb),"After i.v. administration to male mice, paclitaxel clearance (CLtb) was 3.25 ml min-1 kg-1 and the terminal half-life (t1/2) was 69 min.",Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923556/),[ml] / [kg·min],3.25,207946,DB01229,Paclitaxel
,7923556,terminal half-life (t1/2),"After i.v. administration to male mice, paclitaxel clearance (CLtb) was 3.25 ml min-1 kg-1 and the terminal half-life (t1/2) was 69 min.",Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923556/),min,69,207947,DB01229,Paclitaxel
,7923556,CLtb,"After i.v. administration to female mice, paclitaxel CLtb was 4.54 ml min-1 kg-1 and the terminal t1/2 was 43 min.",Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923556/),[ml] / [kg·min],4.54,207948,DB01229,Paclitaxel
,7923556,terminal t1/2,"After i.v. administration to female mice, paclitaxel CLtb was 4.54 ml min-1 kg-1 and the terminal t1/2 was 43 min.",Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923556/),min,43,207949,DB01229,Paclitaxel
,7923556,bioavailability,"The bioavailability of paclitaxel was approximately 10%, 0, and 0 after i.p., p.o., and s.c. administration, respectively.",Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923556/),%,10,207950,DB01229,Paclitaxel
,7923556,bioavailability,"The bioavailability of paclitaxel was approximately 10%, 0, and 0 after i.p., p.o., and s.c. administration, respectively.",Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923556/),,0,207951,DB01229,Paclitaxel
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,1.455,208515,DB01229,Paclitaxel
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,2.344,208516,DB01229,Paclitaxel
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],10.997,208517,DB01229,Paclitaxel
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],7.014,208518,DB01229,Paclitaxel
,8098059,terminal half-life,"Pharmacokinetic studies showed plasma concentrations of taxotere declined in a triexponential manner, with a terminal half-life of 11.8 hours.",Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098059/),h,11.8,209238,DB01229,Paclitaxel
,10071262,maximum-tolerated dose,"After encountering dose-limiting toxicities (DLTs) without G-CSF support, the maximum-tolerated dose was defined as 5 microg/kg of G-CSF subcutaneously starting on day 6.","Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071262/),,5,209304,DB01229,Paclitaxel
,9050899,oral bioavailability,"Consequently, the oral bioavailability in mice receiving 10 mg paclitaxel per kg body weight increased from only 11% in wt mice to 35% in mdr1a(-/-) mice.",Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050899/),%,11,209305,DB01229,Paclitaxel
,9050899,oral bioavailability,"Consequently, the oral bioavailability in mice receiving 10 mg paclitaxel per kg body weight increased from only 11% in wt mice to 35% in mdr1a(-/-) mice.",Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050899/),%,35,209306,DB01229,Paclitaxel
,9050899,cumulative fecal excretion,The cumulative fecal excretion (0-96 hr) was markedly reduced from 40% (after i.v. administration) and 87% (after oral administration) of the administered dose in wt mice to below 3% in mdr1a(-/-) mice.,Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050899/),,40,209307,DB01229,Paclitaxel
below,9050899,cumulative fecal excretion,The cumulative fecal excretion (0-96 hr) was markedly reduced from 40% (after i.v. administration) and 87% (after oral administration) of the administered dose in wt mice to below 3% in mdr1a(-/-) mice.,Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9050899/),%,3,209308,DB01229,Paclitaxel
,10997930,fu,"Using this method, fu has been measured in three patients receiving three consecutive 3-weekly courses of paclitaxel at dose levels of 135, 175, and 225 mg/m(2) and found to range between 0.036 and 0.079.",Measurement of fraction unbound paclitaxel in human plasma. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997930/),,0.036 and 0.079,209488,DB01229,Paclitaxel
,26350560,flow rate,"Chromatographic separation was achieved using an Acquity(®) UPLC(®) BEH™ (2.1×100 mm id, 1.7 μm) reverse-phase C18 column at a flow rate of 0.4 mL/min, using isocratic elution mode containing ammonium acetate/formic acid in water/methanol (30:70 v/v) as mobile phase.",Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),[ml] / [min],0.4,209637,DB01229,Paclitaxel
,26350560,mass-to-charge (m/z),"Docetaxel and its internal standard (paclitaxel) were detected by electrospray ionization mass spectrometry in positive ion multiple reaction monitoring mode using mass-to-charge (m/z) transitions of 808.3→527.0 (quantifier) and 808.3→509.0 (qualifier); and 854.3→569.0 (quantifier) and 854,3→509,0 (qualifier), respectively.",Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),,808,209638,DB01229,Paclitaxel
,26350560,mass-to-charge (m/z),"Docetaxel and its internal standard (paclitaxel) were detected by electrospray ionization mass spectrometry in positive ion multiple reaction monitoring mode using mass-to-charge (m/z) transitions of 808.3→527.0 (quantifier) and 808.3→509.0 (qualifier); and 854.3→569.0 (quantifier) and 854,3→509,0 (qualifier), respectively.",Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),,808.3,209639,DB01229,Paclitaxel
,26350560,mass-to-charge (m/z),"Docetaxel and its internal standard (paclitaxel) were detected by electrospray ionization mass spectrometry in positive ion multiple reaction monitoring mode using mass-to-charge (m/z) transitions of 808.3→527.0 (quantifier) and 808.3→509.0 (qualifier); and 854.3→569.0 (quantifier) and 854,3→509,0 (qualifier), respectively.",Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),,854.3,209640,DB01229,Paclitaxel
,26350560,mass-to-charge (m/z),"Docetaxel and its internal standard (paclitaxel) were detected by electrospray ionization mass spectrometry in positive ion multiple reaction monitoring mode using mass-to-charge (m/z) transitions of 808.3→527.0 (quantifier) and 808.3→509.0 (qualifier); and 854.3→569.0 (quantifier) and 854,3→509,0 (qualifier), respectively.",Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),,854,209641,DB01229,Paclitaxel
,26350560,run time,The run time per sample was 3.5 min.,Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),min,3.5,209642,DB01229,Paclitaxel
greater,26350560,Recovery,Recovery values were greater than 79.4%.,Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350560/),%,79.4,209643,DB01229,Paclitaxel
,30765148,PFS,"Median PFS was 23.5 (95%CI 16.2-35.3) and 25 (95%CI 16.4-42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B.","Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30765148/),month,23,209676,DB01229,Paclitaxel
,30765148,PFS,"Median PFS was 23.5 (95%CI 16.2-35.3) and 25 (95%CI 16.4-42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B.","Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30765148/),month,25,209677,DB01229,Paclitaxel
,30765148,OS,"Median PFS was 23.5 (95%CI 16.2-35.3) and 25 (95%CI 16.4-42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B.","Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30765148/),,68,209678,DB01229,Paclitaxel
,30765148,OS,"Median PFS was 23.5 (95%CI 16.2-35.3) and 25 (95%CI 16.4-42.7) months, respectively; median OS was 68 (95%CI 49.5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B.","Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30765148/),,79,209679,DB01229,Paclitaxel
,10541968,AUC,"The following single-point model was selected as optimal: AUC carboplatin (min mg(-1) ml(-1)) = 418. c(2.5 h)(mg/ml) + 0.43 (min mg(-1) ml(-1)), where c(2.5 h) is the concentration (mg/ml) of carboplatin 2.5 h after the start of a 30-min infusion.",A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541968/),[min] / [mg·ml],418,209893,DB01229,Paclitaxel
,10541968,AUC,"The following single-point model was selected as optimal: AUC carboplatin (min mg(-1) ml(-1)) = 418. c(2.5 h)(mg/ml) + 0.43 (min mg(-1) ml(-1)), where c(2.5 h) is the concentration (mg/ml) of carboplatin 2.5 h after the start of a 30-min infusion.",A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541968/),[min] / [mg·ml],0.43,209894,DB01229,Paclitaxel
,31637669,Overall objective response rate,Overall objective response rate was 46%.,Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31637669/),%,46,210290,DB01229,Paclitaxel
,26042449,bioavailability,"It is established that the bioavailability of sublingual forms of paclitaxel was 42.4%, Cmax = 615 ± 73 ng × ml(-1) and tmax = 30-35 min.",[Study of bioavailability of paclitaxel after sublingual administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26042449/),%,42.4,211046,DB01229,Paclitaxel
,26042449,Cmax,"It is established that the bioavailability of sublingual forms of paclitaxel was 42.4%, Cmax = 615 ± 73 ng × ml(-1) and tmax = 30-35 min.",[Study of bioavailability of paclitaxel after sublingual administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26042449/),[ng] / [ml],615,211047,DB01229,Paclitaxel
,26042449,tmax,"It is established that the bioavailability of sublingual forms of paclitaxel was 42.4%, Cmax = 615 ± 73 ng × ml(-1) and tmax = 30-35 min.",[Study of bioavailability of paclitaxel after sublingual administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26042449/),min,30-35,211048,DB01229,Paclitaxel
,26042449,Vd,"The value of the initial volume of distribution of paclitaxel (Vd = 3,14 ± 0,85 l × kg(-1)) also shows its intensive penetration to the organs and tissues.",[Study of bioavailability of paclitaxel after sublingual administration]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26042449/),[l] / [kg],"3,14",211049,DB01229,Paclitaxel
,26042449,half-life,"The half-life of the drug on the terminal segment of concentration-time curve was averaged 1,06 ± 0,21 h.",[Study of bioavailability of paclitaxel after sublingual administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26042449/),h,"1,06",211050,DB01229,Paclitaxel
,30617139,trough serum drug concentration,"At week 19, median trough serum drug concentration was 132 μg/mL (ABP 215 group) and 129 μg/mL (bevacizumab group).","Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617139/),[μg] / [ml],132,211519,DB01229,Paclitaxel
,30617139,trough serum drug concentration,"At week 19, median trough serum drug concentration was 132 μg/mL (ABP 215 group) and 129 μg/mL (bevacizumab group).","Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617139/),[μg] / [ml],129,211520,DB01229,Paclitaxel
,10496361,Cl175-3 h,The pharmacokinetics of Cremophor EL itself was non-linear as the clearance (Cl) in the 3-h schedules was significantly lower than when using the longer 24- or 96-h infusions (Cl175-3 h = 42.8+/-24.9 ml h(-1) m(-2); CI175-24 h = 79.7+/-24.3; P = 0.035 and Cl135-3 h = 44.1+/-21.8 ml h(-1) m(-1); Cl140-96 h = 211.8+/-32.0; P < 0.001).,Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496361/),[ml] / [(m)^2·h],42.8,211943,DB01229,Paclitaxel
,10496361,CI175-24 h,The pharmacokinetics of Cremophor EL itself was non-linear as the clearance (Cl) in the 3-h schedules was significantly lower than when using the longer 24- or 96-h infusions (Cl175-3 h = 42.8+/-24.9 ml h(-1) m(-2); CI175-24 h = 79.7+/-24.3; P = 0.035 and Cl135-3 h = 44.1+/-21.8 ml h(-1) m(-1); Cl140-96 h = 211.8+/-32.0; P < 0.001).,Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496361/),,79.7,211944,DB01229,Paclitaxel
,10496361,Cl135-3 h,The pharmacokinetics of Cremophor EL itself was non-linear as the clearance (Cl) in the 3-h schedules was significantly lower than when using the longer 24- or 96-h infusions (Cl175-3 h = 42.8+/-24.9 ml h(-1) m(-2); CI175-24 h = 79.7+/-24.3; P = 0.035 and Cl135-3 h = 44.1+/-21.8 ml h(-1) m(-1); Cl140-96 h = 211.8+/-32.0; P < 0.001).,Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496361/),[ml] / [h·m],44.1,211945,DB01229,Paclitaxel
,10496361,Cl140-96 h,The pharmacokinetics of Cremophor EL itself was non-linear as the clearance (Cl) in the 3-h schedules was significantly lower than when using the longer 24- or 96-h infusions (Cl175-3 h = 42.8+/-24.9 ml h(-1) m(-2); CI175-24 h = 79.7+/-24.3; P = 0.035 and Cl135-3 h = 44.1+/-21.8 ml h(-1) m(-1); Cl140-96 h = 211.8+/-32.0; P < 0.001).,Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496361/),,211.8,211946,DB01229,Paclitaxel
,10500531,relative dose intensity (RDI),"The median dose intensity (DI) of weekly TXT (20.63 mg/m2/week) was similar to that of standard TXT, and the median relative dose intensity (RDI) of weekly TXT was 0.98.",[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500531/),,0.98,212086,DB01229,Paclitaxel
,10500531,area under the plasma concentration-time curve (AUC),The median area under the plasma concentration-time curve (AUC) of weekly TXT (1.20 micrograms.h/ml) was smaller than that of standard TXT (1.87 micrograms.h/ml).,[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500531/),[h·μg] / [ml],1.20,212087,DB01229,Paclitaxel
,10500531,area under the plasma concentration-time curve (AUC),The median area under the plasma concentration-time curve (AUC) of weekly TXT (1.20 micrograms.h/ml) was smaller than that of standard TXT (1.87 micrograms.h/ml).,[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10500531/),[h·μg] / [ml],1.87,212088,DB01229,Paclitaxel
,9779712,overall response rate,"The overall response rate was 53% (95% confidence interval [CI], 34% to 72%), with 10% complete responses (CRs) and 43% partial responses (PRs).",Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9779712/),%,53,212140,DB01229,Paclitaxel
,9779712,response duration,"Median response duration was 7.5 months (range, 2 to 11+).",Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9779712/),month,7.5,212141,DB01229,Paclitaxel
<,19395467,absolute neutrophil counts,Eighteen Japanese lung cancer patients who had experienced severe neutropenia (absolute neutrophil counts <0.5 x 10(9) cells/l) were enrolled.,A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395467/),,0.5 x,212909,DB01229,Paclitaxel
,20368717,of,The geometric mean of clearance was 385 l h⁻¹ (range 176-726 l h⁻¹).,Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20368717/),h⁻¹·l,385,213818,DB01229,Paclitaxel
,20368717,clearance,The geometric mean of clearance was 385 l h⁻¹ (range 176-726 l h⁻¹).,Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20368717/),h⁻¹·l,385,213819,DB01229,Paclitaxel
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],7.7,213912,DB01229,Paclitaxel
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],8.8,213913,DB01229,Paclitaxel
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],3.2,213914,DB01229,Paclitaxel
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],4.0,213915,DB01229,Paclitaxel
,10561275,C(max),"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],30,213916,DB01229,Paclitaxel
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],55,213917,DB01229,Paclitaxel
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],106,213918,DB01229,Paclitaxel
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,15.8,213950,DB01229,Paclitaxel
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,11.6,213951,DB01229,Paclitaxel
,27057200,lymph absorption rate,"However, the lymph absorption rate of paclitaxel with or without JWXYS pretreatment was not significantly changed (27 ± 3 and 30 ± 2%, resp.).",Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27057200/),%,27,214120,DB01229,Paclitaxel
,27057200,lymph absorption rate,"However, the lymph absorption rate of paclitaxel with or without JWXYS pretreatment was not significantly changed (27 ± 3 and 30 ± 2%, resp.).",Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27057200/),%,30,214121,DB01229,Paclitaxel
,11336328,overall response rate,"There were seven partial responses among 24 evaluable patients, for an overall response rate of 29%.",Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11336328/),%,29,214212,DB01229,Paclitaxel
,11336328,survival time,The median survival time was 341 days and the 1 year survival rate was 45.8%.,Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11336328/),d,341,214213,DB01229,Paclitaxel
,15198520,infusion time,"The dose was 40 mg/kg, and the infusion time was 8 to 9 minutes.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),min,8 to 9,215661,DB01229,Paclitaxel
,15198520,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1 +/- 3.32 microg-h/mL; Cre-pac: 34.5 +/- 0.994 microg-h/mL), however, the AUC for various tissues was formulation-dependent.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),[μg-h] / [ml],38.1,215662,DB01229,Paclitaxel
,15198520,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1 +/- 3.32 microg-h/mL; Cre-pac: 34.5 +/- 0.994 microg-h/mL), however, the AUC for various tissues was formulation-dependent.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),[μg-h] / [ml],34.5,215663,DB01229,Paclitaxel
,15198520,Cre,"The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1 +/- 3.32 microg-h/mL; Cre-pac: 34.5 +/- 0.994 microg-h/mL), however, the AUC for various tissues was formulation-dependent.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),[μg-h] / [ml],34.5,215664,DB01229,Paclitaxel
,10914699,cumulative fecal excretion,"The cumulative fecal excretion of docetaxel, however, was markedly reduced from 8.47 +/- 2.14% (mean +/- SD) of the dose with the single agent to less than 0.5% in the presence of R101933 (P = 0.0016).",Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914699/),%,8.47,216482,DB01229,Paclitaxel
less,10914699,cumulative fecal excretion,"The cumulative fecal excretion of docetaxel, however, was markedly reduced from 8.47 +/- 2.14% (mean +/- SD) of the dose with the single agent to less than 0.5% in the presence of R101933 (P = 0.0016).",Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914699/),%,0.5,216483,DB01229,Paclitaxel
,16566060,C0,"The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h.",Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16566060/),[ng] / [ml],8977,217044,DB01229,Paclitaxel
,16566060,AUC(0 --> infinity),"The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h.",Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16566060/),[h·ng] / [ml],7477,217045,DB01229,Paclitaxel
,16566060,CL(s),"The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h.",Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16566060/),[ml] / [h·kg],668,217046,DB01229,Paclitaxel
,16566060,V(ss),"The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h.",Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16566060/),[ml] / [kg],1559,217047,DB01229,Paclitaxel
,16566060,V(z),"The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h.",Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16566060/),[ml] / [kg],2557,217048,DB01229,Paclitaxel
,16566060,t(1/2),"The following pharmacokinetics for paclitaxel in the plasma were estimated: C0, 8977 ng/ml; AUC(0 --> infinity), 7477 ng*h/ml; CL(s), 668 ml/h*kg; V(ss), 1559 ml/kg; V(z) 2557 ml/kg and t(1/2), 2.6 h.",Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16566060/),h,2.6,217049,DB01229,Paclitaxel
,15149147,area under the curve (AUC),This study was designed to evaluate the maximum tolerated dose (MTD) of a fixed dose of carboplatin with an area under the curve (AUC) of 6 and escalating doses of weekly paclitaxel with an initial dose of 50 mg/m2 with 10 mg/m2 increments at each level in untreated NSCLC patients (phase I study).,The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15149147/),,6,217050,DB01229,Paclitaxel
,15149147,AUC,"The MTD was: carboplatin AUC = 6 on days 1 and 28 plus paclitaxel 100 mg/m2 (1 hour) on days 1, 8,15, 28.",The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15149147/),,6,217051,DB01229,Paclitaxel
,15149147,duration of response,The median duration of response was 8.0 mos (range: 1.0-19.0).,The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15149147/),mos,8.0,217052,DB01229,Paclitaxel
,15149147,time to progression,The median time to progression was 8.0 mos (range: 7.0-19.0) and the median survival was 14.0 months (range: 9.0-19.0).,The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15149147/),mos,8.0,217053,DB01229,Paclitaxel
,15149147,survival,The median time to progression was 8.0 mos (range: 7.0-19.0) and the median survival was 14.0 months (range: 9.0-19.0).,The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15149147/),month,14.0,217054,DB01229,Paclitaxel
,15149147,survival time,"The survival results were interesting: the median survival time was 14 months (9-19 months) and the 1- and 2-year survival was 59% and 16%, respectively.",The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15149147/),month,14,217055,DB01229,Paclitaxel
,11286326,time to reach peak concentration (tmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,2,217445,DB01229,Paclitaxel
,11286326,peak plasma drug concentration (Cmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],3 to 4,217446,DB01229,Paclitaxel
,11286326,elimination half-life (t(1/2)),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,0.55 to 0.89,217447,DB01229,Paclitaxel
,11286326,Recovery,Recovery of drug-related material in urine and faeces is nearly 100%.,Clinical pharmacokinetics of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),%,100,217448,DB01229,Paclitaxel
,11286326,Cmax,Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],0.22 to 0.31,217449,DB01229,Paclitaxel
,11286326,area under the concentration-time curve (AUC),Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[h·mg] / [l],0.461 to 0.698,217450,DB01229,Paclitaxel
>,16000582,T,"In Kaplan-Meier analyses, T(>0.05) > or = 10.6 hours (P=0.023), AUC of total paclitaxel > or = 4.7 microg/mL x hour (P = 0.047), and AUC of unbound paclitaxel > or = 0.375 microg/mL x hour (P = 0.095) were identified as being potential factors for peripheral neuropathy development.",Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16000582/),h,10.6,217871,DB01229,Paclitaxel
>,16000582,AUC,"In Kaplan-Meier analyses, T(>0.05) > or = 10.6 hours (P=0.023), AUC of total paclitaxel > or = 4.7 microg/mL x hour (P = 0.047), and AUC of unbound paclitaxel > or = 0.375 microg/mL x hour (P = 0.095) were identified as being potential factors for peripheral neuropathy development.",Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16000582/),[μg] / [h·ml],4.7,217872,DB01229,Paclitaxel
>,16000582,AUC,"In Kaplan-Meier analyses, T(>0.05) > or = 10.6 hours (P=0.023), AUC of total paclitaxel > or = 4.7 microg/mL x hour (P = 0.047), and AUC of unbound paclitaxel > or = 0.375 microg/mL x hour (P = 0.095) were identified as being potential factors for peripheral neuropathy development.",Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16000582/),[μg] / [h·ml],0.375,217873,DB01229,Paclitaxel
,16246975,area under the curve,"Patients with tumor evidence of EGFR by immunohistochemistry, performance status of 0 to 2, and measurable disease received paclitaxel 225 mg/m2 with carboplatin area under the curve = 6 on day 1 every 3 weeks.",Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16246975/),,6,218057,DB01229,Paclitaxel
,16246975,time to progression,"With a median follow-up of 19 months, the median time to progression was 5 months, median survival was 11 months, and the 1- and 2-year survival rates were 40% and 16%, respectively.",Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16246975/),month,5,218058,DB01229,Paclitaxel
,7902425,End-of-infusion plasma concentrations,"End-of-infusion plasma concentrations ranged from 0.40 to 6.4 mumol/L, and were not found to be dose-dependent over the range of doses studied.",Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902425/),[μM] / [l],0.40 to 6.4,218117,DB01229,Paclitaxel
,7902425,overall response rate,"A complete response was documented in one patient, partial response in two, and minimal response in one for an overall response rate of 13%.",Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902425/),%,13,218118,DB01229,Paclitaxel
,8874332,plasma,The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL).,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[ng] / [ml],45,218976,DB01229,Paclitaxel
,8874332,concentrations (Cmax),The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL).,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[ng] / [ml],45,218977,DB01229,Paclitaxel
,8874332,concentrations (Cmax),The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL).,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[ng] / [ml],26,218978,DB01229,Paclitaxel
,8874332,clearance,"The mean doxorubicin clearance was 32% lower in the paclitaxel-doxorubicin sequence (34.3 +/- 10.3 L/h v 51.6 +/- 16.1 L/h, P < .01).",Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[l] / [h],34.3,218979,DB01229,Paclitaxel
,8874332,clearance,"The mean doxorubicin clearance was 32% lower in the paclitaxel-doxorubicin sequence (34.3 +/- 10.3 L/h v 51.6 +/- 16.1 L/h, P < .01).",Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[l] / [h],51.6,218980,DB01229,Paclitaxel
,8874332,absolute granulocyte count,The median absolute granulocyte count was 0.2/microL in the paclitaxel-doxorubicin sequence and 1.3/microL in the doxorubicin-paclitaxel sequence.,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),1/[μl],0.2,218981,DB01229,Paclitaxel
,8874332,absolute granulocyte count,The median absolute granulocyte count was 0.2/microL in the paclitaxel-doxorubicin sequence and 1.3/microL in the doxorubicin-paclitaxel sequence.,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),1/[μl],1.3,218982,DB01229,Paclitaxel
,10656433,maximum tolerated dose,The maximum tolerated dose determined during the first cycle was 1000 mg/m2/day for 5 days of 5FU with either 75 or 85 mg/m2 docetaxel.,A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10656433/),,1000,219020,DB01229,Paclitaxel
,7600920,Total urinary excretion,"Total urinary excretion was 14.3 +/- 1.4% (SE) of the dose, with unchanged taxol and an unknown polar metabolite as the main excretion products.",Taxol metabolism and disposition in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),%,14.3,219146,DB01229,Paclitaxel
,7600920,Total fecal excretion,"Total fecal excretion was 71.1 +/- 8.2%, with 6 alpha-hydroxytaxol being the largest component by far.",Taxol metabolism and disposition in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),%,71.1,219147,DB01229,Paclitaxel
,7600920,area under the curve,The plasma area under the curve for unchanged taxol was 20.5 +/- 2.3 microM.hr and that for total taxol metabolites was 14.2 +/- 4.5 microM.hr.,Taxol metabolism and disposition in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h·μM,20.5,219148,DB01229,Paclitaxel
,7600920,area under the curve,The plasma area under the curve for unchanged taxol was 20.5 +/- 2.3 microM.hr and that for total taxol metabolites was 14.2 +/- 4.5 microM.hr.,Taxol metabolism and disposition in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h·μM,14.2,219149,DB01229,Paclitaxel
,7600920,half-life,"The half-life of total metabolites (5.6 +/- 0.4 hr), however, greatly exceeded that of unchanged taxol (2.9 +/- 0.3 hr).",Taxol metabolism and disposition in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h,5.6,219150,DB01229,Paclitaxel
,7600920,half-life,"The half-life of total metabolites (5.6 +/- 0.4 hr), however, greatly exceeded that of unchanged taxol (2.9 +/- 0.3 hr).",Taxol metabolism and disposition in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600920/),h,2.9,219151,DB01229,Paclitaxel
,14977827,clearance,"The mean pharmacokinetic parameter values during course 1 for clearance, volume of distribution, and apparent terminal elimination half-life at the 40 mg/m(2) (recommended Phase II dose) dose level were 21 liters/h/m(2), 826 liters/m(2), and 35 h (excluding one outlier of 516 h), respectively.","Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14977827/),[h·l] / [m(2],21,219226,DB01229,Paclitaxel
,14977827,volume of distribution,"The mean pharmacokinetic parameter values during course 1 for clearance, volume of distribution, and apparent terminal elimination half-life at the 40 mg/m(2) (recommended Phase II dose) dose level were 21 liters/h/m(2), 826 liters/m(2), and 35 h (excluding one outlier of 516 h), respectively.","Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14977827/),[l] / [m(2],826,219227,DB01229,Paclitaxel
,14977827,apparent terminal elimination half-life,"The mean pharmacokinetic parameter values during course 1 for clearance, volume of distribution, and apparent terminal elimination half-life at the 40 mg/m(2) (recommended Phase II dose) dose level were 21 liters/h/m(2), 826 liters/m(2), and 35 h (excluding one outlier of 516 h), respectively.","Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14977827/),h,35,219228,DB01229,Paclitaxel
,17594093,MTD,The MTD of ixabepilone is 50 mg/m2 given over 3 h every 3 weeks.,"Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17594093/),[mg] / [m2],50,219648,DB01229,Paclitaxel
,7497596,Cl,"Using NONMEM [for a patient with mean AGE (52.3 years) and mean BSA (1.68 m2)] and NPML, docetaxel Cl was estimated to be 35.6 l/h (21.2 lh-1 m-2) and 37.2 l/h with interpatient coefficients of variations (CVs) of 17.4% and 24.8%, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),[l] / [h],35.6,219794,DB01229,Paclitaxel
,7497596,Cl,"Using NONMEM [for a patient with mean AGE (52.3 years) and mean BSA (1.68 m2)] and NPML, docetaxel Cl was estimated to be 35.6 l/h (21.2 lh-1 m-2) and 37.2 l/h with interpatient coefficients of variations (CVs) of 17.4% and 24.8%, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),1/[(m)^2·lh],21.2,219795,DB01229,Paclitaxel
,7497596,Cl,"Using NONMEM [for a patient with mean AGE (52.3 years) and mean BSA (1.68 m2)] and NPML, docetaxel Cl was estimated to be 35.6 l/h (21.2 lh-1 m-2) and 37.2 l/h with interpatient coefficients of variations (CVs) of 17.4% and 24.8%, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),[l] / [h],37.2,219796,DB01229,Paclitaxel
,7497596,volume at steady state (Vss,"Discrepancies were found in the mean volume at steady state (Vss; 83.21 for NPML versus 1241 for NONMEM) and in terminal half-lives, notably the mean t1/2 gamma, which was shorter as determined by NPML (7.89 versus 12.2 h), although the interindividual CV was 89.1% and 62.7% for Vss and t1/2 gamma, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),,83.21,219797,DB01229,Paclitaxel
,7497596,volume at steady state (Vss,"Discrepancies were found in the mean volume at steady state (Vss; 83.21 for NPML versus 1241 for NONMEM) and in terminal half-lives, notably the mean t1/2 gamma, which was shorter as determined by NPML (7.89 versus 12.2 h), although the interindividual CV was 89.1% and 62.7% for Vss and t1/2 gamma, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),,1241,219798,DB01229,Paclitaxel
,7497596,t1/2 gamma,"Discrepancies were found in the mean volume at steady state (Vss; 83.21 for NPML versus 1241 for NONMEM) and in terminal half-lives, notably the mean t1/2 gamma, which was shorter as determined by NPML (7.89 versus 12.2 h), although the interindividual CV was 89.1% and 62.7% for Vss and t1/2 gamma, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),h,7.89,219799,DB01229,Paclitaxel
,7497596,t1/2 gamma,"Discrepancies were found in the mean volume at steady state (Vss; 83.21 for NPML versus 1241 for NONMEM) and in terminal half-lives, notably the mean t1/2 gamma, which was shorter as determined by NPML (7.89 versus 12.2 h), although the interindividual CV was 89.1% and 62.7% for Vss and t1/2 gamma, respectively.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),h,12.2,219800,DB01229,Paclitaxel
,7497596,probability,"However, the NPML-estimated probability density function (pdf) of t1/2 gamma was bimodal (5 and 11.4 h), probably due to the imbalance of the data.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),h,5,219801,DB01229,Paclitaxel
,7497596,t1/2 gamma,"However, the NPML-estimated probability density function (pdf) of t1/2 gamma was bimodal (5 and 11.4 h), probably due to the imbalance of the data.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),h,5,219802,DB01229,Paclitaxel
,7497596,t1/2 gamma,"However, the NPML-estimated probability density function (pdf) of t1/2 gamma was bimodal (5 and 11.4 h), probably due to the imbalance of the data.",Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497596/),h,11.4,219803,DB01229,Paclitaxel
,16750622,overall response rate,"There were one complete response and six partial responses, giving an overall response rate of 35%.",A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16750622/),%,35,221103,DB01229,Paclitaxel
,22910790,polydispersity index,"The prepared PTX micelles have a mean particle size of 38.06 ± 2.30 nm, a polydispersity index of 0.168 ± 0.014, a drug loading of 14.89 ± 0.06% and an encapsulation efficiency of 99.25 ± 0.38%.",Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22910790/),,0.168,221438,DB01229,Paclitaxel
,22910790,drug loading,"The prepared PTX micelles have a mean particle size of 38.06 ± 2.30 nm, a polydispersity index of 0.168 ± 0.014, a drug loading of 14.89 ± 0.06% and an encapsulation efficiency of 99.25 ± 0.38%.",Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22910790/),,14.89,221439,DB01229,Paclitaxel
,22910790,encapsulation efficiency,"The prepared PTX micelles have a mean particle size of 38.06 ± 2.30 nm, a polydispersity index of 0.168 ± 0.014, a drug loading of 14.89 ± 0.06% and an encapsulation efficiency of 99.25 ± 0.38%.",Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22910790/),%,99.25,221440,DB01229,Paclitaxel
,29930916,flow rate of mobile phase,"The ultraviolet detector was operated at 230 nm, and the flow rate of mobile phase was 1 ml/min.",Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29930916/),[ml] / [min],1,221844,DB01229,Paclitaxel
,29930916,recovery,The mean recovery of the drug after plasma extraction was 95.67 ± 0.99% for the concentration of 1 μg/ml.,Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29930916/),%,95.67,221845,DB01229,Paclitaxel
,29930916,LOQ,"The LOQ and the limit of detection for DTX in serum were 100 ng/ml and 30 ng/ml, respectively.",Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29930916/),[ng] / [ml],100,221846,DB01229,Paclitaxel
,29930916,limit of detection,"The LOQ and the limit of detection for DTX in serum were 100 ng/ml and 30 ng/ml, respectively.",Development of a Rapid and Precise Reversed-phase High-performance Liquid Chromatography Method for Analysis of Docetaxel in Rat Plasma: Application in Single-dose Pharmacokinetic Studies of Folate-targeted Micelles Containing Docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29930916/),[ng] / [ml],30,221847,DB01229,Paclitaxel
,20406837,MTD level,"The MTD level of sequential paclitaxel 1-hour infusion (day 1) and trabectedin 3-hour infusion (day 2) administered every 2 weeks is 120 and 0.650 mg/m(2), respectively.",Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406837/),[mg] / [m(2],120,221974,DB01229,Paclitaxel
,20406837,MTD level,"The MTD level of sequential paclitaxel 1-hour infusion (day 1) and trabectedin 3-hour infusion (day 2) administered every 2 weeks is 120 and 0.650 mg/m(2), respectively.",Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406837/),[mg] / [m(2],0.650,221975,DB01229,Paclitaxel
,10829051,clearance (CL),Docetaxel clearance (CL) and area under the concentration-time curve averaged 24.5 +/- 6.4 L/h/m(2) and 2.66 +/- 0.91 mg/L 8729.,Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829051/),[h·l] / [m(2],24.5,222671,DB01229,Paclitaxel
,10829051,area under the concentration-time curve,Docetaxel clearance (CL) and area under the concentration-time curve averaged 24.5 +/- 6.4 L/h/m(2) and 2.66 +/- 0.91 mg/L 8729.,Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829051/),[mg] / [l],2.66,222672,DB01229,Paclitaxel
,11895894,AUC,Paclitaxel AUC (16.8 +/- 5.0 microg x h/ml) and clearance (5.1 +/- 1.3 liters/h/m(2)) during the first treatment cycle were comparable with standard 175 mg/m(2) paclitaxel administered in a 3-h schedule.,Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11895894/),[h·μg] / [ml],16.8,222757,DB01229,Paclitaxel
,11895894,clearance,Paclitaxel AUC (16.8 +/- 5.0 microg x h/ml) and clearance (5.1 +/- 1.3 liters/h/m(2)) during the first treatment cycle were comparable with standard 175 mg/m(2) paclitaxel administered in a 3-h schedule.,Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11895894/),[h·l] / [m(2],5.1,222758,DB01229,Paclitaxel
,34417914,overall response rate (ORR),The overall response rate (ORR) was 23.1% and disease control rate (DCR) 74.4%.,"A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417914/),%,23.1,223081,DB01229,Paclitaxel
,23632474,overall response rate (ORR),"Among the 99 evaluable patients in part 2 of the study, the overall response rate (ORR) was 73% (95% confidence interval (CI): 62.9-81.2%), including 7 (7%) patients who achieved a complete response; an additional 9 (9%) patients achieved stable disease for at least 24 weeks.",Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23632474/),%,73,223468,DB01229,Paclitaxel
,23632474,progression-free survival,Kaplan-Meier median progression-free survival was 57.0 weeks (95% CI: 47.7-81.6 weeks).,Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23632474/),weeks,57.0,223469,DB01229,Paclitaxel
,18690878,volume of distribution,"Trastuzumab pharmacokinetics are characterized by a low systemic clearance, a low volume of distribution (4l) and a very long half-life (28 days) comparable to that of endogenous immunoglobulins G.",Clinical pharmacology of trastuzumab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18690878/),l,4,223477,DB01229,Paclitaxel
,18690878,half-life,"Trastuzumab pharmacokinetics are characterized by a low systemic clearance, a low volume of distribution (4l) and a very long half-life (28 days) comparable to that of endogenous immunoglobulins G.",Clinical pharmacology of trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18690878/),d,28,223478,DB01229,Paclitaxel
,7944484,maximum tolerated dose,The maximum tolerated dose was 200 mg/m2.,[Phase I study of paclitaxel]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),[mg] / [m],200,224512,DB01229,Paclitaxel
,7944484,half-life,The paclitaxel plasma concentration declined with a half-life of 10.0 to 24.9 hours.,[Phase I study of paclitaxel]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),h,10.0 to 24.9,224513,DB01229,Paclitaxel
,7944484,Excretion into urine,Excretion into urine within 72 hours was in the range of 7.28 to 11.34% of paclitaxel dosage.,[Phase I study of paclitaxel]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),%,7.28 to 11.34,224514,DB01229,Paclitaxel
,22037881,TTP,Median TTP was 5.5 months (CI 95% 0.9-10.1) and median OS was 8.9 months (CI 95% 0.1-17.6).,Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037881/),month,5.5,224841,DB01229,Paclitaxel
,22037881,OS,Median TTP was 5.5 months (CI 95% 0.9-10.1) and median OS was 8.9 months (CI 95% 0.1-17.6).,Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037881/),month,8.9,224842,DB01229,Paclitaxel
,12008197,plasma clearance,"The plasma pharmacokinetics of docetaxel were not changed by the R101933 regimen at any dose level tested, as indicated by plasma clearance values of 22.5+/-6.2 l/h/m(2) and 24.2+/-7.4 l/h/m(2) (P=0.38) in cycles 1 and 2, respectively.",Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008197/),[h·l] / [m(2],22.5,224911,DB01229,Paclitaxel
,12008197,plasma clearance,"The plasma pharmacokinetics of docetaxel were not changed by the R101933 regimen at any dose level tested, as indicated by plasma clearance values of 22.5+/-6.2 l/h/m(2) and 24.2+/-7.4 l/h/m(2) (P=0.38) in cycles 1 and 2, respectively.",Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008197/),[h·l] / [m(2],24.2,224912,DB01229,Paclitaxel
,12008197,faecal excretion,"However, the faecal excretion of unchanged docetaxel decreased significantly after the combination treatment from 2.5+/-2.1% to less than 1% of the administered dose of docetaxel, most likely due to inhibition of the intestinal P-gp by R101933.",Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008197/),%,2.5,224913,DB01229,Paclitaxel
,7670132,elimination half-life,There was a good tumor retention with a 22 h elimination half-life.,Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7670132/),h,22,225080,DB01229,Paclitaxel
,7670132,Plasma protein binding,Plasma protein binding ranged from 76 to 89%.,Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7670132/),%,76 to 89,225081,DB01229,Paclitaxel
,27542793,peak arterial wall paclitaxel level,"The peak arterial wall paclitaxel level was 3.7 ng/mg at 10 days, with levels decreasing to 50% of peak at 60 days and 10% at 180 days.",Fluorocopolymer-coated nitinol self-expanding paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in a porcine iliofemoral model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27542793/),[ng] / [mg],3.7,225244,DB01229,Paclitaxel
,27679442,area under the curve (AUC0-t,"The area under the curve (AUC0-t, from 4 820±197 to 4 205±186 ng·mL-1·-1) and AUC0-∞ (from 5 237±280 to 4 514±210 ng·mL-1·-1) significantly decreased in response to the 14-day pretreatment with SGD.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[-1·ng] / [ml],4 820,225530,DB01229,Paclitaxel
,27679442,area under the curve (AUC0-t,"The area under the curve (AUC0-t, from 4 820±197 to 4 205±186 ng·mL-1·-1) and AUC0-∞ (from 5 237±280 to 4 514±210 ng·mL-1·-1) significantly decreased in response to the 14-day pretreatment with SGD.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[-1·ng] / [ml],4 205,225531,DB01229,Paclitaxel
,27679442,AUC0-∞,"The area under the curve (AUC0-t, from 4 820±197 to 4 205±186 ng·mL-1·-1) and AUC0-∞ (from 5 237±280 to 4 514±210 ng·mL-1·-1) significantly decreased in response to the 14-day pretreatment with SGD.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[-1·ng] / [ml],5 237,225532,DB01229,Paclitaxel
,27679442,AUC0-∞,"The area under the curve (AUC0-t, from 4 820±197 to 4 205±186 ng·mL-1·-1) and AUC0-∞ (from 5 237±280 to 4 514±210 ng·mL-1·-1) significantly decreased in response to the 14-day pretreatment with SGD.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[-1·ng] / [ml],4 514,225533,DB01229,Paclitaxel
,27679442,Vdss,"The values of Vdss (L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t1/2 (h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[l] / [kg],10.74,225534,DB01229,Paclitaxel
,27679442,Vdss,"The values of Vdss (L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t1/2 (h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[l] / [kg],9.35,225535,DB01229,Paclitaxel
,27679442,CL,"The values of Vdss (L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t1/2 (h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[l] / [kg],0.67,225536,DB01229,Paclitaxel
,27679442,CL,"The values of Vdss (L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t1/2 (h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),[l] / [kg],0.57,225537,DB01229,Paclitaxel
,27679442,t1/2,"The values of Vdss (L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t1/2 (h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),h,11.17,225538,DB01229,Paclitaxel
,27679442,t1/2,"The values of Vdss (L/kg) were 10.74±1.08 and 9.35±0.49, those of CL (L/kg) were 0.67±0.03 and 0.57±0.03 and the t1/2 (h) values were 11.17±0.84 and 11.32±0.93, respectively, for the 14-day SGD pretreatment and intravenous paclitaxel alone.",Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27679442/),h,11.32,225539,DB01229,Paclitaxel
>,17591103,Peak IP/plasma ratio,Peak IP/plasma ratio of > 2000 was obtained at 3 hours after administration.,Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591103/),,2000,225674,DB01229,Paclitaxel
,17591103,Half-life,Half-life of the drug ranged from 17.4 to 65.3 hours.,Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591103/),h,17.4 to 65.3,225675,DB01229,Paclitaxel
,10778948,CL,"CL of docetaxel varied nearly 6-fold (mean, 21.0 liters/h/m2; range, 5.4-29.1 liters/h/m2).",The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778948/),[l] / [h·m2],21.0,225683,DB01229,Paclitaxel
,12830723,K10,"The K10, K12, K21 and AUC of paclitaxel microemulsion were 0.571.h-1, 1.441.h-1, 3.081.h-1 and 34.98 mg.h.L-1.",[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830723/),1/[h],0.571,225892,DB01229,Paclitaxel
,12830723,K21,"The K10, K12, K21 and AUC of paclitaxel microemulsion were 0.571.h-1, 1.441.h-1, 3.081.h-1 and 34.98 mg.h.L-1.",[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830723/),1/[h],1.441,225893,DB01229,Paclitaxel
,12830723,K21,"The K10, K12, K21 and AUC of paclitaxel microemulsion were 0.571.h-1, 1.441.h-1, 3.081.h-1 and 34.98 mg.h.L-1.",[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830723/),1/[h],3.081,225894,DB01229,Paclitaxel
,12830723,AUC,"The K10, K12, K21 and AUC of paclitaxel microemulsion were 0.571.h-1, 1.441.h-1, 3.081.h-1 and 34.98 mg.h.L-1.",[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830723/),[h·mg] / [l],34.98,225895,DB01229,Paclitaxel
,8664192,peak plasma concentration (Cmax),"Relatively low peak plasma concentration (Cmax), with mean values of 6.91 micromol/L (range 3.08 to 8.98) and area under the plasma concentration time curve (AUC), with mean values of 27.04 micromol/L.h (range 14.88 to 40.57), were observed.",Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8664192/),[μM] / [l],6.91,225950,DB01229,Paclitaxel
,8664192,area under the plasma concentration time curve (AUC),"Relatively low peak plasma concentration (Cmax), with mean values of 6.91 micromol/L (range 3.08 to 8.98) and area under the plasma concentration time curve (AUC), with mean values of 27.04 micromol/L.h (range 14.88 to 40.57), were observed.",Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8664192/),[μM] / [h·l],27.04,225951,DB01229,Paclitaxel
,8664192,total body clearance,"The total body clearance was 16.99 L/h (range, 10.25 to 27.39).",Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8664192/),[l] / [h],16.99,225952,DB01229,Paclitaxel
>,8664192,T,"The pharmacokinetic parameter for the prediction of leuko-neutropenia, the duration of the plasma concentration above the threshold of 0.1 micromol/L.h (T > or = 0.1 microM), was 19.72 h (range 10.54 to 26.31).",Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8664192/),μM,0.1,225953,DB01229,Paclitaxel
,24807459,AUC,Carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m²) were administered on day 1 of each 21-day cycle up to a maximum of six cycles.,A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807459/),[mg] / [min·ml],6,226039,DB01229,Paclitaxel
,24807459,Cmax,"At 12.5 mg, linifanib Cmax was 0.32 μg/mL and AUC₂₄ was 4.29 μg h/mL.",A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807459/),[μg] / [ml],0.32,226040,DB01229,Paclitaxel
,24807459,AUC₂₄,"At 12.5 mg, linifanib Cmax was 0.32 μg/mL and AUC₂₄ was 4.29 μg h/mL.",A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807459/),[h·μg] / [ml],4.29,226041,DB01229,Paclitaxel
,12431966,survival,Median survival for all patients was 14.1 months.,"Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12431966/),month,14.1,226101,DB01229,Paclitaxel
,7865433,AUC,"This study was designed in two parts: In part I, a fixed dose of paclitaxel (135 mg/m2 by 24-hour infusion every 21 days) was administered to study patients given escalating doses of carboplatin, beginning at an AUC of 5 and increasing to 7.5 and then to 10.",Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7865433/),,5,226207,DB01229,Paclitaxel
,7865433,AUC,"This study was designed in two parts: In part I, a fixed dose of paclitaxel (135 mg/m2 by 24-hour infusion every 21 days) was administered to study patients given escalating doses of carboplatin, beginning at an AUC of 5 and increasing to 7.5 and then to 10.",Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7865433/),,7.5,226208,DB01229,Paclitaxel
,7865433,AUC,"This study was designed in two parts: In part I, a fixed dose of paclitaxel (135 mg/m2 by 24-hour infusion every 21 days) was administered to study patients given escalating doses of carboplatin, beginning at an AUC of 5 and increasing to 7.5 and then to 10.",Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7865433/),,10,226209,DB01229,Paclitaxel
,20414861,apparent maximal concentration (K (M)),The apparent maximal concentration (K (M)) of the active efflux component was 93.4 µM.,"Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20414861/),μM,93.4,227071,DB01229,Paclitaxel
,20414861,apparent permeability coefficient ( P(app)),The relatively high apparent permeability coefficient ( P(app)) for the apical to basolateral 7-xylosyl-10-deacetylpaclitaxel transport (16.3 ± 6.3 × 10 (-6) cm/s; n = 3) suggests that the drug may still be effectively absorbed in the intestinal tract.,"Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20414861/),[cm] / [s],16.3,227072,DB01229,Paclitaxel
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],"1,791",227126,DB01229,Paclitaxel
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],1920,227127,DB01229,Paclitaxel
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],8367,227128,DB01229,Paclitaxel
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],9757,227129,DB01229,Paclitaxel
,32948918,AUC,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [mg-·min],12.7,227130,DB01229,Paclitaxel
,32948918,plasma ultrafiltrate,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],"1,791",227131,DB01229,Paclitaxel
,32948918,plasma ultrafiltrate,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [min·ml],1920,227132,DB01229,Paclitaxel
,32948918,kidney,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],8367,227133,DB01229,Paclitaxel
,32948918,kidney,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [g·min],9757,227134,DB01229,Paclitaxel
,32948918,bone marrow,"In vivo carboplatin exposure was not significantly affected by iohexol co-administration (platinum AUC combination vs alone: plasma ultrafiltrate 1,791 vs 1920 µg/mL min; kidney 8367 vs 9757 µg/g min; bone marrow 12.7 vs 12.7 µg/mg-protein min).","Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [mg-·min],12.7,227135,DB01229,Paclitaxel
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],38.3,227136,DB01229,Paclitaxel
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],39.4,227137,DB01229,Paclitaxel
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],26.2,227138,DB01229,Paclitaxel
,32948918,microsomal metabolism,Paclitaxel microsomal metabolism was not impacted (combination vs alone: 6-α-OH-paclitaxel 38.3 versus 39.4 ng/mL/60 min; 3-p-OH-paclitaxel 26.2 versus 27.7 ng/mL/60 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[ng] / [60·min·ml],27.7,227139,DB01229,Paclitaxel
,32948918,AUC,Gemcitabine human cytosolic elimination was not impacted (AUC combination vs gemcitabine alone: dFdU 24.1 versus 23.7 µg/mL/30 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [30·min·ml],24.1,227140,DB01229,Paclitaxel
,32948918,AUC,Gemcitabine human cytosolic elimination was not impacted (AUC combination vs gemcitabine alone: dFdU 24.1 versus 23.7 µg/mL/30 min).,"Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32948918/),[μg] / [30·min·ml],23.7,227141,DB01229,Paclitaxel
,17189413,AUC,"Patients with advanced solid malignancies were treated continuously with erlotinib at doses of 100, 125, and 150 mg/d orally along with fixed i.v. doses of paclitaxel 225 mg/m(2) and carboplatin AUC 6 mg x min/mL, both on day 1 every 3 weeks.","Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17189413/),[mg·min] / [ml],6,227158,DB01229,Paclitaxel
,18751444,Overall response rate,"Overall response rate was 30%, with 3% complete responses and 27% partial responses.",Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751444/),%,30,227283,DB01229,Paclitaxel
,18751444,response duration,Median response duration and overall median survival were 5.5 and 10 months respectively.,Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751444/),month,5.5,227284,DB01229,Paclitaxel
,18751444,overall median survival,Median response duration and overall median survival were 5.5 and 10 months respectively.,Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751444/),month,10,227285,DB01229,Paclitaxel
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,3.77,227478,DB01229,Paclitaxel
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,4.57,227479,DB01229,Paclitaxel
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,3.62,227480,DB01229,Paclitaxel
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,8.58,227481,DB01229,Paclitaxel
,11345652,AUC,The AUC achieved after intravenous administration of paclitaxel 175 mg/m2 was 17.95 +/- 3.94 microM.h.,A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,17.95,227482,DB01229,Paclitaxel
,8636777,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 250 mg/m2.,Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636777/),[mg] / [m],250,228418,DB01229,Paclitaxel
,8636777,MTD,The MTD of paclitaxel administered weekly for 6 weeks by 3-hour infusion is 250 mg/m2.,Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636777/),mg,250,228419,DB01229,Paclitaxel
,27647973,area under the curve (AUC),"Ten patients received oral chidamide 20, 25, or 30 mg twice per week continuously with paclitaxel (175 mg/m(2)) and carboplatin [area under the curve (AUC) 5 mg/mL/min] administered in a 3-week cycle.","A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27647973/),[mg] / [min·ml],5,229164,DB01229,Paclitaxel
,20429848,drug payload,The drug payload of paclitaxel was 500 +/- 0.27 mg/g of lyophilized powder.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),[mg] / [g],500,229185,DB01229,Paclitaxel
,20429848,encapsulation efficiency,"The encapsulation efficiency was 99.1 +/- 1.0%, and 1.7 +/- 0.2% of paclitaxel was crystallized after 48 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),%,99.1,229186,DB01229,Paclitaxel
,20429848,encapsulation efficiency,"The encapsulation efficiency was 99.1 +/- 1.0%, and 1.7 +/- 0.2% of paclitaxel was crystallized after 48 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),%,1.7,229187,DB01229,Paclitaxel
,20429848,relative oral bioavailability,The relative oral bioavailability of paclitaxel-loaded nanosponges was 256.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),,256,229188,DB01229,Paclitaxel
,12064370,Ki,"Using human liver microsomes, we have demonstrated that OC144-093 inhibited the CYP3A mediated metabolism of paclitaxel at high concentrations only (Ki = 39.8 +/- 5.1 microM, n=3).",Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064370/),μM,39.8,229354,DB01229,Paclitaxel
,23703778,concentration,"Arterial tissue paclitaxel concentration was 58.8 ± 54.2 ng/mg at 1-hr and 0.3 ± 0.4 ng/mg at 30 days, whereas plasma paclitaxel could no longer be detected after 1 day.","Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23703778/),[ng] / [mg],58.8,229467,DB01229,Paclitaxel
,23703778,concentration,"Arterial tissue paclitaxel concentration was 58.8 ± 54.2 ng/mg at 1-hr and 0.3 ± 0.4 ng/mg at 30 days, whereas plasma paclitaxel could no longer be detected after 1 day.","Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23703778/),[ng] / [mg],0.3,229468,DB01229,Paclitaxel
,24875132,half-life,AZD8931 was rapidly absorbed with a half-life of 12 h.,"Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24875132/),h,12,229581,DB01229,Paclitaxel
,8648372,MTD,The MTD of the combination was 225 mg/m2 of r-verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion.,Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648372/),[mg] / [m2],225,229625,DB01229,Paclitaxel
,8648372,peak,"The median peak and trough serum verapamil concentrations at the MTD were 5.1 micromol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR).",Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648372/),[μM] / [l],5.1,229626,DB01229,Paclitaxel
over,21596124,entrapment efficiency,"PTX-loaded MPEG-PCL nanoparticles (PTX-NPs) displayed that the highest drug loading of PTX was about 25.6% and entrapment efficiency was over 98%, and the optimized average diameter and polydispersity index (PDI) were about 27.6 ± 0.1 nm and 0.05, respectively.","Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21596124/),,98,229924,DB01229,Paclitaxel
,21596124,diameter,"PTX-loaded MPEG-PCL nanoparticles (PTX-NPs) displayed that the highest drug loading of PTX was about 25.6% and entrapment efficiency was over 98%, and the optimized average diameter and polydispersity index (PDI) were about 27.6 ± 0.1 nm and 0.05, respectively.","Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21596124/),nm,27.6,229925,DB01229,Paclitaxel
,21596124,polydispersity index (PDI),"PTX-loaded MPEG-PCL nanoparticles (PTX-NPs) displayed that the highest drug loading of PTX was about 25.6% and entrapment efficiency was over 98%, and the optimized average diameter and polydispersity index (PDI) were about 27.6 ± 0.1 nm and 0.05, respectively.","Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21596124/),,0.05,229926,DB01229,Paclitaxel
,21596124,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of PTX-NPs after single dose in Balb/c mice was above 80 mg PTX/kg body weight (b.w), which was 2.6-fold higher than that of Taxol(®) (30 mg PTX/kg b.w).","Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21596124/),,80,229927,DB01229,Paclitaxel
,21796250,area under the concentration curve (AUC)(0-∞),"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[h·μg] / [ml],20.343,230028,DB01229,Paclitaxel
,21796250,area under the concentration curve (AUC)(0-∞),"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[h·μg] / [ml],5.196,230029,DB01229,Paclitaxel
,21796250,clearance,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[l] / [h·kg],2.050,230030,DB01229,Paclitaxel
,21796250,clearance,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[l] / [h·kg],0.556,230031,DB01229,Paclitaxel
,21796250,elimination half-life,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),h,5.646,230032,DB01229,Paclitaxel
,21796250,elimination half-life,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),h,3.774,230033,DB01229,Paclitaxel
,22645049,nadir,"Smokers treated with paclitaxel had less grade III-IV leukopenia than nonsmokers (12% vs. 25%; P = 0.03), and the white blood cell (WBC) nadir was lower in nonsmokers (median, 2.7 × 10(9)/L; range, 0.05 × 10(9) to 11.6 × 10(9)/L) than in smokers (median, 3.3 × 10(9)/L; range 0.8 × 10(9) to 10.2 × 10(9)/L; P = 0.02).",Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22645049/),,2.7,230897,DB01229,Paclitaxel
,22645049,nadir,"Smokers treated with paclitaxel had less grade III-IV leukopenia than nonsmokers (12% vs. 25%; P = 0.03), and the white blood cell (WBC) nadir was lower in nonsmokers (median, 2.7 × 10(9)/L; range, 0.05 × 10(9) to 11.6 × 10(9)/L) than in smokers (median, 3.3 × 10(9)/L; range 0.8 × 10(9) to 10.2 × 10(9)/L; P = 0.02).",Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22645049/),,3.3 ×,230898,DB01229,Paclitaxel
,9043028,progression-free survival,The overall median progression-free survival was 7 months and the overall mean survival was 13 months.,"Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9043028/),month,7,231085,DB01229,Paclitaxel
,9346219,area under the concentration-time curve,The dose of carboplatin was calculated using a projected area under the concentration-time curve of 5 mg/mL x min.,Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),[mg] / [min·ml],5,231106,DB01229,Paclitaxel
,9346219,overall response rate,"There were eight complete and 10 partial responses, for an overall response rate of 43% (95% confidence interval, 28% to 56%).",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),%,43,231107,DB01229,Paclitaxel
,9346219,Overall response rates,"Overall response rates in platinum refractory patients and in those with early (> or = 3 and < 12 months) and late (> or = 12 months) relapse was 28%, 33%, and 71%, respectively.",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),%,28,231108,DB01229,Paclitaxel
,9346219,Overall response rates,"Overall response rates in platinum refractory patients and in those with early (> or = 3 and < 12 months) and late (> or = 12 months) relapse was 28%, 33%, and 71%, respectively.",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),%,33,231109,DB01229,Paclitaxel
,9346219,Overall response rates,"Overall response rates in platinum refractory patients and in those with early (> or = 3 and < 12 months) and late (> or = 12 months) relapse was 28%, 33%, and 71%, respectively.",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),%,71,231110,DB01229,Paclitaxel
,9346219,response,"Median response duration, progression-free survival, and overall survivals were 8, 6, and 14 months, respectively.",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),month,8,231111,DB01229,Paclitaxel
,9346219,progression-free survival,"Median response duration, progression-free survival, and overall survivals were 8, 6, and 14 months, respectively.",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),month,6,231112,DB01229,Paclitaxel
,9346219,overall survival,"Median response duration, progression-free survival, and overall survivals were 8, 6, and 14 months, respectively.",Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),month,14,231113,DB01229,Paclitaxel
,9346219,area under the concentration-time curve,The combination of paclitaxel 175 mg/m2 as a 3-hour infusion and carboplatin dosed to an area under the concentration-time curve of 5 is an effective therapy in patients previously treated with platinum-based chemotherapy and may be administered safely to outpatients who relapse after one or two lines of chemotherapy.,Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9346219/),,5,231114,DB01229,Paclitaxel
,7481855,area under the concentration-time curves,A patient's previous treatment status determines the fixed carboplatin dose: target area under the concentration-time curves of 4.0 and 4.5 mg.,Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481855/),mg,4.0,231547,DB01229,Paclitaxel
,7481855,area under the concentration-time curves,A patient's previous treatment status determines the fixed carboplatin dose: target area under the concentration-time curves of 4.0 and 4.5 mg.,Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481855/),mg,4.5,231548,DB01229,Paclitaxel
,7481855,beta half-life,Paclitaxel apparently has nonlinear pharmacokinetics with a beta half-life of 6.7 hours (SD +/- 1.3 hours).,Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7481855/),h,6.7,231549,DB01229,Paclitaxel
,7543699,objective response rate,"The objective response rate was only 6%, but response rate by disease site indicated that soft tissue lesions responded in 30% of cases.",High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7543699/),%,6,231618,DB01229,Paclitaxel
,33602685,PFS,"Among 42 evaluable patients, ORR was 59% (complete response, 7% and partial response, 52%), 21% of whom had response lasting >12 months; median PFS was 8.7 months.",Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602685/),month,8.7,231780,DB01229,Paclitaxel
,33602685,PFS,"A total of 40% of patients demonstrated tumor and/or ctDNA PIK3CA mutation; patients with tumor/ctDNA mutation demonstrated better PFS compared with those without mutation (11.9 vs. 7.5 months; HR, 0.44; P = 0.027).",Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602685/),month,11,231781,DB01229,Paclitaxel
,33602685,PFS,"A total of 40% of patients demonstrated tumor and/or ctDNA PIK3CA mutation; patients with tumor/ctDNA mutation demonstrated better PFS compared with those without mutation (11.9 vs. 7.5 months; HR, 0.44; P = 0.027).",Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602685/),month,7,231782,DB01229,Paclitaxel
,33602685,PFS,Patients with normal metabolic status had longer PFS compared with prediabetic/diabetic patients (12 vs. 7.5 months; P = 0.014).,Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602685/),month,12,231783,DB01229,Paclitaxel
,33602685,PFS,Patients with normal metabolic status had longer PFS compared with prediabetic/diabetic patients (12 vs. 7.5 months; P = 0.014).,Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33602685/),month,7.5,231784,DB01229,Paclitaxel
,11551423,survival,"Median survival was 11.2 months (95% CI [8.3-13.2]), and the 1-year survival rate was 45%.","Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11551423/),month,11,231814,DB01229,Paclitaxel
,18841154,orally bioavailable,The compound was orally bioavailable (31% after a single 10 mg kg(-1) dose) and resistant to metabolism.,The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18841154/),%,31,232625,DB01229,Paclitaxel
,23932961,total single run time,A total single run time was as short as 3.0min.,Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23932961/),min,3.0,232817,DB01229,Paclitaxel
,23932961,extraction recoveries,"The mean extraction recoveries of PTX and IS were 94.7% and 87.5%, respectively.",Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23932961/),%,94.7,232818,DB01229,Paclitaxel
,23932961,extraction recoveries,"The mean extraction recoveries of PTX and IS were 94.7% and 87.5%, respectively.",Determination of paclitaxel in hyaluronic acid polymeric micelles in rat blood by protein precipitation-micelle breaking method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23932961/),%,87.5,232819,DB01229,Paclitaxel
,22429777,peak serum concentration,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[ng] / [ml],24 100,232989,DB01229,Paclitaxel
,22429777,peak serum concentration,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[ng] / [ml],108,232990,DB01229,Paclitaxel
,22429777,area under the concentration-time curve from 0 to 48 h,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[h·ng] / [ml],191 000,232991,DB01229,Paclitaxel
,22429777,area under the concentration-time curve from 0 to 48 h,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[h·ng] / [ml],1500,232992,DB01229,Paclitaxel
,22429876,total run time,The total run time was 5.0 min.,A rapid and sensitive LC/ESI-MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429876/),min,5.0,233780,DB01229,Paclitaxel
,16715372,drug payload,The drug payload of paclitaxel was 1.91 +/- 0.01 mg/g of aqueous dispersion.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),[mg] / [g],1.91,234199,DB01229,Paclitaxel
,16715372,encapsulation efficiency,"The encapsulation efficiency was 99.9 +/- 1.0%, and 1.7 +/- 0.1% of paclitaxel was crystallized after 24 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),%,99.9,234200,DB01229,Paclitaxel
,16715372,encapsulation efficiency,"The encapsulation efficiency was 99.9 +/- 1.0%, and 1.7 +/- 0.1% of paclitaxel was crystallized after 24 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),%,1.7,234201,DB01229,Paclitaxel
,16715372,oral bioavailability,The oral bioavailability of Taxol alone was 6.5%.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),%,6.5,234202,DB01229,Paclitaxel
,30559662,t1/2,The mean t1/2 was 20.61-27.31 h for total paclitaxel.,"Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559662/),h,20.61-27.31,234363,DB01229,Paclitaxel
,26670364,flow rate,The separation was achieved on a µ-Bondapak C18 HPLC column using sodium acetate buffer solution (0.01 M)/acetonitrile (58/42 v/v) at pH 5 ± 0.1 and flow rate of 1.9 mL/min.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),[ml] / [min],1.9,234562,DB01229,Paclitaxel
,26670364,recoveries,The mean recoveries of the drug after plasma extraction was 87.4% ± 3.6 while those of tissue homogenates ranged from 62.1± 4.5 to 75.5± 3.2 depending on the type of tissues studied.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),%,87.4,234563,DB01229,Paclitaxel
,26670364,recoveries,The mean recoveries of the drug after plasma extraction was 87.4% ± 3.6 while those of tissue homogenates ranged from 62.1± 4.5 to 75.5± 3.2 depending on the type of tissues studied.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),%,62.1,234564,DB01229,Paclitaxel
,26670364,recoveries,The mean recoveries of the drug after plasma extraction was 87.4% ± 3.6 while those of tissue homogenates ranged from 62.1± 4.5 to 75.5± 3.2 depending on the type of tissues studied.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),%,75.5,234565,DB01229,Paclitaxel
,19899423,area under the concentration/time curve (AUC),"Paclitaxel was administered at 150 mg/m2 for 3 h, followed by administration of 125 mg of carboplatin within 30 min to achieve a target area under the concentration/time curve (AUC) of 5.0 mg/ml x min by Calvert's formula.",Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19899423/),[mg] / [min·ml],5.0,234959,DB01229,Paclitaxel
,19899423,AUC,"However, AUC of free platinum was very low (AUC = 0.98 mg/ml x min).",Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19899423/),[mg] / [min·ml],0.98,234960,DB01229,Paclitaxel
,9213325,overall response rate,"Responses were seen at all dose levels, with an 80% overall response rate at the higher recommended dose; the overall response rate for patients at all dose levels was 66%.",Docetaxel combined with vinorelbine: phase I results and new study designs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213325/),%,66,235338,DB01229,Paclitaxel
,24086173,flow rate,Column elution at a flow rate of 1 mL/minute with UV detection at 225 nm at room temperature was used.,"Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),[ml] / [min],1,235432,DB01229,Paclitaxel
,24086173,extraction efficiency,"To the best of our knowledge, this study also reported for the first time the optimization of different solvents for effective extraction of paclitaxel wherein tert.-butyl methyl ether (TBME): diethyl ether (DEE) in 50: 50 v/v composition was found most efficient with extraction efficiency ranging between 77.99% and 91.74% and between 76.14 and 93.66% in the plasma and cell culture, respectively.","Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),%,77.99,235433,DB01229,Paclitaxel
,24086173,extraction efficiency,"To the best of our knowledge, this study also reported for the first time the optimization of different solvents for effective extraction of paclitaxel wherein tert.-butyl methyl ether (TBME): diethyl ether (DEE) in 50: 50 v/v composition was found most efficient with extraction efficiency ranging between 77.99% and 91.74% and between 76.14 and 93.66% in the plasma and cell culture, respectively.","Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),%,91.74,235434,DB01229,Paclitaxel
,24086173,extraction efficiency,"To the best of our knowledge, this study also reported for the first time the optimization of different solvents for effective extraction of paclitaxel wherein tert.-butyl methyl ether (TBME): diethyl ether (DEE) in 50: 50 v/v composition was found most efficient with extraction efficiency ranging between 77.99% and 91.74% and between 76.14 and 93.66% in the plasma and cell culture, respectively.","Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),%,76.14 and 93.66,235435,DB01229,Paclitaxel
,24783515,polydispersity index,"The results showed that the obtained formulation has a small particle size (mean diameter of 100.2 +/- 15.2 nm), a homogeneous distribution [the polydispersity index was (0.251 +/- 0.018)] and high encapsulation efficiency (90.15 +/- 2.47) % and (80.64 +/- 3.52) % for paclitaxel and cyclosporine respectively with a mild and easy preparation process.",[Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783515/),,0.251,236571,DB01229,Paclitaxel
,24783515,encapsulation efficiency,"The results showed that the obtained formulation has a small particle size (mean diameter of 100.2 +/- 15.2 nm), a homogeneous distribution [the polydispersity index was (0.251 +/- 0.018)] and high encapsulation efficiency (90.15 +/- 2.47) % and (80.64 +/- 3.52) % for paclitaxel and cyclosporine respectively with a mild and easy preparation process.",[Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783515/),%,90.15,236572,DB01229,Paclitaxel
,24783515,encapsulation efficiency,"The results showed that the obtained formulation has a small particle size (mean diameter of 100.2 +/- 15.2 nm), a homogeneous distribution [the polydispersity index was (0.251 +/- 0.018)] and high encapsulation efficiency (90.15 +/- 2.47) % and (80.64 +/- 3.52) % for paclitaxel and cyclosporine respectively with a mild and easy preparation process.",[Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783515/),%,80.64,236573,DB01229,Paclitaxel
,8736622,complete,"As first-line treatment, monotherapy with docetaxel was associated with complete and partial response rates of 5 to 16% and 49 to 53%, respectively, with an overall (complete plus partial) response rate of 54 to 68%.",Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),%,5 to 16,236607,DB01229,Paclitaxel
,8736622,partial response rates,"As first-line treatment, monotherapy with docetaxel was associated with complete and partial response rates of 5 to 16% and 49 to 53%, respectively, with an overall (complete plus partial) response rate of 54 to 68%.",Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),%,5 to 16,236608,DB01229,Paclitaxel
,8736622,partial response rates,"As first-line treatment, monotherapy with docetaxel was associated with complete and partial response rates of 5 to 16% and 49 to 53%, respectively, with an overall (complete plus partial) response rate of 54 to 68%.",Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),%,49 to 53,236609,DB01229,Paclitaxel
,8736622,overall (complete plus partial) response rate,"As first-line treatment, monotherapy with docetaxel was associated with complete and partial response rates of 5 to 16% and 49 to 53%, respectively, with an overall (complete plus partial) response rate of 54 to 68%.",Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),%,54 to 68,236610,DB01229,Paclitaxel
> or =,8736622,overall survival time,The median overall survival time of patients in one study was > or = 71 weeks.,Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),weeks,71,236611,DB01229,Paclitaxel
,8736622,overall response rates,"Docetaxel monotherapy has shown impressive activity as second-line therapy in patients with metastatic breast cancer who had relapsed while receiving adjuvant therapy or who had progressive disease following previous treatment, with overall response rates of 53 and 58% reported in 2 studies.",Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),%,53,236612,DB01229,Paclitaxel
,8736622,overall response rates,"Docetaxel monotherapy has shown impressive activity as second-line therapy in patients with metastatic breast cancer who had relapsed while receiving adjuvant therapy or who had progressive disease following previous treatment, with overall response rates of 53 and 58% reported in 2 studies.",Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8736622/),%,58,236613,DB01229,Paclitaxel
,11221961,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),μM,9.11,237106,DB01229,Paclitaxel
,11221961,area under the plasma concentration time curve (AUC),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),h·μM,145,237107,DB01229,Paclitaxel
,11221961,area under the plasma concentration time curve (AUC),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),[l] / [h·m2],8.06,237108,DB01229,Paclitaxel
,11221961,apparent clearance (Clapp),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),h·μM,145,237109,DB01229,Paclitaxel
,11221961,apparent clearance (Clapp),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),[l] / [h·m2],8.06,237110,DB01229,Paclitaxel
,11221961,t,"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),h,82.4,237111,DB01229,Paclitaxel
,11221961,nadir,Median nadir count for platelets was 66 x 10(9)/l (range 13-160 x 10(9)/l).,The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),,66 x 10,237112,DB01229,Paclitaxel
>,11221961,t,"Pharmacodynamic analysis showed no correlation between pharmacokinetic parameters (Cmax, AUC, t > 0.05 microM) and time to neutropenic nadir, duration of neutropenia, platelet count nadir and grades of neuropathy or mucositis.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),μM,0.05,237113,DB01229,Paclitaxel
,11976829,plasma AUC,"In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml).",Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),[h·mg] / [ml],1680,237233,DB01229,Paclitaxel
,11976829,plasma AUC,"In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml).",Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),[h·mg] / [ml],47.6,237234,DB01229,Paclitaxel
,11976829,serum half-lives,The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.).,Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),h,0.15,237235,DB01229,Paclitaxel
,11976829,serum half-lives,The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.).,Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),h,13.3,237236,DB01229,Paclitaxel
,27592284,flow rate,"The separation of both the analytes and internal standard was achieved on Discovery HS C18 column (250mm×4.6mm, 5μm) using Acetonitrile and TFA (0.025%) in the ratio of (65:35V/V) as the mobile phase in isocratic mode at a flow rate of 1ml/min, with a wavelength of 245nm and at a column oven temperature of 25°Cin a short run time of 12min.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ml] / [min],1,237803,DB01229,Paclitaxel
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],5,237804,DB01229,Paclitaxel
,27592284,limits of,"The limits of detection (LLOD) were 5 and 10ng/ml while the limits of quantification (LLOQ) were 10 and 15ng/ml for sorafenib and paclitaxel, respectively.","A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27592284/),[ng] / [ml],10,237805,DB01229,Paclitaxel
,33021083,maximum paclitaxel plasma concentration,"At the MTD/RP2D of MP5/r 20-20/100-100, the maximum paclitaxel plasma concentration and area under the concentration-time curve until 24 hours were 34.6 ng/mL (coefficient of variation, 79%) and 255 ng • h/mL (coefficient of variation, 62%), respectively.",A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33021083/),[ng] / [ml],34.6,237827,DB01229,Paclitaxel
,33021083,area under the concentration-time curve until 24 hours,"At the MTD/RP2D of MP5/r 20-20/100-100, the maximum paclitaxel plasma concentration and area under the concentration-time curve until 24 hours were 34.6 ng/mL (coefficient of variation, 79%) and 255 ng • h/mL (coefficient of variation, 62%), respectively.",A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33021083/),[h·ng] / [ml],255,237828,DB01229,Paclitaxel
,26111697,absolute bioavailability (AB%),"In the blank group, the average absolute bioavailability (AB%) of orally administered paclitaxel was only 2.81%, compared to that of 7.63% in radix euphorbiae pekinensis group.",[Effect of Radix euphorbiae pekinensis extract on bioavailability of paclitaxel after their oral co-administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111697/),%,2.81,237998,DB01229,Paclitaxel
,26111697,absolute bioavailability (AB%),"In the blank group, the average absolute bioavailability (AB%) of orally administered paclitaxel was only 2.81%, compared to that of 7.63% in radix euphorbiae pekinensis group.",[Effect of Radix euphorbiae pekinensis extract on bioavailability of paclitaxel after their oral co-administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111697/),%,7.63,237999,DB01229,Paclitaxel
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB01229,Paclitaxel
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB01229,Paclitaxel
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB01229,Paclitaxel
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB01229,Paclitaxel
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB01229,Paclitaxel
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB01229,Paclitaxel
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB01229,Paclitaxel
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB01229,Paclitaxel
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB01229,Paclitaxel
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB01229,Paclitaxel
,11087080,retention times,"Using this system, the retention times for docetaxel and paclitaxel are 8.5 min and 10.5 min, respectively, with good resolution and without any interference from endogenous plasma constituents or docetaxel metabolites at these retention times.",Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087080/),min,8.5,238176,DB01229,Paclitaxel
,11087080,retention times,"Using this system, the retention times for docetaxel and paclitaxel are 8.5 min and 10.5 min, respectively, with good resolution and without any interference from endogenous plasma constituents or docetaxel metabolites at these retention times.",Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087080/),min,10.5,238177,DB01229,Paclitaxel
,11087080,total run time needed,The total run time needed is only 13 min.,Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087080/),min,13,238178,DB01229,Paclitaxel
,26190185,arterial,"Group A showed significantly higher arterial paclitaxel concentrations in the first hour after DEB angioplasty (632.05 ng/mg ± 125.75 in group A vs 179.55 ng/mg ± 45.64 and 168.54 ng/mg ± 83.48 in groups B and C, respectively; P < .05).",Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26190185/),[ng] / [mg],632.05,238392,DB01229,Paclitaxel
,26190185,arterial,"Group A showed significantly higher arterial paclitaxel concentrations in the first hour after DEB angioplasty (632.05 ng/mg ± 125.75 in group A vs 179.55 ng/mg ± 45.64 and 168.54 ng/mg ± 83.48 in groups B and C, respectively; P < .05).",Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26190185/),[ng] / [mg],179.55,238393,DB01229,Paclitaxel
,26190185,arterial,"Group A showed significantly higher arterial paclitaxel concentrations in the first hour after DEB angioplasty (632.05 ng/mg ± 125.75 in group A vs 179.55 ng/mg ± 45.64 and 168.54 ng/mg ± 83.48 in groups B and C, respectively; P < .05).",Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26190185/),[ng] / [mg],168.54,238394,DB01229,Paclitaxel
,26190185,concentrations,"Group A showed significantly higher arterial paclitaxel concentrations in the first hour after DEB angioplasty (632.05 ng/mg ± 125.75 in group A vs 179.55 ng/mg ± 45.64 and 168.54 ng/mg ± 83.48 in groups B and C, respectively; P < .05).",Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26190185/),[ng] / [mg],632.05,238395,DB01229,Paclitaxel
,26190185,concentrations,"Group A showed significantly higher arterial paclitaxel concentrations in the first hour after DEB angioplasty (632.05 ng/mg ± 125.75 in group A vs 179.55 ng/mg ± 45.64 and 168.54 ng/mg ± 83.48 in groups B and C, respectively; P < .05).",Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26190185/),[ng] / [mg],179.55,238396,DB01229,Paclitaxel
,26190185,concentrations,"Group A showed significantly higher arterial paclitaxel concentrations in the first hour after DEB angioplasty (632.05 ng/mg ± 125.75 in group A vs 179.55 ng/mg ± 45.64 and 168.54 ng/mg ± 83.48 in groups B and C, respectively; P < .05).",Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26190185/),[ng] / [mg],168.54,238397,DB01229,Paclitaxel
,11745194,maximum tolerated dose,The maximum tolerated dose in a single administration was 270 mg/m2.,"Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745194/),[mg] / [m2],270,238655,DB01229,Paclitaxel
>,17912488,solubilities,Paclitaxel prodrugs had solubilities >5 mg/ml in PEG-b-PCL micelles.,"Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17912488/),[mg] / [ml],5,238669,DB01229,Paclitaxel
>,17912488,t(1/2),"PEG-b-PCL micelles released paclitaxel prodrugs over several days, t(1/2)>3 d.","Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17912488/),d,3,238670,DB01229,Paclitaxel
,7901342,half-lives t1/2(alpha),"With this low quantitation threshold, we found the plasma disappearance of paclitaxel to be triphasic, with half-lives t1/2(alpha), t1/2(beta), and t1/2(gamma) mean values for the different treatment arms of 0.19 hours (range, 0.01 to 0.4), 1.9 hours (range, 0.5 to 2.8), and 20.7 hours (range, 4 to 65), respectively.",Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7901342/),h,0.19,238751,DB01229,Paclitaxel
,7901342,t1/2(beta),"With this low quantitation threshold, we found the plasma disappearance of paclitaxel to be triphasic, with half-lives t1/2(alpha), t1/2(beta), and t1/2(gamma) mean values for the different treatment arms of 0.19 hours (range, 0.01 to 0.4), 1.9 hours (range, 0.5 to 2.8), and 20.7 hours (range, 4 to 65), respectively.",Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7901342/),h,1.9,238752,DB01229,Paclitaxel
,7901342,t1/2(gamma),"With this low quantitation threshold, we found the plasma disappearance of paclitaxel to be triphasic, with half-lives t1/2(alpha), t1/2(beta), and t1/2(gamma) mean values for the different treatment arms of 0.19 hours (range, 0.01 to 0.4), 1.9 hours (range, 0.5 to 2.8), and 20.7 hours (range, 4 to 65), respectively.",Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7901342/),h,20.7,238753,DB01229,Paclitaxel
,12942041,trough marimastat level,"At the 10 mg dose, the mean trough marimastat level was 14.8 Kg/L.",A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942041/),[kg] / [l],14.8,238788,DB01229,Paclitaxel
,18513900,maximal plasma concentrations,"The maximal plasma concentrations of paclitaxel after an oral dose were 1.77+/-0.17 and 3.39+/-0.49microg/ml for Cremophor/ethanol and TPGS 400/ethanol formulations, respectively, with a similar time at 40-47min to reach the maximal plasma concentrations.",Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),[μg] / [ml],1.77,238991,DB01229,Paclitaxel
,18513900,maximal plasma concentrations,"The maximal plasma concentrations of paclitaxel after an oral dose were 1.77+/-0.17 and 3.39+/-0.49microg/ml for Cremophor/ethanol and TPGS 400/ethanol formulations, respectively, with a similar time at 40-47min to reach the maximal plasma concentrations.",Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),[μg] / [ml],3.39,238992,DB01229,Paclitaxel
,18513900,oral bioavailability,The oral bioavailability of paclitaxel in TPGS 400/ethanol (7.8%) was 3-fold higher than that in Cremophor/ethanol (2.5%).,Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),%,7.8,238993,DB01229,Paclitaxel
,18513900,oral bioavailability,The oral bioavailability of paclitaxel in TPGS 400/ethanol (7.8%) was 3-fold higher than that in Cremophor/ethanol (2.5%).,Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),%,2.5,238994,DB01229,Paclitaxel
,15166622,MTD,"The MTD for PLD was 45 mg/m (dose level 3) and the dose-limiting toxicity was febrile neutropenia, occurring in three of five patients.",Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166622/),[mg] / [m],45,239958,DB01229,Paclitaxel
,15166622,overall response rate,The overall response rate was 28% for patients with non-nasopharyngeal tumors [95% confidence interval (CI) 15-45%] and 28.6% for the study population (95% CI 17-43%).,Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166622/),%,28,239959,DB01229,Paclitaxel
,15166622,overall response rate,The overall response rate was 28% for patients with non-nasopharyngeal tumors [95% confidence interval (CI) 15-45%] and 28.6% for the study population (95% CI 17-43%).,Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166622/),%,28.6,239960,DB01229,Paclitaxel
,27863654,systemic availability,"Remarkably, a single dose of DMS-containing CCPM resulted in high systemic availability of about 30% following s.c. injection into the flank of healthy mice, as evidenced by an AUC between 26-37% relative to the AUC attained following i.v. injection.",High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27863654/),%,30,240311,DB01229,Paclitaxel
,27863654,AUC,"Remarkably, a single dose of DMS-containing CCPM resulted in high systemic availability of about 30% following s.c. injection into the flank of healthy mice, as evidenced by an AUC between 26-37% relative to the AUC attained following i.v. injection.",High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27863654/),%,26-37,240312,DB01229,Paclitaxel
,27863654,systemic availability,"Similarly, a single s.c. dose of PTX-containing CCPM resulted in high systemic availability of about 40% compared to i.v. injection and PTX (entrapped plus released) was detected in the blood for at least 3days.",High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27863654/),%,40,240313,DB01229,Paclitaxel
,27863654,systemic availability,"Importantly, the systemic availability of s.c. administered drug-containing CCPM is substantially higher than that of other nanoformulations as reported in the literature (e.g. 3% in rodents).",High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27863654/),%,3,240314,DB01229,Paclitaxel
,17031646,AUC,"Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547,632 in combination with paclitaxel 225 mg/m(2) and carboplatin AUC = 6 every 3 weeks.","A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031646/),,6,240445,DB01229,Paclitaxel
,26446447,unbound paclitaxel clearance,"Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726).",Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446447/),[l] / [h],238,240673,DB01229,Paclitaxel
,26446447,unbound paclitaxel clearance,"Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726).",Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446447/),[l] / [h],385,240674,DB01229,Paclitaxel
,29341619,half-maximum inhibitory concentrations,"The coated SLN significantly decreased the in vitro half-maximum inhibitory concentrations of paclitaxel in M109-HiFR cells (60 vs 340 nM, respectively).",New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341619/),nM,60,240722,DB01229,Paclitaxel
,29341619,half-maximum inhibitory concentrations,"The coated SLN significantly decreased the in vitro half-maximum inhibitory concentrations of paclitaxel in M109-HiFR cells (60 vs 340 nM, respectively).",New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341619/),nM,340,240723,DB01229,Paclitaxel
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],1420,240817,DB01229,Paclitaxel
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],2770,240818,DB01229,Paclitaxel
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],130,240819,DB01229,Paclitaxel
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],320,240820,DB01229,Paclitaxel
,16819185,area under the free plasma concentration versus time curve (AUC),"They were intravenously administered carboplatin (area under the free plasma concentration versus time curve (AUC)=5 mg.min/ml), following the intravenous administration of paclitaxel (175 mg/m(2)).",Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819185/),[mg·min] / [ml],5,240893,DB01229,Paclitaxel
,16819185,clearance,"Carboplatin clearance was 62.0+/-12.7 ml/min (mean+/-S.D.), and linearly related to the individual creatinine clearance (r(2)=0.64, p<0.01).",Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819185/),[ml] / [min],62.0,240894,DB01229,Paclitaxel
,16819185,AUC,"The actual AUC for total carboplatin was 8.20+/-1.11 mg.min/ml, and its inter-individual variability was decreased to 65% of that in carboplatin clearance, indicating the effectiveness of Calvert's formula for dosage adjustment of carboplatin.",Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819185/),[mg·min] / [ml],8.20,240895,DB01229,Paclitaxel
,16819185,AUC,"In conclusion, determining carboplatin dosage based on Calvert's formula decreased the inter-individual variability in the actual AUC compared with that in the carboplatin clearance, and a target AUC of 5 mg.",Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16819185/),mg,5,240896,DB01229,Paclitaxel
,22057853,AUC,Patients received treatment with paclitaxel (200 mg/m(2)) and carboplatin to provide a target AUC of 6 mg min/mL (day 1) every 3 weeks.,A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057853/),[mg·min] / [ml],6,241174,DB01229,Paclitaxel
,18476951,peak plasma concentration,"The peak plasma concentration of the 300 mg/m(2) dose level before and after dialysis was 23.05 and 21.01 ng/mL, respectively, proving that paclitaxel was not dialysable.",High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476951/),[ng] / [ml],23.05,241288,DB01229,Paclitaxel
,18476951,peak plasma concentration,"The peak plasma concentration of the 300 mg/m(2) dose level before and after dialysis was 23.05 and 21.01 ng/mL, respectively, proving that paclitaxel was not dialysable.",High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476951/),[ng] / [ml],21.01,241289,DB01229,Paclitaxel
,18476951,area under the plasma concentration versus time curve,"The area under the plasma concentration versus time curve for the standard and highest dose of paclitaxel was 12,200 ng.h/mL in mean and 40,936 ng.h/mL, respectively.",High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476951/),[h·ng] / [ml],"12,200",241290,DB01229,Paclitaxel
,18476951,area under the plasma concentration versus time curve,"The area under the plasma concentration versus time curve for the standard and highest dose of paclitaxel was 12,200 ng.h/mL in mean and 40,936 ng.h/mL, respectively.",High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476951/),[h·ng] / [ml],"40,936",241291,DB01229,Paclitaxel
,15608135,K(i),"The mechanism of inhibition was competitive, with K(i) values ranging from 0.0092 to 0.15 microM.",Selective inhibition of human cytochrome P4502C8 by montelukast. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608135/),μM,0.0092 to 0.15,241374,DB01229,Paclitaxel
,12509952,clearance of unbound,"The clearance of unbound paclitaxel was 124+/-35.0 (elderly) versus 247+/-55.4 l/h/m(2) (<70 years) (P=0.002), and was inversely related to the patient's age (R(2)=0.857; P<0.00001).",Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12509952/),[h·l] / [m(2],124,241387,DB01229,Paclitaxel
,12509952,clearance of unbound,"The clearance of unbound paclitaxel was 124+/-35.0 (elderly) versus 247+/-55.4 l/h/m(2) (<70 years) (P=0.002), and was inversely related to the patient's age (R(2)=0.857; P<0.00001).",Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12509952/),[h·l] / [m(2],247,241388,DB01229,Paclitaxel
,12509952,Total plasma clearance,Total plasma clearance of the formulation vehicle Cremophor EL (CrEL) was 150+/-60.7 (elderly) versus 115+/-39.2 ml/h/m(2) (<70 years) (P=0.04).,Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12509952/),[h·ml] / [m(2],150,241389,DB01229,Paclitaxel
,12509952,Total plasma clearance,Total plasma clearance of the formulation vehicle Cremophor EL (CrEL) was 150+/-60.7 (elderly) versus 115+/-39.2 ml/h/m(2) (<70 years) (P=0.04).,Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12509952/),[h·ml] / [m(2],115,241390,DB01229,Paclitaxel
,11350890,plasma C(max),"Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),[μg] / [ml],16.4,241513,DB01229,Paclitaxel
,11350890,plasma C(max),"Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),μM,29.1,241514,DB01229,Paclitaxel
,11350890,plasma AUC(0--12 h),"Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),μg,173.4,241515,DB01229,Paclitaxel
,11350890,t(1/2,"h/ml (308 microM. h), and a mean t(1/2 (24--192 h)) of 156.2 +/- 42.9 h.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),h,24-,241516,DB01229,Paclitaxel
,11350890,t(1/2,"h/ml (308 microM. h), and a mean t(1/2 (24--192 h)) of 156.2 +/- 42.9 h.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),h,156.2,241517,DB01229,Paclitaxel
over,15207549,DL50,The DL50 of the conjugate (over 40 ng/ml) as compared to free paclitaxel (about 1 ng/ml) was correlated to the slow drug release.,"Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207549/),[ng] / [ml],40,241585,DB01229,Paclitaxel
,15207549,DL50,The DL50 of the conjugate (over 40 ng/ml) as compared to free paclitaxel (about 1 ng/ml) was correlated to the slow drug release.,"Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207549/),[ng] / [ml],1,241586,DB01229,Paclitaxel
,12853882,cumulative urinary excretion,The median cumulative urinary excretion was 2.4% (range 0.86-7.72%) of the given dose.,Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12853882/),%,2.4,241621,DB01229,Paclitaxel
,12853882,Plasma clearance,"Plasma clearance was found to be 6.71 l/h+/-70% and central volume of distribution was 3.64 l+/-79% (population mean +/- interindividual variability, respectively).",Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12853882/),[l] / [h],6.71,241622,DB01229,Paclitaxel
,12853882,central volume of distribution,"Plasma clearance was found to be 6.71 l/h+/-70% and central volume of distribution was 3.64 l+/-79% (population mean +/- interindividual variability, respectively).",Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12853882/),l,3.64,241623,DB01229,Paclitaxel
,22404965,objective response rate,"Preliminary efficacy was demonstrated by best objective response rate (86%), median time to response (14 days) and median progression-free survival (131 days).",A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404965/),%,86,241641,DB01229,Paclitaxel
,22404965,time to response,"Preliminary efficacy was demonstrated by best objective response rate (86%), median time to response (14 days) and median progression-free survival (131 days).",A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404965/),d,14,241642,DB01229,Paclitaxel
,22404965,progression-free survival,"Preliminary efficacy was demonstrated by best objective response rate (86%), median time to response (14 days) and median progression-free survival (131 days).",A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404965/),d,131,241643,DB01229,Paclitaxel
,21305287,maximum-tolerated dose,The maximum-tolerated dose was established as 170 mg/m(2).,"Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21305287/),[mg] / [m],170,242723,DB01229,Paclitaxel
,28038747,IC50,"In cytotoxicity assay, PTX loaded Pull-LA-CLNPs showed a low IC50 at 0.51μg/mL.",Efficient delivery of paclitaxel into ASGPR over-expressed cancer cells using reversibly stabilized multifunctional pullulan nanoparticles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28038747/),[μg] / [ml],0.51,242960,DB01229,Paclitaxel
,15846465,t(1/2beta),"Pharmacokinetic studies showed that encapsulation of paclitaxel in magnetoliposomes produced marked difference over the drug in Cremophor EL/ethanol pharmacokinetics, with an increased t(1/2beta) 19.37 h against 4.11 h.",Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846465/),h,19.37,243042,DB01229,Paclitaxel
,15846465,t(1/2beta),"Pharmacokinetic studies showed that encapsulation of paclitaxel in magnetoliposomes produced marked difference over the drug in Cremophor EL/ethanol pharmacokinetics, with an increased t(1/2beta) 19.37 h against 4.11 h.",Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846465/),h,4.11,243043,DB01229,Paclitaxel
,9220292,area under the concentration-time curve (AUC),Twenty-three patients were treated with paclitaxel at doses ranging from 175 to 225 mg/m2 followed by carboplatin targeting area under the concentration-time curve (AUC) 7 or 9 mg/mL.min every 3 weeks.,Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],7,244001,DB01229,Paclitaxel
,9220292,area under the concentration-time curve (AUC),Twenty-three patients were treated with paclitaxel at doses ranging from 175 to 225 mg/m2 followed by carboplatin targeting area under the concentration-time curve (AUC) 7 or 9 mg/mL.min every 3 weeks.,Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],9,244002,DB01229,Paclitaxel
,9220292,AUC,"A high rate of intolerable, mutually exclusive toxicities, consisting primarily of thrombocytopenia, as well as neutropenia, nausea and vomiting, and mucositis, precluded escalation of carboplatin above a targeted AUC of 7 mg/mL.min with paclitaxel 225 mg/m2, which approaches the maximum tolerated dose (MTD) of paclitaxel given as a single agent on a 3-hour schedule.",Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],7,244003,DB01229,Paclitaxel
,9220292,AUC,The recommended doses for subsequent clinical trials are paclitaxel 225 mg/m2 as a 3-hour infusion followed by carboplatin at a targeted AUC of 7 mg/mL.min.,Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],7,244004,DB01229,Paclitaxel
,32985911,loading capacity,"Paclitaxel (PTX), a hydrophobic antineoplastic drug, was encapsulated in the emulsions with 99% loading efficiency and 6.4% loading capacity.",Protamine and BSA-dextran complex emulsion improves oral bioavailability and anti-tumor efficacy of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32985911/),%,6.4,244015,DB01229,Paclitaxel
,32985911,bioavailability,"The bioavailability and H22 tumor inhibition efficacy of PTX@BD/PRO were 40% and 70% higher than those of PTX@BD, respectively, after oral administration in the mice.",Protamine and BSA-dextran complex emulsion improves oral bioavailability and anti-tumor efficacy of paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32985911/),%,40,244016,DB01229,Paclitaxel
>,22804749,T(C,It is well known that the time during which paclitaxel plasma concentrations exceed 0.05 μmol/L (T(C>0.05)) correlates with the extent of neutropenia.,Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22804749/),,0.05,244443,DB01229,Paclitaxel
>,22804749,T(C,"Subsequently, we proposed a first-cycle dosing algorithm that accounted for BSA, patient age and sex, while later cycles accounted for the previous-cycle paclitaxel T(C>0.05) (target: 26 to 31 hours) and ANC nadir to adapt the paclitaxel dose for the next treatment cycle.",Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22804749/),,0.05,244444,DB01229,Paclitaxel
>,22804749,T(C,"Subsequently, we proposed a first-cycle dosing algorithm that accounted for BSA, patient age and sex, while later cycles accounted for the previous-cycle paclitaxel T(C>0.05) (target: 26 to 31 hours) and ANC nadir to adapt the paclitaxel dose for the next treatment cycle.",Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22804749/),h,26,244445,DB01229,Paclitaxel
,19843072,area under the curve,"Patients (n = 12) with treatment-naive stage IIIB or IV NSCLC received single-agent PF-3512676 subcutaneously once during the first 7 days (monotherapy phase) in three escalating dose levels (0.1, 0.2, and 0.4 mg/kg) followed by a combination phase during which patients received 0.1 or 0.2 mg/kg PF-3512676 subcutaneously on days 8 and 15 of each 3-week cycle of carboplatin (area under the curve, 6 mg x min/mL) and paclitaxel (200 mg/m(2)).",Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843072/),[mg·min] / [ml],6,244608,DB01229,Paclitaxel
,19843072,half-life,Mean PF-3512676 half-life ranged from 4.8 to 21.6 h (longer with higher doses).,Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843072/),h,4.8 to 21.6,244609,DB01229,Paclitaxel
,16774712,total run time,Paclitaxel and docetaxel are separated on a C18 column and quantitated using a triple-quadrupole MS operating in positive ion electrospray selective reaction monitoring mode with a total run time of 6.0 min.,Determination of paclitaxel in rat plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16774712/),min,6.0,244897,DB01229,Paclitaxel
>,16774712,extraction recovery,"The method has high extraction recovery (> 90%) and accuracy (> 90%), with the intra- and interday precision < 15%.",Determination of paclitaxel in rat plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16774712/),%,90,244898,DB01229,Paclitaxel
,12402144,overall response rate,"Activity was observed at all dose levels and disease sites, and the overall response rate was 42% (95% confidence interval 22-61%).",Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402144/),%,42,244933,DB01229,Paclitaxel
,10697623,Area under the curve (AUC),The dose of C was calculated from the Calvert formula [DOSE(mg) = desired AUC x (GFR + 25)] based on the Glomerular filtration rate (GFR) figure; in our protocol desired Area under the curve (AUC) figure was 5 mg/ml x min.,Efficacy of 51Cr-EDTA clearance to tailor a carboplatin therapeutic regimen in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10697623/),[mg] / [min·ml],5,244991,DB01229,Paclitaxel
,30675689,IC50,IC50 values of PTX-NLCs and Intaxel® after 24-h exposure were found to be 4.19 μM and 11.2 μM.,Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30675689/),μM,4.19,245204,DB01229,Paclitaxel
,30675689,IC50,IC50 values of PTX-NLCs and Intaxel® after 24-h exposure were found to be 4.19 μM and 11.2 μM.,Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30675689/),μM,11.2,245205,DB01229,Paclitaxel
,25967286,overall survival,"The median overall survival was 35.6 months (95 % confidence interval 23.9, not reached).","Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25967286/),month,35.6,245373,DB01229,Paclitaxel
,25967286,response rate,"The response rate and clinical benefit rate were both 83 % (95 % confidence interval 51.6, 97.9).","Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25967286/),%,83,245374,DB01229,Paclitaxel
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,0.40,245889,DB01229,Paclitaxel
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,0.65,245890,DB01229,Paclitaxel
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,0.95,245891,DB01229,Paclitaxel
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,2.00,245892,DB01229,Paclitaxel
,27501037,IC50,"MTT assay on U373MG human astrocytoma cells indicated IC50 values of 0.40, 0.65, 0.95, 2.00 and 3.50μM for PTX loaded SPPI, GPPI, CPPI, PPI formulations, and free PTX, respectively.",Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27501037/),μM,3.50,245893,DB01229,Paclitaxel
,28837250,area under the concentration-time curve,"Patients received veliparib at 100 or 150 mg b.i.d. on days 1-21 with carboplatin (area under the concentration-time curve 6 mg/mL•min) on day 1 and paclitaxel 80 mg/m2 on days 1, 8 and 15 every 3 weeks for up to 6 21-day cycles.",Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28837250/),[mg] / [min·ml],6,246094,DB01229,Paclitaxel
,28837250,objective response rate,"Response, assessed in five patients, was partial in four and complete in one (objective response rate 100%).",Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28837250/),%,100,246095,DB01229,Paclitaxel
,12217752,nadir,"Myelosuppression was the principal toxicity, with a median Cycle 1 nadir absolute neutrophil count of 0.27 x 10(9) cells/L and a 47% overall incidence of Grade 4 neutropenia.","A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217752/),,0.27 x,246205,DB01229,Paclitaxel
,12217752,absolute neutrophil count,"Myelosuppression was the principal toxicity, with a median Cycle 1 nadir absolute neutrophil count of 0.27 x 10(9) cells/L and a 47% overall incidence of Grade 4 neutropenia.","A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217752/),,0.27 x,246206,DB01229,Paclitaxel
,12217752,area under the concentration-versus-time curve (AUC),Paclitaxel area under the concentration-versus-time curve (AUC) (16 +/- 5.3 microg x h/mL) during the first treatment cycle was comparable to standard 175 mg/m(2) paclitaxel administered over 3 h.,"A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217752/),[h·μg] / [ml],16,246207,DB01229,Paclitaxel
,12217752,time-to-disease progression,The median time-to-disease progression was 10 weeks for the intent-to-treat population and 20.7 weeks for the CA-125 responders.,"A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217752/),weeks,10,246208,DB01229,Paclitaxel
,12217752,time-to-disease progression,The median time-to-disease progression was 10 weeks for the intent-to-treat population and 20.7 weeks for the CA-125 responders.,"A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12217752/),weeks,20.7,246209,DB01229,Paclitaxel
,16019859,MTD,"Ten patients participated in the phase I portion of the study which demonstrated that the MTD of hyperthermia was 60 min after either average vaginal and rectal temperatures of 40 degrees C had been achieved or after 30 min of power application, whichever was shorter.",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),min,60,246468,DB01229,Paclitaxel
,16019859,response rate,"There were three partial responses for a response rate of 10% (95% CI: [2%, 27%]) and eight patients (27%; 95% CI: [12%, 46%]) had disease stabilization.",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),%,10,246469,DB01229,Paclitaxel
,16019859,time to progression or death,"The median time to progression or death was 3.4 months (95% CI: [2.6, 5.2]) and the median survival was 10.8 months (95% CI: [8.8, 17.4]).",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),month,3.4,246470,DB01229,Paclitaxel
,16019859,survival,"The median time to progression or death was 3.4 months (95% CI: [2.6, 5.2]) and the median survival was 10.8 months (95% CI: [8.8, 17.4]).",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),month,10.8,246471,DB01229,Paclitaxel
,23860537,area under the curve,"Patients received lenvatinib twice daily (BID) with carboplatin (area under the curve 6 mg ml(-1) min(-1), day 1)/paclitaxel (200 mg m(-2), day 1) every 3 weeks.",Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23860537/),[mg] / [min·ml],6,246690,DB01229,Paclitaxel
,23860537,Response rate,"Response rate and median progression-free survival were 68% and 9.0 months, respectively, with 4 mg BID.",Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23860537/),%,68,246691,DB01229,Paclitaxel
,23860537,progression-free survival,"Response rate and median progression-free survival were 68% and 9.0 months, respectively, with 4 mg BID.",Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23860537/),month,9.0,246692,DB01229,Paclitaxel
,23860537,MTD,The MTD for lenvatinib with carboplatin/paclitaxel is 4 mg BID in advanced NSCLC patients.,Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23860537/),mg,4,246693,DB01229,Paclitaxel
,7616600,Peak paclitaxel concentrations,Peak paclitaxel concentrations in CSF ranged between 5 and 83 nM and occurred between 3.25 and 5 hours after initiation of the paclitaxel infusion.,Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616600/),nM,5 and 83,246717,DB01229,Paclitaxel
up to,28892400,encapsulation efficiency,"Paclitaxel was utilized as the model drug, with an encapsulation efficiency of up to 90.2 ± 4.0%.",Poly(vinyl methyl ether/maleic anhydride)-Doped PEG-PLA Nanoparticles for Oral Paclitaxel Delivery To Improve Bioadhesive Efficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892400/),%,90.2,246813,DB01229,Paclitaxel
,28892400,IC50,"PTX-m-NPs also exhibited a more effective anticancer efficacy, with an IC50 of 0.2 ± 1.4 μg/mL for A549 cell lines, further demonstrating the advantage of bioadhesive nanoparticles.",Poly(vinyl methyl ether/maleic anhydride)-Doped PEG-PLA Nanoparticles for Oral Paclitaxel Delivery To Improve Bioadhesive Efficiency. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892400/),[μg] / [ml],0.2,246814,DB01229,Paclitaxel
,22224040,clearance,The overall mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; mean elimination rate constant was 0.336 ± 0.002/h; mean half-life was 2.086 ± 0.009 h; mean area under the curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h.,Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),[l] / [h],47.5847,246838,DB01229,Paclitaxel
,22224040,volume of distribution,The overall mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; mean elimination rate constant was 0.336 ± 0.002/h; mean half-life was 2.086 ± 0.009 h; mean area under the curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h.,Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),l,142.028,246839,DB01229,Paclitaxel
,22224040,elimination rate constant,The overall mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; mean elimination rate constant was 0.336 ± 0.002/h; mean half-life was 2.086 ± 0.009 h; mean area under the curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h.,Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),1/[h],0.336,246840,DB01229,Paclitaxel
,22224040,half-life,The overall mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; mean elimination rate constant was 0.336 ± 0.002/h; mean half-life was 2.086 ± 0.009 h; mean area under the curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h.,Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),h,2.086,246841,DB01229,Paclitaxel
,22224040,area under the curve (AUC),The overall mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; mean elimination rate constant was 0.336 ± 0.002/h; mean half-life was 2.086 ± 0.009 h; mean area under the curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h.,Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),[mg] / [h·ml],5.5917,246842,DB01229,Paclitaxel
,22224040,mean residence time,The overall mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; mean elimination rate constant was 0.336 ± 0.002/h; mean half-life was 2.086 ± 0.009 h; mean area under the curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h.,Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),h,2.980,246843,DB01229,Paclitaxel
,22224040,peak plasma concentration,"The peak plasma concentration at 130 mg dose level was 2 μ/ml, but an increase in dose was not associated with proportional increase in plasma concentration.",Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224040/),[μ] / [ml],2,246844,DB01229,Paclitaxel
,16126736,MTD,The MTD of DP was 40/150.,"A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16126736/),-1,40,246850,DB01229,Paclitaxel
,16012790,C(max),Mean C(max) of ONT-093 was 9 microM (range 5-15 microM) which were 3- to 5-fold higher than in single agent studies of ONT-093.,"A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012790/),μM,9,248006,DB01229,Paclitaxel
,7834963,plasma protein binding,"Pharmacokinetic studies in which adults have been administered pacliaxel intravenously over 1 to 96 hours have demonstrated the following pharmacokinetic characteristics: extensive tissue distribution; high plasma protein binding (approximately 90 to 95%); variable systemic clearance, with average clearances ranging from 87 to 503 ml/min/m2 (5.2 to 30.2 L/h/m2); and minimal renal excretion of parent drug (< 10%).",Clinical pharmacokinetics of paclitaxel. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834963/),%,90 to 95,248379,DB01229,Paclitaxel
,7834963,clearances,"Pharmacokinetic studies in which adults have been administered pacliaxel intravenously over 1 to 96 hours have demonstrated the following pharmacokinetic characteristics: extensive tissue distribution; high plasma protein binding (approximately 90 to 95%); variable systemic clearance, with average clearances ranging from 87 to 503 ml/min/m2 (5.2 to 30.2 L/h/m2); and minimal renal excretion of parent drug (< 10%).",Clinical pharmacokinetics of paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834963/),[ml] / [m2·min],87 to 503,248380,DB01229,Paclitaxel
,7834963,clearances,"Pharmacokinetic studies in which adults have been administered pacliaxel intravenously over 1 to 96 hours have demonstrated the following pharmacokinetic characteristics: extensive tissue distribution; high plasma protein binding (approximately 90 to 95%); variable systemic clearance, with average clearances ranging from 87 to 503 ml/min/m2 (5.2 to 30.2 L/h/m2); and minimal renal excretion of parent drug (< 10%).",Clinical pharmacokinetics of paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834963/),[l] / [h·m2],5.2 to 30.2,248381,DB01229,Paclitaxel
<,7834963,renal excretion,"Pharmacokinetic studies in which adults have been administered pacliaxel intravenously over 1 to 96 hours have demonstrated the following pharmacokinetic characteristics: extensive tissue distribution; high plasma protein binding (approximately 90 to 95%); variable systemic clearance, with average clearances ranging from 87 to 503 ml/min/m2 (5.2 to 30.2 L/h/m2); and minimal renal excretion of parent drug (< 10%).",Clinical pharmacokinetics of paclitaxel. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834963/),%,10,248382,DB01229,Paclitaxel
,24719940,ratio of AUC,The ratio of AUC in lymph nodes of group A to group B was 0.7495 and that in peritoneal lavage was 1.25.,Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24719940/),,0.7495,248632,DB01229,Paclitaxel
,24719940,ratio of AUC,The ratio of AUC in lymph nodes of group A to group B was 0.7495 and that in peritoneal lavage was 1.25.,Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24719940/),,1.25,248633,DB01229,Paclitaxel
,24719940,t1/2,The t1/2 of paclitaxel in peritoneal lavage of group A was 0.879 as long as that of Group B.,Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24719940/),,0.879,248634,DB01229,Paclitaxel
,24719940,t1/2,The t1/2 of paclitaxel in lymph nodes of group A was 1.097 as long as that of Group B.,Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24719940/),,1.097,248635,DB01229,Paclitaxel
,11345647,C,"Seven patients with solid tumors were treated with paclitaxel infused over 3 h, each at consecutive 3-weekly dose levels of 225, 175 and 135 mg/m2 (CrEL dose level, 18.8, 14.6, and 11.3 ml/m2, respectively).",Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345647/),[ml] / [m2],18.8,248731,DB01229,Paclitaxel
,11345647,C,"Seven patients with solid tumors were treated with paclitaxel infused over 3 h, each at consecutive 3-weekly dose levels of 225, 175 and 135 mg/m2 (CrEL dose level, 18.8, 14.6, and 11.3 ml/m2, respectively).",Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345647/),[ml] / [m2],14.6,248732,DB01229,Paclitaxel
,11345647,C,"Seven patients with solid tumors were treated with paclitaxel infused over 3 h, each at consecutive 3-weekly dose levels of 225, 175 and 135 mg/m2 (CrEL dose level, 18.8, 14.6, and 11.3 ml/m2, respectively).",Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345647/),[ml] / [m2],11.3,248733,DB01229,Paclitaxel
,11345647,blood:plasma concentration ratios,"This was shown to be caused by a CrEL concentration-dependent decrease in paclitaxel uptake in blood cells, as reflected by the blood:plasma concentration ratios which altered significantly from 0.83 +/- 0.11 (at 135 mg/m2) to 0.68 +/- 0.07 (at 225 mg/m2).",Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345647/),,0.83,248734,DB01229,Paclitaxel
,11345647,blood:plasma concentration ratios,"This was shown to be caused by a CrEL concentration-dependent decrease in paclitaxel uptake in blood cells, as reflected by the blood:plasma concentration ratios which altered significantly from 0.83 +/- 0.11 (at 135 mg/m2) to 0.68 +/- 0.07 (at 225 mg/m2).",Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345647/),,0.68,248735,DB01229,Paclitaxel
,30551427,tumor inhibition ratios,"The higher tumor inhibition ratios were observed for the treatments with free and co-encapsulated PTX:DXR in liposomes (66.87 and 66.52%, respectively, P>0.05) as compared to the control.",Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30551427/),%,66.87,248861,DB01229,Paclitaxel
,30551427,tumor inhibition ratios,"The higher tumor inhibition ratios were observed for the treatments with free and co-encapsulated PTX:DXR in liposomes (66.87 and 66.52%, respectively, P>0.05) as compared to the control.",Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30551427/),%,66.52,248862,DB01229,Paclitaxel
,23838193,LD50,"Results of acute toxicity showed the LD50 of paclitaxel nanosuspensions was 98.63 mg/kg, twice more than that of the marketed injection (41.46 mg/kg).",Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23838193/),[mg] / [kg],98.63,248863,DB01229,Paclitaxel
,23838193,LD50,"Results of acute toxicity showed the LD50 of paclitaxel nanosuspensions was 98.63 mg/kg, twice more than that of the marketed injection (41.46 mg/kg).",Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23838193/),[mg] / [kg],41.46,248864,DB01229,Paclitaxel
,10856107,AUC,"The mean AUC values +/- SD after 60, 180, and 300 mg/m(2) of oral paclitaxel were 1.65 +/- 0.93, 3.33 +/- 2.39, and 3.46 +/- 1.37 micromol/L.h, respectively.",Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],1.65,248902,DB01229,Paclitaxel
,10856107,AUC,"The mean AUC values +/- SD after 60, 180, and 300 mg/m(2) of oral paclitaxel were 1.65 +/- 0.93, 3.33 +/- 2.39, and 3.46 +/- 1.37 micromol/L.h, respectively.",Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],3.33,248903,DB01229,Paclitaxel
,10856107,AUC,"The mean AUC values +/- SD after 60, 180, and 300 mg/m(2) of oral paclitaxel were 1.65 +/- 0.93, 3.33 +/- 2.39, and 3.46 +/- 1.37 micromol/L.h, respectively.",Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],3.46,248904,DB01229,Paclitaxel
,10856107,AUC,The AUC of intravenous paclitaxel was 15.39 +/- 3.26 micromol/L.h.,Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],15.39,248905,DB01229,Paclitaxel
,10856107,MTD,The MTD of oral paclitaxel was 300 mg/m(2).,Phase I and pharmacokinetic study of oral paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[mg] / [m],300,248906,DB01229,Paclitaxel
,15494716,time to progression,One partial response was seen in a patient with advanced adenocarcinoma of the oesophago-gastric junction and 12 patients had stable disease with a median time to progression of 184 days (range 60-506 days).,Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15494716/),d,184,249047,DB01229,Paclitaxel
,22966334,AUCs,"Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mg·min/ml and 13.5 μg·h/ml, respectively.",Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22966334/),[mg·min] / [ml],3.48-5.55,249478,DB01229,Paclitaxel
,22966334,AUCs,"Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mg·min/ml and 13.5 μg·h/ml, respectively.",Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22966334/),[h·μg] / [ml],13.5,249479,DB01229,Paclitaxel
,22588463,drug-release rate constants,"Estimated drug-release rate constants (h(-1)): Cre-pac (5.19), L-pac (1.26), A-pac (0.72), T-pac (0.74).",Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588463/),1/[h],5.19,249548,DB01229,Paclitaxel
,22588463,drug-release rate constants,"Estimated drug-release rate constants (h(-1)): Cre-pac (5.19), L-pac (1.26), A-pac (0.72), T-pac (0.74).",Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588463/),1/[h],1.26,249549,DB01229,Paclitaxel
,22588463,drug-release rate constants,"Estimated drug-release rate constants (h(-1)): Cre-pac (5.19), L-pac (1.26), A-pac (0.72), T-pac (0.74).",Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588463/),1/[h],0.72,249550,DB01229,Paclitaxel
,22588463,drug-release rate constants,"Estimated drug-release rate constants (h(-1)): Cre-pac (5.19), L-pac (1.26), A-pac (0.72), T-pac (0.74).",Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588463/),1/[h],0.74,249551,DB01229,Paclitaxel
,11914912,apparent K(i),"The transport of [(3)H]paclitaxel across the Caco-2 monolayer was markedly inhibited in the presence of MS-209, and the apparent K(i)of MS-209 for the active transport of [(3)H]paclitaxel was 0.4 microM.",P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914912/),μM,0.4,250282,DB01229,Paclitaxel
,11051260,MTD,"The MTD in the sequence of doxorubicin after docetaxel was 40 and 50 mg/m2, respectively, with the dose-limiting toxicity of neutropenia.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],40,250387,DB01229,Paclitaxel
,11051260,MTD,"The MTD in the sequence of doxorubicin after docetaxel was 40 and 50 mg/m2, respectively, with the dose-limiting toxicity of neutropenia.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],50,250388,DB01229,Paclitaxel
,11051260,MTD,"On the other hand, the MTD of the sequence of docetaxel after doxorubicin was 70 and 50 mg/m2, respectively.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],70,250389,DB01229,Paclitaxel
,11051260,MTD,"On the other hand, the MTD of the sequence of docetaxel after doxorubicin was 70 and 50 mg/m2, respectively.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],50,250390,DB01229,Paclitaxel
,11157039,area under the curve,"rhuMAbVEGF, 3 mg/kg IV, was administered weekly for 8 weeks with (1) doxorubicin 50 mg/m(2) every 4 weeks; (2) carboplatin at area under the curve of 6 plus paclitaxel 175 mg/m(2) every 4 weeks; and (3) fluorouracil (5-FU) 500 mg/m(2) with leucovorin 20 mg/m(2) weekly, weeks 1 to 6 every 8 weeks.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),,6,250656,DB01229,Paclitaxel
,11157039,peak serum level,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),[μg] / [ml],167,250657,DB01229,Paclitaxel
,11157039,terminal half-life,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),d,13,250658,DB01229,Paclitaxel
,22072863,maximum tolerated dosage,The dose-limiting toxicity was grade 4 neutropenia and the maximum tolerated dosage was 120 mg/m(2).,Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22072863/),mg,120,251550,DB01229,Paclitaxel
,11680814,AUC,"CBCA (AUC 0.4 mg/ml, min/day) was also administrated as 20 min i.v. infusion, starting 1 day before the first radiotherapy fraction.","A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680814/),[mg] / [ml],0.4,252116,DB01229,Paclitaxel
,20028752,MTD,The MTD was 125 mg once daily.,"Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20028752/),mg,125,252138,DB01229,Paclitaxel
,20028752,objective response rates,"The objective response rates were 17%, 0%, and 17% in arms A, B, and C, respectively.","Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20028752/),%,17,252139,DB01229,Paclitaxel
,20028752,objective response rates,"The objective response rates were 17%, 0%, and 17% in arms A, B, and C, respectively.","Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20028752/),%,0,252140,DB01229,Paclitaxel
,32847973,Response rates,Response rates were 48% overall (27) and 64% for ovarian cancers (14).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),%,48,252812,DB01229,Paclitaxel
,32847973,Response rates,Response rates were 48% overall (27) and 64% for ovarian cancers (14).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),%,64,252813,DB01229,Paclitaxel
,32847973,overall,VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),month,7,252814,DB01229,Paclitaxel
,32847973,overall,VEGF-A-1154AA and -7TT recessive homozygous genotypes conferred worse overall survival versus alternative genotypes (7 vs. 22 months).,"Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32847973/),month,22,252815,DB01229,Paclitaxel
,7905005,retention time,The retention time of paclitaxel was 10 min.,High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905005/),min,10,252951,DB01229,Paclitaxel
,7905005,observed recovery,The observed recovery for paclitaxel was 83%.,High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905005/),%,83,252952,DB01229,Paclitaxel
,15963636,Objective response rate,Objective response rate was 57.6% with 6 complete (18.2%) and 13 partial remissions (39.4%).,Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963636/),%,57.6,253115,DB01229,Paclitaxel
,15963636,progression-free interval,"Median progression-free interval and median survival was 6.5 (1-35) and 12 (2.5-58) months, respectively.",Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963636/),month,6.5,253116,DB01229,Paclitaxel
,15963636,survival,"Median progression-free interval and median survival was 6.5 (1-35) and 12 (2.5-58) months, respectively.",Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963636/),month,12,253117,DB01229,Paclitaxel
,9923547,first-order rate constant of elimination (Ke),"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),1/[h],0.312,253364,DB01229,Paclitaxel
,9923547,apparent volume of distribution (Vc),"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),[l] / [m2],52.4,253365,DB01229,Paclitaxel
,9923547,first-order rate constants for,"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),1/[h],0.170,253366,DB01229,Paclitaxel
,9923547,first-order rate constants for,"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),1/[h],0.105,253367,DB01229,Paclitaxel
,9923547,transit from central to peripheral compartments (Kcp),"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),1/[h],0.105,253368,DB01229,Paclitaxel
,9923547,area under the plasma concentration-versus-time curve (AUC),"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),h·μM,16.9,253369,DB01229,Paclitaxel
,9923547,clearance (Cl),"The calculated pharmacokinetic parameters were 0.312 h(-1) for the first-order rate constant of elimination (Ke), 52.4 l/m2 for the apparent volume of distribution (Vc), 0.170 h(-1) and 0.105 h(-1) for the first-order rate constants for transit from central to peripheral compartments (Kcp) and peripheral to central compartments (Kpc), respectively, 16.9 microM x h for the area under the plasma concentration-versus-time curve (AUC), and 273 ml/min per m2 for average clearance (Cl).",Pharmacokinetics of paclitaxel in an anephric patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),[ml] / [m2·min],273,253370,DB01229,Paclitaxel
,9923547,maximal rate of elimination (Vm1-0),"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),[μM] / [h],12.0,253371,DB01229,Paclitaxel
,9923547,rate of elimination,"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),μM,0.158,253372,DB01229,Paclitaxel
,9923547,Kcp,"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),1/[h],0.809,253373,DB01229,Paclitaxel
,9923547,Kpc,"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),1/[h],0.0792,253374,DB01229,Paclitaxel
,9923547,Vc,"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),[l] / [m2],23.5,253375,DB01229,Paclitaxel
,9923547,AUC,"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),h·μM,20.9,253376,DB01229,Paclitaxel
,9923547,Cl,"The calculated pharmacokinetic parameters were 12.0 micromol x h(-1) for the maximal rate of elimination (Vm1-0), 0.158 microM for the concentration at which the rate of elimination is 50% of maximal (Km1-0), 0.809 h(-1) for Kcp, 0.0792 h(-1) for Kpc, 23.5 l/m2 for Vc, 20.9 microM x h for AUC, and 327 ml/min per m2 for Cl.",Pharmacokinetics of paclitaxel in an anephric patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923547/),[ml] / [m2·min],327,253377,DB01229,Paclitaxel
,11395577,maximum plasma concentrations,"The maximum plasma concentrations of paclitaxel, total platinum and free platinum were 3.26, 2.44 and 1.84 microg/ml, respectively.",Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11395577/),[μg] / [ml],3.26,253675,DB01229,Paclitaxel
,11395577,maximum plasma concentrations,"The maximum plasma concentrations of paclitaxel, total platinum and free platinum were 3.26, 2.44 and 1.84 microg/ml, respectively.",Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11395577/),[μg] / [ml],2.44,253676,DB01229,Paclitaxel
,11395577,maximum plasma concentrations,"The maximum plasma concentrations of paclitaxel, total platinum and free platinum were 3.26, 2.44 and 1.84 microg/ml, respectively.",Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11395577/),[μg] / [ml],1.84,253677,DB01229,Paclitaxel
,11395577,AUC,"The AUC of paclitaxel and free platinum were 15.3 and 1.76 microg x h/ml, respectively.",Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11395577/),[h·μg] / [ml],15.3,253678,DB01229,Paclitaxel
,11395577,AUC,"The AUC of paclitaxel and free platinum were 15.3 and 1.76 microg x h/ml, respectively.",Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11395577/),[h·μg] / [ml],1.76,253679,DB01229,Paclitaxel
,30879251,MTD,MTD was established as 250 mg/m2.,Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30879251/),[mg] / [m2],250,253692,DB01229,Paclitaxel
,30879251,half-life,"Paclitaxel micellar had a rapid initial distribution phase, mean half-life 0.55 h, estimated to be completed 3 h after dosing and a mean terminal half-life of 8.8 h.",Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30879251/),h,0.55,253693,DB01229,Paclitaxel
,30879251,terminal half-life,"Paclitaxel micellar had a rapid initial distribution phase, mean half-life 0.55 h, estimated to be completed 3 h after dosing and a mean terminal half-life of 8.8 h.",Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30879251/),h,8.8,253694,DB01229,Paclitaxel
,30879251,clearance,Mean clearance was 13.4 L/h/m2 with fivefold interindividual variability.,Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30879251/),[l] / [h·m2],13.4,253695,DB01229,Paclitaxel
,32745564,emulsification time,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),s,31,254069,DB01229,Paclitaxel
,32745564,poly-dispersibility index,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),,0.35,254070,DB01229,Paclitaxel
,32745564,percentage transmittance,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),%,99,254071,DB01229,Paclitaxel
,32745564,zeta potential,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),mv,36.82,254072,DB01229,Paclitaxel
,19955926,area under the curve,"After debulking surgery, patients with previously untreated epithelial ovarian or primary peritoneal carcinoma received sequential paclitaxel (175 mg/m) and carboplatin (area under the curve, 5 mg x min/mL) on day 1 every 3 weeks for 6 cycles.",Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19955926/),[mg·min] / [ml],5,254199,DB01229,Paclitaxel
,17063712,half-lives,The pharmacokinetics of low-dose suramin followed a 2-compartment model with half-lives of 2 h and 6 days.,Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),h,2,254374,DB01229,Paclitaxel
,17063712,half-lives,The pharmacokinetics of low-dose suramin followed a 2-compartment model with half-lives of 2 h and 6 days.,Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),d,6,254375,DB01229,Paclitaxel
,17063712,distribution volume,"The distribution volume was a 0.34 +/- 0.12 L/kg, and clearance was 1.86 +/- 0.76 mL/kg/h.",Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),[l] / [kg],0.34,254376,DB01229,Paclitaxel
,17063712,clearance,"The distribution volume was a 0.34 +/- 0.12 L/kg, and clearance was 1.86 +/- 0.76 mL/kg/h.",Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),[ml] / [h·kg],1.86,254377,DB01229,Paclitaxel
,25761456,time-above-threshold,"Different limited sampling strategies were tested on their accuracy to estimate the individual paclitaxel time-above-threshold-concentration of 0.05 µmol/L (T c>0.05µM), which is a common threshold for paclitaxel.",Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761456/),[μM] / [l],0.05,254437,DB01229,Paclitaxel
>,25761456,T c,"Different limited sampling strategies were tested on their accuracy to estimate the individual paclitaxel time-above-threshold-concentration of 0.05 µmol/L (T c>0.05µM), which is a common threshold for paclitaxel.",Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761456/),μM,0.05,254438,DB01229,Paclitaxel
>,25761456,T c,A dosing algorithm was developed based on the population distribution of paclitaxel T c>0.05µM and the correlation between paclitaxel T c>0.05µM and CIPN.,Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761456/),μM,0.05,254439,DB01229,Paclitaxel
>,25761456,T c,A single paclitaxel plasma concentration taken 18-30 h after the start of chemotherapy infusion adequately predicted T c>0.05µM.,Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761456/),μM,0.05,254440,DB01229,Paclitaxel
>,25761456,T c,"By using an empirical dosing algorithm to target an average paclitaxel T c>0.05µM between 10 and 14 h, Bayesian simulations of repetitive (adapted) dosing suggested a potential reduction of grade 2 CIPN from 9.6 to 4.4 %.",Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25761456/),μM,0.05,254441,DB01229,Paclitaxel
,28176896,loading content,"The PTX loading content was 3 mg/mL, and encapsulation efficiency (EE) was close to 100%.",Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176896/),[mg] / [ml],3,254556,DB01229,Paclitaxel
,28176896,encapsulation efficiency (EE),"The PTX loading content was 3 mg/mL, and encapsulation efficiency (EE) was close to 100%.",Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176896/),%,100,254557,DB01229,Paclitaxel
,15961435,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) for this regimen was 90 mg/m2/week of paclitaxel for 3 weeks plus 600 mg/m2/day of continuous 5-FU for 5 days.,Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961435/),mg,90,254608,DB01229,Paclitaxel
,27868228,clearance,"Analysis of two blood samples taken 9 and 10 days after docetaxel revealed plasma levels of 4.73 and 4.09 ng ml-1 , respectively, leading to a 79% decreased individual (Bayesian maximum a posteriori) clearance estimate of 9.15 l h-1 , corresponding to an estimated fivefold increase in AUC.",Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27868228/),[l] / [h],9.15,254796,DB01229,Paclitaxel
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,319,255424,DB01229,Paclitaxel
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,350,255425,DB01229,Paclitaxel
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,230,255426,DB01229,Paclitaxel
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,131,255427,DB01229,Paclitaxel
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,0.59,255428,DB01229,Paclitaxel
,28222073,area under the curve,Maximum tolerated dose for the combination was 240 mg per day oral rucaparib and carboplatin area under the curve 5 mg ml-1 min-1.,A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),[mg] / [min·ml],5,255887,DB01229,Paclitaxel
≈,28222073,half-life,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),h,17,255888,DB01229,Paclitaxel
,28222073,bioavailability,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),%,36,255889,DB01229,Paclitaxel
,16842379,clearance,"Patient weight, age and serum glutamic-oxaloacetic transaminase level were determinants of paclitaxel clearance (clearance increased 0.437 l h-1 kg-1; decreased 0.223 l h-1 year-1 and 0.105 l h-1 IU-1).",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[l] / [h·kg],0.437,256423,DB01229,Paclitaxel
,16842379,clearance,"Patient weight, age and serum glutamic-oxaloacetic transaminase level were determinants of paclitaxel clearance (clearance increased 0.437 l h-1 kg-1; decreased 0.223 l h-1 year-1 and 0.105 l h-1 IU-1).",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[l] / [h·year],0.223,256424,DB01229,Paclitaxel
,16842379,clearance,"Patient weight, age and serum glutamic-oxaloacetic transaminase level were determinants of paclitaxel clearance (clearance increased 0.437 l h-1 kg-1; decreased 0.223 l h-1 year-1 and 0.105 l h-1 IU-1).",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[l] / [h·iu],0.105,256425,DB01229,Paclitaxel
,16842379,AU,"In different measures of paclitaxel exposure, AUC was most predictive of toxicity, with higher AUC associated with granulocytopenia [probability of 1% at AUC=1 to 22% at AUC=4 microg l-1 h-1 for performance status (PS)=0].",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),,1,256426,DB01229,Paclitaxel
,16842379,AUC,"In different measures of paclitaxel exposure, AUC was most predictive of toxicity, with higher AUC associated with granulocytopenia [probability of 1% at AUC=1 to 22% at AUC=4 microg l-1 h-1 for performance status (PS)=0].",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[μg] / [h·l],4,256427,DB01229,Paclitaxel
,12932719,t(1/2)beta,"The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes.","Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932719/),min,52.3,256719,DB01229,Paclitaxel
,12932719,t(1/2)beta,"The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes.","Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932719/),min,260,256720,DB01229,Paclitaxel
,12932719,t(1/2)beta,"The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes.","Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932719/),min,665,256721,DB01229,Paclitaxel
,19078952,area under the plasma concentration-time curve,"Patients were randomised to receive </=6 cycles of carboplatin area under the plasma concentration-time curve 6 mg ml(-1) min and paclitaxel 175 mg m(-2) (CP, n=36) or standard therapy plus ASA404 1200 mg m(-2) (ASA404-CP, n=37).",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),[mg·min] / [ml],6,256844,DB01229,Paclitaxel
,19078952,Tumour response rate,"Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),%,31,256845,DB01229,Paclitaxel
,19078952,Tumour response rate,"Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),%,22,256846,DB01229,Paclitaxel
,19078952,time to tumour progression,"Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),month,5.4,256847,DB01229,Paclitaxel
,19078952,time to tumour progression,"Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),month,4.4,256848,DB01229,Paclitaxel
,19078952,survival,"Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),month,14.0,256849,DB01229,Paclitaxel
,19078952,survival,"Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group.",Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19078952/),month,8.8,256850,DB01229,Paclitaxel
,11180028,survival,"In the simulated phase III trial, although median survival was slightly longer in the 125 mg/m2 docetaxel group than in the 100 mg/m2 group (5.49 months versus 5.31 months, respectively), the difference was significant in only 6 of 100 trials.",Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180028/),month,5.49,256953,DB01229,Paclitaxel
,11180028,survival,"In the simulated phase III trial, although median survival was slightly longer in the 125 mg/m2 docetaxel group than in the 100 mg/m2 group (5.49 months versus 5.31 months, respectively), the difference was significant in only 6 of 100 trials.",Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180028/),month,5.31,256954,DB01229,Paclitaxel
,11350887,MTD,The MTD of DP without PSC 833 was 35 mg/m(2) doxorubicin and 150 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,35,257766,DB01229,Paclitaxel
,11350887,MTD,The MTD of DPV without G-CSF was 12.5 mg/m(2) doxorubicin and 70 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,12.5,257767,DB01229,Paclitaxel
,11561776,overall objective response rate,Three patients achieved a complete response and 12 achieved a partial response for an overall objective response rate of 50%.,A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561776/),%,50,257879,DB01229,Paclitaxel
,11561776,freedom from progression,"The median freedom from progression was 35 weeks, with a median survival of 55 weeks.",A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11561776/),weeks,35,257880,DB01229,Paclitaxel
,11976830,peak levels,"The peak levels of platinum were 2.72+/-0.41 microg/ml in plasma and 1.36+/-0.42 microg/ml in PUF at the end of the OPT infusion, and the platinum levels were still detectable at >10 ng/ml 94 h after the OPT infusion.",Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976830/),[μg] / [ml],2.72,258234,DB01229,Paclitaxel
,11976830,peak levels,"The peak levels of platinum were 2.72+/-0.41 microg/ml in plasma and 1.36+/-0.42 microg/ml in PUF at the end of the OPT infusion, and the platinum levels were still detectable at >10 ng/ml 94 h after the OPT infusion.",Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976830/),[μg] / [ml],1.36,258235,DB01229,Paclitaxel
,11976830,terminal t(1/2),"The mean terminal t(1/2) values of total platinum in plasma and in PUF were 58.9 h and 22.8 h, respectively.",Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976830/),h,58.9,258236,DB01229,Paclitaxel
,11976830,terminal t(1/2),"The mean terminal t(1/2) values of total platinum in plasma and in PUF were 58.9 h and 22.8 h, respectively.",Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976830/),h,22.8,258237,DB01229,Paclitaxel
,20339948,MTD,"Following HIPEC, both formulations had a similar MTD: 0.24 mg paclitaxel per ml.",In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20339948/),mg,0.24,258908,DB01229,Paclitaxel
,12902425,effective dose,"The critical organ is gallbladder wall (0.19 mGy/MBq [0.69 rad/mCi]), followed by liver (0.14 mGy/MBq [0.52 rad/mCi]); the effective dose is 0.022 mSv/MBq (0.083 rem/mCi).","Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902425/),[msv] / [Mbq],0.022,259047,DB01229,Paclitaxel
,12902425,effective dose,"The critical organ is gallbladder wall (0.19 mGy/MBq [0.69 rad/mCi]), followed by liver (0.14 mGy/MBq [0.52 rad/mCi]); the effective dose is 0.022 mSv/MBq (0.083 rem/mCi).","Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902425/),[rem] / [mci],0.083,259048,DB01229,Paclitaxel
,22990652,objective response rate,The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n=27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n=21).,Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990652/),%,37.0,259454,DB01229,Paclitaxel
,22990652,objective response rate,The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n=27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n=21).,Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990652/),%,23.8,259455,DB01229,Paclitaxel
,1982732,run time,"The method was linear from 0.10-10 microM injected, with a chromatographic run time of 6 min.",Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982732/),min,6,260436,DB01229,Paclitaxel
,24365981,flow rate,"Chromatographic separation of these anticancer drugs was achieved with an isocratic mobile phase consisting of acetonitrile/aqueous buffer (10 mmol/L ammonium acetate and 0.1% formic acid in 70:30, vol/vol) at a flow rate of 0.25 mL/min in a short time (4.5 minutes).","Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365981/),[ml] / [min],0.25,260934,DB01229,Paclitaxel
,30799919,half-life,S-HM-3 is a tumor angiogenesis inhibitor with short half-life (25 min).,Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799919/),min,25,261369,DB01229,Paclitaxel
,30799919,critical micelle concentration (CMC),Micelles exhibited smooth spherical morphology with 20~30 nm and low critical micelle concentration (CMC) value of 0.000124 mg/mL.,Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799919/),[mg] / [ml],0.000124,261370,DB01229,Paclitaxel
,17009648,area under the concentration/time curve (AUC),The carboplatin dose was chosen to produce a target area under the concentration/time curve (AUC) of 5.0 microg-min/ml according to a published formula.,Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009648/),[μg-min] / [ml],5.0,262418,DB01229,Paclitaxel
,17009648,AUCs,"Pharmacokinetic studies showed that the AUCs of free platinum were 8.03 and 5.69 microg-min/ml in the first and second courses of the chemotherapy, respectively, suggesting that the AUC of carboplatin is affected by hemodialysis.",Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009648/),[μg-min] / [ml],8.03,262419,DB01229,Paclitaxel
,17009648,AUCs,"Pharmacokinetic studies showed that the AUCs of free platinum were 8.03 and 5.69 microg-min/ml in the first and second courses of the chemotherapy, respectively, suggesting that the AUC of carboplatin is affected by hemodialysis.",Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009648/),[μg-min] / [ml],5.69,262420,DB01229,Paclitaxel
<,25950473,IC50,BPT inhibited the growth of several human cancer cells with an IC50<1 μM.,Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25950473/),μM,1,262607,DB01229,Paclitaxel
,17975154,time above paclitaxel plasma concentration,"Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time above paclitaxel plasma concentration of 0.05 to 0.2 micromol/L (t(C > 0.05-0.2)) predicts neutropenia.",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),[μM] / [l],0.05 to 0.2,262894,DB01229,Paclitaxel
>,17975154,t(C,"Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time above paclitaxel plasma concentration of 0.05 to 0.2 micromol/L (t(C > 0.05-0.2)) predicts neutropenia.",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),,0.05-0.2,262895,DB01229,Paclitaxel
,17975154,area under the concentration-time curve,One hundred thirty-nine ovarian cancer patients received paclitaxel (175 mg/m(2)) over 3 h followed by carboplatin area under the concentration-time curve 5 mg/mL*min over 30 min.,Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),[mg] / [min·ml],5,262896,DB01229,Paclitaxel
,17975154,objective response rate,"In 34 patients with measurable disease, objective response rate was 76%.",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),%,76,262897,DB01229,Paclitaxel
>,17975154,t(C,"Paclitaxel t(C > 0.05) was significantly higher in patients with a complete (91.8 h) or partial (76.3 h) response compared with patients with progressive disease (31.5 h; P = 0.02 and 0.05, respectively).",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),h,0.05,262898,DB01229,Paclitaxel
,17975154,t(C,"Paclitaxel t(C > 0.05) was significantly higher in patients with a complete (91.8 h) or partial (76.3 h) response compared with patients with progressive disease (31.5 h; P = 0.02 and 0.05, respectively).",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),h,91.8,262899,DB01229,Paclitaxel
,17975154,t(C,"Paclitaxel t(C > 0.05) was significantly higher in patients with a complete (91.8 h) or partial (76.3 h) response compared with patients with progressive disease (31.5 h; P = 0.02 and 0.05, respectively).",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),h,76.3,262900,DB01229,Paclitaxel
,17975154,t(C,"Paclitaxel t(C > 0.05) was significantly higher in patients with a complete (91.8 h) or partial (76.3 h) response compared with patients with progressive disease (31.5 h; P = 0.02 and 0.05, respectively).",Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),h,31.5,262901,DB01229,Paclitaxel
>,17975154,t,Patients with paclitaxel t(C > 0.05) > 61.4 h (mean value) had a longer time to disease progression compared with patients with paclitaxel t(C > 0.05) < 61.4 h (89.0 versus 61.9 weeks; P = 0.05).,Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),h,61.4,262902,DB01229,Paclitaxel
<,17975154,t,Patients with paclitaxel t(C > 0.05) > 61.4 h (mean value) had a longer time to disease progression compared with patients with paclitaxel t(C > 0.05) < 61.4 h (89.0 versus 61.9 weeks; P = 0.05).,Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975154/),h,61.4,262903,DB01229,Paclitaxel
,8742102,recovery,The recovery of paclitaxel in the feces (0-96 h) was reduced from 58% at the 2 mg/kg dose level to 44% at the 20 mg/kg dose level.,"Tissue distribution, metabolism and excretion of paclitaxel in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742102/),%,58,263286,DB01229,Paclitaxel
,8742102,recovery,The recovery of paclitaxel in the feces (0-96 h) was reduced from 58% at the 2 mg/kg dose level to 44% at the 20 mg/kg dose level.,"Tissue distribution, metabolism and excretion of paclitaxel in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742102/),%,44,263287,DB01229,Paclitaxel
,15668288,overall response rate,"In 30 patients evaluated for response and toxicity, the overall response rate was 37% and 10% of patients achieved stable disease.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),%,37,263607,DB01229,Paclitaxel
,15668288,time to progression,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,5.5,263608,DB01229,Paclitaxel
,15668288,overall survival,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,9,263609,DB01229,Paclitaxel
,26905999,total body clearance,"The population mean estimates of the total body clearance for patients aged 58 years or less and the central volume of distribution for docetaxel were 32.6 L/h and 5.77 L, respectively.",Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26905999/),[l] / [h],32.6,263919,DB01229,Paclitaxel
,26905999,central volume of distribution,"The population mean estimates of the total body clearance for patients aged 58 years or less and the central volume of distribution for docetaxel were 32.6 L/h and 5.77 L, respectively.",Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26905999/),l,5.77,263920,DB01229,Paclitaxel
>,10676993,recovery,"The method involves solid-phase extraction on cyano cartridges (recovery >75%), HPLC separation on symmetry shield column, a mobile phase of NaH2PO4 (10 mM) pH 5.2, acetonitrile (47:53) and detection at 227 nm.",High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676993/),%,75,263992,DB01229,Paclitaxel
,10676993,Retention times,"Retention times of IDN5109, its epiform and internal standard were 15, 24 and 25.5 min, respectively.",High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676993/),min,15,263993,DB01229,Paclitaxel
,10676993,Retention times,"Retention times of IDN5109, its epiform and internal standard were 15, 24 and 25.5 min, respectively.",High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676993/),min,24,263994,DB01229,Paclitaxel
,10676993,Retention times,"Retention times of IDN5109, its epiform and internal standard were 15, 24 and 25.5 min, respectively.",High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676993/),min,25.5,263995,DB01229,Paclitaxel
,10676993,LOQ,LOQ was 50 ng/ml for both compounds.,High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676993/),[ng] / [ml],50,263996,DB01229,Paclitaxel
,28275119,area under the curve [AUC],Pilaralisib was administered once daily (QD); paclitaxel (up to 175 mg/m2) and carboplatin (up to area under the curve [AUC] of 6) were administered on day 1 of 21-day cycles.,"Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28275119/),,6,264897,DB01229,Paclitaxel
,28275119,MTD,The MTD of pilaralisib tablets in combination with paclitaxel and carboplatin was determined to be 200 mg QD.,"Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28275119/),,200,264898,DB01229,Paclitaxel
,19704336,area under the free platinum plasma concentration-time curve (AUC(fp)),Starting doses were paclitaxel 175 mg/m(2) and carboplatin targeting an area under the free platinum plasma concentration-time curve (AUC(fp)) of 5 mg . min/ml (dose level 1).,"Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704336/),[mg·min] / [ml],5,264964,DB01229,Paclitaxel
,19704336,AUC(fp),The carboplatin dose was then increased to AUC(fp) 6 mg . min/ml (dose level 2) after which the paclitaxel dose was increased to 200 mg/m(2) (dose level 3).,"Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704336/),[mg·min] / [ml],6,264965,DB01229,Paclitaxel
,19704336,AUC(fp),"The maximum tolerated doses were carboplatin AUC(fp) 6 mg . min/ml, paclitaxel 175 mg/m(2), and ISIS 5132 2.0 mg/kg/d for 14 days.","Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704336/),[mg·min] / [ml],6,264966,DB01229,Paclitaxel
,12006516,MTD,The MTD was thus determined to be 300 mg/m2 (level 2).,"Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006516/),[mg] / [m2],300,265153,DB01229,Paclitaxel
,21796700,AUC(0-24h),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],280.8,265395,DB01229,Paclitaxel
,21796700,AUC(0-24h),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],543.5,265396,DB01229,Paclitaxel
,21796700,C(max),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[ng] / [ml],44.6,265397,DB01229,Paclitaxel
,21796700,C(max),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[ng] / [ml],86.8,265398,DB01229,Paclitaxel
,21796700,AUC(0-24h),The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],163.6,265399,DB01229,Paclitaxel
,21796700,AUC(0-24h),The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],212.7,265400,DB01229,Paclitaxel
,21796700,clearance,The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[l] / [h·kg],3.2,265401,DB01229,Paclitaxel
,21796700,clearance,The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[l] / [h·kg],2.2,265402,DB01229,Paclitaxel
,15620886,total run time,"Paclitaxel and IS are separated on a 50 x 2.1-mm C18 column and quantified using a triple-quadrupole mass spectrometer operating in positive ion electrospray multiple reaction monitoring mode, with a total run time of 3.5 min.",Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15620886/),min,3.5,265666,DB01229,Paclitaxel
,20523105,IC(50),Silibinin inhibited CYP3A4 enzyme activity with an IC(50) of 1.8 mumol/l.,"Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523105/),[μM] / [l],1.8,266118,DB01229,Paclitaxel
,15010068,whole blood clearance,"The whole blood clearance of total paclitaxel was similar for LEP (15.3+/-8.98 l/h/m(2)) and Taxol (17.5+/-3.43 l/h/m(2)), and the extraliposomal to total drug ratio increased rapidly to unity at later sampling time points.",Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010068/),[h·l] / [m(2],15.3,266617,DB01229,Paclitaxel
,15010068,whole blood clearance,"The whole blood clearance of total paclitaxel was similar for LEP (15.3+/-8.98 l/h/m(2)) and Taxol (17.5+/-3.43 l/h/m(2)), and the extraliposomal to total drug ratio increased rapidly to unity at later sampling time points.",Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15010068/),[h·l] / [m(2],17.5,266618,DB01229,Paclitaxel
,26794876,en,"MPEG2K-C28, the conjugation of monomethoxy Poly(ethylene glycol) 2000 and octacosanol, was readily soluble in aqueous solution and self-assembled to form micelles with small sizes (< 20 nm) that are efficient in encapsulating PTX with a drug loading of 9.38 ± 0.18% and an encapsulation efficiency of 93.90 ± 2.12%.",PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794876/),,93,267004,DB01229,Paclitaxel
,26794876,T1/2,"Pharmacokinetic study revealed that PTX micelles improved the T1/2 and AUC of PTX (compared with Taxol) from 1.910 ± 0.139 h and 13.999 ± 1.109 mg/l × h to 2.876 ± 0.532 h and 76.462 ± 8.619 mg/l × h in vivo, respectively.",PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794876/),h,1.910,267005,DB01229,Paclitaxel
,26794876,T1/2,"Pharmacokinetic study revealed that PTX micelles improved the T1/2 and AUC of PTX (compared with Taxol) from 1.910 ± 0.139 h and 13.999 ± 1.109 mg/l × h to 2.876 ± 0.532 h and 76.462 ± 8.619 mg/l × h in vivo, respectively.",PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794876/),h,2.876,267006,DB01229,Paclitaxel
,26794876,AUC,"Pharmacokinetic study revealed that PTX micelles improved the T1/2 and AUC of PTX (compared with Taxol) from 1.910 ± 0.139 h and 13.999 ± 1.109 mg/l × h to 2.876 ± 0.532 h and 76.462 ± 8.619 mg/l × h in vivo, respectively.",PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794876/),[mg] / [h·l],13.999,267007,DB01229,Paclitaxel
,26794876,AUC,"Pharmacokinetic study revealed that PTX micelles improved the T1/2 and AUC of PTX (compared with Taxol) from 1.910 ± 0.139 h and 13.999 ± 1.109 mg/l × h to 2.876 ± 0.532 h and 76.462 ± 8.619 mg/l × h in vivo, respectively.",PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794876/),[mg] / [h·l],76.462,267008,DB01229,Paclitaxel
,15138560,area under the concentration-time curve (AUC),"Patients received paclitaxel at 180-225 mg/m(2) by intravenous infusion over 3 h, followed by carboplatin at a target area under the concentration-time curve (AUC) of 6 mg/ml x min as a 1-h infusion.",Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138560/),[mg] / [min·ml],6,267204,DB01229,Paclitaxel
,15138560,platelet counts,"The platelet counts at the nadir were significantly higher (p<0.0001) in patients treated with paclitaxel/carboplatin combination (161,000+/-38,000/ micro l) compared with single-agent carboplatin (92,000+/-28,000/ micro l).",Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138560/),1/[μl],"161,000",267205,DB01229,Paclitaxel
,15138560,platelet counts,"The platelet counts at the nadir were significantly higher (p<0.0001) in patients treated with paclitaxel/carboplatin combination (161,000+/-38,000/ micro l) compared with single-agent carboplatin (92,000+/-28,000/ micro l).",Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138560/),1/[μl],"92,000",267206,DB01229,Paclitaxel
,15138560,AUC,The recommended doses are paclitaxel 210 mg/m(2) and carboplatin at an AUC of 6 mg/ml x min every 3 weeks.,Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138560/),[mg] / [min·ml],6,267207,DB01229,Paclitaxel
,11181682,area under the concentration-time curve (AUC),The mean (+/- SD) area under the concentration-time curve (AUC) in patients who received oral docetaxel 75 mg/m(2) without CsA was 0.37 +/- 0.33 mg.h/L and 2.71 +/- 1.81 mg.h/L for the same oral docetaxel dose with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),[h·mg] / [l],0.37,267598,DB01229,Paclitaxel
,11181682,area under the concentration-time curve (AUC),The mean (+/- SD) area under the concentration-time curve (AUC) in patients who received oral docetaxel 75 mg/m(2) without CsA was 0.37 +/- 0.33 mg.h/L and 2.71 +/- 1.81 mg.h/L for the same oral docetaxel dose with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),[h·mg] / [l],2.71,267599,DB01229,Paclitaxel
,11181682,AUC,The mean AUC of IV docetaxel 100 mg/m(2) was 4.41 +/- 2.10 mg.h/L.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),[h·mg] / [l],4.41,267600,DB01229,Paclitaxel
,11181682,absolute bioavailability,The absolute bioavailability of oral docetaxel was 8% +/- 6% without and 90% +/- 44% with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),%,8,267601,DB01229,Paclitaxel
,11181682,absolute bioavailability,The absolute bioavailability of oral docetaxel was 8% +/- 6% without and 90% +/- 44% with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),%,90,267602,DB01229,Paclitaxel
,33826243,AUC,"Model predicted AUC and dose normalized AUC (mean ±SD) in the normal BMI versus overweight obese groups were 23 ± 11.0 µmol*h/L versus 25.7 ± 13.7 µmol*h/L (two-sample t-test p > 0.05) and 0.08 ± 0.04 (µmol*h/L)/ µmol versus 0.08 ± 0.04 (µmol*h/L)/ µmol (2-sample t-test p > 0.05), respectively.",Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33826243/),[h·μM] / [l],23,267666,DB01229,Paclitaxel
,33826243,AUC,"Model predicted AUC and dose normalized AUC (mean ±SD) in the normal BMI versus overweight obese groups were 23 ± 11.0 µmol*h/L versus 25.7 ± 13.7 µmol*h/L (two-sample t-test p > 0.05) and 0.08 ± 0.04 (µmol*h/L)/ µmol versus 0.08 ± 0.04 (µmol*h/L)/ µmol (2-sample t-test p > 0.05), respectively.",Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33826243/),[h·μM] / [l],25.7,267667,DB01229,Paclitaxel
,33826243,dose normalized AUC,"Model predicted AUC and dose normalized AUC (mean ±SD) in the normal BMI versus overweight obese groups were 23 ± 11.0 µmol*h/L versus 25.7 ± 13.7 µmol*h/L (two-sample t-test p > 0.05) and 0.08 ± 0.04 (µmol*h/L)/ µmol versus 0.08 ± 0.04 (µmol*h/L)/ µmol (2-sample t-test p > 0.05), respectively.",Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33826243/),[h·μM] / [l],0.08,267668,DB01229,Paclitaxel
,33826243,dose normalized AUC,"Model predicted AUC and dose normalized AUC (mean ±SD) in the normal BMI versus overweight obese groups were 23 ± 11.0 µmol*h/L versus 25.7 ± 13.7 µmol*h/L (two-sample t-test p > 0.05) and 0.08 ± 0.04 (µmol*h/L)/ µmol versus 0.08 ± 0.04 (µmol*h/L)/ µmol (2-sample t-test p > 0.05), respectively.",Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33826243/),[h·μM] / [·l)·μM],0.08,267669,DB01229,Paclitaxel
,23203544,peak concentration,"The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively.",Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203544/),[ng] / [ml],21.84,268477,DB01229,Paclitaxel
,23203544,peak concentration,"The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively.",Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203544/),[ng] / [ml],294.80,268478,DB01229,Paclitaxel
,12657237,volume of fluid remaining in,"The mean volume of fluid remaining in the peritoneal cavity at 23 h was 900 ml +/-373.7 (SD) with hetastarch, and 285 ml (+/-157.5) with peritoneal dialysis solution (P=0.0022).",A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657237/),ml,900,270202,DB01229,Paclitaxel
,12657237,volume of fluid remaining in,"The mean volume of fluid remaining in the peritoneal cavity at 23 h was 900 ml +/-373.7 (SD) with hetastarch, and 285 ml (+/-157.5) with peritoneal dialysis solution (P=0.0022).",A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657237/),ml,285,270203,DB01229,Paclitaxel
,12657237,total amount,The mean total amount of paclitaxel in the peritoneal cavity at 23 h was 2.597 mg (+/-1.57) with hetastarch and 0.772 mg (+/-0.667) with peritoneal dialysis solution (P=0.0152).,A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657237/),mg,2.597,270204,DB01229,Paclitaxel
,12657237,total amount,The mean total amount of paclitaxel in the peritoneal cavity at 23 h was 2.597 mg (+/-1.57) with hetastarch and 0.772 mg (+/-0.667) with peritoneal dialysis solution (P=0.0152).,A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657237/),mg,0.772,270205,DB01229,Paclitaxel
,8636011,MTD,"The MTD of paclitaxel given as a 3-h infusion was determined to be 240 mg/m2 with dose-limiting toxicities of granulocytopenia, peripheral neuropathy and hypotension.",Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636011/),[mg] / [m],240,270236,DB01229,Paclitaxel
,30948059,relative BA,"The SD formulations and micelles had enhanced bioavailability (BA) compared to that of PTX, showing relative BA values of 667.3% (SD4), 359.6% (SD9), and 365.4% (M2).",Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30948059/),%,667.3,271375,DB01229,Paclitaxel
,30948059,relative BA,"The SD formulations and micelles had enhanced bioavailability (BA) compared to that of PTX, showing relative BA values of 667.3% (SD4), 359.6% (SD9), and 365.4% (M2).",Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30948059/),%,359.6,271376,DB01229,Paclitaxel
,30948059,relative BA,"The SD formulations and micelles had enhanced bioavailability (BA) compared to that of PTX, showing relative BA values of 667.3% (SD4), 359.6% (SD9), and 365.4% (M2).",Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30948059/),%,365.4,271377,DB01229,Paclitaxel
,12525510,area under the curves (AUC),"The area under the curves (AUC) of unbound paclitaxel were similar in both dosing groups, with mean values +/- SD (A v B) of 1.34 +/- 0.158 versus 1.30 +/- 0.329 microM x h, indicating that BSA-based dosing reduced the coefficient of variation by 53.3%.",Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525510/),h·μM,1.34,271765,DB01229,Paclitaxel
,12525510,area under the curves (AUC),"The area under the curves (AUC) of unbound paclitaxel were similar in both dosing groups, with mean values +/- SD (A v B) of 1.34 +/- 0.158 versus 1.30 +/- 0.329 microM x h, indicating that BSA-based dosing reduced the coefficient of variation by 53.3%.",Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525510/),h·μM,1.30,271766,DB01229,Paclitaxel
,12525510,A v B),"The area under the curves (AUC) of unbound paclitaxel were similar in both dosing groups, with mean values +/- SD (A v B) of 1.34 +/- 0.158 versus 1.30 +/- 0.329 microM x h, indicating that BSA-based dosing reduced the coefficient of variation by 53.3%.",Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525510/),h·μM,1.34,271767,DB01229,Paclitaxel
,12525510,A v B),"The area under the curves (AUC) of unbound paclitaxel were similar in both dosing groups, with mean values +/- SD (A v B) of 1.34 +/- 0.158 versus 1.30 +/- 0.329 microM x h, indicating that BSA-based dosing reduced the coefficient of variation by 53.3%.",Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525510/),h·μM,1.30,271768,DB01229,Paclitaxel
,33089874,terminal half-life,"The mean terminal half-life of pevonedistat and drug-related material in plasma was 8.4 and 15.6 h, respectively.","Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),h,8.4,271834,DB01229,Paclitaxel
,33089874,terminal half-life,"The mean terminal half-life of pevonedistat and drug-related material in plasma was 8.4 and 15.6 h, respectively.","Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),h,15.6,271835,DB01229,Paclitaxel
,33089874,whole-blood-to-plasma ratio,Pevonedistat distributed preferentially in whole blood with a mean whole-blood-to-plasma ratio for pevonedistat AUC∞ of 40.8.,"Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),,40.8,271836,DB01229,Paclitaxel
,33089874,AUC∞,Pevonedistat distributed preferentially in whole blood with a mean whole-blood-to-plasma ratio for pevonedistat AUC∞ of 40.8.,"Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),,40.8,271837,DB01229,Paclitaxel
,33089874,recovery,"By 1 week post dose, the mean recovery of administered radioactivity was 94% (41% in urine and 53% in feces).","Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),%,94,271838,DB01229,Paclitaxel
,33089874,recovery,"By 1 week post dose, the mean recovery of administered radioactivity was 94% (41% in urine and 53% in feces).","Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),%,41,271839,DB01229,Paclitaxel
,33089874,recovery,"By 1 week post dose, the mean recovery of administered radioactivity was 94% (41% in urine and 53% in feces).","Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089874/),%,53,271840,DB01229,Paclitaxel
,7509380,final elimination half-life,"Taxol plasma concentrations declined in a triexponential fashion, with a final elimination half-life of 10 to 12 hours.",Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7509380/),h,10 to 12,273487,DB01229,Paclitaxel
,14578679,apparent clearance,"The apparent clearance of Cu was not significantly different between the two groups, with mean +/- standard deviation (+/- SD) values of 230 +/- 56.0 and 202 +/- 49.9 L/h/m2 in the absence and presence of valspodar, respectively (P = 0.17).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [h·m2],230,273540,DB01229,Paclitaxel
,14578679,apparent clearance,"The apparent clearance of Cu was not significantly different between the two groups, with mean +/- standard deviation (+/- SD) values of 230 +/- 56.0 and 202 +/- 49.9 L/h/m2 in the absence and presence of valspodar, respectively (P = 0.17).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [h·m2],202,273541,DB01229,Paclitaxel
,14578679,volume of Cu distribution,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [m2],1160,273542,DB01229,Paclitaxel
,14578679,volume of Cu distribution,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [m2],1620,273543,DB01229,Paclitaxel
,14578679,terminal disposition half-life,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),h,6.12,273544,DB01229,Paclitaxel
,14578679,terminal disposition half-life,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),h,8.50,273545,DB01229,Paclitaxel
,10071290,overall 50%,"The overall 50% PSA response rate was 63% (95% confidence interval [CI], 28% to 81%).",Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071290/),%,63,273724,DB01229,Paclitaxel
,10071290,area under the curve,"At 80 mg/m2, the measured area under the curve was 8.37 (standard deviation, 0.724), which was significantly higher than the previously reported values.",Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071290/),,8.37,273725,DB01229,Paclitaxel
,10997809,overall response rate,"Objectives responses were seen at all dose levels, with an overall response rate of 43% (95% confidence interval (95% CI): 25.5%-62.6%) in 30 evaluable patients.",Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997809/),%,43,273906,DB01229,Paclitaxel
